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ABBREVIATIONS AND SYMBOLOGY 
 
Amino acids are written in three-letter code. Other abbreviations are: 
abs  absolute 
Anal. Calcd. analysis calculated 
asymm.  asymetric 
br  broad 
brs  broad singlet 
Bu  butyl 
Bz   benzyl 
Cat G   cathepsin G 
COPD   chronic obstructive pulmonary disease 
13C NMR carbon isotope C-13 nuclear magnetic resonance 
d   doublet 
DCM  dichloromethane 
dd   doublet of doublets 
ddd   doublet of doublet of doublets 
DEPT   distortionless enhancement by polarization transfers 
DMSO  dimethylsulfoxide 
dt  doublet of triplets 
dq  doubet quartet 
EREF   enzyme rate enhancement factor 
MS   mass spectrometry 
Et  ethyl 
EtOAc   ethyl acetate 
EtOH   ethanol 
eq.  equivalent 
EWG   electron-withdrawing group 
exc.  excess 
h  hour 
HCMV  human cytomegalovirus 
HCV   hepatitis C virus 
HEPES  N-(2-Hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) 
HLE   human leukocyte elastase 
1H NMR  proton nuclear magnetic resonance 
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HOMO  highest occupied molecular orbital 
HPLC   high performance liquid chromatography 
iPr   isopropyl 
IR   infrared  
J  proton-proton coupling constant 
LG   leaving group 
lit.   literature 
LUMO  lowest unoccupied molecular orbital 
m  multiplet 
(M)+  molecular ion peak (in mass spectrometry) 
Me  methyl 
MMP   matrix metalloproteases 
m.p.   melting point 
MW  molecular weight 
m/z  mass to charge ratio 
Naph  naphthyl 
NMR   nuclear magnetic resonance 
PBS   phosphate buffer solution 
Ph   phenyl 
PR3   proteinase 3 
PPE   porcine pancreatic elastase 
Pyr   pyridine 
q  quartet 
rt  room temperature 
s  singlet (in the context of NMR data ) or seconds 
symm.  symmetric 
t  triplet 
TEA   triethylamine 
TLC   thin layer chromatography 
UV  ultraviolet 
vmax  maximum wave number 
v/v  volume/volume fraction solution 
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ABSTRACT 
 
Human leukocyte elastase (HLE, EC 3.4.21.37) is a neutrophil serine protease capable of 
degrading a great variety of proteins, such as elastin and collagens. HLE is an attractive 
therapeutic target since unregulated activity of this enzyme has been implicated in many 
inflammatory disorders, such as chronic obstructive pulmonary disease. The present work 
focused on the design of synthetic irreversible inhibitors of HLE based on the-lactam 
scaffold (azetidin-2-ones and azetidine-2,4-diones), as potential drug candidates. Kinetic 
studies of enzyme inhibition in vitro were performed to determine the inhibitory potency. 
Intrinsic chemical reactivity studies, using hydroxide as a model of serine residue, were 
performed to evaluate the stability towards non-specific nucleophiles. 
The effect of different leaving groups at C-4 on the intrinsic chemical reactivity and 
elastases (PPE and HLE) inactivation by N-carbamoylazetidin-2-ones is described. In 
both cases, the rate limiting step is the formation of the tetrahedral intermediate, and the 
-lactam ring opening is not concerted with the departure of the substituent from C-4. 
3,3-Unsubtituted derivatives inhibited PPE (kon ranging from 11.3 to 290 M-1s-1), while 
3,3-diethyl counterparts inhibited HLE (kon ranging from 310 to 14600 M-1s-1). Taft I 
values suggests that the HLE catalyzed hydrolysis occurs in an earlier position along the 
reaction coordinate than the alkaline hydrolysis, due to favorable binding interactions of 
the inhibitor to the enzyme. Sulfones at C-4 improve the inhibitory potency, activating the 
-lactam and leading to an irreversible covalent enzyme-inhibitor adduct with sulfinate 
departure, as shown by X-ray crystallography.  
Azetidine-2,4-diones were designed as isosteric analogues of highly reactive 3-oxo--
sultams inhibitors of PPE. The synthesis and preliminary studies as PPE inhibitors are 
described. The inhibitory activity is a result of nucleophilic attack by catalytic serine 
residue to a carbonyl carbon and four-membered ring opening to form the acyl-enzyme 
complex. Good Hammett correlations were found for the para-substituted derivatives, 
giving a p value lower for PPE inhibition than the obtained for the chemical process. 
This result agrees with favorable binding interactions of the inhibitor within the active 
site, as revealed by docking studies. 4-Oxo-β-lactams were found to be novel, potent 
time-dependent irreversible inhibitors of PPE, while decreasing dramatically the 
reactivity towards hydroxide ion when compared to the 3-oxo--sultams analogues.  
  xviii
A comprehensive SAR study of 4-oxo--lactams is described, including differently 
substituted derivatives at C-3 and N-1 for exploiting S and S´subsites of HLE, which gave 
potent irreversible inhibitors of HLE (kon ranging from 2102 to 3106 M-1s-1). Inhibitory 
activity is strongly dependent on the nature of substituents at C-3. 3,3-Diethyl derivatives 
with a para-heteroarylthiomethyl group on the N1-aryl moiety were found to be potent 
acylating agents of HLE, with higher than 106 M-1s-1 kon values and Ki values ranging 
from 0.50 to 9.5 nM. Inhibition is a result of ring-opening to form a tight enzyme-
inhibitor adduct, but with no expulsion of the thiol leaving group. 4-Oxo--lactams were 
selective towards HLE rather than PPE, proteinase 3 or cathepsin G and were inactive 
against cystein protease papain. The stability of some compounds at 37 ºC in pH 7.4 
phosphate buffer and human plasma as well as a biodistribution study in mice for a 
selected derivative were also performed. The results from this thesis demonstrate 
convincingly the superiority of the azetidine-2,4-dione scaffold over 3-oxo--sultams and 
simple -lactams in the design of inhibitors of serine proteases. 
 
 
KEYWORDS: -lactam, azetidine-2,4-dione, serine proteases, irreversible inhibitors, 
elastase, reactivity. 
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RESUMO 
 
A elastase leucocitária humana (HLE, EC 3.4.21.37) é uma protease de serina dos 
neutrófilos capaz de degradar uma grande variedade de proteínas, como o colagénio e a 
elastina. A HLE é um interessante alvo terapêutico, uma vez que a actividade 
descontrolada desta enzima está associada a várias patologias infalamatórias, como a 
doença pulmonar obstructiva crónica. O presente trabalho teve como objectivo o desenho 
de inibidores irreversíveis da HLE com base no núcleo -lactâmico (azetidin-2-onas e 
azetidine-2,4-dionas), numa perspectiva terapêutica. Neste âmbito, foram realizados 
estudos cinéticos de inhibição enzimática in vitro, de forma a determinar a potência 
inibitória e, também, estudos de reactividade química intrínseca, usando o ião hidróxido 
como modelo do resíduo serina, de forma a avaliar a estabilidade dos compostos perante 
nucleófilos não específicos. 
É descrito o efeito relativo de diferentes grupos abandonantes em C-4 quer na 
reactividade química quer na inibição enzimática por N-carbamoilazetidin-2-onas. Em 
ambos os casos, a etapa determinante da velocidade da reacção é a formação do 
intermediário tetraédrico e a abertura do anel -lactâmico não é concertada com a saída 
do substituinte em C-4. Os derivados não substituídos em C-3 inibiram a PPE (kon variou 
entre 11.3 a 290 M-1s-1), enquanto que os 3,3-dietilssubstituídos inibiram a HLE (kon 
variou de 310 a 14600 M-1s-1). Valores de Taft I sugerem que a reacção catalisada pela 
HLE envolve um estado de transição precoce na coordenada da reacção em relação ao 
processo químico, devido a interacções favoráveis entre a enzima e o inibidor. Sulfonas 
em C-4 aumentaram a potência inibitória por activação do anel -lactâmico (efeito 
indutivo), resultando numa inibição irreversível por formação da acil-enzima e expulsão 
do sulfinato, como demonstrado por estudos de cristalografia de raios-X. 
É descrita a síntese bem como estudos preliminares de inibição enzimática de azetidine-
2,4-dionas. Estas foram desenvolvidas como isósteros de 3-oxo--sultamas, as quais são 
inibidores da PPE com uma elevada reactividade química intrínseca. A actividade 
inibitória de azetidine-2,4-dionas resulta do ataque nucleofílico do resíduo serina do 
centro activo a um dos carbonos carbonílicos, com abertura do anel de quatro membros 
para formar o aducto inibidor-enzima. Boas correlações de Hammett foram obtidas para 
os derivados para-substituídos, tendo-se verificado um valor de Hammett p para a 
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inibição da PPE inferior do que para o processo químico  Este resultado sugere a 
existência de interacções favoráveis entre o inibidor e a enzima, tal como indicado por 
estudos de docking. As azetidine-2,4-dionas representam uma nova clase de potentes 
inibidores irreversíveis da protease de serina PPE, apresentando uma reactividade 
química intrínseca drasticamente inferior aos isósteros 3-oxo--sultamas.  
É descrito um abrangente estudo de relação-estrutura-actividade de 4-oxo--lactamas, 
incluindo derivados com diferentes substituintes em C-3 e N-1 para explorar bolsas de 
ligação S e S´ da HLE. Obtiveram-se potentes inibidores irreversíveis da HLE (kon entre 
2102 to 3106 M-1s-1). A potência inibitória depende fortemente da natureza do 
substituinte em C-3. Derivados 3,3-dietil para-substituídos em N1-aril com um grupo 
heteroariltiometil revelaram-se potentes agentes acilantes da HLE, com valores de kon 
notáveis, acima de 106 M-1s-1 e valores de Ki entre 0.50 e 9.5 nM. A inibição resulta da 
abertura do anel de quatro membros para formar um aducto enzima-inibidor estável, 
todavia sem ocorrer expulsão do grupo abandonante tiol. As 4-oxo--lactamas 
mostraram-se selectivas para a HLE quando comparadas com a PPE, a proteinase 3, ou a 
catepsina G e foram inactivas contra a protease de cisteína papaína. Foram ainda 
efectuados estudos de estabilidade de alguns compostos a 37 ºC em tampão fosfato pH 
7.4 e plasma humano bem como um estudo de biodistribuição em ratinhos. Os resultados 
obtidos demonstram a clara superioridade das azetine-2,4-dionas sobre 3-oxo--sultamas 
e azetidin-2-onas no desenho de inibidores de proteases de serina. 
 
 
PALAVRAS-CHAVE: -lactama, azetidine-2,4-diona, proteases de serina, inibidores 
irreversíveis, elastase, reactividade. 
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1. INTRODUCTION 
1.1. OVERVIEW OF PROTEASES  
Proteases, also known as peptidases, are enzymes that selectively catalyse the 
hydrolysis of peptide bonds. Proteases are classified as hydrolases (Class E.C. 3), by 
the Enzyme Commission of the International Union of Biochemistry and Molecular 
Biology, and, under hydrolases, they belong to Subclass E.C. 3.4, the Peptidases.1 
Based on their catalytic mechanism, there are six types of proteases known: Serine-, 
Cysteine-, Aspartic-, Threonine-, Glutamic- and Metallo-proteases.2 These are further 
classified into clans that share structural homology and then into families with similar 
sequence. 
1.2. SERINE PROTEASES 
Serine proteases are so named due to the common nucleophilic serine residue present 
at the active site. Serine proteases are endopeptidases (E.C. 3.4.21), cleaving peptide 
bonds internally in peptides and proteins.3 Almost one-third of all proteases can be 
classified as serine proteases. These enzymes are widely distributed in nature and 
found in all kingdoms of cellular life. Over 26000 serine proteases are grouped into 
13 clans and 40 families in the MEROPS database (http://merops.sanger.ac.uk). Clan 
PA of serine proteases is the largest and well-studied, from which chymotrypsin is the 
prototype member. 
1.2.1 Serine Proteases as Therapeutic Targets 
By cleaving proteins, serine proteases play multifarious roles in physiological events, 
including digestion, blood coagulation, signal transduction, reproduction, cell 
differentiation, tissue homeostasis, the immune response and apoptosis.4-7 It is known 
that serine proteases are involved in vital processes not only in humans but also in 
pathogens.  
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At present, proteases are recognized not only as protein degrading enzymes, but also 
as important signalling molecules of a complex biochemical network, requiring tight 
regulation.8 Disorders in protease regulation are known to be related with aetiology 
and progression of several pathologies. In particular, excessive proteolysis, which is 
most often a result of unwanted activation of protease signalling pathways, is related 
to tissue damage and/or aberrant processing of other proteins, playing a crucial role in 
cancer, cardiovascular, inflammatory, immunological, respiratory, neurodegenerative 
diseases, diabetes and infections.9, 10 Thus, serine proteases, have emerged as 
important drug targets and one of the great challenges in medicinal chemistry is the 
design and development of serine protease inhibitors.6, 8, 11 In Table 1.1 some known 
serine proteases targeted for pharmacological intervention are listed. Most of them 
have inhibitors currently under clinical trials.9  
 
Table 1.1 Example of some serine proteases with relevance as drug targets and therapeutic 
indication of their inhibitors. 
 
Targeted-Serine Proteases Therapeutic Indication 
HCMV protease6 Cytomegalic inclusion disease (viral 
infection) 
HCV NS3 protease6, 9, 12 Hepatitis C (viral infection) 
Urokinase type plasminogen activactors6, 13  Cancer 
Prostate Specific Antigen14  Cancer 
Tryptase6, 9, 15 Allergic asthma, rhinitis, urticaria 
Human leukocyte elastase6, 9, 16 Respiratory diseases (including COPD), 
inflammation 
Proteinase 316, 17 Respiratory diseases (including COPD), 
inflammation, Wegener´s 
granulomatosis 
Cathepsin G16 Inflammation 
Dipeptidyl peptidase IV8, 9 Diabetes type 2 
Thrombin6, 9, 18 Thrombosis 
Factor VIIa6, 9, 18 Thrombosis 
Factor IXa6, 9, 18 Thrombosis 
Factor Xa6, 9, 18 Thrombosis 
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However, from the many thousands of serine proteases inhibitors already developed, 
only a few have successfully progressed through clinical trials and been approved for 
commercial use (Table 1.2).8, 9 For example, although proteases related with 
coagulopathies have been validated targets for more than a half century, only a few 
direct thrombin inhibitors have been launched in the market, but almost all of them 
have the inconvenience of being restricted to parenteral administration.8 Only one 
thrombin inhibitor for oral administration is currently available, 1 (Table 1.2), 
commercialized in European Union very recently, in April 2008, as a prodrug.19  
Despite great efforts over more than 30 years in the design of human leukocyte 
elastase inhibitors (discussed later in this chapter), only one drug for inhibition of this 
enzyme was approved for clinical use, in Japan, sivelestat (ONO-5046) (3, Table 1.2), 
as an injectable formulation.9  
As far as the author knows, besides thrombin inhibitors and 3, there are only two 
more direct inhibitors of serine proteases available in the marketplace to date (in 
Japan): 4 and 5 (Table 1.2), both indicated for treatment of pancreatitis. Their 
mechanism has not been fully understood, but involves broad-spectrum/trypsin-like 
serine protease inhibition.8, 9  
With this background, it is of interest to improve serine protease inhibitors. However, 
a case of success of protease inhibition in clinic is the well-known and widely use of 
-lactam antibiotics, such as penicillins and cephalosporins, inhibitors of bacterial 
serine enzymes transpeptidases.20 These bacterial enzymes are related with serine 
proteases, but differ by these because of being carboxypeptidases.1 
At present, protease-targeted therapy is a promising area, taking advantage of recent 
developments in genomics, proteomics and combinatorial chemistry, and using a 
variety of tools, such as X-ray crystallography and high-field NMR.  
The attractiveness of serine proteases as therapeutic targets results not only from their 
pathophysiological role in disease, but also from structural determinants of their 
catalysis. In particular, either the structure of the active site, suitable for high-affinity 
interactions with inhibitors, or features of the catalytic mechanism, make protease 
inhibition a fascinating area for therapeutic intervention.21 
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Table 1.2 - Serine protease inhibitors approved for clinical use.8 
Target Compound Company 
Thrombin 
O
O
N
H2N
NH N
N
N
O
N
O
O1
 
Dabigatran 
Boehringer-
Ingelheim 
Thrombin 
N
H
S
NH
NH2N
NH2
ON
O
OH
O O
2  
Argatroban 
Mitsubishi Pharma 
 
Thrombin 
 
Naturally occurring in the salivary glands of medicinal 
leeches hirudin-based peptide drug. 
Lepirudin 
 
Aventis 
 
Thrombin 
 
Naturally occurring in the salivary glands of medicinal 
leeches hirudin-based peptide drug. 
Desirudin 
 
Novartis 
Human leukocyte 
elastase 
O
O
S
H
N
O O
H
NO
OH
O
3  
Sivelestat (ONO-5046) 
Ono 
Trypsin-like serine 
proteases 
N
H
O
O
O
N
H2N
NH
O
O
4
 
Camostat mesilate 
Ono 
Broad-spectrum 
N
H
O
H2N
NH
O
5
NH2
NH
 
Nafomostat mesilate 
Japan Tobacco 
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1.2.2 Active Site Topology and Catalytic Mechanism 
Serine proteases active site involves not only the catalytic triad, formed by Ser-195, 
His-57 and Asp-102 (chymotrypsin numbering), but also extended molecular 
recognition binding sites for interaction with the peptidic substrate. 
The Schechter and Berger nomenclature22 is used to define the interaction of a 
protease with a substrate. The amino acid residues of the substrate are named P1, P2, 
P3,… Pn from the scissile peptide bond to the amino-terminus, while those towards 
carboxyl-terminus direction are designated P1´, P2´, P3´,… Pn´. These residues are 
accommodated in the corresponding binding sites of the enzyme, referred to S1, S2, 
S3,… Sn and S1´, S2´, S3´,,… Sn´, respectively (Figure 1.1). These sites are located in 
clefts and crevices in the protein and are determinant for substrate specificity. S1 is the 
primary specificity binding pocket in serine proteases, being critical to the molecular 
recognition (complementary). 
R
H
N
N
H
H
N
N
H
H
N
N
H
O
O
O
O
O
O
P3 P1 P2´
P2 P1´
S3
S2 S1´
S2´S1
P3´
O
H
N
R´
S3´
 
Figure 1.1 - Interactions between the specific subsites of a protease and the respective residues of 
the substrate.22  
 
The initial interactions between the inhibitor and the enzyme are noncovalent and 
reversible, and provide a specific orientation of the substrate at the active site, 
aligning the catalytic triad. 
The general catalytic mechanism of serine proteases is presented in Figure 1.2. Once 
the substrate is non-covalently bound, the carbonyl carbon of the scissile peptide bond 
is attacked by the hydroxyl group of the catalytic Ser-195 residue. His-57 acts as a 
general base catalyst and enhances the nucleophilicity of Ser-195, by removing the 
hydroxyl proton. This process is facilitated by the polarising effect of Asp-102 
(Figure 1.2a).  
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The tetrahedral intermediate (TI) is formed and its oxyanion is stabilized by hydrogen 
bonds formed to the backbone NH groups of Ser-195 and Gly-193 residues. This 
region is named the oxyanion hole. The imidazolium ion of His-57 assists the collapse 
of the TI via general acid catalysis, by protonation of the amine leaving group, 
releasing the amino-terminus peptide (Figure 1.2b). Simultaneously, the peptide bond 
is broken and the acyl-enzyme complex is formed. 
Subsequently, (Figure 1.2c), a water molecule attacks the acyl-enzyme, assisted by 
general base catalysis by His-57, forming a new TI (omitted in Figure 1.2). By 
breakdown of this intermediate, Ser-195 recovers its hydrogen from His-57, while the 
acid product (carboxy-terminus peptide) diffuses out (Figure 1.2d).23, 24  
 
Michaelis complex
HN
NH
O
O
O
Asp-102
O
O
N
N
H
His-57
O
Ser-195
P1´
P1
HN
NH
O
O
O
Asp-102
O
O
N
N
H
His-57
OSer-195
P1´
P1
H H
H
H
N Ser-195
N
Gly-193
Oxyanion Hole
NH
O
O
Asp-102
O
O
N
N
H
His-57
P1
H O
H
NH2
O
P1´
OSer-195
Asp-102
O
O
N
N
H
His-57
O
Ser-195
H
HO
NH
O
O
P1
Tetrahedral intermediate
Carboxy-terminus peptide
Acyl-enzyme
Amino-terminus peptide
(a) (b)
(d) (c)
 
Figure 1.2 - General catalytic mechanism of serine proteases.23, 24 
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1.3. CHYMOTRYPSIN SUPERFAMILY 
The chymotrypsin superfamily, which belongs to clan PA, is the largest group of 
serine proteases. Serine proteases of the chymotrypsin superfamily consist of two 
similar domains, each of which is an antiparallel -barrel structure and these enzymes 
are classified based on the nature of the P1 residue in the peptidic substrate.25 Subtle 
differences in primary sequence of these enzymes account for differences in substrate 
specificity. There are three major classes of chymotrypsin superfamily serine 
proteases: trypsin-like accepts positively charged side chains at P1, chymotrypsin-like 
accepts aromatic hydrophobic residues and elastase-like prefers small hydrophobic 
ones.4 Based on the combined knowledge of the active site topology, the catalytic 
mechanism, and regulation pathways, research groups worldwide undertook studies to 
design more selective inhibitors of these enzymes. In particular, human leukocyte 
elastase, a validated target for therapeutic intervention, as mentioned earlier, is the 
major target of this work. Human leukocyte elastase is a neutrophil serine protease of 
the chymotrypsin superfamily implicated in several inflammatory disorders. 
Therefore, a short description of neutrophil serine proteases and their role in health 
and disease will follow. 
1.4. NEUTROPHIL SERINE PROTEASES 
Neutrophils are leukocytes of the first line of defence against infection, presenting a 
potent antimicrobial arsenal for degradation of foreign materials. In particular, in their 
azurophil granules, neutrophils have many degradative enzymes, including three 
serine proteases: human leukocyte elastase, proteinase 3 and cathepsin G. These 
serine enzymes are synthesized as zymogens, but stored in the azurophil granules in 
the active form. Other serine proteases are also present in neutrophils26, but in 
granules different than the azurophil ones and will not be discussed here. In Table 1.3 
the main characteristics of these enzymes are listed.  
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1.4.1 Human Leukocyte Elastase (HLE) 
HLE is a glycoprotein containing 218 amino acid residues and four intramolecular 
disulfides bonds. There are at least four isoforms of HLE, differing in carbohydrate 
content.27 In the promyelocytic stage of granulocyte development, HLE is produced, 
post-translationally processed and stored.28 The S1 binding pocket of HLE is 
hydrophobic in nature, containing Val-190, Phe-192, Ala-213, Val-216, Phe-228 and 
a disulfide bond Cys-191-Cys-220. HLE prefers small hydrophobic residues at S1, 
such as valine, leucine, norvaline and isoleucine (Table 1.3).29 The preferred residue 
in S2 is proline. Nearly 67000 molecules of HLE are stored in each azurophil granule, 
at a mean concentration of 5.33 mM. The term elastase is partly a misnomer, as not 
only HLE degrades elastin, but also degrades almost all extracellular matrix and 
plasma proteins.30  
1.4.2 Proteinase 3 (PR3) 
PR3 is a glycoprotein containing 222 amino acid residues which has three isoforms, 
differing in their carbohydrate. PR3 is not restricted to the azurophil granules (major 
source), since it is also present in secondary granules and at membrane of secretory 
vesicles of neutrophils. PR3 is an elastase-like serine protease, being highly 
homologous with HLE (57%)29. The S1 binding pocket of PR3 is hemispheric, 
hydrophobic, but smaller than that of HLE (Table 1.3), due to the replacement of both 
Val/Ile at position 190 and Ala/Asp at position 213.29 The Sn’ subsites are more polar 
than that of HLE. PR3 is involved in Wegener´s granulomatosis disease, a systemic 
autoimmune vasculitis characterized by circulating antineutrophil cytoplasmatic 
antibodies (ANCAs) that recognize PR3.31  
1.4.3 Cathepsin G (Cat G) 
Cathepsin G is a glycoprotein containing 235 amino acid residues and three disulfide 
bridges, presenting moderate homology with HLE (37%).29, 32 The S1 binding pocket 
is larger than that of HLE and PR3 (Table 1.3). Unlike HLE and PR3, Cat G 
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accommodates both basic and aromatic P1 residues (trypsin and chymotrypsin-like 
preference), due to the presence of a glutamate residue (Glu-226) at the bottom of the 
S1 subsite, and the absence of the Cys-191Cys-220 disulfide bond. Thus, Cat G may 
accept at S1 Phe, Tyr, Lys, Arg.29  
 
Table 1.3- Main characteristics of human leukocyte elastase (HLE), proteinase 3 (PR3) and 
cathepsin G (Cat G)29 
 
 
1.4.4 Physiological Functions 
In response to infection, neutrophils migrate from blood to the tissue and engulf 
pathogens. Upon such inflammatory stimuli, neutrophil serine proteases are released 
from their granules and act intracellularly within phagolysomes to destroy pathogens, 
via combination of reactive oxygen species and antimicrobial peptides.33 These 
enzymes are also released to the extracellular medium, where they can inactivate 
microorganisms34, facilitate neutrophil migration through tissue, degrade extracellular 
matrix proteins (elastin, collagen, fibronectin and proteoglycans) or remodel damage 
tissue.35 It appears that elastase is the most efficient neutrophil serine protease in the 
turnover of these proteins, presenting a broad range of substrates and a powerful 
 HLE PR3 Cat G 
EC number EC.3.4.21.37 EC.3.4.21.76 EC.3.4.21.20 
Gene, locus ELA2, 19p13.3 PRTN3, 19p13.3 CTSG, 14q11.2 
MW (kDa) 29-33 29-32 28.5 
Residues 218 222 235 
Substrate P1  Small hydrophobic 
Val, Leu, Met, Ile, Ala, 
norVal 
Small hydrophobic 
Val, Leu, Ala 
Aromatic or positively 
charged: Phe, Tyr, Lys, 
Arg 
Source Neutrophil (major) 
Monocyte 
Mastocyte 
Eosinophil 
Neutrophil (major) 
Monocyte 
Basophil 
Mastocyte 
Neutrophil (major) 
Monocyte 
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proteolytic activity.36 Elastase can also activate several matrix metalloproteases 
(MMP-2, -3, -9), playing an important role in tissue repair.37 
Recently, it has become clear that neutrophil serine proteases also play an important 
role in modulation of the inflammatory response.38 These enzymes are mediators and 
secretagogues in inflammation, due to proteolysis of chemokines (chemoattractant 
proteins that play an important role in recruiting leukocytes to the sites of 
inflammation), and growth factors; activation/inactivation of cytokines, such as 
interleukin 1 (IL-1) and tumor necrosis factor- (TNF-), and activation of specific 
cell surface receptors.29, 33, 38, 39 Furthermore, it was suggested that these enzymes can 
induce cellular apoptosis at the sites of inflammation, due to a caspase-like activity.33  
Under physiological conditions, tissues are protected from excessive proteolysis due 
to strict regulation through compartmentalization or natural inhibitiors.27 The most 
relevant natural inhibitor is 1-antitrypsin (also called 1-antiproteinase inhibitor), 
and belongs to serpins, a family of serine protease inhibitors.40 Other inhibitors of 
neutrophil serine proteases are 2-macroglobuline, secretory leukocyte proteinase 
inhibitor (SLPI) and elafin.31  
1.4.5 Roles in Human Disease 
Unregulated extracellular activities of these enzymes are implicated in the aetiology 
and development of a variety of diseases associated with a massive influx of 
neutrophils. In particular, excessive proteolysis of elastin (an essential component of 
lung connective tissue, arteries, skin and ligaments), and other structural proteins 
cause tissue damage implicated in inflammatory diseases, such as 
glomerulonephritis41, 42, atherosclerosis43, arthritis44 and mostly respiratory diseases, 
including chronic obstructive pulmonary disease (COPD),45, 46 acute respiratory 
distress syndrome28, 47 and cystic fibrosis.30, 48 A brief description of COPD and the 
pathophysiologic role of neutrophil serine proteases will follow. 
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1.4.5.1 Chronic Obstructive Pulmonary Disease 
CODP is the fourth leading cause of death in the world49, 50 and is predicted to 
become the third by 2020.51 COPD is an inflammatory disorder characterized by a 
slowly, progressive development of airflow limitation that is not fully reversible.50 
One type of COPD is pulmonary emphysema, which involves an enlargement of 
airspaces and destruction of the lung parenchyma, with loss of lung elasticity.46  
Cigarette smoking is the most common cause of COPD (more than 95%). The 
mechanism of development and progression of the disease involves the interplay of 
multiple processes, including a protease-antiprotease imbalance, which leads to 
excessive proteolytic activity, inflammation, oxidative stress, matrix remodelling and 
straining mechanical forces.52, 53 As no currently available treatment halt the 
progression of the disease,54 the research for new drugs has considerable interest. 
1.4.5.2 The Protease-Antiprotease Hypothesis and the Relevance of HLE 
This hypothesis considers the imbalance of protease-antiprotease as a major 
pathogenic contributor of tissue destruction in inflammatory diseases55 as COPD, and 
it results from some experimental findings.  
- It is known that the genetic deficiency in 1-antitrypsin, the major natural inhibitor 
of HLE, is responsible for the early onset of pulmonary emphysema.56 This situation 
is especially notable for individuals with exposure to cigarette smoking.40 1-
Antitrypsin is produced in the liver and circulates from there to the lung where it 
provides the major anti-HLE protection in the lower respiratory tract.  
- On the other hand, in normal individuals, 1-antitrypsin can be inactivated by 
oxygen radicals, released by neutrophils under circumstances of overwhelming 
stimuli.  
- Furthermore, cigarette smoking may cause a protease-antiprotease imbalance in the 
lung of normal individuals, not only by oxidative inactivation of 1-antitrypsin, but 
also because it promotes the increase of the number of neutrophils in the pulmonary 
parenchyma, with release of proteolytic enzymes.40, 57 Thus, it leaves the activity of 
proteases unchecked for excessive proteolysis, especially elastolysis, leading to 
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emphysema. The acquired functional deficiency of 1-antitrypsin is transient. In fact, 
cessation of cigarette smoking is the only therapeutic intervention capable to reduce 
progression of diseases as COPD.58, 59  
- It was demonstrated that intra-tracheal injection of HLE in animals induces 
emphysema, supporting the protease-antiprotease hypothesis.60 In addition, a 
correlation between the severity of emphysema and proteolytic burden was found.45 
Within neutrophil serine proteases, HLE is likely to play the major role in devastating 
the extracellular matrix, not only because it has a powerful proteolytic activity,61 but 
also because activates other proteases and upregulates inflammation.37 In addition, 
HLE has the ability to cleave lung surfactant,62 to inhibit ciliarly motility and to 
induce airway submucosal gland mucus secretion,48 with consequent implications in 
aggravating disorders, such as emphysema, cystic fibrosis and bronchitis. Indeed, 
millimolar concentrations of HLE released from azurophil granules of activated 
neutrophils lead to evanescent quantum bursts of proteolysis. When the fine balance 
between HLE and its endogenous inhibitors is disturbed, the deleterious effect of HLE 
is responsible of tissue injury. 
Thus, an attractive therapeutic strategy for treatment of COPD and other 
inflammatory disorders is restoring the balance protease-antiprotease.59, 63  Therefore, 
intensive efforts have been made in the discovery of inhibitors of neutrophil serine 
proteases, in particular, HLE inhibitors.6, 9, 25, 64  
1.5. SYNTHETIC INHIBITORS OF HUMAN LEUKOCYTE ELASTASE  
Strategies to re-establish the balance protease-antiprotease include: 
- the use of external supplement of naturally-occurring/recombinant proteic 
inhibitors (1-antitrypsin, secretory leukocyte proteinase inhibitor, elafin)  
- the use of low molecular weight synthetic inhibitors of HLE. 
The first strategy has some disadvantages, in particular: risk of immunological 
response, low serum half-life, high cost-effectiveness ratio (involving maintenance of 
plasmatic levels of purified protein, typically by i.v. administration) and the need of 
1. Introduction 
 
 
 
13
an alternative drug delivery system as aerosolization. The inhaled mode of delivery 
may complicate the determination of dose responsiveness and clinical efficacy.63, 65  
In contrast, low molecular weight synthetic inhibitors are promising therapeutic 
agents for inflammatory diseases, as a result of a potential greater oral absorption with 
potential oral activity, decreased risk of immunological reactions and a less expensive 
therapy, in particular for long-term use as required for chronic diseases, such as 
COPD. 
A general approach to design synthetic inhibitors of serine proteases involves 
somehow trapping the nucleophilic serine residue. Therefore, a relatively stable 
enzyme-inhibitor adduct is formed, taking advantages of binding interactions with the 
catalytic machinery. X-ray crystal structural data for neutrophil serine proteases are 
available in the PDB databank and in particular for HLE.66 A number of therapeutic 
strategies involve peptide and non-peptide inhibitors, with reversible and irreversible 
mechanism of action. The most important classes of enzyme inhibitors in drug design 
are the transition state analogues, the affinity labels, the acylating agents (alternate 
substrate inhibitors) and the mechanism-based inhibitors. 
1.5.1 Transition State Analogue Inhibitors 
This class of inhibitors were designed keeping in mind the ability of the enzyme to 
stabilize the transition state. They react with the enzyme to form stable tight-binding 
tetrahedral transition state-like complexes, through non-covalent binding interactions 
with the subsites of the enzyme and a covalent bond to Ser-195. No acyl-enzyme 
complex is released, due to the absence of a leaving group.21 Kinetically, transition 
state analogues behave as slow tight-binding inhibitors. In principle, slow tight-
binding inhibitors have clinical advantages over rapidly reversible inhibitors. In fact, 
the high affinity for their target, and an extended residence time on the enzyme, due to 
a long dissociation half-life, allow minimizing the drug dose and its intervals, with a 
much longer duration of action, less side effects, improving clinical efficacy.21 
Peptidic aldehydes were the first transition state analogue inhibitors of HLE. They 
were designed retaining a recognition sequence of the peptidic substrate, and 
terminating it in an aldehyde function (Figure 1.3, X = H), which acts as a serine trap.  
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Figure 1.3 - Design of a peptidic transition state analogue inhibitor of HLE from a peptidic 
substrate.64 
 
By reaction with the enzyme, these inhibitors lead to a hemiacetal enzyme-inhibitor 
complex. However, aldehydes are easily oxidized to the corresponding carboxylic 
acids, prone to racemization or may also inhibit cystein proteases,23 leading to toxicity 
and poor bioavailability. To avoid these problems, other types of serine trap were 
developed such as peptidyl ketones. 
Electron-withdrawing substituents were used to increase the electrophilicity of the 
carbonyl carbon of the ketone, for activation towards nucleophilic attack by Ser-195. 
The ketone-activating group also stabilizes the charged hemiketal of the enzyme-
inhibitor adduct. Some examples of highly electrophilic ketones are peptidyl -
trifluoromethyl ketones (Figure 1.3, X = CF3), -ketoesters (X = COOR), -
ketoamides (X = CONHR)64 and -ketoheterocycles, as -ketobenzoxazoles.67  
To overcome unsuitable pharmacokinetic properties of most peptidic compounds, a 
more challenging goal consists on designing non-peptidic inhibitors. A rational 
approach involves retaining the serine trap, and exploiting multiple non-covalent 
binding interactions at the active site of the enzyme, in order to increase the adduct 
stability and improve the inhibitory potency.  
For example, pyridone trifluoromethyl ketones are potent non-peptidic inhibitors of 
HLE. They were designed from peptidic substrate structures, by use of computer 
modelling, X-ray crystallography and structure activity relationship (SAR) studies. 
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Besides the covalent bond formed between the electrophilic carbonyl carbon and Ser-
195, many non-covalent binding interactions are established (Figure 1.4):  
-  the oxyanion is stabilized in the oxyanion hole (hydrogen bonds) 
- the iso-propyl group of the inhibitor lies in the S1 binding pocket (hydrophobic 
interactions); 
- the phenyl substituent on the 6-position lies in the S2 subsite (hydrophobic 
interactions); 
- the 3-amino and the carbonyl groups of the pyridone ring form antiparallel hydrogen 
bonding with Val-216 of the enzyme.  
These favorable binding interactions stabilized the final enzyme-inhibitor complex. 
This model of binding was supported by X-ray crystallography studies of a hemiketal 
adduct, obtained from a pyridone trifluoromethyl ketone and a closely related 
enzyme, porcine pancreatic elastase, (PPE).68  
 
 
 
 
 
 
 
 
 
 
Figure 1.4 - Scheme of binding mode of pyridone-containing trifluoromethyl ketones to HLE.68 
 
 
Some potent orally active pyridone trifluoromethyl ketone derivatives were 
developed, by an appropriate substitution on the amino group of the pyridone ring 
(ex.: R = SO2CH2Ph, Figure 1.4). 
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Another approach was the development of non-peptidic orally active inhibitors 
containing an -keto-1,3,4-oxadiazole moiety as serine trap, such as ONO-6818, 6. 
ONO-6818 binds to HLE in a similar mode to that of pyridone-containing 
trifluoromethyl ketones. In addition, the oxadiazole ring allows hydrogen bonding 
with the imidazol group of His-57, contributing to the stabilization of the hemiketal 
adduct.69 ONO-6818 was in Phase II Clinical Trials for treatment of COPD, but it was 
discontinued (2002) due to hepatic toxicity.70  
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In fact, because of the reactive electrophilic function present in these inhibitors, they 
may lead to toxic side effects. On the other hand, due to the reversible nature of the 
established bonds, the enzyme may recover its activity. Thus, irreversible 
inactivactors of HLE, presenting a leaving group which departure may release an 
acyl-enzyme complex, have emerged as an alternative strategy in drug design. 
1.5.2 Affinity Labels  
An affinity label is an active site-directed irreversible inhibitor containing a 
chemically reactive functionality (electrophilic) that modifies covalently a nucleophile 
at the active site. Once the inhibitor is reversibly bound to the enzyme, it reacts with 
the enzyme by acylation or alkylation (SN2) mechanisms. 
The first affinity labels irreversible inhibitors of HLE were derivatives of peptidyl 
chloromethyl ketones, 7 (Figure 1.5)25. They were designed from the structure of the 
peptidic substrate, retaining the recognition sequence attached to a serine trap. By 
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contrast to transition state analogues, in this case, the serine trap is a -chloromethyl 
ketone moiety (Figure 1.3, X = CH2Cl), presenting a chloride leaving group. These 
compounds function as alkylating agents of the active site histidine residue, 
accordingly to the mechanism depicted in Figure 1.5.  
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Figure 1.5 - Proposed mechanism of inhibition of serine proteases by peptidyl chloromethyl 
ketones.25  
 
However, they are chemically reactive towards other serine or cystein proteases, or 
also bionucleophiles such as glutathione, leading to loss of selectivity and toxic 
effects.23 Thus, the lack of target enzyme specificity is a critical liability for these 
agents as drug candidates. Furthermore, because highly reactive compounds 
exacerbate the formation of irreversible protein-drug conjugates, the risk of 
idiosyncratic immunological reactions in the turnover of those conjugates is another 
problem for clinical safety of affinity labels. All these aspects make this class of 
inhibitors less attractive for therapeutics.21 
1.5.3 Acylating Agents (Alternate Substrate Inhibitors) 
An acylating agent, also known as alternate substrate inhibitor, reacts with the enzyme 
to form a stable acyl-enzyme covalent complex that suspended the enzyme activity at 
a point within the catalytic process (Scheme 1.1). The acyl-enzyme complex [E-I] 
undergoes very slow deacylation (hydrolysis k2), leading in practical terms, to an 
irreversible inhibition.71 The acylation rate, kon is equivalent to k1, and the off rate, 
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koff, is given by the sum of all pathways of breakdown of the acyl-enzyme complex 
[E-I], koff= k-1+ k2. The steady-state dissociation constant of the enzyme-inhibitor 
complex is given by Ki = koff/kon. 
 
E I E - I
k1
E + X
k-1
k2
H2O  
Scheme 1.1 - General kinetic scheme for an alternate substrate inhibitor.71 
 
The stability of [E-I] is dependent on electronic and steric effects, in order to increase 
the acylation rate and decrease the deacylation rate.72 The mechanism of "acylation-
deacylation” of alternate substrate inhibitors is important for their safety profile 
relative to completely irreversible inhibitors.  
Many acylating agent of HLE were already developed, using different templates, such 
as the pivaloyloxybenzene derivatives73, which include the unique commercially 
marketed inhibitor of HLE, sivelestat, 3 (mentioned earlier),74 launched in Japan as an 
injectable formulation. Sivelestat is a potent inhibitor of HLE (IC50 0.044 M), and 
suppresses lung damage induced in hamsters by elastase administered intratracheally 
(ID50 82 g/Kg).75 This inhibitor works via acylation of the catalytic serine residue by 
its pivaloyl group. 
Other acylating agents scaffolds include 2-amino-4H-3,1-benzoxazin-4-ones 8 (Figure 
1.6).76 The reaction of HLE with 8 leads to the formation of an acyl-enzyme complex 
9, due to Ser-195 nucleophilic attack at the C-4 carbonyl carbon and ring opening. 
The deacylation of 9 occurs by two ways, being the intramolecular cyclization (k2) a 
rapid process. It is of interest to obstruct deacylation pathways koff , koff = k-1 + k2 + k3 
(Figure 1.6), in order to increase the lifetime of 9 and improve the inhibitory potency.  
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Figure 1.6 - Formation of an acyl-enzyme complex between 2-amino-4H-3,1-benzoxazin-4-ones 
and HLE and deacylation pathways to regenerate free enzyme.77  
 
 
The impact of R and R5 substituents on the HLE inhibition by benzoxazinones is 
presented in Table 1.4.77  
 
Table 1.4 - HLE inhibition by 8. Impact of R and R5 substituents on Ki, k1 e koff.77 
 
R R5 Ki, M k1, M
-1s-1 koff, s-1 
H H 63 810 0.051 
i-Pr H 0.052 59000 0.0030 
i-Pr Et 0.00094 70000 0.000066 
 
 
The incorporation of a bulky R substituent, such as R = i-Pr, depresses the cyclization 
rate of deacylation k2 (steric effect). On the other hand, substitution at ortho position 
to the carbonyl carbon, C-5, such as R5 = Et, shield the carbonyl carbon of 9 from 
nucleophilic attack. Furthermore, the combined substitution on R and R5 has a 
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synergistic effect in HLE inhibition, as 2-(isopropylamino)-5-ethylbenzoxazinone 
results in 86-fold increase in k1 and a 770-fold decrease in koff versus 8 (Figure 1.6, R 
= H, R5 = H).76, 77  
1.5.4 Mechanism-Based Irreversible Inhibitors 
Mechanism-based irreversible inhibitors are not inherently reactive, but they are 
transformed by reaction with the target enzyme to reactive inhibitory compounds, 
which inactivates the enzyme through the formation of stable enzyme-inhibitor 
complexes (suicide type inhibition). Because unmasking of the reactive functionality 
requires catalysis by the enzyme, these inhibitors are quite selective for their target. 
Enzyme inactivation involves a “double hit” mechanism, i.e, after the nucleophilic 
attack by serine residue, a reactive specie, capable of forming a second covalent bond 
to the active site, is formed only after the normal catalytic mechanism has taken 
place.78  
E I E . I E - I´
k2k1
k-1
E - I
k4
k3
E + P  
Scheme 1.2 - General kinetic scheme for a mechanism-based irreversible inhibitor.78 
 
Thus, the reactive acyl-enzyme [E-I] undergoes either further reaction with a second 
nucleophile of the active site (presumably with His-57), leading to permanent 
inactivation of the enzyme [E-I´], or undergoes deacylation, escaping from the active 
site to regenerate the free enzyme (k3) (Scheme 1.2). Therefore, for a persistent 
irreversible inhibition, the stoichiometry of inactivation must be less than 1:1 and 
must occur prior to release of the reactive specie from the active site.21 The ratio k3/k4 
is called partition ratio r, which means the number of turnovers that gives a released 
product per inactivation event, being indicative of the number of molecules of 
inhibitor necessary to inactivate a single molecule of enzyme. An ideal inhibitor has a 
partition rate r=0, thus the reactive intermediate does not escape to react with off-
target enzymes, being exclusively sequestered to form [E-I´]. 
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As the equilibrium k1/k-1 is set up rapidly and k4 is a fast step, the rate limiting step is 
given by k2, being the inactivation rate constant, kinact. The inactivation kinetics is 
saturable (the pseudo-first-order rate constant for enzyme inhibition, kobs is a 
rectangular hyperbolic function of [I]) and increasing substrate concentration protects 
against enzyme inhibition. These inhibitors display a slow tight-binding behaviour, 
with a time-dependent inhibition. Thus, besides target selectivity, mechanism-based 
inhibitors explore the same potential advantages described above for tight binding 
inhibitors, but requiring fewer doses. Therefore, they are very attractive in drug 
design.21, 78 
The design of HLE mechanism-based inhibitors requires a suitable template 
presenting not only elements for molecular recognition but also intrinsic reactivity on 
the carbonyl carbon. Several heterocyclic templates are used in this purpose, such as 
isocoumarins 10,79, 80 succinimides 11,81 hydantoins 12,82 phthalimides 13,83 
saccharins 14,84 1,2,5-thiadiazolidin-3-one 1,1 dioxides 15,85-87 and -lactams.88, 89  
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1.6. -LACTAMS INHIBITORS OF HLE 
-Lactams are widely used in clinic due to antibiotic properties, including well-known 
penicillins 16 and cephalosporins 17. These agents inhibit bacteria cell wall synthesis 
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via inactivation of transpeptidases, such as penicillin binding proteins (PBPs). These 
bacterial enzymes are related with serine proteases because they have a catalytic 
serine residue at the active site. Inhibition of transpeptidases by -lactam antibiotics 
involves the formation of a stable covalent enzyme-inhibitor complex with acylation 
of the catalytic serine residue. Other -lactams largely used in clinic, such as 18 (R = 
H, clavulanic acid), are well-known inhibitors of bacterial Class A and Class C -
lactamases.20 
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The first study that demonstrated that -lactams derivatives are inhibitors of HLE was 
developed by Merck Research Laboratories, in 1986: benzyl clavulanate, 18 
(R=CH2Ph) was found to be an inhibitor of HLE. It was the first time that -lactams 
compounds were used in a different purpose than the antibiotic therapy. Since than, 
there has been a growing interest in studying these compounds as inhibitors of serine 
proteases, and in particular, HLE inhibitors. Other serine enzymes inhibited by -
lactam derivatives include Cytomegalovirus protease, prostate specific antigen, 
thrombin, co-enzyme A independent transacylase, -amino-butyric acid (GABA) 
aminotransferase and phospholipase A2.20  
Within the -lactam derivatives developed as inhibitors of HLE, cephalosporins 
(byciclic structures) and azetidin-2-ones (monocyclic--lactam) 19 are the most 
important inhibitors.   
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1.6.1 Cephalosporins Derivatives 
The Merck pioneered study discovered that the cephalosporin nucleus, 17, after 
appropriate structural adjustments, can selectively inhibit HLE.88 One requirement to 
develop irreversible inhibitors of HLE is C-4 carboxyl acid esterification or 
amidation. Free acids are inactive towards HLE (this enzyme is an endopeptidase 
while transpeptidases are carboxypeptidases).  
In addition, other structural elements improve inhibitory potency, such as: 
- the incorporation of a -substituent at C-7, such as 7-methoxy, allowing 
interaction with the enzyme´s small S1 binding pocket. A 7-chloro moiety also 
increases the intrinsic chemical reactivity of the -lactam.  
- the oxidation of the sulfur atom into a sulfone (cephalosporin 1,1-dioxide), 
enhancing chemical reactivity and hydrogen bonding opportunities.  
- electron-withdrawings substituents on the leaving group in C-3 '.  
An example of a cephalosporin inhibitor of HLE is compound 20 (Figure 1.7),  which 
is a mechanism-based irreversible inhibitor of elastase, as revealed by X-ray 
crystallography studies.90 Inhibition occurs as a result of the nucleophilic attack of 
Ser-195 on the -lactam carbonyl carbon, with formation of a tetrahedral intermediate 
(TI), which collapses with -lactam ring opening by N5-C8 bond fission.  
The resulting acyl-enzyme intermediate may hydrolyze or react further, with 
expulsion of the acetate from C3´, loss of HCl, generating a -unsaturated reactive 
imine, trapped by His-57 in a Michael addition. Thus, a stable adduct is formed, with 
two covalent bonds at the active site of the enzyme: acylation of Ser-195 and 
alkylation of  His-57, in “double-hit” mechanism (Figure 1.7).90  
For 7-methoxy derivatives, the reaction with HLE also involves a “double-hit” 
mechanism, but this group is not lost throughout catalysis.91  
Although being potent inhibitors of HLE, cephalosporin derivatives suffer some 
drawbacks for therapeutic use, such as poor oral bioavailability and low chemical 
stability in plasma.92 Thus, these derivatives were not useful for systemic 
administration.  
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Figure 1.7 - Proposed “double-hit” mechanism of HLE inactivation by cephalosporin 
derivatives.90 
 
 
The best compromise between stability and activity 
of cephalosporin mechanism-based inhibitors was 
found with compound 21 (L-658,758), kinact = 0.007 
s-1, Ki =1.7 M, giving a second-order rate constant 
for HLE inhibition, kinact/Ki = 4.1x103 M-1s-1. This 
inhibitor was developed by Merck Research 
Laboratories and selected for clinical studies in a 
aerosol delivery system.93  
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1.6.2 Monocyclic -Lactams Derivatives 
These compounds emerged in order to optimize pharmacokinetic properties limited in 
bicyclic derivatives (especially the need of oral bioavailability) to achieve 
systemically useful inhibitors of HLE. Such optimization results of an advantageous 
balance between stability, inhibitory potency and selectivity. Merck researchers 
anticipated that monocyclic -lactams (azetidine-2-ones), containing structural 
requirements for both molecular recognition and chemical reactivity, were able to 
ensure the “double-hit” mechanism for HLE inactivation, seen in bicyclic structures.94 
The initial lead structure for design of monocyclic -lactam inhibitors of HLE was 22.  
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By SAR studies, the lead structure 23 was found, in which R1 and R2 are small alkyl 
substituents and LG is a leaving group, such as an acetoxy moiety. The mechanism of 
HLE inhibition by 23 is shown in Figure 1.8. The nucleophilic serine residue attacks 
on -lactam carbonyl carbon, C-2, which leads to the ring opening (C-2 and N-1 bond 
fission), and can result in expulsion of the leaving group at C-4. Consequently, a 
reactive imine is formed (N-1 and C-4), which can be trapped by the active site 
histidine in a Michael addition (“double-hit” mechanism). 
However, an alternative mechanism may occur, with nucleophilic attack of a water 
molecule instead of His-57 to the reactive imine, to form a carbinolamine. In fact, the 
formation of the carbinolamine was demonstrated using ESI-MS and two-dimensional 
NMR techniques. Mass spectrum data indicates an increase of 18 mass units in the 
acyl-enzyme complex generated after expulsion of the leaving group. That increment 
can be explained by addition of water.95 
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Figure 1.8 - Proposed mechanism of inhibition of HLE by monocyclic -lactams with a leaving 
group LG at C-4.95  
 
Indeed, the carbinolamine is a stable acyl-enzyme complex, in which the hydroxyl 
group can be stabilized by hydrogen bonding with the active site histidine residue. 
Thus, the “double-hit” mechanism of inhibition suffers the competition of addition of 
water (Figure 1.8).95 
 
Nevertheless, it was suggested that the 
substituent at C-4 is not essential to achieve an 
irreversible inhibition. In fact, compound 24, 
which lacks a leaving group at C-4, shows a fast 
inactivation and low reactivation rates of HLE, 
yielding a stable acyl-enzyme complex (at least 
as stable as that derived from inhibitors 
presenting a good leaving group).96 However, 
opening of the -lactam ring of 24 cannot generate an electrophilic imine. It was 
demonstrated by mass spectroscopy that the enzyme-inhibitor complex derived from 
24 was consistent with the mass of the entire inhibitor.95 These observations suggest 
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that a simple -lactam, without leaving group at C-4, may react in complex hydrolytic 
pathways to protect the acyl-enzyme from hydrolysis. Thus, the stability of the acyl-
enzyme is independent of the nature of the C-4 leaving group.96 Furthermore, these 
data suggest that the formation of stable complexes between the HLE and -lactam 
inhibitors does not necessarily require the “double-hit” mechanism.95  
Several SAR studies were conducted in order to optimize the inhibitory potency and 
stability of monocyclic -lactam inhibitors of HLE. 
 
Effect of the Substituents at C-3. It was found that small hydrophobic substituents at 
C-3as 23, R2 = ethyl group, can interact with the hydrophobic S1 pocket of HLE. 
Thus, this group was selected for C-3 position. In addition, the incorporation of a C-
3 group larger than methyl not only increases hydrolytic stability, by preventing the 
attack on the carbonyl carbon by nonspecific nucleophiles, but also improves 
inhibitory potency. This C-3 group does not impair inhibition, since the hydroxyl 
group of Ser-195 attacks the -face of the -lactam ring.97, 98 Retaining the 3-ethyl 
group, the 3-ethyl and 3-n-propyl derivatives showed improved both stability and 
in vivo activity. Although 3-n-butyl analogue showed to be more potent than 3-
ethyl in vitro, there was a loss of activity in vivo, probably related with an increased 
protein-binding of the more lipophilic derivative. Thus, the diethyl substituent was 
chosen at C-3.97  
 
Effect of the Substituents at C-4. The C-4 acetoxy group is unstable to nucleophiles. 
Studies performed in order to evaluate the effect of C-4 substituents in 23 revealed 
that these substituents are important to achieve oral activity. Incorporating an 
appropriate substituted phenol in this position retains inhibitory activity and improves 
aqueous solubility. These effects are remarkable for carboxylic acid derivatives, such 
as 4-hydroxybenzoic acid and 4-hydroxyphenylacetic acid ethers.99  
A substituent with S configuration at C-4 increases the inhibitory potency compared 
to the configuration R, which may be explained by interaction of the S-aryl carboxylic 
acid ether with the enzyme subsites S2 - S3. In contrast, the R configuration does not 
allow this interaction.97 Conversely to what one might expect the nature of the leaving 
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group is not a crucial factor to influence the rate of acylation. In fact, there is a weak 
correlation between enzyme inhibition and the ability of the leaving group, expressed 
by the pKa of the substituted phenol.99  
 
Effect of the Substituents at N-1. Many SAR studies were performed in order to 
optimize the substituent at N-1.98, 100, 101 The N-acetyl group of the lead structure 22 is 
labile and prompted the search for more stable substituents. It was found that the N-
carbamoyl substituent (giving a urea moiety, as in 23) improves the hydrolytic 
stability of monocyclic -lactams, as this group is less electron-withdrawing than an 
acyl substituent. Derivatives incorporating a benzylurea substituent, 25, were the first 
orally active -lactams inhibitors of HLE.98 Using 25 as lead structure, several SAR 
studies were performed in order to select the substituent on the urea moiety, to 
achieve potent inhibitors both in vitro and in vivo. In vivo studies involve 
measurement of the percentage of inhibition of HLE-induced lung hemorrhage in 
animals, with -lactams inhibitors administrated orally prior of lung hemorrhage 
induction.102  
 
 
Compound 26, which contains a four-carbon link between the nitrogen atom and the 
aromatic ring, is a better in vitro inhibitor of HLE than 25. However, in vivo activity 
diminishes due to an increase in hydrophobicity.98  
In contrast, it was found that the incorporation of an alkyl substituent on the 
benzylurea methylene group, with an R configuration in this position, allows 
interaction with a hydrophobic pocket of the enzyme, improving inhibitory potency. 
Thus, Merck Research Laboratories developed potent, selective orally active 
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inhibitors of HLE, such as compound 27, L-680,833, which second-order rate 
constant for enzyme inhibition is kinact/Ki = 6.22 x 105 M-1s-1.103  
By ESI-MS and NMR spectroscopic studies, it was demonstrated that the mechanism 
of HLE inhibition by 27 involves a carbinolamine as a stable acyl-enzyme complex.95  
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Oral bioavailability studies of 27 were performed in rodents and Rhesus monkeys, 
with effective inhibition of HLE-mediated lung injury. In addition, an excellent 
specificity against HLE was demonstrated, not only in studies performed with 
monkey, rat, dog and human elastases, but also in experiments with other serine 
proteases.104 These results suggest that low-molecular-weigh synthetic inhibitors of 
HLE such as monocyclic -lactam 27 have promising therapeutic value.  
Indeed, the analogue -lactam 28, also developed by Merck, is one of the most potent 
derivatives ever reported, with a second-order rate constant of enzyme inhibition of 
1.25 x 107 M-1s-1.105 In addition, it was reported that compound 29, DMP-777, 
presenting a kon value of 3.78 x 106 M-1s-1,106  was in Phase II clinical trials for cystic 
fibrosis, juvenile rheumatoid arthritis and emphysema.6  
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1.6.2.1 Monocyclic -Lactams with the Leaving Group on a Different Position 
than C-4 
A different strategy to design monocyclic -lactam as potential mechanism-based 
irreversible inhibitors of HLE is to incorporate the leaving group on C-1´ instead of 
C-4. Thus, after acylation of the catalytic serine residue, and departure of the leaving 
group, a reactive imine is formed, serving as electrophile for a second nucleophile of 
the active site.94 Examples of time-dependent irreversible inhibitors of HLE with the 
leaving group on C-1´ are the N-acyloxymethyl- and N-aminocarbonyloxymethyl 
azetidin-2-ones, 30 (Figure 1.9), previously developed at the host laboratory.107 The 
leaving group on C-1´ is a carboxylic or a carbamic acid. X is an electron-
withdrawing group, such as a phenylsulfone moiety, that increases the acylating 
power of the -lactam by reducing the pKa of the amine leaving group by ring 
opening (C-N fission). The diethyl substituent at C-3 interacts with the S1 pocket of 
HLE. The proposed mechanism of HLE inhibition is shown in Figure 1.9.  
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Figure 1.9 - Potential suicide-type mechanism of HLE inhibition by N-acyloxymethylazetidin-2-
ones.107  
 
Docking studies suggests that enzyme inhibition involves departure of the leaving 
group on C-1´ rather than at C-4. The oxidation state of the sulfur atom in the C-4 
substituent plays an important role in inhibitory potency, as phenylsulfones were 
found to be more potent inhibitors than the correspondent sulfides.107 This result is in 
conformity with the higher HLE inhibitory activity presented by cephalosporins 
sulfones compared to the correspondent sulfides.88  
 
Similarly, N--heterofunctionalized compounds, as 31, were 
reported as irreversible inhibitors of HLE, in which LG is a 
leaving group. X can be an electron-withdrawing substituent, 
such as a phenylsulfone moiety.108, 109 The electron-
withdrawing ethoxycarbonyl group activates the intermediate 
imine generated after ring opening, allowing a potential 
31
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suicide type inhibition pathway. A diethyl substituent at C-3 (R = R´= Et) interacts 
with the S1 binding pocket of HLE.109  
 
Monocyclic -lactam inhibitors of HLE with a leaving group in a different position 
are the functionalized N-aryl azetidin-2-ones, such as 32, 110 reported as being 
potential mechanism-based inhibitors of HLE.111, 112 The susceptibility to release a 
latent quinoniminium methide function with the formation of the acyl-enzyme allows 
the suicide type inhibition (Figure 1.10). 
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Figure 1.10 - Postulated suicide-type mechanism of HLE inhibition by functionalized N-aryl 
azetidin-2-ones.111  
 
The presence of a gem-dihalogeno group at C-3 reduces the pKa of the aniline leaving 
group (inductive effect) and activates the carbonyl carbon towards nucleophilic 
attack. It was found that compounds displaying the functionalized methylene group in 
the ortho position, as in 32, were more potent inhibitors than the para-analogues. 
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1.6.2.2 Monocyclic -Lactam Analogues Acylating Agents of HLE 
As the “double-hit” mechanism is not necessary to achieve a persistent inhibition (as 
mentioned earlier), it has highlighted different strategies to design monocyclic -
lactam derivatives as acylating agents of HLE.  
An example is the symmetric 1,3-diazetidine-2,4-dione, 33 (Figure 1.11), which is a 
functionalized -lactam used as a peptidomimetic template.113 On both nitrogen atoms 
of the heterocycle are incorporated small alkyl substituents. One of the P1 substituent 
interacts with the S1 pocket of HLE (ex.: P1 = Et), being involved in molecular 
recognition. After nucleophilic attack of Ser-195 at one of the carbonyl carbons, an 
acyl-enzyme complex is generated by ring opening (C-N fission), as illustrated in 
Figure 1.11. By changing the nature of the P1 substituent, one can modulate the 
selectivity towards other serine proteases. Interestingly, the correspondent azetidin-2-
one analogue of 33 (lacking one nitrogen and one carbonyl group), i.e., a typical -
lactam, showed no inhibitory activity. These results suggest that 1,3-diazetidine-2,4-
dione nucleus is much more reactive than the correspondent azetidin-2-one, and 
activates the carbonyl carbon through electronic effects and bond angle strain.113  
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Figure 1.11 - Inhibition of HLE by 1,3-diazetidine-2,4-diones.113 
 
A different strategy involved the design of 4-alkyliden--lactams, such as 34, 
containing a double carbon-carbon bond on the C-4 position, in order to activate the 
carbonyl carbon towards nucleophilic attack. These compounds, in which OTBS is a 
tert-butyldimethylsilyloxy group, were reported as being potent inhibitors of HLE. It 
was reported that the IC50 for 34 (IC50= 4 M) was better than that for the reference 
azetidin-2-one L-680,833 (27, IC50= 9 M).114  
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By contrast, the correspondent C-4 saturated analogue 
of 34 was found to be a weak inhibitor of HLE (20% 
inhibition at 100 M versus 82% inhibition at 100 M 
for 34). These results reflect the activator effect of the 
presence of a C=C double bound on the acylating 
power of 4-alkyliden--lactams.114, 115  
 
Another approach to design -lactam analogues as acylating agents of elastase is to 
incorporate a sulfonyl group next to the nitrogen within the four-membered ring, 
giving a 3-oxo--sultam, 35. This compound is simultaneously a -sultam and a -
lactam, thus it has two electrophilic centers available for nucleophilic attack. 
Therefore, nucleophilic attack at 35 could involve either attack at the carbonyl group, 
ring opening by C-N bond fission and expulsion of the sulfonamide leaving group 
(acylating agent) or attack at the sulfonyl group, S-N bond fission and expulsion of an 
amide leaving group (sulfonalyting agent).116  
3-Oxo--sultam 35 was reported as being a time-dependent inhibitor of porcine 
pancreatic elastase, PPE (which is a model of HLE as discussed in section 1.7). PPE 
inhibition is a result of acylation of the catalytic serine residue, C-N bond fission and 
expulsion of a sulfonamide (Figure 1.12). The second-order rate constant for enzyme 
inhibition by 35 is 768 M−1s−1 at pH 6.116 However, alkaline hydrolysis of the 3-oxo-
-sultam takes place at the sulfonyl group with S-N fission (Figure 1.12), as 
demonstrated by NMR and ESI-MS techniques.117 This is a very rapid process, 
occurring with a second-order rate constant for alkaline hydrolysis, kOH-, of ca. 2 × 
105 M−1s−1.116 In fact, the 3-oxo--sultam is chemically extraordinarily reactive, and 
its kOH- value is nearly 106 times higher than those of most clinically useful -lactams 
(kOH- 10-1 – 1.0 M-1s-1).92 Highly reactive inhibitors may lead to off-target reactions, 
toxic effects, loss of selectivity and reduced bioavailability.72 Thus, one may conclude 
that the 3-oxo--sultam is not a suitable scaffold for studies towards therapeutic 
application. 
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Figure 1.12 - Nucleophilic attack at 3-oxo--sultam. PPE inhibition involves C-N fission while 
alkaline hydrolysis involves S-N fission.116  
 
1.7. PORCINE PANCREATIC ELASTASE 
Several elastase inhibition studies are performed using porcine pancreatic elastase, 
PPE, which is a serine protease readily available and economically more accessible 
than HLE. 
PPE (EC 3.4.21.36) is presented as a single chain peptide of 240 amino acid residues 
depending on the cation Ca2+ for its stabilization, and it has no carbohydrates as 
prosthetic group.  PPE is topologically close to HLE, with 40% homology, being the 
two enzymes particularly similar in their active site regions (catalytic triad and 
residues forming the central core of the binding site).27 X-Ray crystallography studies 
have contributed to the elucidation of their structures. PPE has the advantage that it 
crystallizes easily and numerous crystallographic studies of PPE in complexes with 
inhibitors are documented. In particular, this technique demonstrated that a 
cephalosporin inhibited PPE by a “double-hit mechanism”.90 On the other hand, X-ray 
crystallography studies are less documented for HLE, since the crystals of native or 
inhibitor-complexed enzyme are obtained with difficulty.27 
Both enzymes have similar substrate specificities, as a result of a similar geometry 
and hydrophobic nature of the S1 binding pocket. However, due to steric constraints, 
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this pocket is smaller in PPE, consistent with the preference for alanine by this 
enzyme. By contrast, HLE also accepts Val and Leu. In this context, it is important to 
stress that the chromogenic substrate used in vitro for HLE is N-methoxy-succinyl-L-
Ala-L-Ala-L-Pro-L-Val-p-nitroanilide, while for PPE is N-succinyl-L-Ala-L-Ala-L-
Ala-p-nitroanilide. These features emphasize that the design of irreversible inhibitors 
of HLE requires human sources of elastase. SAR studies of potent inhibitors for PPE 
do not necessarily lead to potent inhibitors against HLE.27  
1.8. DESIGN OF POTENTIAL IRREVERSIBLE INHIBITORS OF HLE 
As a summary of what has been discussed before, an irreversible enzyme inhibition 
involving a covalent modification may be achieved using monocyclic -lactams as an 
enzyme acylating agent. The acyl-enzyme must be stable in order to achieve an 
effective inhibition, thus the regeneration of the enzyme, by reaction with 
nucleophiles such as water, must be a very slow process.72  
The reaction of HLE with an acylating agent involves an acyl transfer process, which 
occurs in a stepwise process. First, it involves the nucleophilic attack of the catalytic 
serine residue at the carbonyl carbon to generate a four-coordinate tetrahedral 
intermediate. The tetrahedral intermediate breaks down back to the reactants or gives 
the product, with displacement of a leaving group (Figure 1.13). Therefore, the rate 
limiting step can be the formation (k-1, k2 > k1) or the breakdown (k-1, k1 > k2) of the 
tetrahedral intermediate. 
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Figure 1.13 - General acyl transfer process (Nu = nucleophile; LG = leaving group). 
 
The main requirements for an effective enzyme inhibition by an acylating agent are: 
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1. the rate of acylation must be faster than the rate of the turnover of the natural 
substrate; 
2. the inhibitor must be relatively stable under in vivo conditions. 
With regard to the rate of acylation, it depends on two important factors: 
i) the “chemical” reactivity of the inhibitor 
ii) the molecular recognition by the target enzyme.72  
The chemical reactivity is related with electronic effects, such as the electrophilic 
nature of the carbonyl group and the nucleofugacity (leaving group ability) of the 
group displaced. In addition, it involves steric and strain effects that influence the 
intrinsic chemical reactivity of the inhibitor.72, 118 Increasing the intrinsic chemical 
reactivity of an inhibitor may lead to a faster rate of reaction with the target enzyme.72 
On the other hand, extremely reactive scaffolds (ex. 35) may cause a decrease in 
selectivity, increasing hydrolytic instability and reactions with non-specific 
nucleophiles, with potential toxic effects. 
Molecular recognition allows a gain in the enzyme catalyzed reaction rate, since it 
involves using the enzymatic apparatus for favorable non-covalent interactions at the 
various subsites of the enzyme and inhibitor. Thus, the ideal inhibitor should have an 
optimal molecular recognition by hydrophobic and other non-covalent interactions 
with the enzyme, minimizing the enzyme inactivation by a covalent modification. 
Improving the inhibition properties of a compound may be achieved by: 
- modifying the chemical reactivity 
- the molecular recognition 
- or a combination of both.  
Structural modifications of the inhibitor in order to increase chemical reactivity can 
affect the ease of bond-making and breaking by electronic factors (such as inductive 
and resonance) and steric effects. However, the variation in rate constants for the 
various inhibitors reacting with the enzyme, which reflects the difference in energies 
between the initial reactant and the transition state, is affected not only by the 
chemical reactivity but also by favorable binding energies due to molecular 
recognition.72 
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1.8.1 The Second-Order Rate Constant for Alkaline Hydrolysis, kOH-, as an 
Important Tool in Drug Design 
It was suggested that the magnitude of the second-order rate constant for alkaline 
hydrolysis, kOH-, is a crude guide to determine the usefulness of a potential inhibitor 
as an enzyme acylating agent.72 It was suggested the use of the alkaline hydrolysis 
model as hydroxide mimics the reaction of the catalytic serine residue with the 
potential irreversible inhibitor. On the other hand, kOH- value is also useful since is 
indicative of the metabolic stability towards non-specific nucleophiles. In order to 
deduce the importance of the molecular interactions between the enzyme and the 
inhibitor on the enzyme-catalyzed hydrolysis, it is necessary to separate intrinsic 
chemical effects from specific binding interactions. Thus, the “enzyme rate 
enhancement factor”, EREF, which is given by the ratio of the second-order rate 
constant of the enzyme catalyzed reaction, kon, by kOH-,72, 119 is indicative of the ability 
of the enzyme to use its catalytic machinery to increase the rate of the reaction. 
Modifications in the structure of an enzyme acylating agent attempt to increase 
molecular recognition, as well as the rate of acylation of the target enzyme, without 
prejudice of aspects of hydrolytic stability. Similarly, substitutions in the structure can 
reduce the susceptibility towards non-specific hydrolysis, maintaining the acylating 
power.72 Thus, alkaline hydrolysis studies (and in particular kOH- value) are an 
important tool in drug design. 
1.9. AIM OF THE THESIS 
The main purpose of this thesis was to contribute to the research of -lactam-based 
irreversible inhibitors of serine proteases, in particular HLE inhibitors, as potential 
candidates for the treatment of several inflammatory disorders, such as COPD, adding 
a small piece in the puzzle of rational drug design, in the context of drug discovery.  
The rational underlying the inhibitor design is based on the following considerations: 
- The monocyclic -lactam scaffold has been successfully used to develop potent 
time-dependent acylating agents and mechanism-based inhibitors of HLE, some of 
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them presenting oral activity. Moving away from the well-known, simple and 
versatile -lactam core scaffold would be difficult and time-consuming. 
- It is known the preference for small alkyl substituents at C-3 on the -lactam 
template to allow hydrophobic interaction for molecular recognition at the S1 binding 
pocket of HLE. 
- Taking into account that increasing the intrinsic chemical reactivity of a compound 
may led to a faster rate of reaction with the target enzyme,72 it was reasoned that 
monocyclic -lactams, retaining elements for molecular recognition, and presenting 
electron-withdrawing groups that increase the intrinsic chemical reactivity, provide an 
interesting motif for development of irreversible inhibitors of HLE with an improved 
inhibitory potency. To achieve this goal, the present project was subdivided in two 
main tasks: i) the development of irreversible inhibitors of HLE based on azetidin-2-
ones presenting different substituents at C-4 and ii) the development of azetidine-2,4-
diones (4-oxo--lactams) as a new template for drug design. 
1.9.1 C-4 Substituted Azetidin-2-ones (Simple -Lactams) as Inhibitors of Serine 
Proteases 
This part of the present study was integrated in the stepwise methodological training 
of the doctoral program and involved synthesis, alkaline hydrolysis studies and serine 
proteases PPE and HLE inhibition studies (enzyme kinetics and in vitro inhibitory 
potency), following studies on N-carbamoylazetidin-2-ones started by Dr. Luísa 
Martins at the host laboratory.120 
The inhibitor design rational was based on previous work on -lactams as irreversible 
inhibitors of elastase. Merck Research Laboratories, as mentioned in Section 1.6., 
developed cephalosporins sulfones and N-carbamoylazetidin-2-ones, such as 27 
(which the structure is appropriately repeated in Figure 1.14), as potent HLE 
inhibitors. Since it is known that N-carbamoylazetidin-2-ones are much more stable in 
blood than bicyclic structures, they were chosen as a template for elastase inhibition 
studies. In order to modify the intrinsic chemical reactivity of the -lactam motif, 
different substituents at C-4 were chosen, including compounds presenting a sulfone 
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function, in analogy to the cephalosporin sulfone 36 (Figure 1.14); and also a phenoxy 
substituent, in analogy to 27. Since it is known that the gem-diethyl substituent at C-3 
of 27 interacts with the S1 binding pocket of the enzyme, this substituent was retained 
in the design of HLE inhibitors (Figure 1.14).  
Therefore, the aims of this study were to: 
- synthesize azetidin-2-ones with different substituents at C-4.  
- elucidate how the C-4 substituents contribute to the chemical reactivity towards 
hydroxide and to the enzymatic reactivity towards the catalytic serine residues of PPE 
and HLE, in a mechanistic study of hydrolysis. 
- to find out if there was any correlation between intrinsic chemical reactivity and 
serine proteases inhibition in C-4 substituted -lactams. (Chapter 2) (Papers I and II). 
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Figure 1.14 - Rational design of C-4 substituted N-carbamoylazetidin-2-ones. 
 
1.9.2 Azetidine-2,4-diones (4-Oxo--lactams) as Inhibitors of Serine Proteases   
In a second phase, the aim of this project was to develop azetidine-2,4-diones (4-oxo-
-lactams), as a novel class of irreversible inhibitors of serine proteases, with 
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improved activity when compared to known simple -lactam (azetidin-2-one) 
inhibitors.  
On the basis of the design rational, it was reasoned that incorporating a second sp2 
carbonyl carbon at C-4 within the four-membered ring, i.e., converting the azetidin-2-
one 39 into an azetidine-2,4-dione 40, increases the intrinsic chemical reactivity of the 
inhibitor, which may improve the inhibitory potency against elastase. Thus, as a result 
of i) an increased susceptibility of the carbonyl carbon towards nucleophilic attack, as 
well as ii) an enhanced nucleofugacity of the leaving group amide, facilitating the C-
N bond fission and ring opening, and also iii) a distortion on the -lactam ring with 
increased ring strain, the azetidine-2,4-dione may lead to a greater acylating power. 
On the other hand, the azetidine-2,4-diones 40 were designed as a result of an 
isosteric substitution on 3-oxo--sultam 41, replacing the sulfonyl group responsible 
for hydrolytic lability, by a carbonyl group, in order to improve hydrolytic stability 
and reduce off-target reactions by non-specific nucleophiles.  
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Firstly, the research interest was focused on a computer assisted drug-design, 
including N-carbamoylazetidine-2,4-diones, for comparison with the N-
carbamoylazetidin-2-ones with a leaving group at C-4. Due to problems related with 
synthesis, only N-aryl and N-alkyl azetidine-2,4-diones were prepared. Preliminary 
enzymatic studies were performed with PPE and the main goals were to compare the 
results for inhibitory activity with those obtained for alkaline hydrolysis of the same 
compounds, in order to provide information on the effectiveness of the 4-oxo--
lactam scaffold as a therapeutically useful acylating agent, on the sensitivity of the 
enzyme to the intrinsic chemical reactivity versus molecular recognition, and on the 
mechanism of hydrolysis (Chapter 3) (Paper III). 
1. Introduction 
 
 
 
42
In order to explore S and S´ subsites of HLE for molecular recognition, azetidine-2,4-
dione derivatives with different substituents on C-3 and N-1 were prepared, as both 
acylating agents and potential mechanism-based inhibitors of HLE. In particular, a 
mechanism-based inhibition may be achieved with functionalized N-aryl azetidine-
2,4-diones containing a potential thiol leaving group. Enzyme kinetic studies with 
HLE and biochemical assays on serine proteases human cathepsin G and proteinase 3 
and against a cystein protease, papain, were performed. The stability in human plasma 
for selected compounds and finally a biodistribution study in mice were described, in 
anticipation of using these inhibitors in rodent efficacy models (Chapter 4) (Papers IV 
and V).  
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2.  C-4 SUBSTITUTED N-CARBAMOYLAZETIDIN-2-ONES: 
CHEMICAL REACTIVITY AND ENZYME INHIBITION  
Integrated in the research-oriented doctoral program, this part of the project was 
developed following the study of hydrolysis of N-carbamoylazetidin-2-ones started by 
Dr. Luísa Martins at the host laboratory.120 
2.1. SYNTHESIS 
-Lactams (azetidin-2-ones) presenting different substituents on C-4 were synthesized 
using methodologies described in the literature.98 The choice of the substituents was 
based on previous studies performed on -lactams as irreversible inhibitors of HLE,97-
99, 120 as mentioned earlier. Two series of N-carbamoylazetidin-2-ones (2.6, Scheme 
2.1) were synthesized: the C-3 gem-diethyl derivatives were prepared for S1 
molecular recognition by HLE; the C-3 unsubstituted compounds were prepared to 
assess the impact of the C-4 substituents on PPE inhibition when interaction with the 
S1 pocket is reduced. 
The synthethic pathway to give direct access to differently C-4 substituted azetidin-2-
ones key intermediates 43 and 44 or 46 used the appropriate 4-acetoxy-azetidin-2-one 
42 as the starting material (Scheme 2.1). The C-3 unsubstituted 42a is commercially 
available, while the 42b counterpart was prepared as described in the literature, 
involving a [2+2] cicloaddition of N-chlorosulfonyl isocyanate with a previously 
synthesized enol ester 49 (Scheme 2.2).98  
Reaction of 42 with nucleophiles, such as phenol or thiols, involving elimination-
nucleophilic addition, gave compound 43-44 as racemic mixtures. Two different 
routes were used to synthesize compounds 44: i) reaction of 42 with the respective 
thiol and sodium hydroxide in acetone at room temperature121 or ii) reflux in benzene 
in the presence of a catalytic amount of triethylamine.122 Interestingly, the second 
procedure, carried out in absence of water, provided superior yields. Treatment of 
thioethers 44 with 3-chloroperbenzoic acid (MCPBA) yielded the corresponding 
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sulfones 45. The C-4 unsubstituted 3,3-diethylazetidin-2-one 46 intermediate was 
prepared by reduction of 42b with NaBH4 in ethanol at 0 ºC.109 The correspondent C-
3 unsubstituted analogue is commercially available. The synthesized N-unsubstituted 
intermediates 43-46 are listed in Table 2.1. Finally, reaction of intermediates with 
benzyl isocyanate gave the N-carbamoyl -lactams 47 in good yield (Scheme 2.1). 
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Scheme 2.1 - Synthesis of N-carbamoylazetidin-2-ones. Reagents and conditions: (i) ArOH, NaOH, 
acetone; (ii) R2SH, NaOH, acetone; (iii) R2SH, TEA, C6H6, reflux; (iv) MCPBA, DCM; (v) NaBH4, 
EtOH, 0 ºC; (vi) PhCH2NCO, TEA, DCM. 
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42b48 49
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Scheme 2.2 - Synthesis of 3,3-diethyl-4-acetoxy-azetidin-2-one, 42b. Reagents and conditions: (i) 
acetic anhydride, sodium acetate; (ii) N-chlorosulfonyl isocyanate, DCM; (iii) H2O. 
 
 
Table 2.1 - N-unsubstituted key intermediates synthesized 43-46. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To prepare compound 44d, the respective thiol 2-mercaptobenzo[d]oxazole-5-
carboxylic acid 51 (Scheme 2.3) was synthesized, by refluxing 3-amino-4-
hydroxybenzoic acid 50 and potassium ethyl xanthate (EtOCS2K) in aqueous ethanol, 
adapting described techniques.123 
Compound R1 =  R2 X 
43a H OPh 
43b Et OPh 
43c Et 
O
CO2H  
44a H SPh 
44b Et SPh 
44c Et S
O
N
 
44d Et S
O
N CO2H
 
44e Et S
S
N
 
44f Et N
N
S
 
44g Et 
O
N N
S Ph  
45a H SO2Ph 
45b Et SO2Ph 
46 Et H 
NH
R1
R1
X
O
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NH2
OH
HO2C
(i) (ii)
HO2C
O
N
SH
50 51  
Scheme 2.3 - Synthesis of 2-mercaptobenzoxazole-5-carboxylic acid 51. Reagents and conditions: 
(i) EtOCS2K, EtOH 95%, H2O, reflux; (ii) HCl, H2O. 
 
 
The final N-carbamoylazetidin-2-ones synthesized in this work were 47a-g (Table 
2.2). Compounds 47j-k were synthesized by Dr. João Neres and are also listed in this 
table because they were studied in this work as inhibitors of HLE. Compounds 47h-i 
were synthesized and studied at the host laboratory by Dr. Luísa Martins,120 but were 
also included in Table 2.2, since the obtained results are relevant to be discussed here. 
Compound 47k, developed by Merck Research Laboratories103 as an inhibitor of 
HLE, was used in the present work as standard for HLE inhibition assays. 
 
 
Table 2.2 - Final N-carbamoylazetidin-2-ones 47 studied in this work. 
 
 
 
 
 
 
 
 
 
 
a Synthesized and studied by Dr. Luísa Martins.120; b Synthesized by Dr. João Neres; c Merck’s 
Research Laboratories compound103.  
Compound R1 =  R2 X 
47a H H 
47b H OPh 
47c H SPh 
47d H SO2Ph 
47e Et H 
47f Et OPh 
47g Et SPh 
47ha Et SO2Ph 
47ia Et SCH2Ph 
47jb Et SO2CH2Ph 
47kb,c Et OC6H4-4-CO2H 
N
O
R1
R1
X
O
HN
47
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2.1.1 NMR Spectral Characterisation 
All C-4 substituted azetidin-2-ones synthesized were racemic mixtures, presenting a 
chiral estereocenter at C-4. Thus, the adjacent protons are chemically and 
magnetically non-equivalent, being diastereotopic to one another.  
Inspection of the 1H NMR spectra of the C-3 unsubstituted derivatives reveals dd 
signals for the C-3 methylene protons, as a result of geminal coupling with each other 
and with the neighbour C-4 proton. For some synthesized N-unsubstituted azetidin-2-
ones, such as 43a, the C-3 methylene protons give peculiar signals (Figure 2.1). One 
C-3 proton consists of a d signal (Figure 2.1, at right), while the other is a ddd (Figure 
2.1, at left). This can be explained as follows: the coupling constant of one proton at 
C-3 with the proton at C-4 is small and the signal seems like a doublet. For the other 
proton at C-3, which presents a ddd signal, an additional coupling with the N-H 
proton over long distance occurs, as revealed by COSY. Thus, the splitting pattern 
illustrated in Figure 2.2 is proposed for the proton whose signal appears as a ddd: 
geminal coupling (2J = 15.8 Hz), vicinal coupling with the proton at C-4 (3J = 3.6 Hz) 
and long distance coupling with the proton at N-1 (4J = 2.4 Hz). 
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Figure 2.1 - Expansion of the observed signals of the spectrum of 1H NMR for the protons at C-3 
of compound 43a. 
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Figure 2.2 -Splitting pattern diagram of the signal corresponding to a ddd for the proton at C-3 of 
compound 43a. 
 
 
Similarly, for the C-3 substituted derivatives, the methylene protons of the diethyl 
group at this position are diastereotopic and present distinct signals in the 1H NMR 
spectra. Each of these protons present a doublet of quadruplets, due to geminal 
coupling with each other and with the neighbours –CH2CH3 (Figure 2.3). 
 
 
ppm (f1)
1.701.801.902.002.102.20
0
500
1000
2.061
2.042
2.023
2.006
1.987
1.968
1.886
1.867
1.855
1.849
1.837
1.818
1.799
1.
00
2.
99
 
Figure 2.3 - Expansion of the observed signals of the spectrum of 1H NMR for the –CH2 protons 
of the diethyl group at C-3 of compound 47f. 
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The multiplet at right in Figure 2.3 consists of coincided resonance frequencies which 
integrate for 3 protons. The signal in the left is a doublet of quadruplets (2J = 14.4 Hz; 
3J = 7.2 Hz) and integrates for 1 proton. The proposed splitting pattern for this proton 
is illustrated in Figure 2.4.  
For the C-4 substituted N-carbamoylazetidin-2-ones 47, the methylene protons of the 
benzylurea moiety are also diastereotopic, exhibiting doublet of doublets for each 
methylene proton in the 1H NMR spectra (Figure 2.5), in an AB splitting pattern. 
 
14.4 Hz
7.2 Hz 7.2 Hz 7.2 Hz 7.2 Hz7.2 Hz
 
Figure 2.4 - Splitting pattern diagram of the signal corresponding to a doublet of quadruplets 
(Figure 2.3, left) for a methylene proton of the diethyl group at C-3 of compound 47f. 
 
 
ppm (f1)
4.3504.4004.4504.5004.5504.6004.6504.700
0
500
1000
4.565
4.550
4.526
4.511
4.488
4.473
1.
96
 
Figure 2.5 - Expansion of the observed signals of the spectrum of 1H NMR for the methylene 
NHCH2Ph protons of compound 47f. 
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2.1.2 IR Spectroscopy 
All synthesized compounds presented the characteristic -lactam C=O IR stretching 
frequency, nearly 1745 cm-1. The N-unsubstituted synthesized derivatives, 42, 43 to 
46 presented the N-H stretching frequencies (3200-3280 cm-1). Compounds 47 
exhibited an additional C=O IR stretching frequency, corresponding to the carbonyl 
group of the urea moiety (1700 cm-1).  
2.2. ALKALINE HYDROLYSIS STUDIES 
2.2.1 Introductory Remarks 
As already mentioned, alkaline hydrolysis studies are an important tool in the design 
of serine protease inhibitors. The general reaction of hydroxide-ion catalyzed 
hydrolysis is presented in Scheme 2.4, and the rate law can be described by Equation 
2.1, 
Substrate Product
H2O, OH-
 
Scheme 2.4 - The general reaction of hydroxide-ion catalyzed hydrolysis. 
 
-d[S]/dt = k0[S] + kOH-[OH-][S]     (2.1) 
 
where [S] is the concentration of the substrate, k0 is the kinetic constant of the 
uncatalyzed reaction (spontaneous) and kOH- is the kinetic constant of the reaction 
catalyzed by hydroxide ion. Since the concentration of hydroxide ion, [OH-], is much 
higher than [S], it is assumed that it remains constant (pseudo-first order conditions), 
giving: 
 
kobs = k0 + kOH-[OH-]        (2.2) 
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being kobs the pseudo-first-order rate constant and kOH- the second-order rate constant 
for alkaline hydrolysis. Kinetic studies were performed by UV-spectroscopy at 25 ºC, 
in aqueous buffers of sodium hydroxide, with 0.5 M ionic strength (NaClO4) and 20% 
(v/v) acetonitrile, under pseudo-first-order conditions.  
2.2.2 Results and Discussion 
First, the wavelengths to be used in the kinetic studies were selected, by following the 
reaction of hydroxide with each compound, in a repeated spectral scanning over the 
wavelength range of 400-200 nm. Then, the kinetic measurements were performed at 
the selected wavelength in a time course mode. The hydrolysis showed first-order 
kinetics and the kobs values were determined following the absorbance decrease or 
increase until at least 4 half-lifes. In Figure 2.6 are represented the progress curves of 
the alkaline hydrolysis of 47f in three different concentrations of hydroxide. 
 
0
0.5
1
1.5
2
2.5
0 10000 20000 30000 40000 50000 60000
time / s
A
bs
.
0.03 M
0.05 M
0.10 M
[OH-]
 
Figure 2.6 -Time course for the alkaline hydrolysis of 47f. Concentrations of sodium hydroxide: 
0.03 M, 0.05 M and 0.10 M (25 ºC, ionic strength = 0.5 M,  = 238 nm). 
 
A linear dependence between kobs and the concentration of hydroxide ion [OH-] was 
observed for all compounds (kobs values presented in Appendix 1, Section A1.1), and 
the gradients of the plots of kobs versus [OH-] gave the second-order rate constant for 
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alkaline hydrolysis, kOH-. The intercepts of those plots were indistinguishable from 
zero, thus accordingly to Equation 2.2, k0 is zero. Next, the results for the 
determination of kOH- are presented and the final kOH- values are listed in Table 2.3. 
 
r2 = 0.990
0
5
10
15
20
25
0 5 10 15 20 25
102 [OH-] / M
10
2  k
ob
s  /
 s
-1
 
Figure 2.7 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of 
compound 47b, against hydroxide concentration, at 25 ºC and ionic strength 0.5 M. Points are 
experimental and the line is from linear regression analysis of the data. 
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Figure 2.8 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of 
compound 47e, against hydroxide concentration, at 25 ºC and ionic strength 0.5 M. Points are 
experimental and the line is from linear regression analysis of the data. 
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Figure 2.9 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of 
compound 47f, against hydroxide concentration, at 25 ºC and ionic strength 0.5 M. Points are 
experimental and the line is from linear regression analysis of the data. 
 
 
2.2.2.1 Free Energy Relationships for the Alkaline Hydrolysis of 47 
The alkaline hydrolysis of C-4 substituted N-carbamoylazetidin-2-ones 47 involves 
nucleophilic attack of hydroxide at the carbonyl carbon of the -lactam, in a ring-
opening reaction, with expulsion of the leaving group at C-4, as previously 
demonstrated by Merck Research Laboratories104 and also by Dr. Luísa Martins at the 
host laboratory.120 In this work we investigated the effect of the C-4 substituents on 
the intrinsic chemical reactivity and on the mechanism of hydrolysis, and the results 
are presented in this section. It was of interest to investigate if the departure of the 
leaving group at this position was concerted with the -lactam ring opening, as 
previously suggested by Merck.104 Thus, combining the kinetic data of alkaline 
hydrolysis obtained by Dr. Luísa Martins120 with the results of the present study, two 
series of Taft of N-carbamoylazetidin-2-ones with different substituents at C-4 of 
general structure 47 are obtained (Table 2.3).  
One of the series is not substituted at C-3, and it includes compound 47b. The other 
series is substituted at this position, and it includes compounds 47e and 47f. Thus, 
from the data set of Table 2.3, it is possible to establish empirical correlations of 
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kinetics of each series with the substituent at C-4, using the respective linear free 
energy relationships for alkaline hydrolysis. 
 
 
Table 2.3 - The second-order rate constants for the alkaline hydrolysis of 4-substituted N-
carbamoylazetidin-2-ones, kOH-, at 25 ºC, and the pKa and σI for the C-4 substituents. 
 
 
 
 
 
 
 
a From ref.124; b From ref. 125; c From ref. 126; d Data from ref. 120. 
 
C-3 unsubstituted series 
R1 = H 
Compound X pKa (XH)  I c kOH- / M-1s-1 
47a H 35 a  0 0.130 d 
47b PhO 9.92 b 0.39 0.990 
47c PhS 6.52 b 0.3 0.441 d 
47d PhSO2 1.29 b 0.57 4.16 d  
C-3 gem-diethyl substituted series 
R1 = Et 
Compound X pKa (XH)  I  c kOH- / M-1s-1 
47e H 35 a 0 1.64 x 10-3 
47f PhO 9.92 b 0.39 7.22 x 10-3 
47g PhS 6.52 b 0.3 7.13 x 10-3 d 
47h PhSO2 1.29 b 0.57 1.42 x 10-1 d 
47i PhCH2S 9.27 b 0.25 3.62 x 10-3 d 
47j PhCH2SO2 1.45 b 0.6 1.27 x 10-1 d 
N
O
R1
R1
X
O
HN
47
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Effect of the pKa of the leaving group at C-4. A consequence of the dependency of 
the hydroxide-ion catalyzed hydrolysis upon the C-4 leaving group ability would be 
rate dependency on the pKa of the leaving group. However, comparison of the kOH- 
values presented in Table 2.3 reveals that the reactivity of -lactams 47, for both C-3 
substituted and unsubstituted series, correlates poorly to the pKa of the leaving group 
at C-4 of the -lactam moiety. For example, compound 47c is only two-fold more 
reactive than 47a, despite the 5-fold difference on the pKa of the substituent at C-4. A 
poor correlation (r2 = 0.734) was found between log kOH- values and the pKa of the 
leaving group at C-4 for compounds 47a-d, corresponding to a lg value of -0.04. 
Furthermore, for the 3,3-diethyl series 47e-j, a poorer correlation was observed (r2 = 
0.588), corresponding to a lg value of -0.05 (for Brönsted plots, see Appendix 1, 
Figures A1.1 and A1.2). These small lg values are indicative that there is effectively 
no change in the effective charge on the leaving group on going from the ground state 
to the transition state for both series.  
 
Effect of the Electronic Properties (I) of the C-4 Substituent. The rate of alkaline 
hydrolysis (log kOH-) is linearly correlated with I values for the substituents at C-4, 
yielding I values of 2.8 and 3.4 for the series 47a-d and 47e-j, respectively (Figure 
2.10). It is important to stress that the C-4 substituent in compounds 47a and 47e is 
X = H, and departure of the C-4 substituent would involve the expulsion of hydride 
ion, which does not occur. However, for each series, the substituents at C-4 which 
might be and those which cannot be expelled are correlated in the same correlations of 
free energies. These results suggest that the nucleophilic attack by hydroxide to the -
lactam carbonyl carbon atom is not concerted with the departure of the leaving group 
at C-4 and there is no expulsion of the leaving group at C-4 in the rate-limiting step of 
hydrolysis. 
These I values are large end positive (Figure 2.10), and are consistent with the 
development of substantial negative charge in the transition-state, suggesting that the 
rate-limiting step is the attack of hydroxide-ion on the -lactam carbonyl atom and 
that the effect exerted by C-4 substituents on the alkaline hydrolysis of 47 is purely 
inductive. 
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Figure 2.10 - Linear correlation between the second-order rate constants for the alkaline 
hydrolysis, kOH- of C-3 unsubstituted β-lactams 47a-d () and C-3 gem-diethyl β-lactams 47e-j 
() and the Taft I value for the X substituents in C-4, yielding I values of 2.8 and 3.4 for the 
series 47a-d and 47e-j, respectively. Lines are from linear regression analysis of data.  
 
 
The higher I value determined for the 3,3-diethyl series compared to the C-3 
unsubstituted series is consistent with a less favourable high energy tetrahedral 
intermediate, 52 (Figure 2.11) in which the two C-O bonds are eclipsed with the ethyl 
groups at C-3. According to the Hammond postulate,127 this higher I value 
corresponds to a later transition state for the C-3 diethyl series, with significant 
negative charge buildup, and thus more susceptible to the stabilizing effect of 
electron-withdrawing groups at C-4. 
 
O
N
R
HO
NR
OH
O
52  
Figure 2.11 - Tetrahedral intermediate 52 (R=CONHCH2Ph) for hydroxide ion attack at a 3,3-
diethyl derivative, 47e, and the respective Newman projection obtained from looking along the 
C2-C3 bond of the -lactam, showing the two C-O bonds eclipsed with the ethyl groups at C-3. 
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The results obtained for -lactams 47 are comparable to those previously reported for 
the alkaline hydrolysis of the vinylogous cephalosporins containing a potential 
leaving group X at C-3’, 53 (Figure 2.12). It was suggested that the mechanism of 
base-catalyzed hydrolysis of cephalosporins 53 involves nucleophilic attack on the -
lactam carbonyl carbon concerted with expulsion of the leaving group at C-3´(Figure 
2.12, path a).128  
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Figure 2.12 - Mechanism of ring-opening of a cephalosporin with a leaving group X at C-3´ by 
nucleophilic attack at the -lactam carbonyl carbon.129 
 
However, a Brönsted lg value close to zero was reported for the substituents at C-3´ 
in alkaline hydrolysis of cephalosporins 53 (lg = -0.06),130 which is comparable with 
the lg found in the present study for the alkaline hydrolysis of 47. In addition, for the 
cephalosporin 53 in which X = H, the chemical reactivity was also similar to that of 
derivatives presenting a leaving group in this position. Furthermore, a thermodynamic 
correlation of log kOH- and I values for the substituents at C-3´ of 53was found, 
including the compound in which X = H, giving a I value of 1.35.92 Thus, the effect 
exerted by the substituents at C-3´ of cephalosporins 53 was purely inductive, and the 
rate-limiting step for the alkaline hydrolysis of 53 was the formation of the tetrahedral 
intermediate, similarly to the effect exerted by the C-4 substituents in the alkaline 
hydrolysis of 47. 
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The difference in the magnitude of I values of 53 and the compounds of the present 
study almost certainly reflects the shorter distance between the substituents and the 
nitrogen atom in the -lactam scaffold of 47. 
2.2.2.2 Mechanism of the Alkaline Hydrolysis Reaction of 47 
C-3 Substituted Series. Previously reported studies on the alkaline hydrolysis of C-4 
substituted 3,3-diethyl-N-benzylcarbamoylazetidin-2-ones, included the identification 
of the reaction products.104, 120 It was demonstrated that the intermediate imine formed 
by expulsion of the leaving group from C-4 partitioned between hydrolysis giving 
benzylurea and a aldehyde-acid (path a, Figure 2.13) or decarboxylation, to produce a 
vinyl adduct (path b, Figure 2.13).104 Taking into account these results with those 
obtained in the present study, the following mechanism is proposed for the alkaline 
hydrolysis of C-3 gem-diethyl 47e-j derivatives. Contrary to the Merck’s suggestion, 
it was now clarified that the nucleophilic attack of hydroxide at the -lactam carbonyl 
carbon atom is not concerted with the expulsion of a leaving group at C-4. 
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Figure 2.13 - Proposed mechanism of alkaline hydrolysis of C-3 substituted derivatives 47. 
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C-3 Unsubstituted Series. The UV spectrum of the hydroxide solution containing the 
alkaline hydrolysis product from the C-3 unsubstituted compound 47b had a broad 
maximum max at 255 nm. By addition of concentrated hydrochloric acid to the 
mixture, it was detected the emergence of a band at max 265 nm. After the 
subsequent addition of hydroxide, the band at 265 nm disappeared and the spectrum 
overlapped with the one acquired before the addition of acid, being indicative of an 
acid-base equilibrium. These data showed that a product was formed with max 255 
nm, which did not absorb in acidic conditions. Similar observations were made by Dr. 
Luísa Martins for the alkaline hydrolysis of 47c-d.120  
Analogue pH-dependent pattern of UV changes has also been reported for the alkaline 
hydrolysis of C-3 unsubstituted 4-aryloxy and 4-arylthioazetidin-2-ones,121 and also 
N-acyloxymethylazetidin-2-ones,131 and for such compounds it was reported to be a 
result of the formation of the enolate of 3-oxopropanamide, 54, with a max 265 nm. 
Upon acidification, 54 reverted to its neutral form (Figure 2.14), with a max 237 
nm.121 
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Figure 2.14 - The enolate of 3-oxopropanamide, 54, formed by the alkaline hydrolysis of C-3 
unsubstituted 4-aryloxy and 4-arylthioazetidin-2-ones,121 and N-acyloxymethylazetidin-2-ones.131 
 
With this background, it seems that an enolate is also formed for the alkaline 
hydrolysis of C-3 unsubstituted N-carbamoyl derivatives 47 and the proposed 
mechanism is illustrated in Figure 2.15.  
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Figure 2.15 - Proposed mechanism of alkaline hydrolysis of C-3 unsubstituted derivatives 47. 
 
 
Compound 55 (Figure 2.15) is likely to be the enolate responsible for the pH-
dependent UV pattern, with a broad maximum max of 255, which is near of the 
previously reported for the analogue enolate 54.  
Inspection of Figures 2.13 and 2.15 reveals that the alkaline hydrolysis reaction 
mechanism is similar for both C-3 substituted and unsubstituted series. However, the 
C-3 gem-diethyl analogues cannot form the enolate, thus they do not present the UV-
pH dependent pattern with max of 255. 
 
For both series, the rate limiting step of the alkaline hydrolysis reaction is the 
formation of the tetrahedral intermediate. Thus, the strain energy of the four-
membered ring is not released in the transition state to lower the activation energy. In 
fact, the reactivity of -lactams could be a consequence of the inherent 
thermodynamic strain of cyclic amide within the four-membered ring, involving bond 
angle as well as rigid torsional strain, and the rate-limiting step could be the 
2. C-4 Substituted N-carbamoylazetidin-2-ones 
 
 
 
63
breakdown of the tetrahedral intermediate. However, the reluctance of the -lactam 
ring to open has been noted previously.132, 133 It was demonstrated that the chemical 
reactivity of -lactams is not much different to that of acyclic amides, as the second-
order rate constant for the alkaline hydrolysis, kOH-, of the N-methyl--lactam 56 
(6.1x10-6 M-1s-1) is only 3-fold superior than N,N-dimethyl ethanamide, 57 (2.3x10-6 
M-1s-1).134 This is in contrast to the possible up to 1020-fold rate enhancement 
estimated from releasing the strain energy of a four-membered ring (26-29 kcal mol-1) 
than an analogous acyclic system. Thus, the -lactam ring must be intact in the rate-
limiting step.130 
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In the present study, the ureido anion expulsion from the tetrahedral intermediate of 
47 may occur at a rate that is comparable or even faster than that for hydroxide ion. 
Electron-withdrawing substituents at C-4 facilitate the alkaline hydrolysis, dispersing 
the negative charge density at the reaction site and stabilizing the negatively charged 
transition state. Thus, derivatives containing the electron-withdrawing 4-
phenylsulfonyl group were the most reactive for both series.  
The rate of alkaline hydrolysis depends not only on the electronic properties of the 
substituent on C-4, but also on the substitution on C-3. Indeed, there is a large steric 
effect of the substituents at C-3 on the rate of the reaction, as comparison of 
compounds 47a and 47f reveals a decrease in reactivity in about 135-fold for the C-3 
substituted derivative. These results are also compatible with the rate-limiting step 
being the formation of the tetrahedral intermediate. 
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2.3. ENZYME INHIBITION STUDIES 
2.3.1 PPE Inhibition Studies 
2.3.1.1 Introductory remarks 
The inhibitory activity of PPE was determined at 25 ºC, using the chromogenic 
substrate N-suc-(L-Ala)3-p-nitroanilide, 58 (Figure 2.16). By PPE-catalyzed 
hydrolysis of this substrate, the p-nitroaniline is released, being the reaction 
monitored at 390 nm.  
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Figure 2.16 - Hydrolysis of the chromogenic substrate N-suc-(L-Ala)3-p-nitroanilide, 58. 135 
 
It was demonstrated by Hinchliffe et al that this substrate undergoes hydrolysis in the 
presence of hydroxide, with a pH-independent reaction above pH 13.135 On the other 
hand, accordingly to the pH-PPE-activity profile reported by the same authors, the 
enzyme has an active site ionisable group with a pKa of 6.88 (presumably His-57), 
and it is only active when this group is deprotonated, with a pH optimum of 8.5. Thus, 
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inhibition assays were performed at pH 7.2, in order to avoid competition of non-
enzymatic-mediated hydrolysis. 
2.3.1.2 Determination of the Km  
The determination of Km was performed at 25 ºC, collecting the initial rates of the 
hydrolysis of the substrate 58 catalyzed by PPE, at different concentrations of 
substrate, with no saturation of the enzyme (Appendix 1, Section A1.3). 
The Lineweaver-Burke plot was used to obtain the kinetic parameters of PPE catalysis 
(Figure 2.17). Rates in Ms-1 were obtained by dividing the initial absorbance increase 
in A s-1 by the molar extinction coefficient for the hydrolysis product p-nitroaniline 
at 390 nm, 390, which was previously determined by a Beer-Lambert plot under 
identical experimental conditions (data presented in Appendix 1, Section A1.2). 
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Figure 2.17 - Lineweaver-Burke plot for the PPE-catalyzed hydrolysis of N-suc-(L-Ala)3-p-
nitroanilide, 58, in 0.1 M HEPES buffer, pH 7.2, at 25 ºC, [PPE] = 1x10-6 M. 
 
 
The obtained results are: Km = (3.81 ± 0.53) x10-3 M, Vmax= (9.75 ± 1.02) x10-6 Ms-1, 
kcat = 9.75 s-1 and the second-order rate constant kcat/Km = 2.56 x103 M-1s-1. This Km 
value is consistent with the one reported in the literature (Km= 4.92 x10-3 M).135 In 
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fact, although being convenient for UVs assays, the substrate N-suc-(L-Ala)3-p-
nitroanilide has a relatively high Km value, reflecting a poor degree of enzyme-
substrate binding.  
2.3.1.3 Inhibition Assays 
In order to determine the effect of the substituent at C-4 of N-carbamoylazetidin-2-
ones in the PPE-mediated hydrolysis in the absence of molecular recognition elements 
for S1 binding pocket, compounds 47a-d were assayed. To determine the effect of the 
C-3 substituent, compound 47f was also tested. Kinetics inhibition assays were 
performed using the Kitz and Wilson’s pre-incubation method.136 Thus, both PPE and 
inhibitor were incubated together, in 0.1 M HEPES buffer, pH 7.2, at 25 ºC. Aliquots 
of the incubation mixture were withdrawn at different time intervals and assayed for 
PPE activity, monitoring spectrophotometrically the hydrolysis of N-suc-(L-Ala)3-p-
nitroanilide, 58. The experiments were repeated at least twice for each concentration 
and different concentrations of inhibitor were used. For time-dependent inhibitors, the 
enzyme activity tends towards zero increasing incubation time and also depends on 
the concentration of the inhibitor.  
Control assays were performed under the same conditions, but in absence of inhibitor, 
and the enzyme activity remained constant throughout the experiments; with the 
initial rate for the hydrolysis of the substrate, vi, being equal to 100% of PPE activity. 
The remaining activity at incubation time t was expressed as percentage, and was 
given by (vt/vi) x 100, being vt the reaction rate at time t. The pseudo-first-order rate 
constants of enzyme inactivation were calculated by exponential regression-type 
analysis of PPE remaining activity versus time, using Equation 2.3 (an example is 
given in Figure 2.18), 
A = A0 e-kt               (2.3) 
 
being A the PPE activity at a time t; A0 the PPE activity in the control assay; k, the 
pseudo-first-order rate constants of PPE inactivation (kobs) and t the incubation time in 
second. The observed rate constant kobs of the reaction of an irreversible inhibitor with 
an enzyme may be described by Kitz and Wilson’s model, (Scheme 2.5).136 
2. C-4 Substituted N-carbamoylazetidin-2-ones 
 
 
 
67
E  +  I E I
Ki
E~I
kinact
 
Scheme 2.5 - Kitz and Wilson’s model for irreversible enzyme inhibition.136 
 
where Ki is the dissociation constant of the enzyme-inhibitor complex and kinact is the 
first-order rate constant for the inactivation step. Overall, this process is described by 
Equation 2.4. This kinetic expression corresponds to a hyperbolic dependence of kobs 
with the concentration of inhibitor, [I].  
 
kobs = kinact [I] / (Ki + [I])      (2.4) 
 
However, when Ki >> [I], Equation 2.4 simplifies to Equation 2.5, and kobs is linearly 
dependent on [I]. 
kobs/[I] = kinact/Ki                  (2.5) 
 
Thus, the second-order rate constants for PPE inhibition, kobs/[I], were given by the 
gradient of the plots of kobs against the inhibitor concentration and are indicative of the 
inhibitory potency. 
 
2.3.1.4 Results and Discussion 
Compound 47a was found to be non inhibitor of PPE, even when assayed at a 
concentration of 1 mM in the incubation mixture. Compounds 47b-d were found to be 
time-dependent inhibitors of PPE, suggesting an irreversible process of inactivation. 
The kobs values for compounds 47b-d, calculated as shown in Figure 2.18, are listed in 
Appendix 1, Table A1.3 and the final plots for determination of kobs/[I] for these 
compounds are represented in Figures 2.19 and 2.20. 
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Figure 2.18 - Plot of the PPE remaining activity against incubation time for compound 47d, at 10 
M (), 20 M (), 40 M (), and 50 M (), in the incubation mixture, at 25 ºC, in 0.1 M 
HEPES buffer, pH 7.2. Points are experimental and lines are from exponential regression analysis of 
the data, to yield the kobs values for each concentration, accordingly to Equation 2.3. 
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Figure 2.19 - Plot of the pseudo-first-order rate constants, kobs for the inactivation of PPE by 
compounds 47b (), and 47c (), against inhibitor concentration, at 25 ºC and pH 7.2 buffer. 
Points are experimental and lines are from linear regression analysis of the data, giving the second-
order rate constants, kobs/[I] = 11.33 ± 0.92 M-1s-1 for 47b, and kobs/[I] = 21.67 ± 1.20 M-1s-1 for 47c. 
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Figure 2.20 - Plot of the pseudo-first-order rate constants, kobs for the inactivation of PPE by 
compound 47d, against inhibitor concentration, at 25 ºC and pH 7.2 buffer. Points are 
experimental and the line is from linear regression analysis of the data, giving the second-order rate 
constant for PPE inhibition kobs/[I] = 290.4 ± 18.96 M-1s-1. 
 
 
The 3,3-diethyl derivative 47f, was completely inactive against PPE in a 
concentration up to 0.5 mM. The results for PPE inhibition are listed in Table 2.5. 
Values of kOH- were also included for comparison with the inhibitory potency as well 
as the respective enzyme rate enhancement factors, EREFs, given by kobs/[I]/kOH-. 
 
Structure Activity Relationships. The C-3 unsubstituted compounds presenting 
leaving groups at C-4, 47b-d, were time-dependent inhibitors of PPE, while the 
compound without a leaving group 47a was inactive. The second-order rate constants 
of the PPE-catalyzed hydrolysis of 47 revealed a low correlation with the pKa of the 
leaving group at C-4 (values of pKa were presented in Table 2.4). Interestingly, the 
Brönsted plot gave a lg value of -0.16 for the PPE-catalyzed reaction (r2 = 0.954, 
Appendix 1, Figure A1.5), but it was determined with only three points and must be 
analyzed with caution. This small value may indicate a small change in charge on the 
leaving group on going from the ground state to the transition state. One must note 
that the phenylsulfonyl derivative 47d was only 25-fold more active than its 4-
phenoxy analogue, 47b, despite the 9-fold difference between the leaving group 
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abilities of phenylsulfinate and phenolate. Compared with the lg value of -0.04 for 
the alkaline hydrolysis (data presented Appendix 1, Figure A1.1), this lg value of -
0.16 surprisingly may indicate more change in charge, with a little more dependence 
of the rate of the enzyme catalyzed reaction with the inhibitor’s C-4 leaving group 
ability.  
 
 
Table 2.4 - Second-order rate constants for the time-dependent inactivation of PPE in pH 7.2 
buffer at 25 ºC and for the hydroxide-catalyzed hydrolysis of compounds 47a-f. 
 
 
 
 
 
 
 
 
 
 
 a EREF enzyme rate enhancement factor; b No inhibition; c Data  from ref. 120. 
 
In addition, a greater I value was found for the PPE-mediated hydrolysis of C-3 
unsubstituted derivatives (data presented in Appendix 1, Figure A1.6), compared with 
the hydroxide-ion catalyzed reaction (4.7 versus 2.6). Once again, it was determined 
with only three points. These results may reflect a later transition state in the 
formation of the tetrahedral intermediate for the PPE-catalyzed reaction. This could 
be a result of the lack of molecular recognition elements at C-3, in such a way that it 
does not allow a favourable orientation of the tetrahedral intermediate for stabilization 
at the oxyanion hole. In this context, the magnitude of the EREF values for 47b-d 
(Table 2.4) are very small compared with the EREFs values reported for an enzyme-
Compound R1 X kobs/[I]/ M-1s-1 kOH-/ M-1s-1 EREFa 
47a H H NIb 0.221 c 
47b H OPh 11.3± 0.92 0.990 11.4 
47c H SPh 21.7± 1.20 0.441 c 49.0 
47d H SO2Ph 290±19.0 4.16c  70.0 
47f Et OPh NIb 7.22x10-3 
N
O
R1
R1
X
O
HN
47
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catalyzed reactions, which are of nearly 104-106 orders of magnitude.72 However, it is 
important to note that the C-3 substituted compound 47f was found to be a non 
inhibitor of this enzyme. Indeed, the gem-diethyl group of 47f may lead to a non-
productive binding at the small S1 pocket of PPE, which does not compensate the 
unfavourable steric hindrance introduced.  
Interestingly, compound 47c, which was chemically less reactive than 47b, revealed a 
gain in molecular recognition by PPE rather than the 4-phenoxy analogue (Table 2.4, 
EREF). The sulfone derivative 47d presented the higher EREF value and it was also 
found to be the best inhibitor of PPE of this series, with a kobs/[I] value of 290 M-1s-1. 
This result suggested that the electron-withdrawing sulfone function is a powerful 
activator of the -lactam carbonyl carbon atom towards the Ser-195 hydroxyl group, 
even in the absence of an adequate molecular recognition moiety at C-3 in the -
lactam scaffold. Furthermore, compound 47d was also the most reactive in the 
alkaline hydrolysis studies; thus increasing the intrinsic chemical reactivity led to a 
faster rate of enzyme inactivation (superior kobs/[I] value). 
 
Inhibition of PPE by these compounds led to the -lactam ring-opening with 
expulsion of the leaving group at C-4, with formation of a reactive imine which could 
be trapped by a second nucleophile within the active site. In fact, it could be trapped 
by His-57 in a possible suicide-type mechanism, or by a water molecule, in analogy 
with the mechanism of elastase inhibition discussed in Chapter 1, Figure 1.8. Thus, 
compound 47d was further studied on the titration of enzymatic activity, to determine 
the partition ratio of inhibitory efficiency, and on crystallography studies of the 
correspondent acyl-enzyme complex. 
 
Titration of PPE Activity by 47d. Further evidence of the efficiency of 47d as an 
irreversible inhibitor of PPE comes from the determination of the partition ratio, r, 
which represents the number of molecules of inhibitor necessary to inactivate a single 
molecule of enzyme. The r value was calculated by plotting the percentage of 
remaining enzyme activity, vt/vi, after a 30 min incubation period with the inhibitor 
versus the initial ratio of inhibitor to enzyme, i.e. [I]/[E]0 (Table 2.5). The extent of 
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inactivation was found to be linearly dependent on the inhibitor-to-enzyme molar 
ratio and extrapolation of the line to vt/vi = 0 yielded a partition ratio of ca. 1.2 
equivalents for 47d (Figure 2.21). Such high inhibitory efficiency was also reported 
for HLE inactivation by 3,3-diethylmonobactams.137 For example, 1.3 equiv of the 
Merck’s inhibitor L-680,833 are required to inactivate HLE to approximately 99%.137 
 
 
Table 2.5 - Percentage of remaining PPE activity, vt/vi, after a 30 min incubation period with 47d 
at 25 ºC, versus the initial ratio of inhibitor to enzyme, [I]/[E]0. 
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Figure 2.21 - Inactivation of PPE as a function of the molar ratio of inhibitor 47d to enzyme. PPE 
(10 M) and various amounts of inhibitor 47d (20-0.4 M) in 0.1 M HEPES buffer, pH 7.2, were 
incubated at 25 °C for 30 min, and aliquots were withdrawn for assay. Points are experimental and 
the line is from linear regression analysis of the data. 
[I]/[E]0 vt/vi (%) 
0 100.0 
0.04 96.67 
0.10 89.41 
0.40 67.78 
0.50 58.40 
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X-Ray Crystallography Studies. In order to confirm i) the formation of a covalent 
bond between the -lactam carbonyl carbon of 47d and the hydroxyl group of 
catalytic serine residue of PPE, and ii) the departure of the leaving group at C-4 with 
formation of a stable acyl-enzyme, X-ray crystallography studies were performed. 
These studies were kindly developed by Dr. Tania F. Oliveira and Prof. Margarida 
Archer, from the ITQB, Oeiras. PPE was incubated with 47d for 30 minutes, and 
good quality crystals were grown and subjected to X-ray analysis. Data collection and 
crystallographic refinement statistics for the porcine pancreatic structure bound to 47d 
are shown in Appendix 1, Table A1.4.  
The electron density maps at the catalytic site and inspection of the structure 
determined at 1.66 Å (Figure 2.22) show that PPE inactivation by 47d involves: 
- -lactam ring-opening, as revealed by the ester formed with Ser-195 O.  
- departure of the leaving group phenylsulfinate from C-4.  
- Interestingly, the crystal structure reveals the presence of a hydroxyl group at C-3 
(-lactam numbering), as a result of attack of a water molecule to the reactive acyl-
enzyme formed. No “double-hit mechanism” adduct, due to attack of His-57 to the 
acyl-enzyme was found.  
The structure of the crystallized acyl-enzyme is also represented in 59 (Figure 2.23). 
The presence of a hydroxyl group at C-3 is an unexpected result when compared with 
previous X-ray crystallographic studies of elastase complexed with -lactams 
containing leaving groups at C-4. For example, inactivation of elastase by 4-aryloxy-
3,3-diethyl--lactams leads to a carbinolamine acyl-enzyme, resulting from reaction 
of water at C-4 of the imine intermediate (discussed earlier in Section 1.6.2, Chapter 
1).138  
In order to realize if this pattern of enzymatic reactivity to give 59 was inherent to the 
inhibitor 47d or a function of the enzyme active site, a reaction of inhibitor 47d was 
undertaken with excess of sodium methoxide in methanol, which has been reported as 
a good model reaction for the acylation of serine enzymes.72, 84 The product of the 
reaction was 3-benzylpyrimidine-2,4(1H,3H)-dione, 60, in 80% yield (Figure 2.24). 
This result is consistent with methoxide-catalyzed β-lactam ring opening followed by 
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pyrimidine ring formation and phenylsulfinate elimination (or first the elimination 
then the ring closure). 
 
 
 
 
 
 
 
Figure 2.22 - A) A stereoview of the |F0| − |Fc| electron density map calculated, with Ser-195 and 
inhibitor 47d (code JM54) omitted from the model, showing the acyl-enzyme, with the -lactam 
carbonyl carbon of 47d covalently linked to Ser-195, with the corresponding interactions with 
PPE active site. B) Detail of the crystal structure of the acyl-enzyme complex, with the -carbon 
trace of the protein displayed as a ribbon. 
A 
B 
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Figure 2.23 - The structure of the crystallized acyl-enzyme 59 resulting from PPE-catalyzed 
hydrolysis of 47d. 
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Figure 2.24 - By reaction of 47d with excess of MeO- in MeOH, compound 60 is formed. 
 
Clearly, the enzyme active site must preclude the ring closure process. In fact, the 
acyl-enzyme structure equivalent to 60 would be a cis-enamine 62 or a trans-enamine 
63 (Figure 2.25). It would be expected the imine 61, or the tautomeric enamine forms 
62 or 63 (Figure 2.25), to add water to C-4 (-lactam numbering) to give 64, rather 
than to the C-3 atom, in contradiction with the obtained crystal structure of 59.  
These results suggest that a different pathway may be available in the active site of 
PPE, subsequently to -lactam ring-opening. In this regard, it is of interest to note that 
the distance between C-4 of PPE-47d complex and the Cα of Gln-192 is only 3.4 Å. 
This close approach (Figure 2.22A) might suggest a reason as to why the presence of 
a hydroxyl group in the C-4 position is precluded. 
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Figure 2.25 - The -lactam ring-opening of 47d catalyzed by PPE involves the departure of 
phenylsulfinate from C-4, generating an imine 61 and tautomers enamines 62 or 63, but it would 
be expected to add water to C-4, to give 64, rather then to C-3. 
 
 
The obtained crystal structure 59 has an (R)-configuration at the C-3 chiral carbon (-
lactam numbering). This could be a result of a favourable chiral environment of the 
enzyme active site for this configuration. The (S)-diastereoisomer of the acyl-enzyme 
was not obtained, probably due to unfavourable geometrical differences that rely on 
juxtaposition of amino acid residues on the active site or, the structure, although 
formed, was not crystallographed. 
 
Interestingly, X-ray crystallography studies were also reported for the reaction of C-3 
unsubstituted -lactams, in particular penem sulfones such as tazobactam (65), with 
class A -lactamases, which contains a catalytic serine residue (Ser-70).139, 140 The 
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proposed reaction mechanism of tazobactam with a SHV-1 -lactamase is illustrated 
in Figure 2.26 (suicide-type inhibition).  
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Figure 2.26 - Proposed reaction mechanism of tazobactam with SHV-1 -lactamase.139 
 
 
The obtained crystal structure for reaction of 65 with a SHV-1 -lactamase is a 
composite of two complexes:  
- an imine acyl-enzyme intermediate, 66, formed by -lactam ring opening and 
departure of the sulfinate leaving group at the C-5 position, and  
- an acrylate acid, 67, resulting from nucleophilic attack at the acyl-enzyme 
intermediate by a second residue at the active site (Ser-130), followed by hydrolysis 
of the respective acrylate ester (Figure 2.26). It is important to note that allowing the 
reaction of 65 with the enzyme to go for a longer time would label all molecules in 
the form of 67.139 This mechanism allows the formation of a reactive imine, 66, and 
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the tautomeric forms cis- and trans-enamine. Similar situation was discussed for PPE 
inactivation by 47d. However, the isolated complex 67 results from the nucleophilic 
attack of Ser-130 of the -lactamase at C-5 rather than C-6 (penem sulfone 
numbering), which would be equivalent to attack at C-4 of 47d. 
Interestingly, in the case of penem sulfones, such as 65, the departure of the sulfinate 
leaving-group is not rate-limiting in the inactivation process (but is an indispensable 
component for the irreversible inactivation of -lactamase).141 Similar situation was 
found in the present study for the inhibition of PPE by 47d. 
 
2.3.2 HLE Inhibition Studies 
2.3.2.1 Introductory remarks 
The compounds studied in the present work against HLE were 47e-h. The inhibitor 
47k, developed by Merck Research Laboratories,103 was used as standard of HLE 
inhibition assays. Inhibition of HLE by compounds 47i-j was previously studied by 
Dr. Luísa Martins, and the obtained results will be included here for a better 
discussion in terms of structure activity relantionships.120  
The C-3 gem-diethyl substituted compounds 47e-h and 47k were assayed against 
HLE, using MeO-Suc-(L-Ala)2-L-Pro-L-Val-p-NA, 68, as the chromogenic substrate 
for HLE inhibition assays. By hydrolysis of 68 mediated by the enzyme, p-
nitroaniline is released, being the reaction monitored at 410 nm. The molar extinction 
coefficient for the product p-nitroaniline at 25 ºC, 410 nm, 410, was previously 
determined by a Beer-Lambert plot, under identical experimental conditions of the 
enzymatic assays (data presented in Appendix 1, Figure A1.7). 
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The HLE inhibition assays were performed at 25 ºC in 0.1 M HEPES buffer, pH 7.2, 
similarly to the PPE inhibition. However, HLE was reconstituted in 50 mM sodium 
acetate, pH 5.5, to avoid autolysis and to maintain stability upon reconstitution.  
 
2.3.2.2 Results and Discussion 
Inhibition assays were performed using the progress curve method, accordingly to the 
slow-binding inhibition described by Morrison and Walsh.142 Thus, the reaction is 
initiated by addition of HLE to a solution of the inhibitor and the chromogenic 
substrate in 0.1 M HEPES buffer, pH 7.2, at 25 ºC. The characteristics non-linear 
progress curves of slow-biding irreversible inhibition were obtained for all inhibitors 
assayed against HLE, reflecting the establishment of the equilibrium between the 
enzyme and the inhibitor. An example is illustrated in Figure 2.27. The control assays 
(without inhibitor) gave a linear progression curve. 
Progress curves were fitted to Equation 2.6, 
 
  0/)exp(1)( AktkvvtvA obsobssis        (2.6) 
 
where A is the absorbance at 410 nm related to the concentration of 4-nitroaniline 
formed by enzymatic hydrolysis, A0 is the absorbance at time t=0, vi and vs are the 
initial and final rates of product formation in A/t units and kobs is the pseudo-first-
order rate constant of enzyme inhibition. The vi, vs and kobs parameters were calculated 
using non-linear least-squares regression methods, using the routine ENZFIT, 
developed at CECF/i-Med.UL, Faculty of Pharmacy, University of Lisbon, by Prof. 
Luís Gouveia (fitting residuals typically less than +/-0.001 Abs units).  
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Figure 2.27 - Progress curves for HLE inhibition by compound 47g. Reaction conditions: [HLE] = 
20 nM, [MeO-Suc-(L-Ala)2-L-Pro-L-Val-p-NA] = 1mM, 0.1M HEPES buffer, pH 7.2, 3% DMSO, 25 
ºC. Inhibitor concentrations: (a) absence of inhibitor, (b) 2, (c) 10, (d) 50, (e) 100 M. 
 
Accordingly to the slow-binding inhibition kinetics described by Morrison and Walsh, 
two general reaction mechanisms explain the enzyme inhibition, being represented in 
Figure 2.28 (E is the free enzyme, I is the inhibitor and S is the substrate).142 
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Figure 2.28 - General mechanisms of slow binding inhibition of enzyme-catalyzed reactions.142 
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Mechanism A assumes that the formation of the EI complex is a single, slow step, in 
which the isomerization to form EI* does not occur and can be represented as follows: 
 
E  +  I E I
kon
koff  
Scheme 2.6 –Mechanism A of slow binding inhibition. 
 
where kon, which is equivalent to k3, is the second-order rate constant for HLE 
acylation, and expresses the inhibitory potency, and koff, which equivalent to k4, is the 
first-order rate for deacylation. This is a simplified mechanism, because the product of 
deacylation (I) is not identical to the reactant (I). Specifically, being I a -lactam 
inhibitor, the deacylation of the acyl-enzyme (hydrolysis) does not involve -lactam 
ring closure to give the intact inhibitor.95  
For mechanism A, the plots of the pseudo-first order rate constant for enzyme 
inhibition, kobs, versus concentration of [I] are linear and an apparent value, kon´, is 
determined by the slope, accordingly to Equation 2.7. 
 
  offonobs kIkk  /´       (2.7) 
Then, it is necessary to make a correction taking into account the reaction of the 
enzyme with the substrate, allowing the establishment of equilibrium to form ES 
(Figure 2.28). Partial saturation of the enzyme by the reporter substrate slightly 
reduces the concentration of enzyme susceptible to inactivation. The corrected kon 
value is given by Equation 2.8,  
 
  )/1´( monon KSkk      (2.8) 
 
being [S] the substrate concentration used (1 mM), and Km the Michaelis constant for 
the substrate 68. The Km value had been previously determined at the host laboratory, 
Km = 1.60 x 10-4 M.109  
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It is important to note that for the incubation method, described previously for PPE 
inhibition assays, such correction is not required, because the inhibitor reacts with the 
enzyme in the absence of substrate (incubation mixture).  
 
The steady-state dissociation constant of the enzyme-inhibitor complex, Ki  is defined 
as142 
Ki = koff / kon        (2.9). 
 
For mechanism A, Ki is calculated using the steady-state velocities, vs together with v0 
(where v0 is the rate for product formation in the absence of inhibitor), fitting by non-
linear regression to Equation 2.10,143 which yields an apparent Ki´. Then it is 
corrected using Equation 2.11 to give Ki. 
 
   1´/
0


i
s KI
vv        (2.10) 
 
  )/1(´ mii KSKK      (2.11) 
 
On the other hand, mechanism B (Figure 2.28) assumes the rapid formation of a 
collision complex EI that undergoes a slow and favourable isomerization to an EI* 
complex (k3 > k5), and can be written as in Scheme 2.7, 
 
E  +  I E I
kinact
EI*
koffKi  
Scheme 2.7 - Mechanism B of slow binding inhibition. 
 
where kinact is equivalent to k5 (Figure 2.28), being the first-order rate constant for the 
chemical inactivation step and koff is equivalent to k6. When koff tends to zero, the 
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inhibitor becomes a slow tight-biding irreversible inhibitor, leading to a stable 
enzyme-inhibitor complex from which the inhibitor is, in practice, not released. For 
mechanism B, kinact and Ki, the dissociation constant for EI, are given by non-linear 
analysis using . It is important to note that using Equation 2.12, an apparent Ki´ value 
is obtained, which is then corrected by Equation 2.11 to give Ki.  
 
 
    offi
inact
obs kIK
Ikk 


  ´
     (2.12) 
 
The second-order rate constants for the formation of EI* (HLE inactivation) are given 
by Equation 2.13, being an index of inhibitory potency.  
 
iinacton Kkk /        (2.13) 
 
For each compound several concentrations were tested, with the exception for 
inhibitor 47e. Thus, since only one concentration was carried out for 47e, the second-
order rate constant for HLE inactivation was obtained by dividing kobs by the inhibitor 
concentration, kobs/[I], and then corrected due to the presence of the substrate. A linear 
behaviour of kobs with [I] was assumed, yielding a final kobs/[I] value of 310 ± 73 M-1s-
1 for this compound. 
 
The kobs values obtained at different concentrations of inhibitor for compounds 47f-h 
and 47k are presented in Appendix 1, Table A1.5, and the final plots are given in 
Figures 2.29, 2.31 to 2.33. From data of Figure 2.30 the Ki for 47f was calculated, 
using Equations 2.10 and 2.11. The final results for HLE inhibition studies are listed 
in Table 2.6 (kOH- values were included for comparison and also the EREFs). For 
compounds 47g-h and 47k koff was indistinguishable from zero. 
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Figure 2.29 - Plot of the pseudo-first-order rate constants, kobs for the HLE inhibition by 
compound 47f, against inhibitor concentration, at 25 ºC and pH 7.2 buffer. Points are experimental 
and the line is from linear regression analysis of the data (Equation 2.7). After correction using 
Equation 2.8, the second-order rate constant for HLE inhibition by 47f is kon= 2120 ± 69 M-1s-1, 
accordingly to the mechanism A of Figure 2.28. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.30 - Plot of the steady-state rates versus [I] for the inhibition of HLE by compound 47f. 
Points are experimental and the line is from non linear regression analysis of the data presented in 
Appendix 1, Table A1.6, using Equation 2.10, for Ki´ = 1.13 M, which gave after correction using 
Equation 2.11, Ki = 0.16 ± 0.02 M.  
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Figure 2.31 - Plot of the pseudo-first-order rate constants, kobs for the HLE inhibition by 
compound 47g, against inhibitor concentration, at 25 ºC and pH 7.2 buffer. Points are 
experimental and the line is from non linear regression analysis of the data to Equation 2.12, 
accordingly to the mechanism B of Figure 2.28, giving, kinact = (3.63 ± 0.22) x 10-3 s-1 and Ki´ = 4.81 ± 
0.97 M. By correction using Equation 2.11, Ki = 0.66 ± 0.13 M, and kon, the second-order rate 
constant for HLE inhibition, given by kinact/Ki, is 5480 ± 160 M-1s-1. 
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Figure 2.32 - Plot of the pseudo-first-order rate constants, kobs for the HLE inhibition by 
compound 47h, against inhibitor concentration, at 25 ºC and pH 7.2 buffer. Points are 
experimental and the line is from non linear regression analysis of the data to Equation 2.12, 
accordingly to the mechanism B of Figure 2.28, giving kinact = (4.06 ± 0.27) x 10-3 s-1 and Ki´ = 2.01 ± 
2. C-4 Substituted N-carbamoylazetidin-2-ones 
 
 
 
86
0.61 M. By correction using Equation 2.11, Ki = 0.28 ± 0.13 M, and kon, the second-order rate 
constant for HLE inhibition, given by kinact/Ki, is 14600 ± 443 M-1s-1. 
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Figure 2.33 - Plot of the pseudo-first-order rate constants, kobs for the HLE inhibition by 
compound 47k, against inhibitor concentration, at 25 ºC and pH 7.2 buffer. Points are 
experimental and the line is from non linear regression analysis of the data to Equation 2.12, 
accordingly to the mechanism B of Figure 2.28, giving kinact = (3.77 ± 0.08) x 10-3 s-1 and Ki´ = 3.41 ± 
0.29 M. By correction using Equation 2.11, Ki = 0.47 ± 0.04 M, and kon,, the second-order rate 
constant for HLE inhibition, given by kinact/Ki, is 8040 ± 292 M-1s-1. 
 
 
 
Structure Activity Relationships. Inspection of Table 2.6 reveals that 3,3-diethyl -
lactams 47 inhibited HLE very efficiently: the second-order rate constant for HLE 
inactivation ranges from 102 to 104 orders of magnitude. As a hyperbolic dependence 
of kobs versus [I] was found in most cases (Figures 2.31-2.33), a preassociation 
complex of high affinity was formed, allowing the determination of kinact (Table 2.6). 
A comprehensive study of the C-4 substituents on the inhibitory activity will follow. 
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Table 2.6 - Second-order rate constants for the time-dependent inactivation of HLE, kon, at 25 C, 
pH 7.2 buffer and for the hydroxide-catalyzed hydrolysis of compounds 47e-k at 25 ºC. 
 
 
 
 
 
 
       a EREF enzyme rate enhancement factor;  b kobs/[I];  c kinact/Ki;  d Data from ref.120; e Not determined. 
 
 
Effects of the pKa of the leaving group at C-4. A correlation was found between the 
logarithms of the second-order rate constants for HLE inactivation and the pKa of the 
leaving group at C-4, giving a small lg value of -0.047 (see data in Appendix 1, 
Figure A1.8), suggesting that there is essentially no change in the effective charge on 
the leaving group from going from the ground state to the transition state. Similar 
results were found for alkaline hydrolysis of the same compounds, previously 
discussed in this chapter. The 4-phenylsulfonyl derivative 47h is only 7-fold more 
potent than its 4-phenoxy analogue, 47f, despite the nearly 9-fold difference between 
the leaving group abilities of phenylsulfinate and phenolate, suggesting that the rate of 
enzyme inactivation is largely independent on the pKa of the leaving group at C-4. 
Compd X kon/ M-1s-1 103 kinact /s-1 Ki/M kOH-/ M-1s-1 EREFa 
47e H 310 ± 73 b - - 1.64 x 10-3 1.89 x 105 
47f OPh 2120 ± 69  - 0.16 7.22 x 10-3 2.94 x 105 
47g SPh 5480 ± 160 c 3.63± 0.22 0.66 7.13 x 10-3 d 7.69 x 105 
47h SO2Ph 14600 ± 443 c 4.06± 0.27 0.28 1.42 x 10-1 d 1.03 x 105 
47i SCH2Ph 4464 c ,d - - 3.62 x 10-3 d 1.23 x 106 
47j SO2CH2Ph 11741 c ,d - - 1.27 x 10-1 d 9.24 x 104 
47k OC6H4-4-CO2H 8040 ± 292 c 3.77±0.08 0.47 NDe NDe
N
O
X
O
HN
47
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Effects of the Electronic Properties (I) of the C-4 Substituent. A correlation was 
found between log (kon) and the I values for the substituent at C-4 of compounds 
47e-j, including X=H (47e), yielding a corresponding I value of 2.5 (Figure 2.34). 
These findings suggest that the rate-limiting step in HLE inactivation is the formation 
of the tetrahedral intermediate and that the expulsion of the leaving group at C-4 is 
not concerted with the -lactam ring opening. Thus, the C-4 substituents exerted only 
an inductive effect. 
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Figure 2.34 - Linear correlation between the second-order rate constants for HLE inactivation by 
3,3-diethyl β-lactams 47e-f (), and the I value for the X substituents in C-4, giving a I = 2.5. 
For comparison, the linear correlation for the alkaline hydrolysis, kOH- () for the same 
compounds was included, giving a I value of 3.4. Lines are from linear regression analysis of data.  
 
Interestingly, this I value of 2.5 is superior to that reported for the HLE inactivation 
by cephalosporins sulfones 53 (Figure 2.12), which gave a I = 1.83144. This 
difference in magnitude of I values for HLE inhibition by 47 and cephalosporins 
sulfones 53 certainly reflects, once again, the shorter distance between the 
substituents and the nitrogen atom in the -lactam scaffold of 47. 
It is important to note that the obtained I value of 2.5 is lower compared with the 
previously discussed I value of 3.4 for the alkaline hydrolysis for the same 
compounds (Figure 2.34). Thus, the difference in magnitude between these I values 
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suggest that the enzyme-mediated hydrolysis of 47e-j involves an earlier transition 
state than the hydroxide-catalyzed one, consistent with the establishment of 
favourable binding interactions between the inhibitor and the enzyme in order to 
facilitate the attack by Ser-195. This can be ascribed, at least in part, to the molecular 
recognition at S1 binding pocket, since it is known the hydrophobic interaction 
between the diethyl substituent at C-3 on the -lactam and the S1 pocket of HLE.99 
Thus, it allows alignment of the catalytic triad and positions the oxyanion hole of the 
enzyme to stabilize the negative charge in the transition state, affording a more 
favourable reaction pathway. This is consistent with the high magnitude of EREF 
values obtained for 47e-j, ranging from 105 to 106 (Table 2.6). It reflects the ability of 
HLE to increase the rate of reaction when compared to alkaline hydrolysis, by using 
its catalytic apparatus.  
 
Inspection of Table 2.6 reveals that the C-4 unsubstituted derivative 47e is a weak 
inhibitor of the enzyme. Replacing the oxygen atom of the C-4 substituent of 47f by a 
sulfur atom to give 47g, increased the rate of HLE inactivation up to 2.5-fold and 
allowed the accumulation of a high affinity EI* complex (hyperbolic dependence of 
kobs versus [I], Figure 2.31). This suggests a favourable orientation for 47g rather than 
simple sensitivity to intrinsic chemical reactivity.  
Oxidation of the sulfur atom to the respective sulfone increased the inhibitory 
potency. In fact, the sulfones 47h and 47j were the most actives compounds of the 
series, presenting kinact/Ki values superior to that of the Merck’s compound 47k, used 
as standard in inhibition assays  
 
In effect, for both PPE and HLE inhibition studies, the sulfones were the most potent 
inhibitors and these results can be ascribed to the powerful electron-withdrawing 
properties of the sulfone function. Similarly, it is known that the oxidation state of the 
sulphur atom of cephalosporin plays an important role in the inhibitory potency 
against HLE, being the sulfones more potent than the correspondent sulfides or -
sulfoxides, while -sulfoxides are inactive.88, 144, 145 Similar results were also found in 
N-acyloxymethylazetidin-2-ones inhibitors of HLE,107 as mentioned in Chapter 1.  
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Although not being completely correct to compare the results of different enzymes, 
using different inhibitors and substrates, i.e, to compare the results obtained for PPE 
and HLE inhibitions assays, it is important to note that the respective EREFs show a 
significant difference in magnitude (values for PPE inhibition were given in Table 
2.4). Remarkably, the 3,3-gem diethyl derivatives 47e-k exhibited EREF values ca. 
104-fold higher towards HLE than those of their C-3 unsubstituted analogues 47b-d 
towards PPE. An eventual steric hindrance to the carbonyl carbon, due to the presence 
of the gem-diethyl substituent in derivatives 47e-k, seems to be largely compensated 
by hydrophobic interactions with the S1 pocket of HLE. This interaction probably 
positions the -lactam carbonyl within the oxyanion hole of HLE, thus enhancing the 
rate of the reaction, with an improvement on inhibitory potency. The best EREF value 
was found for compound 47i, suggesting favourable biding interactions for the 4-
SCH2Ph derivative. 
 
A weak correlation was found between log (kon) for HLE inhibition and log (kOH-) for 
compounds 47e-j, as illustrated in Figure 2.35.  
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Figure 2.35 - Plot of the second-order rate constants for HLE inactivation by 3,3-diethyl β-
lactams 47e-f against the second-order rate constants for alkaline hydrolysis, kOH- by the same 
compounds. Line is from linear regression analysis of data.  
 
2. C-4 Substituted N-carbamoylazetidin-2-ones 
 
 
 
91
These results suggest that increasing the intrinsic chemical reactivity of a compound 
may lead to a faster rate of enzyme inactivation, without detriment of favourable 
binding interactions. Nevertheless, the enzyme may be more sensitive to molecular 
recognition elements rather than intrinsic chemical reactivity (ex.: 47g versus 47f).  
Interestingly, the sulfones were not only the best inhibitors in both series towards PPE 
and HLE, but also the ones that showed the greatest intrinsic chemical reactivity. 
These results reflect the efficiency of this substituent in activating the -lactam 
scaffold towards serine proteases and hydroxide ion.  
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3.  AZETIDINE-2,4-DIONES (4-OXO--LACTAMS): SYNTHESIS, 
AND PRELIMINARY STUDIES AS ENZYME INHIBITORS  
3.1. INTRODUCTORY REMARKS 
As already mentioned in Section 1.9, the aim of the second phase of this project was 
to develop 4-oxo--lactams as inhibitors of elastase, and at this phase of the work, 
azetidine-2,4-diones had never been reported as inhibitors of elastase.  
Molecular modelling techniques were used prior to synthesis, in order to select some 
4-oxo--lactam lead structures, and speeding up the optimization to obtain highly 
potent inhibitors.  
 
3.1.1 Molecular Modelling  
In order to perform a computational-assisted inhibitor drug design, a database of 260 
differently substituted 4-oxo--lactams was created (Appendix A2). The choice of the 
substituents was based on prior studies with simple -lactams inhibitors of HLE. For 
example, based on the results obtained with C-4 substituted N-carbamoylazetidin-2-
ones (Chapter 2), 47, in which LG is a leaving group, it was of interest to synthesize 
compound 69 (R1 = R2 = Et) to evaluate the effect of the incorporation of a 4-oxo 
substituent on the inhibitory potency compared with 47. 
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The presence of a second sp2 centre at C-4 on the -lactam ring of 69 would increase 
the chemical reactivity of the carbonyl carbon, and reduce the basicity of the leaving 
group by C-N fission, as it would change the leaving group from an amide in 47 to an 
imide in 69. Interestingly, the two acyl groups would be equivalent, increasing the 
probability of nucleophilic attack at a “reactive” carbonyl carbon. Analogues 69 with 
different C-3 substituents for molecular recognition were included on the database, as 
R1 = iso-Pr, R2 = H. The iso-propyl substituent resembles the side chain of a valine 
residue, which is known that binds best in the S1 pocket of HLE. 
Compound 70 (LG = leaving group, EWG = electron-withdrawing group) allows a 
potential mechanism-based inhibition of the target, in analogy with simple N-hetero-
functionalized -lactams, discussed earlier in Chapter 1, Section 1.6.2.1.  
A virtual screening study was carried out at the host institution, by Dr. Rita Guedes, to 
investigate the binding mode of potential inhibitors within the active site of HLE (see 
Experimental Section for details). Thus, compounds that afforded the best results 
were selected for synthesis. An example of an interesting candidate for synthesis was 
compound 70, R1 = iso-Pr, R2 = H, LG = OCOPh, EWG = CO2Et. PPE inhibition and 
alkaline hydrolysis assays would be performed with the selected azetidin-2,4-diones, 
in a preliminary study with these compounds. 
 
3.2. SYNTHESIS 
Retrosynthetic analysis indicates that N-carbamoylazetidine-2,4-diones should be 
accessible by coupling the N-unsubstituted azetidine-2,4-dione, 71, with benzyl 
isocyanate, as illustrated in Scheme 3.1.  
Since 71 is not commercially available, it was necessary to prepare it. Interestingly, 
N-unsubstituted azetidine-2,4-diones may also function as a key intermediate to 
prepare 70.  
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Scheme 3.1 - Retrosynthetic analysis of N-carbamoylazetidine-2,4-diones. 
 
3.2.1 Attempted Synthesis of N-Unsubstituted 4-Oxo--lactams, Using Published 
Routes 
In this phase of the project, published routes were considered for synthesis of N-
unsubstituted azetidine-2,4-diones (4-oxo--lactams), 71 (Scheme 3.2): 
- a) ring closure of malonic acid monoamides146, 147 
- b) cycloaddition of ketenes with isocyanates148, 149 
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Scheme 3.2 - Strategic routes for the synthesis of N-unsubstituted 4-oxo--lactams based on 
published procedures (X = SO2 or CO). 
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3.2.1.1 Ring closure of 2,2-Diethyl Malonic Acid Monoamide (Malonamic 
Acid) and Derivatives 
A synthetic route involving ring closure of 2,2-diethylmalonic acid monoamide 
(malonamic acid) has been reported previously for the synthesis of N-unsubstituted 
3,3-gem-diethyl derivative 71 (R1 = R2 = Et), and the described methodology was 
used in the present work.146, 147 The 2,2-diethylmalonamic acid 74 was obtained in 
31% yield from hydrolysis of respective cyanoacetic ester 73 (Scheme 3.3).147 
Compound 73 is not commercially available and was prepared from alkylation of 72, 
using sodium ethoxide and iodoethane (76% yield). It was reported that the ring 
closure of malonic acid monoamide 74 to give 71 was obtained by reaction with 
thionyl chloride and pyridine, in toluene (inert atmosphere), with formation of a by-
product, as represented in Scheme 3.4. The described technique was used.146  
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Scheme 3.3- Alkylation of the cyano-ester 72 to give a gem-diethyl derivative 73, which was 
hydrolised to give 74. Reagents and conditions: (i) EtO-/EtOH at 50 ºC, EtI and reflux, (ii) H2SO4 
conc. at 110 ºC for 30 min, (iii) ice. 
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Scheme 3.4 - Attempted ring closure of malonic acid monoamide to give N-unsubstituted 
azetidine-2,4-dione 71.146, 147 Reagents and conditions: SOCl2, Pyr, toluene, reflux. 
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Since TLC was not useful in monitoring the reaction, it was kept in reflux during the 
time reported (30 min). Then, the chloridrate was filtered-off and the residue was 
purified by distillation under reduced pressure (0.4 mm Hg). The obtained product 
was characterized by NMR and ESI-MS as being the by-product 75 (Scheme 3.4), 
with 37 % yield. The formation of the nitrile bond of 75 is explained in Scheme 3.5. 
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Scheme 3.5 - The nitrile bond of compound 75 results from reaction of thionyl chloride with the 
amide carbonyl carbon atom. 
 
In order to prevent the formation of 75, a different strategy was investigated to 
achieve ring closure, using the ethyl ester of the malonic acid monoamide as starting 
material, 76 (Scheme 3.6). Compound 76 was obtained by a partial hydrolysis of 73, 
following a described procedure147 (21% yield).  
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Scheme 3.6 - Synthesis of 76 from acid hydrolysis of 73147 Reagents and conditions: H2SO4 conc. at 
90 ºC for 5 min; ice. 
 
It was reasoned that reaction of dilute 76 with ethoxide in a 1:2 molar ratio, in dry 
ethanol allows the cyclisation to occur (Scheme 3.7). Reaction was carried out at 
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room temperature and also using reflux. TLC was ineffective in monitoring the 
reaction. After work-up, only starting material 76 was recovered.  
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Scheme 3.7 - Attempted synthesis of 3,3-diethylazetidine-2,4-dione 71 by cyclisation of 76 
catalyzed by base. 
 
Thus, a stronger deprotonating agent, lithium diisopropylamide (LDA, 1.2 eq.), was 
chosen instead of ethoxide, but the cyclisation process also failed. Experimental 
attempts involving variation of the temperature and the order of addition of the 
reagents remained unsuccessful. It is important to note that the procedure involving 
malonic acid monoamides ring closure, illustrated in Scheme 3.4, was reported in an 
old reference (1959), and the products were only analyzed using IR and elemental 
analysis, with no NMR characterization.146  
 
The route involving cicloaddition of ketenes with chlorosulfonyl isocyanates to 
prepare N-unsubstituted 4-oxo--lactam 71 was not tested, because it was reported 
that the resulting N-chlorosulfonyl 4-oxo--lactam was difficult to handle, due to 
decomposition with SO2 evolution, prior to hydrolysis to give 71.149 However, the 
synthetic pathway using ketenes and isocyanates to prepare 4-oxo--lactams will be 
discussed in Chapter 4 (including a route using chlorocarbonyl isocyanate). 
As a result of the unsuccessful approaches for the synthesis of N-unsubstituted 4-oxo-
-lactams, a different method was investigated, in order to synthesize derivatives 
substituted at both C-3 and N-1. 
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3.2.2 Condensation of Malonyl Dichlorides with Primary Amines to give C-3 and 
N-1 Substituted 4-Oxo--lactams 
One reported route for the synthesis of the 4-oxo--lactam (azetidine-2,4-dione) 
nucleus involves the condensation of malonyl dichlorides with primary amines.150, 151 
Golik reported the synthesis of a 3,3-diethyl-N-alkylazetidine-2,4-dione 77 (Scheme 
3.8, R1 = R2 = Et, R = CH2CO2Et), in 12% yield, by refluxing commercially available 
diethyl malonyl dichloride with ethyl glycinate hydrochloride, in the presence of 
triethylamine as catalyst (inert atmosphere). Accordingly to the described procedure, 
the catalyst is added dropwise during 1.5 h to the reaction mixture. The same author 
reported the simultaneous formation of the disubstitution product 78 (R = CH2CO2Et), 
an acyclic malondiamide (22% yield). Both products 77 and 78 were characterized, 
including NMR techniques.151 Thus, this procedure was completely followed as 
described in the literature, in order to assert a synthetic pathway for 4-oxo--lactams. 
In addition, the 3,3-gem-diethyl substituent is known to be important for molecular 
recognition at S1 binding pocket of elastase and, therefore, the synthesis of 77 and 
analogues was interesting as potential elastase inhibitors.  
Based on this synthetic route, different 4-oxo--lactams 77 were prepared, as 
represented in Scheme 3.8, and they were easily purified by column chromatography, 
being the first fraction eluted. Since it was reported that aliphatic amines decreases the 
yield of the reaction by leading to favored formation of the malondiamide, anilines 
were preferentially used.151 In particular, para-substituted anilines with different 
electronic properties of the para-substituent were chosen to asses the impact of the 
substituent on the chemical reactivity and on the inhibitory potency.  
 
 
Cl Cl
O O
R1 R2
N
O
OR
1
R2
R
(i)
N
H
N
H
O O
R1 R2
R R
77 78  
Scheme 3.8 - Synthesis of azetidine-2,4-diones 77, using the method described by Golik.151 
Reagents and conditions: (i) RNH2 (1 eq), TEA (2.6 eq), dioxane, reflux. 
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3,3-Gem-dimethyl (R1 = R2 = Me, 77) derivatives were synthesized from 
commercially available dimethyl malonyl dichloride. Compound 77h was synthesized 
as an isoster analogue of the 3-oxo--sultam 35 (previously presented in Figure 1.12, 
Chapter 1).  
This method suffered a drawback by giving low yields (Table 3.1). But it allowed the 
synthesis of 4-oxo--lactam derivatives in a simply and unique step. 
 
Table 3.1 - Synthesized 4-oxo--lactams 77a-i. 
 
 
 
 
 
 
 
 
In most cases, decreasing the basicity of the primary amine increased the yield for the 
cyclisation process. In this way, N-aryl derivatives 77c-g provided better yields than 
the N-benzyl derivative 77b (the best was obtained for the p-cyano derivative). On the 
other hand, highly reactive dimethylmalonyl dichloride provided lower yields than the 
diethyl counterpart. 
 
3.2.3 Attempted Synthesis of N-Unsubstituted 4-Oxo--lactam from N-Protected 
Azetidine-2,4-diones 
Once synthesized these 4-oxo--lactams, more attempts were made for the synthesis 
of the N-1 unsubstituted key intermediate 71. Since the main difficulty on the 
Compound R1 R Yield (%) 
77a Et CH2CO2Et 16 
77b Et CH2Ph 9 
77c Et C6H4-4-OMe 11 
77d Et C6H4-4-Me 10 
77e Et C6H5 15 
77f Et C6H4-4-Cl 14 
77g Et C6H4-4-CN 19 
77h Me CH2Ph 4 
77i Me C6H4-4-Cl 6 
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published routes for 71 arose from the difficulty on cyclisation of the ring (Section 
3.2.1), attempted N-deprotection strategies of potential N-protected azetidine-2,4-
diones were used (Scheme 3.9).  
 
N
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OMe
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NH
O
O
77c
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N
O
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77b
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N
O
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Ph
CF3SO3H, TFA, 0ºC
Ph
Ph2CHNH2
Cl Cl
O O
 
Scheme 3.9 - Attempted synthesis of N-unsubstituted 4-oxo--lactams based on N-protected 
azetidine-2,4-diones. 
 
3.2.3.1 Attempted Oxidative N-Dearylation of N-(p-Methoxy)-
phenylazetidine-2,4-dione, 77c 
Keeping in mind the well-known oxidative N-dearylation of N-(p-methoxy)-
phenylazetidine-2-ones (simple-lactams, 1 eq.) using ceric ammonium nitrate 
(CAN, 3 eq.)152, this method was used for the preparation of the N-unsubstituted 4-
oxo--lactam from 77c (Scheme 3.10). TLC analysis of the reaction mixture after 4h 
of reaction (eluant hexane/EtOAc 8:2), revealed starting 77c (Rf = 0.72) and the 
formation of a new compound with a lower Rf value (Rf = 0.38). However, after 
work-up (extraction with EtOAc and purification by column chromatography) only 
starting material 77c was recovered (47%). An alternative approach was investigated 
by using silica-gel supported cerium ammonium nitrate,153 but this procedure also 
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failed. Both 1H-NMR and ESI-MS analysis of the product after work-up were 
inconsistent with the expected product and could not be assigned to another structure. 
N
O
O
OCH3
(i)
NH
O
O
O
O
77c
 
Scheme 3.10 - Attempted synthesis of N-unsubstituted 4-oxo--lactam from 77c. Reagents and 
conditions: (i) CAN (ceric ammonium nitrate), CH3CN/H20. 
 
3.2.3.2 Attempted N-Debenzylation of 77b by Catalytic Hydrogenation  
The removal of the N-benzyl group from a wide variety of compounds is well-known. 
Thus, the following approach was considered (Scheme 3.11). 
High pressure catalytic hydrogenation by using a Parr hydrogenator was carried 
out,154 but no reaction took place after 28 h of stirring in methanol at room 
temperature (77b, 86% recovered). The reaction was repeated using formic acid or 
acetic acid, but only 77b was recovered after work-up. Surprinsingly, 77b was likely 
to be “inert” under such severe conditions. 
 
N
O
O
NH
O
O(i)
77b  
Scheme 3.11 - Attempted synthesis of N-unsubstituted 4-oxo--lactam from 77b. Reagents and 
conditions: (i) H2 / Pd Charcoal, Parr hydrogenator, MeOH or formic acid.  
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3.2.3.3 Attempted Deprotection of N-benzhydryl azetidine-2,4-dione, 79 
The route involving deprotection of the N-benzhydryl protecting group155 by using 
triflic acid in TFA at 0 ºC,156 began with the attempted preparation of 79 (Scheme 
3.9). Following the described procedure for obtention of azetidine-2,4-diones, the 
diethyl malonyl dichloride reacted with benzhydrylamine Ph2CHNH2, but 79 was not 
detected after work-up. NMR analysis of the product was consistent with the 
disubstitution product (malondiamide) 78, R = Ph2CH, R1 = Et (12% yield). This 
route was no further investigated. 
 
3.2.4 Attempted Bromination at C-1´ of Azetidine-2,4-diones 
Since it was not feasible to synthesize N-unsubstituted azetidine-2,4-diones for further 
reaction to prepare N-substituted derivatives, a different strategy was considered, 
which consisted in the bromination at C-1´ of 77a by using NBS with a radical 
initiator (Scheme 3.12).  
The brominated compound 80 may function as a building molecule for 70 (Scheme 
3.12). However, no bromination reaction took place after 24 h of reflux, being 
recovered the starting azetidine-2,4-dione 77a (79%). Attempted benzylic 
bromination of 77b also failed. This route was no further investigated. 
 
N
O
O
77a (R = CO2Et)
R
(i)
N
O
O
80 (R = CO2Et)
R
Br
N
O
O
EWG
GL
70  
Scheme 3.12 - Attempted bromination of 77a. Reagents and conditions: (i) NBS, CCl4, benzoyl 
peroxide, reflux. EWG of compound 70 is CO2Et. 
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In fact, none of the 4-oxo--lactams studied by molecular modelling techniques was 
able to be synthesized. Thus, in this phase of the project, it was of interest to perform 
preliminary studies on both serine protease inhibition and intrinsic chemical reactivity 
with the prepared 4-oxo--lactams 77. 
 
3.2.5 NMR Spectral Characterisation 
The 1H-NMR spectrum of compound 73 (Scheme 3.5) presents prochiral methylene 
protons on the diethyl substituent. These protons are attached to a prochiral carbon 
atom and are therefore non-equivalent. Each of these protons presents a doublet of 
quadruplets, due to geminal coupling with each other and with the neighbours 
CH2CH3, as presented in Figure 3.1. The proposed splitting pattern for each proton is 
illustrated in Figure 3.2. Similar situation was found for compounds 74, 75 and 76. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 - Expansion of the observed signals of the spectrum of 1H NMR for the methylene 
protons -CH2CH3 of the diethyl substituent of compound 73. 
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Figure 3.2 - Splitting pattern diagram for each methylene proton of the diethyl group of 
compound 73. 
 
With regard to 4-oxo--lactams 77, all of them presented a plane of symmetry. Thus, 
the methylene protons of the gem-diethyl substituent at C-3 of 77a-g are equivalent, 
and appear as a quartet in the 1H-NMR spectra, integrating for 4 protons; while the 
protons of the methyl groups appear as a triplet, integrating for 6 protons. The 
methylene protons of N-benzyl derivatives give a singlet (eg. Figure 3.3a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 - Expansion of the observed signals of the spectrum of 1H NMR for a) the singlet 
corresponding to two methylene protons -CH2Ph, b) the quartet corresponding to four CH2CH3 
protons and c) the triplet corresponding to six CH2CH3 protons of compound 77b.  
 
a) b) c) 
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For the C-3 gem-dimethyl derivatives, 77h-i, the six methyl protons are equivalent 
and appear as a singlet in the 1H-NMR spectra. For the synthesized 4-oxo--lactams 
presenting a substituent on the para position of the aromatic ring at N-1, the aromatic 
protons belong to the AA´BB´system (Figure 3.4), being chemically equivalent by 
symmetry but magnetically non-equivalent.  
It would be expected HA proton coupling with HB and then to the HA', in such a way 
that: J (HAHB) = J (HA´HB´) and J (HAHA´) = J (HBHB´), being J (HAHB) > J (HAHA´). 
However, the signals of these protons appear as broad doublets in the 1H-NMR 
spectrum (400 MHz). 
 
X
Y
HA´
HB´
HA
HB
 
Figure 3.4 - AA´BB´ protons in a 1,4-disubstituted aromatic ring. 
 
As a result of the plane of symmetry, both carbonyl carbon atoms C-2 and C-4 of all 
4-oxo--lactams 77 are equivalent and give only one signal on the 13C-NMR spectra. 
 
3.2.6 IR Spectroscopy 
All synthesized 4-oxo--lactams 77 presented two bands due to carbonyl stretching: 
one high intensity C=O IR stretching band, which frequency is nearly 1730 cm-1 
(asymmetric stretching) and a low intensity band, corresponding to symmetric 
stretching, nearly 1860 cm-1.  
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3.2.7 Mass Spectroscopy 
The synthesized 4-oxo--lactams were analyzed by mass spectrometry, using the 
electron-impact method of ionisation. A common route of fragmentation observed for 
all azetidin-2 ,4-diones 77 is the opening of the ring with formation of a ketene ion 
fragment and isocyanates. For the 3,3-diethyl derivatives 77a-g some characteristic 
fragments were detected, identified in Schemes 3.13 and 3.14 (m/z). 
 
N
O
O
R
C O + N CR O
C O + N CR O
m/z 98
 
Scheme 3.13 - Fragmentation of 3,3-diethylazetidin-2,4-diones with formation of diethylketene 
and the respective isocyanate. 
 
 
 
C O
m/z 98
-CH3 O
m/z 83
-C2H4 O
m/z 55
 
Scheme 3.14 - Further fragmentation of the diethylketene ion. 
 
 
Similarly, by fragmentation of the 3,3-dimethylazetidin-2,4-dione, 77h-i, the 
dimethylketene is formed (m/z = 70). 
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3.3. ALKALINE HYDROLYSIS STUDIES OF 4-OXO--LACTAMS  
3.3.1 Results and Discussion 
The chemical reactivity studies began with the selection of the wavelength to be used 
in the UV-kinetic measurements (as described earlier for the alkaline hydrolysis of N-
carbamoylazetidin-2-ones in Chapter 2, Section 2.2), and an example of a repeated 
spectral scanning for the reaction of hydroxide ion with a 4-oxo--lactam is given is 
Appendix 3, Figure A3.1. 
 
Table 3.2 - Azetidine-2,4-diones (4-oxo--lactams) studied in the present work on the intrinsic 
chemical reactivity and indication of the selected wavelength for kinetic measurements by UV 
spectroscopy. 
 
 
 
 
 
 
 
 
 
The obtained kobs values for each hydroxide-ion concentration used are given in 
Appendix 3, Section A3.1. The second-order rate constants for the ring-opening by 
alkaline hydrolysis were determined graphically and the respective plots of kobs versus 
[OH-] will follow. 
Compound  (nm) 
77b 221 
77c 247 
77d 260 
77e 247 
77f 260 
77g 280 
77h 255 
77i 260 
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Figure 3.5 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of the N-
benzyl derivatives 77b () and 77h (), against hydroxide concentration, at 25 ºC, ionic strength 
0.5 M. Points are experimental and the lines are from linear regression analysis of the data, giving kOH- 
= 0.0742 ± 0.002 M-1s-1 for 77b and kOH- = 1.80 ± 0.05 M-1s-1 for 77h. 
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Figure 3.6 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of the 
3,3-diethyl-N-(p-methoxyphenyl)-azetidine-2,4-dione 77c (), and N-(p-methylphenyl) 
counterpart 77d (), against hydroxide concentration, at 25 ºC, ionic strength 0.5 M. Points are 
experimental and the lines are from linear regression analysis of the data, giving kOH- = 0.225 ± 0.004 
M-1s-1 for 77c and 0.240 ± 0.004 M-1s-1 for 77d. 
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Figure 3.7 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of the p-
unsubstituted, 77e (), the p-chloro 77f () and the p-cyanophenyl 77g () 4-oxo--lactams, 
against hydroxide concentration, at 25 ºC, ionic strength 0.5 M. Points are experimental and the 
lines are from linear regression analysis of the data, giving kOH- = 0.340 ± 0.003 M-1s-1 for 77e, 0.581 ± 
0.008 M-1s-1 for 77f and 1.78 ± 0.02 M-1s-1 for 77g. 
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Figure 3.8 - Plot of the pseudo-first-order rate constants, kobs for the alkaline hydrolysis of 77i () 
against hydroxide concentration, at 25 ºC, ionic strength 0.5 M. For comparison, the results for 
the 3,3-diethyl counterpart 77f () were included. Points are experimental and the lines are from 
linear regression analysis of the data, giving kOH- = 9.67 ± 0.12 M-1s-1 for 77i. 
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A summary of the second-order rate constants for the alkaline hydrolysis of the 
studied 4-oxo--lactams 77b-i is presented in Table 3.3. 
 
3.3.1.1 Structure Activity Relationships for the Alkaline Hydrolysis 
By alkaline hydrolysis reaction, nucleophilic attack of hydroxide-ion at a carbonyl 
carbon with -lactam ring opening occurs. It is of interest to evaluate the effect of 
substitution on N-1 and C-3 on the rate of the reaction (Table 3.3).  
 
 
Table 3.3 - The second-order rate constants, kOH-, for the alkaline hydrolysis of 4-oxo--lactams 
77, at 25 °C and ionic strength adjusted to 0.5 M with NaClO4. The p values are given as an 
indicator of the polar effect of the substituent in the para position of the aromatic ring. 
 
N
O
OR
1
R1
R
77  
 
a Referred to the para-substituent on the aromatic ring; b From reference 125. 
 
 
Compound R1 R p  a, b kOH- / M-1s-1 
77b Et CH2Ph - 0.0742 ± 0.002 
77c Et C6H4-4-OMe -0.28 0.225 ± 0.004 
77d Et C6H4-4-Me -0.14 0.240 ± 0.004 
77e Et C6H5 0 0.340 ± 0.003 
77f Et C6H4-4-Cl 0.24 0.581 ± 0.008 
77g Et C6H4-4-CN 0.70 1.78 ± 0.02 
77h Me CH2Ph - 1.80 ± 0.05 
77i Me C6H4-4-Cl 0.24 9.67 ± 0.12 
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The substitution of the N-benzyl by N-phenyl in 4-oxo--lactams changes the leaving 
group from an amide to an anilide and causes an increase in the rate of ring opening 
by hydroxide ion, as 77e is 5-fold more reactive than 77b. N-Substitution would be 
expected to have a large effect on rate-limiting C-N fission but a much smaller one if 
nucleophilic attack on the carbonyl carbon and formation of the tetrahedral 
intermediate is the rate-limiting step. Electron withdrawing substituents (such as 4-
cyanophenyl, 77g and 4-chlorophenyl, 77f) produce a modest increase the rate of the 
alkaline hydrolysis, whereas electron donating groups with lone pairs on the atoms 
adjacent to the  system (4-OMe, 77c), decrease kOH, by increasing the electron 
density through a resonance donating effect (Figure 3.9). Overall, 77g is nearly 8-fold 
more reactive than 77c. These relative rates suggest that the rate-limiting step is 
hydroxide-ion attack and formation of the tetrahedral intermediate.  
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Figure 3.9 - Comparison of the chemical reactivity towards hydroxide between the less reactive 
3,3-diethyl-N-aryl derivative 77c (), and the most reactive one, 77g (), at 25 ºC. 
 
For the 3,3-diethyl-N-aryl derivatives 77c-g, a good correlation between the kinetic 
data and the electronic parameter p of the para-substituent on the aromatic ring was 
found, giving a Hammett p value of 0.96 (Figure 3.10). This p value is positive, 
being indicative of the development of significant negative charge on the transition 
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state. This is consistent with rate limiting formation of the tetrahedral intermediate in 
the hydroxide-ion catalyzed reaction. 
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Figure 3.10 - Hammett plot for the second-order rate constants for the alkaline hydrolysis, kOH-, 
of 77c-g at 25ºC, yielding a p value of 0.96. Line is from linear regression analysis of the data. 
 
 
There is a large steric effect of substituents  to the carbonyl carbon on the rate of 
alkaline hydrolysis. The -gem-diethyl compounds 77b and 77f are about 20-fold less 
reactive than the corresponding -gem-dimethyl compounds 77h and 77i (Figures 3.5 
and 3.8), which is also compatible with rate limiting formation of the tetrahedral 
intermediate. 
It is also important to note that the strained cyclic imide 77h 
presented similar reactivity to that reported for the acyclic 
imide 81 (kOH 1.54 M-1s-1),72 showing that there is no 
significant rate enhancement due to ring strain, once again 
compatible with the rate limiting step being the formation of 
the tetrahedral intermediate.  
 
The mechanism for the alkaline hydrolysis of 4-oxo--lactams 77 is illustrated in 
Figure 3.11. The hydrolysis product is the corresponding -amido acids, 82. 
N
O O
81  
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Figure 3.11 - The mechanism of alkaline hydrolysis of 4-oxo--lactams 77. 
 
Interestingly, at this stage of the project, another laboratory has also been 
investigating 4-oxo--lactams, in particular, 77h, as a peptidomimetic template for 
elastase inhibition, and been performing alkaline hydrolysis studies to evaluate the 
intrinsic chemical reactivity as well. Thus, it was reported that the second-order rate 
constant for alkaline hydrolysis of 77h at 30 ºC, 1% DMSO (v/v), and 1.0 M ionic 
strength is kOH- = 8.38 M-1s-1.157 Furthermore, this result was compared with the 
alkaline hydrolysis of N-benzoyl--lactam 83, in the same condition, in order to 
evaluate the effect of an exo- and endo-cyclic N-acyl substituent on the intrinsic 
chemical reactivity. In fact, compound 77h has an increased ring strain compared to 
83, due to the incorporation of the N-acyl group into the four-membered ring. 
However, it was reported that kOH- for 77h was, remarkably, only 7-fold greater than 
that for the corresponding N-benzoyl--lactam 83, demonstrating the surprisingly 
small effect of introducing another 3-coordinate carbon, formally a sp2 centre, in the 
already strained four-membered ring. Indeed, for both derivatives, the rate-limiting 
step is the formation of the tetrahedral intermediate and the release of strain does not 
occur in the transition state.157  
Since 4-oxo--lactam were designed as a result of an isosteric substitution at 3-oxo--
sultams, in order to improve hydrolytic stability, as stated in Section 1.9, the most 
remarkable result from alkaline hydrolysis studies of 4-oxo--lactams is the notably 
lower intrinsic chemical reactivity compared to 3-oxo--sultams like 35.  
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3.4. PPE INHIBITION STUDIES 
3.4.1 Results and Discussion  
In a preliminary study of 4-oxo--lactams as elastase inhibitors, the synthesized 
compounds were tested against serine protease PPE and the obtained results are 
presented next. Firstly, PPE inhibition assays were performed using the incubation 
method.136 However, incubation resulted in most cases (77c-g), in a very rapid time-
dependent loss of activity, which did not allow the determination of the inhibition 
constants.  
Therefore, inhibition was studied at 25 ºC using the progress curve method,142 by 
monitoring continuously the hydrolysis of the reporter substrate, N-succinyl-(L-Ala)3-
p-nitroanilide at 390 nm.  
Different concentrations [I] for each 77c-g derivative were assayed and typical slow-
binding inhibition progress curves were obtained, as illustrated in Figure 3.12. 
Progress curves data were analysed by slow binding kinetics.142 Thus, the initial and 
steady state velocities vi and vs, and the pseudo-first-order rate constants, kobs, were 
calculated similarly with the previously described for HLE inhibition studies, in 
Chapter 2, using Equation 2.6. 
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Figure 3.12 - Progress curves for slow-binding inhibition of PPE by 77f. Reaction conditions: 
[PPE] = 0.2 M, [N-Suc-(L-Ala)3-p-NA] = 0.3 mM, 0.1 M HEPES buffer, pH 7.2, 5% DMSO, 25 ºC. 
Inhibitor concentrations: (a), in absence of inhibitor; (b), 10; (c), 15; (d), 20; (e), 30; (f), 60; (g) and 75 
M. 
 
The obtained kobs values for each inhibitor are presented in Appendix 3, Table A3.2. 
The final plots of kobs versus [I] for 77c-g are illustrated in Figures 3.13-15. 
The plots of kobs versus the concentration of 4-oxo--lactams 77c-g were linear and 
thus consistent with the inhibition mechanism depicted earlier in Scheme 2.6, Section 
2.3.2.2 (Mechanism A).  
In this way, 77c-g react with the enzyme as alternate substrate inhibitors, leading to 
the acylation of the active site serine residue, EI, followed by slow hydrolysis to 
regenerate the free enzyme.  
The linear dependence of kobs versus concentration of inhibitor [I], as well as the 
observation that the initial velocities, vi, are all identical and equal the initial velocity 
in the absence of inhibitor (Figure 3.13), suggest that isomerization of the acyl-
enzyme did not occur under the inhibitor concentration range used. Thus, the 
inhibitory potencies of 4-oxo--lactams 77c-g, given by kon values, were calculated 
using Equations 2.7 and 2.8.  
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Figure 3.13 - Effect of inhibitor concentration on the onset of inhibition of PPE by 77c (●) and 
77d (), at 25 ºC. Points are experimental and lines are from linear regression analysis of data, giving: 
koff = 2.02 x 10-3 s-1 (ordinate intercept) and kon´ = 115 ± 7.1 M-1s-1 (slope) for 77c; and koff = 1.35 x 10-3 
s-1 and kon´ = 189 ± 3.7 M-1s-1 for 77d. By correction using Equation 2.8, kon = 124 ± 7.6 M-1s-1 for 77c 
and kon = 204 ± 4.0 M-1s-1 for 77d. Ki was obtained by the ratio koff/kon 
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Figure 3.14 - Effect of inhibitor concentration on the onset of inhibition of PPE by 77e at 25 ºC. 
Points are experimental and the line is from linear regression analysis of the data, giving koff = 1.81 x 
10-3 s-1 (intercept) and  kon´ = 191± 13.5 M-1s-1 (slope). By correction using Equation 2.8, kon = 206 ± 14 
M-1s-1. Ki was obtained by the ratio koff/kon 
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Figure 3.15- Effect of inhibitor concentration on the onset of inhibition of PPE by 77f (●) and 77g 
(). Points are experimental and the lines are from linear regression analysis of the data, giving koff = 
1.97 x 10-3 s-1 and kon´ = 251 ± 8.2 for 77f; and koff = 2.91 x 10-3 s-1 and kon´ = 629± 36 M-1s-1 for 77g. 
By correction using Equation 2.8, kon = 271± 8.2 M-1s-1 for 77f and 679 ± 39 M-1s-1 for 77g. Ki was 
obtained by the ratio koff/kon 
 
 
In these preliminary studies, a simplistic way was used to obtain koff, by the intercept 
of the plots of kobs versus the inhibitor concentration (Figures 3.13-3.15), and thus Ki 
was obtained by the ratio koff/kon.  
However, a different way to determine Ki uses Equations 2.10 and 2.11. In Appendix 
3, Section A3.2.1 the analysis of the inhibition kinetics and the determination of Ki 
based on these equations for a representative compound, 77e, are presented. In this 
way, koff is given by Equation 2.9. The obtained Ki and koff values from this method 
were consistent with those obtained from Figure 3.15. The kinetic parameters for PPE 
inhibition by 4-oxo--lactams 77c-g are listed below (Table 3.4) and discussion of 
these results will be made later in this chapter (Section 3.4.1.1). 
 
In contrast to the slow-binding inhibition kinetics displayed by 3,3-diethyl-N-aryl-4-
oxo--lactams 77c-g, progress curves for the 3,3-dimethyl analogue 77i presented 
strictly linear time courses for the hydrolysis of substrate, i.e. no initial exponential 
phase towards a steady-state was observed. Thus, the Kitz and Wilson’s method of 
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incubation was used to investigate the time-dependent inhibition.136 However, 
incubation of 15 mM of 77i with PPE, in a molar ratio inhibitor to enzyme of 15, led 
to a labile PPE inhibition, followed by a rapid increase in enzymatic activity to nearly 
90% within a few minutes of reaction (Figure 3.16). 
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Figure 3.16 - Plot of the remaining PPE activity after incubation with 77i ([I] = 15 mM) at 25 ºC, 
pH 7.2, [I]/[E] = 15, leading to a rapid increase of enzymatic activity. Points are experimental and 
reflect the withdrawn aliquots at different time intervals from the incubation mixture for measuring the 
enzymatic activity. 
 
For comparison, the 3,3-diethyl counterpart 77f, which was found to be an effective 
irreversible inhibitor of PPE, was also studied using the incubation method. Thus, it 
was possible to investigate the stability of the corresponding acyl-enzyme complex. In 
contrast to Figure 3.16, Figure 3.17 suggests that the interaction of 77f with PPE leads 
to a stable acyl-enzyme, EI, which slowly breaks down and regenerates the free, 
active enzyme, E, within a few hours of reaction and the inhibitor function as 
alternate substrate inhibitor of PPE, accordingly to Scheme 2.6, with an almost 
complete recovery of enzymatic activity. In fact, the less sterically hindered dimethyl 
derivative 77i allowed the acyl-enzyme to undergo a more rapid hydrolysis (see 
discussion later in this chapter), and the Lineweaver-Burke plot (Figure 3.18) was 
used to determine the inhibition kinetic. The respective concentrations of substrate 
and initial rates are given in Appendix 3, Section A3.2.2. 
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Figure 3.17 - Time-dependent loss of enzymatic activity. Excess of inhibitor 77f ([I] = 150 M) 
was incubated with PPE ([E] = 10 M) in 0.1 M HEPES buffer, pH 7.2, 25 ºC. Points are 
experimental and reflect withdrawn aliquots at different time intervals for measuring the enzymatic 
activity. 
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Figure 3.18 - Lineweaver-Burke plot for the PPE catalyzed hydrolysis of the substrate: in the 
absence of inhibitor (); and in the presence of 77i at 100 M, [I]/[E] = 100 () and at 60 M, 
[I]/[E] = 60 (). Points are experimental and lines are from linear regression analysis of data. At 100 
M, the obtained Ki was 9.29 M, being in good agreement with that obtained at 60 M (10.8 M). 
Thus, the Ki value for 77i, given by the average, is 10 M. 
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The trend lines in Figure 3.18 have the same ordinate intercept, indicating that Vmax is 
unaltered, but an increase in apparent Km´ agrees with Equation 3.1. Thus, 77i 
behaves as a competitive reversible inhibitor of PPE and Ki was determined 
graphically. 
Km´ = Km (1 + [I] / Ki)      (3.1) 
 
Besides the equilibrium between the enzyme and the substrate ES, a rapid reversible 
equilibrium is established between the enzyme and the inhibitor EI (Scheme 3.15), 
giving Ki = 10 M. For 77h a similar behavior was found, and the respective plot is 
depicted in Figure 3.19, giving Ki = 184 M (see data in Appendix 3, Section A3.2.2). 
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Scheme 3.15 - Competitive reversible enzyme inhibition mechanism. 
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Figure 3.19 - Lineweaver-Burke plot for the PPE catalyzed hydrolysis of the substrate, in the 
absence of inhibitor () and in the presence of inhibitor 77h at 30 M, [I]/[E] = 30 () and at 100 
M, [I]/[E] = 100 (). Points are experimental and lines are from linear regression analysis of data, 
giving Ki = 184 M for 77h. 
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By contrast, the N-alkyl-3,3-diethyl derivatives 77a and 77b were found to be non-
inhibitors of PPE, even when assayed at a final concentration of 60 M. Next, the 
results of PPE inhibition studies for the whole set of 4-oxo--lactam 77 is presented 
(Table 3.4).  
In order to explore the relationships between intrinsic chemical reactivity and enzyme 
inhibitory activity, the values for the second-order rate constant for alkaline 
hydrolysis, kOH-, for the same compounds are included in Table 3.4 and also the 
respective EREFs. Thus, the results of inhibitory activity are analyzed in conjunction 
with the data from reactivity studies. 
 
 
Table 3.4 - Kinetic parameters for PPE inhibition at pH 7.2 and 25 ºC by 4-oxo--lactams 77. For 
comparison, kOH- for the alkaline hydrolysis of the same compounds at 25 °C are included and 
also the respective EREFs. 
 
 
a No inhibition; b By using Equations 2.10-2.11, Ki = 20.2 ± 1.7 M and koff = 4.15 x 10-3 s-1, as 
presented in Appendix 3, Section A3.2.2. 
 
Compound Ki / M kon / M-1s-1 103 koff / s-1 kOH- / M-1s-1 EREF 
77a NIa NIa - - - 
77b NIa NIa - 0.0742  - 
77c 16.3 124 ± 7.6 2.02  0.225  551 
77d 6.62 204 ± 4.0 1.35 0.240  850 
77e 8.78b 206 ± 14 1.81b 0.340  606 
77f 7.28 271 ± 8.2 1.97 0.581 466 
77g 4.29 679 ± 39 2.91 1.78  381 
77h 184 - - 1.80  - 
77i 10.0 - - 9.67 - 
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3.4.1.1 Structure Activity Relationships and Molecular Modeling 
Inhibition of PPE by 4-oxo--lactams is a result of Ser-195 nucleophilic attack at one 
of the carbonyl carbons of the 4-oxo--lactam (cyclic imide), with ring opening, and 
expulsion of an amide leaving group by C-N bond fission. It is of interest to evaluate 
the effect of the substituents on C-3 and N-1 on the inhibitory potency against PPE. 
Inspection of Table 3.4 indicates that the most potent inhibitors contain an N-aryl 
group as well as two ethyl groups at C-3. In contrast, N-alkyl-4-oxo--lactams are 
either inactive (77a-b) or weak inhibitors that rapidly regenerate the active enzyme 
(77h).  
 
Free Energy Relationships for PPE Catalyzed Hydrolysis of 77c-g. The rate of 
PPE inhibition by 3,3-diethyl-N-aryl 4-oxo--lactams 77c-g was found to be linearly 
correlated with the Hammett p values for the substituent at the para position on the 
aromatic ring, giving a p value of 0.68 (Figure 3.20). For comparison, the Hammett 
plot for alkaline hydrolysis of the same compounds at 25 ºC is conveniently repeated 
in this figure. 
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Figure 3.20 - Hammett plots for the second-order rate constants, kon, for the inhibition of PPE by 
4-oxo--lactams 77c-g () and for the hydroxide-ion-catalyzed hydrolysis, kOH-, of the same 
compounds () at 25ºC.  
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The obtained positive p value for the PPE-catalyzed reaction is consistent with the 
development of significant negative charge on the transition state, indicative of rate 
limiting formation of the tetrahedral intermediate.  
In comparison to PPE inhibition studies, the alkaline hydrolysis of 4-oxo--lactams 
77c-g gave a Hammett p value of 0.96, suggesting a much greater change in charge 
on going to the transition state. Both enzyme catalyzed acylation and alkaline 
hydrolysis of the 4-oxo--lactams involve rate limiting nucleophilic attack on the -
lactam carbonyl carbon, and the strain energy of the four-membered ring is not 
released in the transition state. The different Hammett  values indicate that the attack 
of serine residue occurs at an earlier position along the reaction coordinate compared 
with the hydroxide-ion-catalyzed hydrolysis.  
This is consistent with the Hammond postulate in that these results suggest that the 4-
oxo--lactam scaffold promotes the enzyme’s ability to use its catalytic apparatus to 
stabilise the transition state and increase the rate of serine acylation, which might be 
achieved by favourable non-covalent binding of enzyme and inhibitor, stabilization of 
the tetrahedral intermediate in the oxyanion hole of the active site and compensation 
for the entropy loss required in the bimolecular reaction, being reflected in the EREF 
values (Table 3.4).  
The hydrolysis of 4-oxo--lactams catalyzed by PPE is represented in Figure 3.21, 
being in accordance with Scheme 2.6 (Chapter 2). These inhibitors function as 
acylating agents of PPE to yield an acyl-enzyme complex 84, which suffers 
deacylation (hydrolysis), regenerating the free enzyme. 
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Figure 3.21 - The hydrolysis of 4-oxo--lactams mediated by PPE. 
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Table 3.4 indicates that the most active inhibitor contains a 4-CN electron-
withdrawing substituent on the N-aromatic ring (77g) that increase the chemical 
reactivity of the carbonyl carbon towards nucleophilic attack of the Ser-195 hydroxyl 
group (inductive effect) and is nearly 5 fold more potent than 77c, which is the less 
active inhibitor of this series and contains an electron donating substituent (4-OMe) 
(Figure 3.22).  
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Figure 3.22 - Comparison between the effect of 4-oxo--lactam concentration on the onset of 
inhibition of PPE by 77c (), the most potent inhibitor of the series and 77g (), the less potent 
one, at 25 ºC. Points are experimental and lines are from linear regression analysis. 
 
 
Therefore, increasing the intrinsic chemical reactivity of 4-oxo--lactams 77c-g 
increases the rate of PPE acylation (Table 3.4), giving a good correlation (Figure 3.23, 
r2 = 0.922). For these compounds, kOH- functions as a guide to indicate the potential 
acylating power as serine enzyme PPE inhibitors. 
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Figure 3.23 - Linear correlation between the second-order rate constant for PPE inhibition, kon 
and the second-order rate constant for alkaline hydrolysis, kOH-. Line is from linear regression 
analysis of data. 
 
Molecular Modeling Studies. To rationalize the trends observed in the enzyme 
assays, the molecular interactions between some 4-oxo--lactams 77 and PPE were 
investigated using the automated GOLD docking program (see Experimental Section 
for details). These studies were performed by Dr. Rita Guedes (iMed.UL, Lisbon). 
Docking of the most potent inhibitor 77g into the active site of PPE revealed that only 
one ethyl substituent of the 3,3-diethyl group lies in the S1 pocket (Figure 3.24A). 
This binding mode is not much different than that observed for the interaction of 3,3-
diethyl--lactams with HLE, in which both ethyl substituents are accommodated in 
the larger S1 pocket.109 The distance between the closest carbonyl carbon of 77g and 
the Ser-195 hydroxyl oxygen atom is about 3.18 Å (4.79 Å for the other carbonyl 
carbon atom), which indicates that nucleophilic attack by Ser-195 to the 4-oxo--
lactam is possible. Interestingly, the “reactive” carbonyl of 77g is not involved in the 
H-bond network with the so-called oxyanion hole defined by the backbone NHs of 
Gly-193 and Ser-195: the distance between the amidic hydrogen atoms of Gly-193 
and Ser-195 to the carbonyl oxygen atom is 6.75 and 5.28 Å, respectively. This result 
may indicate that the oxyanion hole is not used to stabilize the TI derived from 77g. 
However, some several key interactions seem to stabilize 77g in the active site.  
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Figure 3.24 - Docking of 77g (A), 77c (B) and 77d (C) in the active site of PPE (see text for details). 
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First, strong hydrogen bonds involve the oxygen atom of the reactive carbonyl group 
and the NH of His-57 and the hydroxyl group of Ser-195. Second, an additional 
hydrogen bond involves the oxygen atom of the unreactive carbonyl and the amide 
group of Gln-192. Finally, enhanced Van der Waals contacts between the N-aryl 
moiety with Val-99, Phe-215 and His-57 were observed.  
For compound 77c, a less potent inhibitor, an inverted binding mode was observed, in 
which the 4-OMe substituent of the aromatic ring lies on the S1 pocket, while one of 
the ethyl substituents is close to the S1’ pocket (Figure 3.24B). The distance between 
the closest carbonyl carbon and the Ser-195 hydroxyl oxygen atom is 3.62 Å (4.38 Å 
for the other carbonyl carbon atom). However, in contrast to 77g, the “reactive” 
carbonyl of 77c is involved in the H-bond network with the NHs of Gly-193 and Ser-
195, which suggests that the oxyanion hole may be used to stabilize the resulting TI 
and to compensate the energy required for the enzyme to overcome the distance 
between Ser-195 and the carbonyl carbon. Compound 77d also presents the N-aryl 
moiety sitting in the S1 pocket of the enzyme (Figure 3.24C), but in this case the 
distance between the closest carbonyl carbon and the Ser-195 hydroxyl oxygen atom 
is 3.27 Å, i.e. close to that of 77g. This binding mode suggests that nucleophilic attack 
by Ser-195 to the 4-oxo--lactam 77d is feasible and is consistent with the EREF 
value of 850, the highest of the present series of compounds 77. 
Indeed, as 4-oxo--lactam 77 have two acyl centers, there could be interaction of 
either the C-3 (as in 77g) or the N-1 substituents (as in 77c-d), with the S1 binding 
pocket. In principle the latter could reduce the rate of acylation as a result of non-
productive binding. 
 
 
The Effects of the Substituent at C-3. It is known that the C-3 substituents allow 
interaction with the S1 binding pocket of PPE, being preferred small hydrophobic 
substituents with two carbon atoms.104 However, the C-3 dimethyl 4-oxo--lactam 
77h, interacts with PPE in a similar binding mode to that of the C-3 diethyl 
derivatives 77c-d, i.e. aromatic ring lying on the S1 pocket (Appendix 3, Figure A3.6) 
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and with the “reactive” carbonyl involved in the oxyanion hole H-bond network, as 
revealed by docking studies. 
The bigger gem-diethyl group at C-3 only provided enzyme inhibition when 
combined with chemically more electron-withdrawing N-aryl substituents, being the 
N-alkyl analogues non inhibitors. For the 3,3-diethyl derivatives, expulsion of an 
anilide by C-N fission from the decomposition of TI, contributes significantly to the 
time-dependent inhibition of PPE rather than an aliphatic amide (being 77c-g 
irreversible inhibitors while 77a-b, non-inhibitors). By contrast, both N-alkyl and N-
aryl 3,3-dimethyl derivatives 77h-i inhibited PPE, but rapidly regenerated the free-
active enzyme. 
An important criterion for the successful inhibition of serine enzymes by an acylation 
process depends upon the lifetime of the acyl-enzyme intermediate. The less sterically 
hindered acyl-enzyme intermediate 85, formed by reaction of the 3,3-dimethyl 
derivative 77i with PPE, suffered rapid hydrolysis (Figure 3.16), while the 
correspondent acyl-enzyme 86, obtained by reaction of its 3,3-diethyl counterpart 77f, 
persisted during hours (Figure 3.17). The bigger gem-diethyl group is likely to 
significantly block attack by water of the active site at the acyl-enzyme ester of 86, 
increasing its lifetime. 
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Thus, 77f is an effective time-dependent irreversible inhibitor of PPE because of its 
relatively fast acylation and slow deacylation of the enzyme, while the dimethyl 
counterpart 77i, although being a potential time-dependent inhibitor, allow the 
enzyme to turnover rapidly due to a relatively facile deacylation pathway, behaving 
macroscopically as a competitive inhibitor. 
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4-Oxo--lactams versus 3-Oxo--sultams in PPE Inhibition. Since 4-oxo--
lactams were designed as isosteric analogues of previously discussed 3-oxo--
sultams, it was of interest to compare the inhibitory properties for both scaffolds. As 
discussed in Section 1.6.2.2, PPE inhibition by 3-oxo--sultams results in a stable 
acyl-enzyme complex from enzyme-mediated ring opening by C-N bond fission, and 
expulsion of the sulfonamide leaving group.116 
On the other hand, reaction of 4-oxo--lactams 77 with PPE involves serine 
nucleophilic attack at a reactive carbonyl carbon, with expulsion of a poorer amide 
leaving group, which may improve selectivity against the target enzyme. It is 
interesting to note that the N-benzyl-3,3-dimethyl-4-oxo--lactam 77h has also been 
studied as inhibitor of PPE by W. Tsang et al, from a different laboratory, and the 
correspondent results are interesting to be discussed here. It was reported that the rate 
of formation, kon, and breakdown, koff, of the acyl-enzyme obtained by reaction of 
PPE with 77h are, respectively, 63 M-1s-1 and 0.00997 s-1, at pH 6.157 Interestingly, 
moving the C-4 carbonyl group of 77h to N-1 to give the corresponding N-acyl--
lactam 83 (Section 3.3.1.1) decreased the rate of PPE acylation, as the respective kon 
was reported to be 16.2 M-1s-1.157 This result reflects the superior inhibitory property 
of the 4-oxo--lactam scaffold over simple -lactams. 
The same author found that the rate of PPE acylation by 77h is 12-fold slower than 
that observed for the 3-oxo--sultam counterpart, 35 (35, Figure 1.12, kon = 7.68102 
M-1s-1), with the same enzyme and at pH 6.0. By contrast, the rate of deacylation in 
the reaction of PPE with 77h was reported to be 500-fold faster than that of the 
reactivation of the enzyme inhibited with 35 (35, koff = 2.0810-5 s-1).157  
Nucleophilic attack at the carbonyl centre of 35 and that of 77h generates a 
sulfonamide and an amide leaving group, respectively, being the correspondent acyl-
enzyme complexes compounds 87 and 88. Accordingly to W. Tsang, although 
sulfonamides and amides have different electronic properties (for example, 
sulfonamides are generally more acidic than amides by about 5 pKa units),158 the 
stability of the acyl ester of the acyl enzymes was unlikely to be affected by this 
property as the groups were some distance from the acyl ester. However, the sulfonyl 
group of 87, being bigger in size, was likely to severely impair attack by water for 
deacylation, increasing the half-life of 87, and thus explaining the decrease by 500-
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fold on the rate of deacylation compared with that observed with the amide leaving 
group, 88.157 The acyl-enzyme generated from the C-4 unsubstituted N-benzoyl -
lactam 83 has the structure shown in 89 and, despite the presence of the gem-dimethyl 
group, moving the carbonyl group further down in the ring-opened product reduced 
steric congestion around the acyl-enzyme ester, decreasing its half-life compared to 
88.  
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In the present study, good PPE irreversible inhibitory activity was found for 3,3-
diethyl-N-aryl derivatives 77c-g. Thus, the 4-oxo-β-lactams represent an attractive 
new class of serine proteases inhibitors.  
These exciting results prompted this project to find out the effectiveness of 4-oxo--
lactam as a suitable scaffold to design potent irreversible inhibitors of the therapeutic 
target HLE.  
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
AZETIDINE-2,4-DIONES (4-OXO--LACTAMS) AS 
POTENT AND SELECTIVE INHIBITORS OF HLE
  
 
 
4. Azetidine-2,4-diones as Potent and Selective Inhibitors of HLE 
 
 
 
137
4. AZETIDINE-2,4-DIONES (4-OXO--LACTAMS) AS POTENT 
AND SELECTIVE INHIBITORS OF HLE 
4.1. 4-OXO--LACTAM-BASED INHIBITOR DESIGN RATIONALE 
Based on the promising results obtained for 4-oxo--lactams inhibitors of serine 
protease PPE, it was reasoned that this nucleous might inactivate the therapeutic 
target HLE via a similar acylation mechanism.  
Thus, besides the synthesized azetidine-2,4-diones (Chapter 3), differently N-1 and C-
3 substituted 4-oxo--lactams were prepared, in order to investigate the structure-
activity relationships (SAR) towards HLE. These structural modifications attempt to 
improve both inhibitory potency and target selectivity, exploiting S and S´ subsites of 
the enzyme (Figure 4.1). 
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Figure 4.1 – Schematic drawing of the spatial arrangement of C-3 and N-1 substituents of 
azetidine-2,4-diones in the active site of HLE. 
 
Therefore, different groups at C-3 (gem-diethyl, gem-dimethyl, ethylbenzyl, 
methylbenzyl, ethyl-iso-butyl, ethyl-n-butyl) were incorporated to evaluate the impact 
at the S1 binding pocket of HLE for molecular recognition versus other neutrophil 
serine proteases (Cat G and PR3).  
The effect of different amide leaving groups by C-N fission in the rate of serine 
acylation was explored, by varying N-1 from N-benzyl, -phenyl, -naphtyl and -3-
pyridinyl substituents. Precedent literature stated that substitution at N-1 in -lactams 
4. Azetidine-2,4-diones as Potent and Selective Inhibitors of HLE 
 
 
 
138
allows interaction with the S1’ subsite of HLE.97, 109 On the other hand, 
aryl/heterocyclic sulfides and sulfonyl substituents have been successfully used in the 
design of HLE inhibitors based on different templates, such as the 1,2,5-
thiadiazolidin-3-one 1,1-dioxide scaffold (15, Section 1.5.4, Chapter 1).86, 159, 160 
Those substituents were used as recognition elements to probe the S1’- S3’subsites of 
serine proteases, in order to afford selective mechanism-based irreversible inhibitors. 
Subtle structural differences in the S´ subsites of HLE with closely related proteases, 
such as PR3, have been explored in this manner. In fact, in contrast to PR3, the 
overall character of these subsites in HLE is hydrophobic, enabling hydrophobic 
binding interactions with the aryl/heterocyclic sulfides to improve selectivity.  
With this background, and in an effort to obtain highly potent and selective 
irreversible inhibitors based on the azetidine-2,4-dione scaffold, it was rationalized 
that N-aryl derivatives with a para- or ortho- thioether function, could act as potential 
mechanism-based inhibitors of this enzyme. These derivatives were designed in 
analogy with the N-aryl azetidin-2-one 32 discussed in Chapter 1 (Figure 1.10). The 
expected suicide-type mechanism of enzyme inactivation (which is somehow similar 
to the one depicted in Figure 1.10), is given in Scheme 4.1 for an ortho-thioether 
functionalized azetidine-2,4-dione.  
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Scheme 4.1 Expected “double-hit” mechanism for HLE inactivation by 4-oxo--lactams 
containing a potential thiol leaving group. 
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Accordingly, nucleophilic attack of the serine residue at a carbonyl carbon atom 
would lead to ring-opening with departure of the thiol leaving group, generating a 
reactive acyl-enzyme, which ultimately would suffer Michael addition (“double-hit” 
inhibition mechanism).  
Taking into account that i) reported mechanism-based selective inhibitors of HLE 
used the phenylsulfonyl leaving group for binding into the Sn´ subsites (eg. 1,2,5-
thiadiazolidin-3-one 1,1-dioxide scaffold)85 and ii) in this work the phenylsulfonyl 
substituent best activated the azetidin-2-one scaffold towards HLE, as discussed in 
Chapter 2, a 4-oxo--lactam presenting this group was also synthesized, by oxidation 
the sulfur atom of the corresponding sulfide moiety.  
Besides these substituents, other functionalities at N-1 were interesting to be 
investigated for 4-oxo--lactam-based HLE inhibitors, such as N-sulfonyl derivatives, 
since the electron-withdrawing sulfonyl group would activate the -lactam motif. 
 
4.2. SYNTHESIS 
4-Oxo--lactams 77 with different C-3 and N-1 substituents were synthesized, and the 
procedure used in most cases consisted in the condensation of the appropriate malonyl 
dichloride with a primary amine, in the presence of TEA (Scheme 4.2). As already 
stated in the previous chapter, diethyl and dimethyl malonyl dichlorides 89 (Scheme 
4.2, respectively R1 = R2 = Et and R1 = R2 = Me) are commercially available, while 2-
ethyl-2-iso-butyl, 2-ethyl-2-benzyl and 2-methyl-2-benzyl malonyl dichlorides (89a-
c) were obtained by synthesis (Scheme 4.3).  
 
Cl Cl
O O
R1 R2
N
O
OR
1
R2
R3
(i)
N
H
N
H
O O
R1 R2
R3 R3
7789  
Scheme 4.2 - Synthesis of 4-oxo--lactams 77. Reagents and conditions: (i) R3NH2, TEA, dioxane, 
reflux. 
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Thus, commercially available 2-monosubsituted malonates 90, were alkylated to give 
the corresponding 2,2-disubstituted derivatives 91, then hydrolyzed to the 
corresponding di-acids 92, which subsequently reacted with tionyl chloride to afford 
the respective dichlorides 89a-c (Scheme 4.3). Synthesized compounds 89a-c were 
used immediately, without any purification. 
 
 
O O
OO
RR
R1
(i)
O O
OO
RR
R1 R2
HO OH
OO
R1 R2
(ii)
Cl Cl
OO
R1 R2
(iii)
90 91
89 92
90a,  R = Me, R1 = iso-Bu
90b,  R = Et, R1 = Bz
89a, R1= iso-Bu, R2 = Et 
89b, R1 = Bz, R2 = Et 
89c, R1 = Bz, R2 = Me
91a, R = Me, R1= iso-Bu, R2 = Et 
91b, R = Et, R1 = Bz, R2 = Et 
91c, R = Et, R1 = Bz, R2 = Me
92a, R1= iso-Bu, R2 = Et 
92b, R1 = Bz, R2 = Et 
92c, R1 = Bz, R2 = Me  
Scheme 4.3 - Synthesis of disubstituted malonyl dichlorides 89 from the appropriate malonates 
90. Reagents and conditions: (i) NaEtO-, R2I, reflux; (ii) exc. NaOH aq., reflux; (iii) exc. SOCl2, reflux. 
 
 
The azetidine-2,4-diones synthesized by this method are listed in Table 4.1, including 
those derivatives studied in Chapter 3, 77a-i.  
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Table 4.1 - Azetidine-2,4-diones 77 synthesized using the method illustrated in Scheme 4.2. 
 
 
As already observed in the previous chapter, decreasing the basicity of the primary 
amine increased the yield for the cyclisation process (particularly remarkable for 
pyridinyl derivatives). However, in most cases this method gave the azetidine-2,4-
diones 77 in poor yields Thus, a different strategy was investigated for synthesis of 
azetidine-2,4-diones. 
4.2.1 Cicloaddition of Ketenes Generated in situ with Isocyanates 
The synthesis of azetidine-2,4-diones 77 was also reported previously as a result of 
cicloaddition of ketenes 93 and isocyanates 94 (Scheme 4.4) in good yields.150, 161, 162 
Ketenes 96 are characterized by a carbon atom doubly bond to an oxygen atom as 
well as to another carbon atom. The HOMO is perpendicular to the plane of ketene, 
while LUMO is on ketene plane, thus allowing polarization of the oxygen and the -
Compound R1 R2 R3 Yield (%) 
77a Et Et CH2CO2Et 16 
77b Et Et CH2Ph 9 
77c Et Et C6H4-4-OMe 11 
77d Et Et C6H4-4-Me 10 
77e Et Et C6H5 15 
77f Et Et C6H4-4-Cl 14 
77g Et Et C6H4-4-CN 19 
77h Me Me CH2Ph 4 
77i Me Me C6H4-4-Cl 6 
77j Et Et C6H4-2-Me 6 
77k Et Et pyridin-3′-yl 47 
77l Et Et 6′-methylpyridin-3′-yl 39 
77m Et Et 1′-naphthyl 5 
77n Et iso-Bu C6H5 12 
77o Et CH2Ph C6H5 22 
77p Me CH2Ph C6H5 5 
77q Me Me C6H5 11 
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carbon, which is attached to the R1 and R2 substituents. By contrast, the -carbon has 
a slight positive charge, being more susceptible for nucleophilic attack, explaining the 
high reactivity of these compounds. Disubstituted ketenes are more stable than 
monosubstituted counterparts, and larger the R1 and R2 substituents, higher is the 
stability, with an increased ketene lifetime (mainly due to steric reasons). 
Staudinger first reported (1913) the reaction of ketenes 93 with isocyanates 94 to give 
azetidine-2,4-diones, 77 (R1 = R2 = R3 = Ph).161 The proposed mechanism for the 
cicloaddition reaction is presented in Scheme 4.4. 
 
N
R3-O
R2
R1
N
O
OR
1
R2
R3
93 94 77
C
O
N
C
O
R3
O
C
R1R2
 
Scheme 4.4 - Proposed mechanism for the cicloaddition of ketenes and isocyanates. 
 
 
Some published procedures for the cicloaddition synthesis of azetidine-2,4-diones 
used ketenes generated by pyrolysis.161, 162 This process for ketene generation was not 
studied in this work, since it requires cumbersome /speciallized equipment and tricky 
conditions.163 A different published procedure for obtaining ketenes consisted in the 
in situ dehydrohalogenation reaction of the respective acid chloride 95, using a 
tertiary amine such as triethylamine (Scheme 4.5).164, 165  
 
Cl
O
R2
H
R1
N
Et
Et Et
C O
R1
R2
+ + +NHEt3Cl-
95 93  
Scheme 4.5 - Ketene generated by reaction of the respective acid chloride with triethylamine. 
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In this way, 3-butyl-3-ethyl-N-phenylazetidine-2,4-dione, 77r was synthesized using 
the technique described by Dai et al.165 Thus, TEA (1.2 eq.) was added dropwise over 
a period of 4-6 h to a solution of 2-ethylhexanoyl chloride 95 (R1 = Et, R2 = n-Bu, 1 
eq.) and phenyl isocyanate 94 (R3 = Ph, 1.9 eq.) in xylene, so that the in situ 
ethylbutylketene concentration was maintained at a minimum throughout the reaction, 
in order to enhance the yield. Then, the reaction mixture was refluxed (xylene was 
used as solvent) and after work-up 77r was obtained in reasonable yield (39%).  
 
N
O
O
Et
Bu
77r  
 
Because ethylbutylketene is much more stable and easier to handle at room 
temperature than dimethyl or diethylketene,165 this ketene, generated from the 
respective acid chloride, was selected for the attempted synthesis of 3-butyl-3-ethyl-
N-tosylazetidine-2,4-dione 96 is illustrated in Scheme 4.6.  
 
N
O
O
Et
Bu
SO2
N
C
O
SO2
96
(i)
Cl
O
Bu
H
Et
 
Scheme 4.6  Attempted synthesis of 3-butyl-3-ethyl-N-tosylazetidine-2,4-dione 96. Reagents and 
conditions: (i) TEA, THF, rt + reflux. 
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By reflux, the medium turned from coloress to brown, and thus only 20 min of reflux 
were allowed. However, after workup, the cicloaddition product 96 was not obtained 
and the isolated product was the 2-ethyl-N-tosylhexanamide 97 (40 % yield). This 
product is likely to be the result of hydrolysis and subsequent decarboxylation of 
highly reactive azetidine-2,4-dione 96. Another explanation would be the hydrolysis 
of the tosyl isocyanate to give the corresponding sulfonamide, which would react with 
the ketene. Nevertheless, since the tosylamine has a reduced nucleophilic power due 
to the electron-withdrawing sulfone function, this route seems to be less important for 
97.  
 
O
N
H
S
O
O
97  
 
The strategy of cicloaddition of ketenes and isocyanates was also investigated to 
prepare N-acyl azetidine-2,4-diones 98 (Scheme 4.7). Thus, reaction of 
chlorocarbonyl isocyanate 94 (R3 = COCl, 1.3 eq.) with ethylbutylketene (generated 
in situ from 2-ethylhexanoyl chloride 95, R1 = Et, R2 = n-Bu, 1 eq. and TEA, 1.1 eq.) 
was carried out in inert atmosphere at room temperature, adopting described 
procedures.148 After 2h30 of reaction, that is, more 30 min. than the time reported for 
99 using ethylbutylketene generated by pyrolysis, aniline (1.1 eq.) was carefully 
added (Scheme 4.7) (evolution of hydrogen chloride).  
The reaction mixture was stirred at rt and TLC analysis revealed the formation of new 
products. A white solid precipitated in the reaction medium, which was filtered-off 
and purified by column chromatography. Compound 100 was isolated, which is a 
result of the reaction of two molecules of aniline with one of chlorocarbonyl 
isocyanate. Purification of the solid in the filter also afforded a white solid that gave a 
complex 1H-NMR spectrum, inconsistent with the desired product and, even 
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combined with data from mass spectrometry, it could not be assigned to another 
structure. The solvent of the filtrate was removed under reduced pressure, and the 
residue purified by column chromatography on silica gel. However, 98 was not 
isolated and compounds 100 (purified from the solid and the filtrate in a total yield of 
33%, the major product) and 101 (20% yield) were obtained. 
 
Bu
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O
ClN
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O
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Scheme 4.7 - Attempted synthesis of 3-butyl-3-ethyl-N-phenylcarbamoylazetidine-2,4-dione 98. 
Reagents and conditions: (i) TEA, THF, rt; (ii) aniline, rt. 
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This strategy for N-acyl derivatives was no further investigated. Similarly, no further 
attempts were made for N-sulfonyl 4-oxo--lactams. In fact, the intrinsic chemical 
reactivity of these activated 4-oxo--lactams was likely to be exceedingly high, 
compromising their interest as potential therapeutic agents.  
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4.2.2 Thioether Functionalized N-aryl-azetidine-2,4-diones 
Derivatives 103a-j were synthesized by first converting N-methylaryl 4-oxo--
lactams 77d, 77j and 77l into their N-bromomethylaryl derivatives 102a-c (Scheme 
4.8 and Table 4.3), using NBS, and then reacting these with the appropriate thiol in 
the presence of triethylamine. Compound 103k was prepared by oxidation of the 
corresponding sulfide 103j using meta-chloro-perbenzoic acid (MCPBA) (Scheme 
4.8). The synthesized final azetidine-2,4-diones 103 are listed in Table 4.2.  
 
 
77d, 77j or 77l
N
O
O
X
Br
(i)
102a, X = CH, p-CH2Br
102b, X = CH, o-CH2Br
102c, X = N, p-CH2Br
(ii)
N
O
O
X
SAr
103a-j
103j
(iii)
N
O
O
SPh
N
O
O
SO2Ph
103k
o
p
o
p
 
 
Scheme 4.8 – Synthesis of N-heteroarylthiomethyl azetidine-2,4-diones 103a-k. Reagents and 
conditions: (i) NBS, CCl4, benzoyl peroxide; (ii) ArSH, Et3N, THF; (iii) meta-chloro-perbenzoic acid 
(MCPBA), DCM. 
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Table 4.2 - Synthesized N-heteroarylthiomethyl azetidine-2,4-diones 103a-k. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound Z Yield (%) 
103a S
S
N
 
68 
103b S
O
N
 
95 
4.15c S N
O
N
Ph 
87 
103d 
S
N
N
Me  
70 
103e S
S
N
 
73 
103f S
O
N
 
59 
103g S
O
N
CO2H
 
24 
103h S N
O
N
Ph 
71 
103i N S
S
N
 
61 
103j 
S
Ph 
79 
103k 
S
Ph
O O
 
83 
103
N
O
O
Z
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Compound 103g was prepared by reaction of 102a with synthesized 2-
mercaptobenzoxazole-5-carboxylic acid (51, Scheme 2.3, Chapter 2).  
 
Table 4.3 - Key intermediates N-bromomethylaryl azetidine-2,4-diones 102a-c. 
N
O
O
X
o
p
102a-c
Br
 
 
 
 
 
 
4.2.3 NMR Spectral Characterisation 
Similarly to that discussed in Chapter 3, all synthesized 4-oxo--lactam derivatives 
preseting a gem-diethyl substituent at C-3 presented a quartet (integrating for four 
protons) and a triplet (integrating for six protons) in the 1H-NMR spectra, 
corresponding respectively to the methylene and methyl protons.  
In the same way, the methylene protons of the benzyl substituent at C-3 of 
compounds 77o and 77p are equivalent and give a singlet in the 1H-NMR spectra. 
Likewise, the methylene protons of the ethyl substituent at C-3 of compounds 77n-o 
and 77r give a quartet, integrating for two protons. 
The two methylene protons of the N-C6H5CH2X substituent at N-1 (X= Br or SAr) of 
compounds 102 and 103 appear as a singlet in the 1H-NMR spectra, integrating for 
two protons (ranging 4.5-4.6 for 102 and 4.1- 4.7 ppm for 103). 
Compound X Bromethyl position Yield (%) 
102a CH para 71 
102b CH ortho 66 
102c N para 36 
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4.2.4 IR Spectroscopy 
All 4-oxo--lactams synthesized displayed two carbonyl carbon stretching bands in 
the IR spectra: one high intensity band (corresponding to asymmetric stretching) at 
nearly 1730 cm-1 and a low intensity band (symmetric stretching) at nearly 1860 cm-1. 
 
4.2.5 Mass Spectroscopy 
All synthesized 4-oxo--lactams were analysed using the electron-impact method of 
ionization. Compounds 77 presented a common fragmentation rout, involving 
formation of ketene ion and isocyanate fragment, in the same way as discussed in 
Chapter 3, Section 3.2.7. 
4-Oxo--lactams 102 presented the expected double molecular ion at m/z = M+ and 
(M+2)+. A common fragmentation route was observed, involving loss of the terminal 
bromine atom, and formation of the respective quinone methide imine ion (m/z 230 
for 102a-b and 231 for 102c, due to the replacement of one CH by a nitrogen atom N 
on the aromatic ring), which subsequently fragmented to the respective isocyanate and 
diethylketene. As an example, the fragmentation pathway for 102a is given in Scheme 
4.9.  
All 4-oxo--lactams 103 also presented a similar fragmentation route, due to C-S 
fission to form the quinone methide imine ion, which further fragmented to the 
corresponding isocyanate and diethylketene.  
For the para-substituted analogues 103e-h and 103j-k, the same quinone methide 
imine ion illustrated in Scheme 4.9, as well as identical further fragments were 
observed. For 103i the isocyanate differed in one unit of mass (m/z = 133). In 
addition, an isocyanate still linked to the sulfur moiety was also found for this 
compound, as a result of an earlier 4-membered ring fission.  
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Scheme 4.9 - Fragmentation of 3,3-diethyl-N-(4-(bromomethyl)phenyl)-azetidine-2,4-dione, 102a. 
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4.3. ENZYME INHIBITION STUDIES 
4.3.1 HLE Inhibition Studies: Results and Discussion 
With exception for the bromomethylphenyl intermediates 102, all synthesized 
azetidine-2,4-diones were assayed against HLE to evaluate the inhibitory activity. In 
fact, due to the presence of bromide as a potential leaving group, 102 would lead to 
potential toxic effects associated with bromide, with no interest as drug candidates. 
The progress curve method was used for kinetic studies of HLE inhibition.142 All 4-
oxo--lactams 77 and 103 displayed time-dependent inhibition of HLE and for each 
inhibitor several concentrations were tested. The exception was compound 77q, as 
only one concentration of this inhibitor was assayed ([I] = 0.5 M). The progress 
curves presented an initial exponential phase followed by a linear steady-state 
turnover of the substrate and were analyzed by the formalism of slow binding 
kinetics, using the Equation 2.6, presented at Section 2.3.2.2, Chapter 2.  
For the more potent inhibitors, 103e-j, an extremely rapid enzyme inactivation at very 
low inhibitor concentrations was found. In these experimental conditions, in which 
the inhibitor concentration was not much higher than that of HLE (i.e. < 10[E]), the 
progress curves had the same shape as those described by Equation 2.6, but were 
fitted by non-linear least-squares regression analysis to Equation 4.1, which accounts 
for the tight-binding nature of those inhibitors.21 Examples of typical progress curves 
for HLE inhibition by 4-oxo--lactams 77a, 77l and 103f, at different concentrations 
are given in Figures 4.2-4.4, respectively. It is important to note that 77a is one of the 
least potent inhibitors tested, while 103f is the most potent one. 
 
         01/exp1ln/1)( AtkkvvtvA obsobssis    (4.1) 
 
where 
       2/1/ is vvIE   (4.2) 
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Figure 4.2- Typical progress curves for the inhibition of HLE by 77a. Reaction conditions: [HLE] 
= 20 nM, [MeOSuc-Ala-Ala-Pro-Val-p-NA] = 1 mM, 0.1 M HEPES buffer, pH 7.2, 3% DMSO, 25 ºC. 
Inhibitor concentrations: (a) in absence of inhibitor, (b) 2500, (c) 10000, (d) 25000 and (e) 50000 nM. 
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Figure 4.3 - Typical progress curves for the inhibition of HLE by 77l. Reaction conditions: [HLE] 
= 20 nM, [MeOSuc-Ala-Ala-Pro-Val-p-NA] = 1 mM, 0.1 M HEPES buffer, pH 7.2, 3% DMSO, 25 ºC. 
Inhibitor concentrations: (a) in absence of inhibitor, (b) 75, (c) 100, (d) 250, (e) 375, (f) 500 and (g) 
750 nM. 
a 
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b 
c 
 
d 
e, f, g 
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Figure 4.4 - Typical progress curves for HLE inhibition by compound 103f. Reaction conditions: 
[HLE] = 20 nM, [MeO-Suc-(L-Ala)2-L-Pro-L-Val-p-NA] = 1mM, 0.1M HEPES buffer, pH 7.2, 3% 
DMSO, 25 ºC. Inhibitor concentrations: (a) absence of inhibitor, (b) 6.25, (c) 12.5, (d) 25, (e) 50 and (f) 
75 nM. 
 
 
For each compound, the progress curves data for each concentration were fitted by 
non-linear regression analysis to the appropriate Equation (2.6 or 4.1), through a 
routine ENZFIT software. This programme was developed at iMed.UL by Prof. Luís 
Gouveia, enabling calculation of i, s and kobs parameters with high accuracy (fitting 
residuals typically less than +/-0.001 Abs units).  
The obtained kobs values for compounds 77 and 103 (given in Appendix 4, Section 
A4.1.1, Table A4.1), displayed a linear or a hyperbolic dependence with the 
concentration of inhibitor, [I], in accordance with the previously discussed 
mechanisms A or B for slow-binding enzyme inhibition (Figure 2.28, Chapter 2).  
 
In most cases (77a-c, 77e, 77h-p, 77r, 103d-e, 103h-j) the plots of kobs versus 
concentration of [I] were linear, in agreement with mechanism A, as can be seen at 
Figure 4.5 and at Appendix 4, Section A4.1.2, Figures A4.1-12. Good linear 
regressions using Equation 2.7 (Chapter 2) gave the apparent second-order rate 
constants for HLE acylation, kon´, with high accuracy. Subsequent corrections by 
Equation 2.8 (Chapter 2) afforded kon values as an index of the inhibitory potency.  
a 
 
 
 
b 
c 
 
d 
e,f 
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In such situations, the initial velocities, vi, are all identical and equal the initial 
velocity in the absence of inhibitor, v0 (eg., Figures 4.2 and 4.3). The steady-state 
dissociation constants of the enzyme-inhibitor complex, Ki were calculated using the 
steady-state velocities, vs, together with v0, fiting by non-linear regression to Equation 
2.10 (using GraphPad Prism™ software), and then correcting through Equation 2.11. 
Therefore, Ki values were afected by the errors presented by those previous 
parameters, but, in most cases, the respective uncertainty presented quite acceptable 
values with no signs of bias. The data for determination of Ki, as well as the 
respective plots of vs versus the concentration of inhibitor, are given in Appendix 4, 
Section A4.1.3. The first-order rate constant for deacylation, koff, were given by 
Equation 2.9. 
 
As an example, the determination of kinetic parameters for HLE inhibition by 
compound 77l (mechanism A) from data shown in Figure 4.3 is presented next (Table 
4.4 and Figures 4.5 and 4.6).  
 
 
Table 4.4 - kobs and vs obtained from non-linear regression analysis using Equation 2.6 for HLE 
inhibition by compound 77l. 
 
 
 
 
 
 
 
 
 
 
109 [77l] / M 103 kobs /s-1 105 vs / s-1 
0 - 104.3 
75.0 3.18 12.96 
100 3.44 8.24 
250 7.03 3.30 
375 10.0 2.36 
500 12.4 1.58 
750 18.7 1.09 
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Figure 4.5 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77l. The values 
for kobs were obtained as average of as least duplicate assays from fits to Equation 2.6 of data shown in 
Figure 4.3. Points are experimental and the line is from linear regression analysis of the data presented 
in Appendix 4, Table A4.1, 77l, giving kon´ = (2.30 ± 0.05) x 104 M-1s-1 accordingly to mechanism A. 
By correction using Equation 2.8, kon = (1.67 ± 0.04) x 105 M-1s-1 for 77l. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 - Plot of the steady-state rates versus [I] for the inhibition of HLE by compound 77l. 
The values for the steady-state rates were obtained from fits to the data shown in Figure 4.3. Points are 
experimental and the line is from non linear regression analysis of the data shown in Appendix 4, Table 
A4.2, 77l, using Equation 2.10, for Ki´= 9.69 ± 0.50 nM, which gave after correction using Equation 
2.11, Ki = 1.33 ± 0.07 nM. The insert is a Dixon plot to show the linearity. 
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For the remaining inhibitors (77d, 77f-g, 103a-c, 103f-g), a hyperbolic plot of kobs 
versus [I] was observed (eg. Figure 4.7). In such cases, the initial velocities decrease 
with increasing the inhibitor concentration (eg. Figure 4.4). Thus, it suggested that a 
preassociation complex EI accumulated under the experimental conditions used, 
which then isomerized relatively slowly to the tight or stable complex, EI*, in 
agreement with mechanism B of Figure 2.28. By non-linear regression analysis using 
Equation 2.12 (Section 2.3.2.2), kinact (the first-order rate constant for the chemical 
inactivation step), Ki´ (the apparent dissociation constant for EI) and koff were 
obtained. The corrected Ki was given by Equation 2.11 and the overall dissociation 
constant for EI*, Ki*, was calculated from Equation 4.3.  
As an example, the determination of the inhibition parameters for compound 103f is 
presented in Figure 4.7. 
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Figure 4.7 - Effect of inhibitor concentration on the onset of inhibition of HLE by 103f. The values 
for the pseudo-first order rate constants (Appendix 4, Table A4.2, 103f) were obtained from fits to the 
data shown in Figure 4.4, using Equation 4.1. The solid line was obtained using non-linear regression 
analysis to Equation 2.12. From this plot, kinact = (9. 57 ± 0.08) x 10-3 s-1, Ki´ = 21.4 ± 5.6 nM and koff = 
(1.23 ± 0.36) x 10 -3 s-1. By correction (Equation 2.11), Ki = 2.96 ± 0.78 nM and Ki* = 0.34 nM. 
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The overall dissociation constant for 103f, Ki*, defined by Equation 4.3, was found to 
be 0.34 nM, while Ki was found to be 2.96 nM. In fact, accordingly to the mechanism 
B of slow binding inhibition, Ki* is lower than Ki, and conforms to the observed 
formation of EI* during the experimental assay. The second-order rate constant for 
the formation of EI*, kon, given by Equation 2.13 (Section 2.3.2.2), was found to be 
3.24 x 106 M-1s-1 for 103f. Remarkably, this association rate constant compare 
favorably with those of other very potent HLE inhibitors. For example, the kon value 
for HLE inactivation by 103f is one order of magnitude higher than that reported for 
β-lactam L-680,833 (compound 27, Chapter 1).103  
The plots of kobs versus the inhibitor concentration for the remaining compounds 77d, 
77f-g, 103a-c and 103g are presented in Appendix 4, Section A4.1.4. The value of koff 
for compounds 77d, 77f and 103c could not be distinguished from zero, and thus the 
corresponding Ki* were not determined. 
 
The relevant kinetic data for the whole set of 4-oxo--lactams are outlined in Table 
4.5. The kon values, ranging from 2102 to 3106 M-1s-1, were used as an index of 
inhibitory potency. Discussion of these results will be made in Section 4.3.1.1.  
 
To study the efficiency of inactivation, titration of enzymatic activity studies were 
performed, in which HLE was incubated during 30 minutes with different 
concentrations of 77g at pH 7.2 (see data in Appendix 4, Section A4.1.5). The 
fractional remaining activity was found to be proportional to the molar ratio of 
inhibitor to enzyme, as illustrated in Figure 4.8. The extrapolation of the linear part of 
the curve to the line to vt/vi = 0 (complete inactivation) gives the partition ratio; 
approximately 1.5 molecules of 77g are required to completely inactivate one 
molecule of enzyme. This result suggests that 77g is a very efficient irreversible 
inhibitor of HLE, and is consistent with the formation of a tight complex as revealed 
by the hyperbolic dependence of kobs versus [I]. Similar low partition ratios were also 
reported for monocyclic -lactams inhibitors of HLE, as 1.3 molecules of -lactam L-
680,833 (compound 27, Chapter 1) are required to inactivate HLE to approximately 
99%.137 
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Table 4.5 - Kinetic data for HLE inhibition by 4-oxo--lactams. See text for definition of each 
kinetic parameter. 
 
Comp R1 R2 R3 kon/M-1s-1 koff /s-1 kinact/s-1 
Ki (or 
Ki*)/nM 
77a Et Et CH2CO2Et 7.33x102 1.61x10-4 -- 219  
77b Et Et CH2Ph 1.76x103 2.01x10-4 -- 114  
77c Et Et C6H4-4-OMe 3.05x105 2.16x10-4 -- 0.708  
77d Et Et C6H4-4-Me 6.47x105 ~0 3.12x10-2 
48.2 
(ND)  
77e Et Et C6H5 2.41x105 2.92x10-4 -- 1.21  
77f Et Et C6H4-4-Cl 6.61x105 ~0 3.83x10-2 
57.9 
(ND )  
77g Et Et C6H4-4-CN 5.08x105 7.08x10-4 3.23x10-2 
63.5  
(1.36a) 
77h Me Me CH2Ph 6.21x103 2.14x10-4 -- 34.4 
77i Me Me C6H4-4-Cl 3.94x105 9.38x10-3 -- 23.8 
77j Et Et C6H4-2-Me 1.11x103 2.58x10-4 -- 233  
77k Et Et pyridin-3′-yl 1.01 x105 2.26x10-4 -- 2.24  
77l Et Et 6′-methylpyridin-3′-yl 1.66 x105 2.22x10-4 -- 1.33  
77m Et Et 1′-naphthyl 4.35x103 1.48x10-4 -- 33.9  
77n Et iso-Bu C6H5 2.85x104 1.10x10-4 - 3.87  
77o Et CH2Ph C6H5 2.00x103 2.54x10-4 -- 127  
77p Me CH2Ph C6H5 2.67x102 1.19x10-3 -- 4450 
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77q Me Me C6H5 1.87x105 c ND -- ND 
77r Et n-Bu C6H5 2.86x105 2.42x10-4 -- 0.85  
103a Et Et 
 
1.50x104 1.49x10-3 4.24x10-3 
283 
(73.7a) 
103b Et Et 
 
3.49x104 2.74x10-4 7.15x10-3 
205 
(7.57 a) 
103c Et Et 
 
5.99x104 a ~0 2.12x10-2 
353 
(ND) 
103d Et Et 
 
1.26x103 2.56x10-4 -- 203 
103e Et Et 
 
1.15x106 9.40x10-4 -- 0.82 
103f Et Et 
 
3.24x106 1.23x10-3 9.57x10-3 
2.96 
(0.34 a) 
103g Et Et 
 
1.77x106 1.99x10-3 1.68x10-2 
9.50 
(1.01a) 
103h Et Et 
 
2.28x106 2.56x10-3 -- 1.12 
103i Et Et 
 
3.18x106 1.59x10-3 -- 0.50 
103j Et Et 
 
1.17x106 2.08x10-3 -- 1.78 
103k Et Et 
 
1.46x106 1.32x10-3 -- 0.90 
 
a Value for Ki* (using Equation 4.3); b kobs/[I] determined at [77q] = 0.5 µM 
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Figure 4.8- Inactivation of HLE as a function of the ratio [77g]/[enzyme] at a fixed [HLE] of 10 
M. Various amounts of inhibitor 77g (25-800 nM) in 0.1M pH 7.2 HEPES buffer were incubated 
at 25 °C for 30 min, then aliquots were withdrawn and measured for the remaining enzyme 
activity. Points are experimental and the line is from linear regression analysis of data shown in 
Appendix 4, Table A4.3, giving a partition ratio of nearly 1.5. 
 
 
4.3.1.1 Structure Activity Relationships  
Substitution at C-3. N-phenylazetidine-2,4-diones 77e and 77n-q and 77r were 
assayed against HLE, and it was found that the rate of HLE inhibition depends on the 
size of the substituent at C-3. The gem-diethyl 77e, as well as the ethyl-n-butyl 77r 
were the most potent inhibitors of this series, as measured by the corresponding kon 
values. By replacing one ethyl substituent in 77e by a larger benzyl moiety, as in 77o, 
the inhibitory potency (kon) decreases by 120-fold and increased Ki ca. 100-fold. By 
changing the gem-diethyl group of 77e to a methylbenzyl moiety, i.e. 77p, drastically 
decreases the kon value by 900-fold, and dramatically increases the Ki nearly 3700-
fold. In addition, the iso-butyl derivative is nearly 8-fold less potent than 77e. In 
contrast, the most potent inhibitor in the N-phenyl series was the 3-ethyl-3-n-butyl 
derivative, 77r, with kon = 2.9105 M-1s-1 and Ki = 0.85 nM. Overall, these results are 
consistent with the known preference of HLE for small hydrophobic aliphatic 
substituents at C-3 of monocyclic -lactams for optimal interaction with the S1 
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binding pocket of the enzyme.97 As previous work had demonstrated that an ethyl-n-
butyl substituent rather than a gem-diethyl group on C-3 of monobactams, have a 
reduced inhibitory activity in vivo (probably due to a greater protein binding)97, the 
gem-diethyl series were preferentially synthesized. 
Furthermore, the C-3 gem-diethyl derivative 77f is nearly 2-fold more active than the 
gem-dimethyl counterpart 77i, and allows accumulation of the acyl-enzyme 
(hyperbolic kinetics), as the koff value is indistinguishable from zero. Thus, it reflects 
an increased affinity to HLE, while the gem-dimethyl counterpart shows a linear 
dependence of kobs with [I]. By contrast, for the N-benzylazetidine-2,4-diones, the 
gem-dimethyl derivative 77h is nearly 4-fold more active than its gem-diethyl 
counterpart 77b. 
 
 
Substitution at N-1. Derivatives with different N-aryl and N-alkyl substituents on N-
1 were tested, in order to evaluate the effect of the ability of the amide leaving group 
by C-N bond fission on the inhibitory potency of 3,3-diethyl-4-oxo--lactams. 
Replacing the N-benzyl by an N-phenyl derivative significantly increases in the rate of 
enzyme inhibition, as the kon value for 77e is nearly 137-fold higher than that of 77b. 
This effect can be ascribed to the different leaving group abilities of the amide formed 
from the decomposition of the tetrahedral intermediate generated from 77e and 77b. 
However, the amide leaving group ability is not the only factor affecting inhibitory 
potency. For example, the N-1-naphthyl derivative, 77m, is 55 times less reactive 
towards HLE than its N-phenyl counterpart, 77e, suggesting that rigid substituents at 
this position may be responsible for some non-productive binding interactions. 
Compound 77d is 583-fold more potent than 77j, the ortho positional isomer, and 
may reflect the less stereochemically hindered carbonyl carbon of 77d towards 
nucleophilic attack. 
 
The inhibitory potency of 4-oxo--lactams 77c-g towards HLE does not correlate 
with the Hammett p value of substituents at the aromatic moiety (p values were 
presented in Table 3.3, Chapter 3). Thus, all p-substituted derivatives of this set (77c-
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d and 77f-g) were found to be more potent inhibitors than 77e, p-unsubstituted, being 
the inhibitory potency independent on the electron-withdrawing strength of the 
appendage. Analysis of the data for the N-aryl, 77c-g, and N-(3′-pyridyl), 77k-l, series 
indicate that potency is not significantly affected by the electronic properties of 
substituents in the aromatic moiety. For example, the 4-methylphenyl and 4-
chlorophenyl derivatives (77d and 77f, respectively) have roughly the same kon values 
(ca. 6.5105 M-1s-1), which were ca. 3- and 6-fold higher than those of the 
unsubstituted and 3′-pyridyl counterparts, 77e and 77k, respectively. This can be 
explained by a significant degree of molecular recognition of these derivatives by 
HLE.  
 
For both ortho and para N-functionalized derivatives 103, the incorporation of a 
thioether function ortho or para to the azetidine ring nitrogen, improved the inhibitory 
potency (kon) towards HLE when compared to the unfunctionalized counterparts 77j, 
77d and 77l. For example, 103a, 103e and 103i are respectively 14, 2 and 20-fold for 
more potent than the methylphenyl analogues 77j, 77d and 77l.  
Remarkably, all para-substituted derivatives of the set of compounds containing a 
thioether function (i.e. 103e-k) afforded extraordinarily high inhibitory potencies, 
with values of kon ranging from 1.2 x 106 to 3.2 x 106 M-1s-1, and very low Ki values, 
ranging from 0.50 to 9.5 nM. These inhibitors are even more potent than previously 
reported monocyclic -lactams inhibitors of HLE, such as L-680,833 (27, Chapter 1, 
kon = 6.22 x 105 M-1s-1).103 The high inhibitory potency of 103e-k against HLE is 
remarkably of the same order of magnitude of DMP-777 (compound 29, Chapter 1, 
kon = 3.78 x 106 M-1s-1),106 which was reported to be in Phase II clinical trials for 
cystic fibrosis, juvenile rheumatoid arthritis and emphysema.6  
In contrast, the ortho-substituted derivatives 103a-d demonstrated lower kon and much 
higher Ki values than the corresponding para-analogues, in line with results observed 
for their unfunctionalized analogues, 77d and 77j. For example, para-substituted 
inhibitors 103e, 103f and 103h presented higher kon values than the corresponding 
103a-c, respectively by nearly 90-, 80- and 40-fold. In addition, 103e has a 345-fold 
lower Ki than 103a. 
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Two inhibitors from the para-substituted set, 103f and 103g, exhibited a hyperbolic 
dependence of kobs versus [I] (Figure 4.7 and Figure A4.38, Appendix 4, Section 
A4.1.4). Since both are derivatives of the thiol 2-mercaptobenzoxazole, one may 
suspect that this moiety allows specific interaction within the active site of the 
enzyme, thereby facilitating formation of a specific preassociation enzyme-inhibitor 
complex.  
Replacing the oxygen atom of the benzoxazole moiety of 103f by a sulfur atom, 
giving a benzothiazole moiety (as in 103e), decreases the inhibitory potency by nearly 
3-fold. This reinforces the idea that the benzoxazole substituent effects a gain in 
molecular recognition, with its oxygen atom involved in hydrogen bonding within the 
active site. Interestingly, the incorporation of a meta nitrogen atom into the aromatic 
ring, as in 103i, improves inhibitory potency when compared to its carba counterpart, 
103e. This finding contrasts with the lower potency of 77k and 77l compared with the 
corresponding N-phenyl analogues. The electron-withdrawing phenylsulfone moiety 
of 103k allows a better acylation rate and a lower Ki than the corresponding sulfide 
103j. 
 
 
Stability of the acyl-enzyme complex. In order to study the stability of the acyl-
enzyme complex, HLE was incubated with a 5-fold excess of 103a or 103e, 
respectively the ortho- or para-substituted methyl-(2-mercaptobenzothiazole) 
derivatives. Either 103a or 103e led to a very rapid time-dependent inactivation of 
HLE, enabling the formation of a tight acyl-enzyme adduct which persists during 
hours and slowly regenerates the free, active enzyme (the half-life for enzyme 
reactivation is nearly 5 hours for both, as shown in Figures 4.9 and 4.10). While 
incubation of HLE with 103a allowed a complete regain of enzymatic activity within 
24h, the para isomer 103e allowed a partial regain. 
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Figure 4.9 - 1M of inhibitor 103a was incubated with 0.2 M of HLE in 0.1 M pH 7.2 HEPES 
buffer, at 25ºC. Points are experimental and reflect aliquots withdrawn at different time intervals from 
the incubation mixture for determining remaining enzymatic activity. 
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Figure 4.10 - 1M of inhibitor 103e was incubated with 0.2 M of HLE in 0.1 M pH 7.2 HEPES 
buffer, at 25ºC. Points are experimental and reflect aliquots withdrawn at different time intervals from 
the incubation mixture for determining remaining enzymatic activity. 
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4.3.1.2 Molecular Modeling Studies 
In order to gain further insight and understanding into the observed inhibitory 
potencies shown by 4-oxo--lactams, molecular docking simulations were performed 
using inhibitors 77p, 103e, 103f and 103i. The molecular interactions between these 
compounds and the HLE were performed by Dr. Rita C. Guedes (iMed.UL, Lisbon), 
using the program GOLD166 (PDB code 1HNE). The top 15 conformations (i.e. those 
with the highest GoldScore fitness score) were visually analyzed for hydrophobic 
interactions between the ligand and the residues defining the S1 pocket and the 
distance between the O oxygen atom of Ser-195 and both 4-oxo-β-lactam carbonyl 
carbon atoms (OSer195-CO). 
Modeling 103e into the active site of HLE revealed multiple attractive binding 
interactions. Both ethyl substituents at C-3 of the 4-oxo-β-lactam moiety are 
accommodated in the S1 pocket where they interact with Val-190, Phe-192 and Val-
216 (Figure 4.11A). This binding mode is in good agreement with that observed for 
3,3-diethylazetidin-2-ones with HLE.109 Enhanced van der Waals contacts between 
the benzothiazole moiety with Leu-99 and His-57 were also observed. The OSer195-
CO distances for 103e are 2.6 and 2.8 Å, suggesting that nucleophilic attack by Ser-
195 at the 4-oxo--lactam is likely to be a facile process. Moreover, the carbonyl of 
103e closest to Ser-195 is involved in the H-bond network of the so-called oxyanion 
hole defined by the backbone NHs of Gly-193 and Ser-195, suggesting that the 
oxyanion hole is used to stabilize the tetrahedral intermediate derived from 103e.  
Docking of 103f and 103i into the active site of HLE revealed two binding poses: the 
normal pose (12 and 14 conformations out of the top 15 solutions, respectively), in 
which the ethyl groups at C-3 of the 4-oxo-β-lactam moiety sit in the S1 pocket and 
the carbonyl carbon atoms lie close to the Ser-195 hydroxyl oxygen atom (OSer195-
CO = 2.5/2.7 Å and 2.5/2.8 Å, respectively, Figure 4.11B and C); and the inverted 
pose, in which the benzothiazole (103i) and benzoxazole (103f) moieties are within 
the S1 site, while the four-membered ring is sitting outside the active site. The 
inverted binding mode does not favour HLE acylation, as the average shortest 
OSer195-CO distance is 5.3 Å.  
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Figure 4.11 - Docking poses of 103e (A), 103f (B), and 103i (C) in the active site of HLE, obtained 
from PDB 1HNE. Pictures were prepared using Pymol.167     
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However, its low frequency of occurrence is consistent with the observed inhibitory 
efficiency (three-fold higher kon values for 103f and 103i as compared with 103e). The 
presence of such inverted binding modes in top ranking conformations has been 
reported for other potent irreversible thrombin inhibitors.168 In contrast, all top 
ranking docking solutions of 77p correspond to the inverted pose, with the N-phenyl 
group inside the S1 pocket and an average shortest OSer195-CO distance of 5.5 Å 
(Figure 4.12), a result entirely consistent with the weaker HLE inhibition profile of 
77p.  
 
 
Figure 4.12 - Docking pose of 77p in the active site of HLE, obtained from PDB 1HNE. (Picture 
prepared using Pymol).167 
 
4.3.2 Selectivity Studies 
4.3.2.1 Proteinase 3 Inhibition Studies 
PR 3 inhibition studies were perfomed using the progress curve method, by measuring 
the release of p-nitroaniline from the hydrolysis of the chromogenic substrate MeO-
Suc-(L-Ala)2-L-Pro-L-Val-p-NA (the same used for HLE inhibition assays). This 
substrate is known to be hydrolyzed less efficiently by PR3 than HLE, due to a 100-
His 57 
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Phe 41 
Phe 192 
Val 190 
Val 216 
Leu 99 
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fold lower proteolytic coefficient kcat/Km for PR3.169 Thus, it required longer 
experiences for monitoring PR3-catalyzed reactions.  
Only one concentration of each representative 4-oxo--lactam was tested, at least in 
duplicate, and the progress curves were analysed by the formalism of slow binding 
kinetics as described for HLE inhibition. An example of progress curves for PR3 
inhibition is depicted in Appendix 4, Section A4.2, Figure A4.39. The obtained 
pseudo-first-order rate constants for PR3 inhibition by 4-oxo--lactams are given in 
Appendix 4, Table A4.4. The inhibitory activities for the assayed compounds, 
expressed in terms of the bimolecular rate constant kobs/[I] in M-1s-1, are given in 
Table 4.6.  
With the exception of 77g and 77p, all 4-oxo--lactams assayed were found to be 
time-dependent inhibitors of PR3, although with significantly lower activity compared 
with HLE. The most potent inhibitor towards PR3 was found to be the sulfone 103k, 
with a second-order rate constant of nearly 5 x 103 M-1s-1. In contrast, the sulfide 
counterpart 103j was found to be a weak inhibitor of PR3. Compound 103f, which 
was the most potent 4-oxo--lactam inhibitor against HLE, was ca. 105 times less 
potent inhibitor of PR3.  
Dual inhibition of HLE and PR3 is not surprising as it reflects the close similarity of 
the primary specificity S1 sites of both enzymes29 and is consistent with similar 
observations previously described for other scaffolds.86 As both of these neutrophil 
serine proteases are involved in inflammation and extracellular matrix destruction 
observed in pulmonary diseases, a potent inhibition of HLE combined with a weaker 
inhibition of PR3, may be an advantage for therapeutics. 
 
4.3.2.2 Cathepsin G Inhibition Studies 
Cathepsin G inhibition studies were also performed using the progress curve 
method.142 Assays were performed at 25 ºC, 0.1 M pH 7.5 HEPES buffer, by 
monitoring the release of p-nitroaniline from the enzyme-catalyzed hydrolysis of the 
substrate N-Suc-L-(Ala)2-L-Pro-L-Phe-p-NA. One or two concentrations (near to the 
limit of solubility) of representative 4-oxo--lactams were assayed at least in 
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duplicate and an example is illustrated in Appendix 4, Section A4.3, Figure A4.4. The 
obtained kobs values are given in Table A4.4. The inhibitory activities, expressed in 
terms of the bimolecular rate constant kobs/[I], are given in Table 4.6. By contrast with 
PR3 assays, most of these derivatives were inactive (77o, 77p, 103b, 103f, 103g, 
103i, 103j) or only weakly active against Cat G (Table 4.6). 
 
 
Table 4.6 - Inhibitory activity of selected 4-oxo-lactams against neutrophil serine proteases 
HLE, PR3 and Cat G 
 
 kon /M-1s-1 kobs/[I]/M-1s-1 
Compound HLE Proteinase 3 Cathepsin G 
77g 5.08x105 16% a 36.5 
77m 4.35x103 ND 35.6 
77o 2.00x103 20.2 NI 
77p 2.67x102 22% b NI 
77r 2.86x105 ND 47.3 
103b 3.49x104 361 NI 
103f 3.24x106 29.6 NI 
103g 1.77x106 689 NI 
103i 3.18x106 4080 NI 
103j 1.17x106 122 ND 
103k 1.46x106 4998 41.4 
 NI: no inhibition at 60 µM; ND: not determined; a at 10 µM; b at 60 µM 
 
 
In particular, the most potent inhibitors towards HLE, compounds 103f and 103k, 
were found to be non inhibitors of Cat G, even when assayed at 20and 5 M, 
respectively. A similar selectivity pattern was also observed for 103g, while the 
sulfone derivative 103k inhibited all three serine proteases with a HLE/PR3/Cat G 
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ratio of 3.5104/120/1. Indeed, while sulfide 103j was found to be non inhibitor of 
cathepsin G, its sulfone counterpart 103k inhibited this enzyme, giving kon = 41.4 M-
1s-1.  
The fact that most 4-oxo--lactams assayed did not inhibit Cat G is consistent with 
the known substrate specificity, since this enzyme has a trypsin and a chymotrypsin-
like preference for P1, accepting aromatic and positively charged side chains.29 
Surprisingly, neither the methyl benzyl (77p) nor the ethyl benzyl (77o) derivatives 
inhibited Cat G at 60 µM, despite the presence of an aromatic substituent at P1. This 
result may be ascribed to the restricted conformational mobility imparted by the 
geminal ethyl and methyl groups at C-3. 
 
4.3.2.3 Papain Inhibition Studies 
The group of derivatives assayed for activity against PR3 and Cat G (Table 4.6) 
was also evaluated against papain, a cystein protease. These compounds were found 
to be inactive even when incubated at 50-100 M for 1h at 25 ºC with papain, 
suggesting a high degree of selectivity of the azetidine-2,4-dione scaffold towards 
serine proteases. 
 
4.3.2.4 PPE Inhibition versus HLE Inhibition 
N-aryl-4-oxo--lactams 77c-g, previously studied against porcine pancreatic elastase 
(PPE) (Chapter 3), were found to be much more potent inhibitors of HLE. In fact, the 
second-order rate constant for HLE inactivation for these compounds ranges from 
2.4105 to 6.6105 M-1s-1, some three orders of magnitude larger than those 
previously discussed for PPE inhibition (Table 3.4, Chapter 3). The observed relative 
inhibitory potencies for 77c-g accords with the S1 binding pocket of HLE being larger 
than that of PPE,27 thereby allowing optimal interaction with the diethyl group at the 
C-3 of the 4-oxo--lactam moiety. Furthermore, the tight preassociation inhibitor-
HLE complex (mechanism B) observed for compounds 77d, 77f and 77g contrasts 
with the simple association mechanism reported for PPE inhibition.  
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By contrast with HLE inhibition, compounds 77c-g showed a good Hammett 
correlation towards PPE (as discussed in Figure 3.20, Chapter 3), indicating that PPE 
is much more susceptible to intrinsic chemical reactivity effects rather than favorable 
binding interactions by 77. N-alkyl derivatives 77a-b, which were non-inhibitors of 
PPE, were found to be time-dependent irreversible inhibitors of HLE. 
 
4.4. HYDROLYTIC STABILITY STUDIES 
The postulated mechanism of inactivation by compounds 103 was previously given in 
Scheme 4.1. In order to confirm the departure of the thiol leaving group to generate a 
highly reactive quinone methide imine function and provide valuable insights 
regarding the mechanism of action, a representative derivative 103f was incubated in 
hydroxide buffer at 25 ºC, being the reaction monitored by UV spectroscopy (Figure 
4.13a).  
Equimolar 2-mercaptobenzoxazole (used as standard) was separately incubated with 
hydroxide at 25 ºC, for identification of a characteristic band in UV spectra, which 
was nearly at 295 nm (Figure 4.13b).  
It was expected to observe that band, corresponding to 2-mercaptobenzoxazole, from 
the reaction of 103f with hydroxide, as a result of nucleophilic attack of hydroxide at 
a carbonyl carbon atom and four-membered ring opening, with departure of the thiol. 
However, the incubation of 103f with hydroxide did not generate any band at 295 nm 
(Figure 4.13a). 
Thus, it suggests that there is no expulsion of the thiol from nucleophilic attack of 103 
(it does not function as a leaving group). If this is the case, derivatives 103 are not 
mechanism-based inhibitors because they cannot form the reactive acyl-enzyme for a 
“double-hit mechanism”, but simple acylating agents of HLE.  
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Figure 4.13 - UV spectra depicting the reactions, at 25 ºC of (a) 103f (150 M) and (b) 2-
mercaptobenzoxazole (150 M) in 10 mM NaOH, containing NaClO4 to maintain the ionic 
strength at 0.5 M (reaction monitored by 120 sec/scan, being depicted scans 1, 2, 3, 4, 5, 6, 7, 8, 10, 
20, 30, 40, 50). 
 
 
4.4.1 The Product of Hydrolysis of 103 
The product of alkaline hydrolysis of azetidine-2,4-diones is the corresponding N-
aryl-2,2-diethylpropanedioic acid monoamide 104 (Scheme 4.10). As an example, a 
reaction of 103a with excess of sodium hydroxide was performed, to give the 
corresponding ring-opened product 104. From this result one may conclude that 
a b 
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departure of the thiol leaving group would not be an efficient process under 
physiological conditions.  
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Scheme 4.10 - The alkaline hydrolysis product of 4-oxo--lactam 103 is the corresponding -
amidoacid, 104, without departure of the thiol leaving group. 
 
 
Thus, nucleophilic attack at 103, leading to -lactam ring opening, does not involve 
expulsion of the thiol leaving group, being these results in consonance with those 
obtained by spectrophotometrically monitoring the reaction of 103f with hydroxide 
ion (Figure 4.13). So, compounds 103 behave as simple alternate substrate inhibitors 
(acylating agents) of HLE and the formation of the electrophilic quinone methide 
imine by C-N fission is likely to do not occur.  
As a result, the mechanism of HLE inactivation by 4-oxo--lactams 103 is similar to 
that discussed for 77 in Chapter 3 for PPE inactivation (Figure 3.21): serine 
nucleophilic attack at a carbonyl carbon to form a stable acyl-enzyme by four-
membered ring-opening.  
In order to support and establish unequivocally the reaction mechanism of 103 with 
HLE, attempted X-ray crystallography studies of this enzyme with selected 
derivatives were performed. However, the attempted obtention of the acyl-enzyme 
crystal structure remained unsuccessfull. 
4. Azetidine-2,4-diones as Potent and Selective Inhibitors of HLE 
 
 
 
174
4.4.2 Stability in pH 7.4 Buffer and in 80% Human Plasma 
The promising results obtained for in vitro inhibitory potency and selectivity of 4-
oxo--lactams, prompted to obtain further insight to the mechanism of hydrolysis and 
stability of 103. The stability of selected compounds (103a, 103e, 103i and 103k) was 
evaluated in pH 7.4 phosphate buffer saline and in 80% human plasma at 37 ºC.  
Indeed, stability towards hydrolysis is a prerequisite for maintaining the 
therapeutically useful concentrations in biological fluids, such as pulmonary epithelial 
lining fluid and plasma.  
As an example, the profiles of mean concentration of 103a versus time after 
incubation in phosphate buffer saline (PBS) and 80% human plasma, at 37 ºC, are 
shown in Figures 4.14 and 4.15, respectively. These plots allowed the determination 
of the respective half-lifes, by exponential regression analysis of data. Calibration 
curves, used for the quantification of assayed compounds, as well as the plots for 
determination of the half-lifes for 103e, 103i and 103k are given in Appendix 4, 
Section A4.4, Figures A4.41-50. The obtained results for stability in phosphate buffer 
saline and human plasma are listed in Table 4.7. 
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Figure 4.14 - Profile of concentration of 103a versus time after incubation in phosphate buffer 
saline, at 37 ºC. Points are experimental and line is from exponential regression analysis of data, 
giving the kinetic rate constant of hydrolysis k = 3.14 x 10-4 min-1. From this value, the half-life was 
determined, t1/2 = 37h. 
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In human plasma, these compounds were rapidly hydrolyzed, with half-lives ranging 
from 0.1 to ca. 2h. These half-lifes were lower than that in phosphate buffer, 
indicating that these compounds are very susceptible to the hydrolysis catalyzed by 
plasma enzymes (as esterases). This situation is notable for compound 103i, as the 
half-life for the hydrolysis in human plasma was found to be ca. 65 times lower than 
that in PBS (Table 4.7).  
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Figure 4.15 - Profile of concentration of 103a versus time after incubation in 80% human plasma, 
at 37 ºC. Points are experimental and line is from exponential regression analysis of data, giving the 
kinetic rate constant of hydrolysis k = 7.08 x 10-3 min-1. From this value, the half-life was determined, 
t1/2 = 1.63h. 
 
 
Table 4.7 - Aqueou s and plasma stability at 37 ºC for compounds 103a, 103e, 103i and 103k. 
 
 
 
 
 
 t1/2 / h 
Compound Buffer pH 7.4 80% Human plasma 
103a 37 1.6 
103e 10 0.4 
103i 13 0.2 
103k 1.0 0.1 
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Compound 103k was found to be the most reactive compound in both PBS and 
plasma and may be a consequence of the powerful electron-withdrawing sulfone 
function, activating the 4-oxo--lactam carbonyl carbon towards nucleophilic attack.  
The obtained results for these derivatives are in line with the pronounced 
susceptibility of neutral β-lactam derivatives (e.g. penicillin esters) to undergo 
plasma-catalyzed hydrolysis of the β-lactam ring.170 Similarly, the previously reported 
half-life of cephalosporin sulfones in PBS pH 7.4 is 1.1 h.34 By contrast, N-
carbamoyl-azetidine-2-ones, as 27, were reported to be much more stable, for more 
than 23 days, in PBS pH 7.5, at 37 ºC.[35] 
These results indicate that the oral availability of 4-oxo-β-lactams might be limited by 
compound stability.  
 
4.5. BIODISTRIBUTION STUDIES OF A SELECTED 4-OXO--LACTAM  
In anticipation of using 4-oxo--lactams in rodent efficacy models, a biodistribution 
study in mice was carried out with a representative derivative, 103k. These studies 
were kindly performed by Dr. Sandra Simões, from INETI/iMed.UL. All 
experimental procedures were carried out with the permission of the local laboratory 
committee, and in accordance with international accepted principles. 
Thus, 103k was determined after administration of a single dose of 30 mg/kg, given 
intraperitoneally in mice, in mice blood and tissues (lung, spleen and liver), at 
different times after the challenge, in an ex vivo study.  
Three mice per time point were used. At appropriate time intervals, blood was 
collected into heparinised tubes and stored at -30 ºC and mice were euthanized. The 
lung, spleen and liver of mice were removed and stored at -70 ºC. A control group of 
mice was used, which did not receive the administration of 103k. Standard solutions 
of 103k were prepared for calibration curves and the quantification of the 4-oxo--
lactam in mice blood and tissues was performed by HPLC (see Experimental Section 
for extraction and quantification details). Data used for calibration curves are given in 
Appendix 4, Tables A4.7-A4.10. 
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Figures 4.16, 4.17 and 4.18 show, respectively, the mean-total mice blood, spleen and 
lung concentration-time profile after administration of 103k. Compound 103k was not 
detected in mice liver.  
Blood levels of 103k decreased rapidly after ip administration in mice, in particular 
within the first 10 min, due to the hydrolytic instability. A similar pattern was 
observed in mice spleen and lung. The obtained Cmax values of 103k are 1207  440 
g/total blood, 179  30 g/g spleen and 106  440 g/g lung, suggesting that 103k 
distributes well into tissues.  
Although in a lower concentration than the observed for spleen, the 4-oxo--lactam 
103k reached the lungs (major target). By contrast, this compound was completely 
eliminated within 5 min in this tissue (Figure 4.18), suggesting a potential reaction of 
103k with mice elastase. Interestingly, after an initial clearance from blood, levels of 
103k increased after 30 min of administration and a similar situation was found in 
tissues, with relevance in lung, where 103k appeared again after 30 min after the 
challenge. 
 
 
0
200
400
600
800
1000
1200
1400
1600
1800
0 1 2 5 10 30 60
time / min
µ
g 
10
3k
/ t
ot
al
 b
lo
od
 
Figure 4.16 - Mean pharmacokinetic profile in total mice blood after administration of a ip 30 
mg/kg dosage of 103k. Data are mean  sd. 
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Figure 4.17 - Mean pharmacokinetic profile in mice spleen after administration of ip 30 mg/kg 
dosage of 103k. Data are mean  sd. 
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Figure 4.18 - Mean pharmacokinetic profile in mice lung after administration of a ip 30 mg/kg 
dosage of 103k. Data are mean  sd. 
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A biliar clearance is a very likely elimination pathway, with 103k entering in an 
enterohepatic cycle, which might explain the increase of concentrations in blood and 
lungs after 30 min of administration. It is important to note that 103k was 
undetectable in liver, which suggests a high metabolization by liver enzymes. This 
result agrees with the high reactivity of this compound, demonstrated in Section 4.4. 
For comparison, reference -lactam DMP-777 (29, Section 1.6.2, Chapter 1) was 
reported to have a half-life of 1.8 h in rat blood after a 5 mg/kg dose given iv, and to 
be degraded in a pathway believed to be catalyzed by esterases, with -lactam ring 
opening. Similarly, elimination of this compound involved metabolism in liver, 
followed by excretion of the metabolites in feces, via bile.171 
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5. CONCLUSIONS  
From the results presented in the previous chapters, one may conclude that potent 
time-dependet -lactam-based irreversible inhibitors of elastases, including simple 
azetidin-2-ones or azetidine-2,4-diones, were achieved.  
- For the N-carbamoylazetidin-2-one derivatives, nucleophilic attack at the -lactam 
carbonyl carbon results in ring opening with expulsion of the leaving group at C-4. 
3,3-Unsusbtituted 47b-d inhibited PPE (kon values ranged from 11.3 to 290 M-1s-1), 
while 3,3-gem-diethyl analogues 47e-k inhibited HLE (kon values ranged from 310 to 
14600 M-1s-1). A proof of the covalente bond stablished between the enzyme and the 
inhibitor was obtained by X-ray crystallography studies of the acyl-enzyme complex 
resulting from reaction of PPE with 47d.  
- In both alkaline hydrolysis and elastase inactivation, the rate limiting step is the 
formation of the tetrahedral intermediate, and the -lactam ring opening is not 
concerted with the departure of the substituent from C-4. However, HLE-catalyzed 
reaction is likely to involve a more favorable pathway than the hydroxide-ion 
catalyzed one, resulting in an earlier transition-state (lower I value). Thus, 
hydrophobic interactions of the gem-diethyl group of 47e-k with the S1 binding 
pocket of HLE seem to improve the inhibitory potency and EREF by molecular 
recognition.  
- A moderate correlation was found between intrinsic chemical reactivity and HLE 
inactivation by C-4 substituted azetidin-2-ones. Electron-withdrawing sulfone 
derivatives 47h-j provided not only the more active inhibitors (even more potent than 
the reference 47k from Merck Research Laboratories), but also the more reactive 
compounds towards hydroxide, being efficient in activating the -lactam scaffolf 
towards nucleophilic attack (inductive effect).  
- Preliminary studies with azetidine-2,4-diones, designed as isoster analogues of 3-
oxo--sultams, revealed that these compounds are effective irreversible inhibitors of 
PPE. Enzyme inhibition is a result of nucleophilic attack of the catalytic serine residue 
at one of the carbonyl carbons, with ring opening to form a stable acyl-enzyme 
complex. On the other hand, while 3-oxo--sultams are unsuitable for therapeutic 
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application due to a very high intrinsic chemical reactivity (Section 1.6.2.2),116 their 
4-oxo--lactam analogues were found to be dramatically less reactive towards 
hydroxide, as 77h is 100 000-fold less reactive than its 3-oxo--sultam counterpart 
35. Not only the magnitude of kOH- for most of 77 derivatives is within the range 
acceptable for a pharmacologically useful acylating agent (that is, kOH- values ranging 
10-1 - 1.0 M-1s-1, as shown in Table 3.3),72 but also 77g is almost as potent as 35, 
indicating the effectiveness of the 4-oxo--lactam (azetidine-2,4-dione) scaffold as a 
therapeutically important lead structure to design serine protease inhibitors.  
- 4-Oxo--lactams were found to be very potent inhibitors of HLE and both linear and 
hyperbolic dependences of pseudo-first order rate constants, kobs, with the inhibitor 
concentration were observed. The inhibitory potency, expressed by kon values, ranges 
from 2102 to 3106 M-1s-1. Small alkyl substituents at C-3 such as a gem-diethyl 
group improved the inhibitory potency when compared to gem-methyl benzyl or ethyl 
benzyl groups. 
- The same derivatives assayed against PPE presented nearly three orders of 
magnitude larger kon values towards HLE (77c-g) and, by contrast, inhibitory activity 
against HLE does not parallel chemical reactivity towards hydroxide, indicating good 
molecular recognition by the human enzyme. In addition, representative 4-oxo--
lactams 77 and 103 were found to be relatively selective towards HLE, when 
compared to proteinase 3 and cathepsin G, but displayed absolute specificity when 
compared to cystein protease papain. 
- The best inhibitor of this thesis was compound 103f, with a remarkable kon value of 
3.24 x106 M-1s-1, which is one order of magnitude superior to that reported for 
Merck´s derivative 27 (Chapter 1)103 and of the same order that reported for 29 
(Chapter 1).6 Docking studies, performed for selected 4-oxo--lactam inhibitors, 
supported the trends observed in the HLE inhibition assays.  
- Although designed as potential mechanism-based inhibitors, derivatives 103 
function as simple acylating agents (alternate substrate inhibitors), as the departure of 
the thiol leaving group does not occur under physiological conditions. Mass 
spectrometry techniques (ESI-MS) would be useful in identifying the inhibitor-
complexed HLE structure. Although being very potent HLE inhibitors, compounds 
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103 suffer a drawback for systemic use. Indeed, the results obtained from hydrolytic 
stability as well as biodistribution studies suggest that these compounds are 
exceedingly reactive, being susceptible to off-target reactions, particularly by plasma 
and liver enzymes (esterases). However, these inhibitors might find pharmacological 
applicability as potential drug candidates suitable for aerosolization, a route of 
administration employed for other agents used for lung diseases.93  
- New azetidine-2,4-diones, retaining the optimized potency and with an improved 
hydrolytic stability, would be useful drug candidates for COPD and other 
inflammatory disorders. Derivatives 77, such as 77d, provided high levels of 
inhibitory potency against HLE combined with good hydrolytic stability, being 
important candidates for further optimization using computer-assisted techniques. An 
interesting approach for optimization of 103 is suggested in 105 (X = CH, N; Y = O, 
S). The ortho substituent may increase hydrolytic stability and the half-life of the 
acyl-enzyme complex. In addition, it is known that the basic piperidinoethoxy group 
increases water solubility and allows the penetration of the inhibitor into the 
bronchoalveolar fluid.172  
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- Taken together, the results from this thesis demonstrate the superior activity of 
azetidine-2,4-dione over both 3-oxo--sultams and simple azetidin-2-one in the 
design of serine protease inhibitors. The use of the 4-oxo--lactam (azetidine-2,4-
dione) scaffold as a lead template for potential drug candidates for COPD is the 
ultimate and most important goal of the research line initiated in this thesis. A fine 
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balance between intrinsic chemical reactivity, target selectivity, hydrolytic instability, 
stability of the acyl-enzyme complex, biodistribution and toxicity is important to 
achieve suitable inhibitors for therapeutic application. 
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6. EXPERIMENTAL SECTION 
6.1. SYNTHESIS 
6.1.1 Reagents, solvents and chromatography 
Reagent grade chemicals were bought from Sigma-Aldrich and Merck. TEA was 
dried over potassium hydroxide and distilled under atmospheric pressure. 
Dichloromethane (DCM) was dried by distillation from calcium hydride. THF, 
benzene, toluene and dioxane were dried by distillation from sodium-benzophenone. 
The remaining compounds were used without further purification. Column 
chromatography was performed with silica gel (Merck, 230-400 mesh ATM). 
Preparative TLC was performed on silica gel GF254 (Merck 1.07730). TLC was 
performed on pre-coated silica gel 60 F254 (Merck) and visualized under UV light and 
/ or by exposure to iodine vapour. All the reactions were monitored by TLC unless 
otherwise stated. 
6.1.2 Equipment 
Melting points were determined using a Kofler camera Bock Monoscope M and are 
uncorrected. The infrared spectra were collected on a Nicolet Impact 400 FTIR 
infrared spectrophotometer using thin films on NaCl plates (wavenumbers in cm-1) 
and the NMR spectra on a Brucker 400 Ultra-Shield (1H 400 MHz; 13C 100.61 MHz), 
in CDCl3 (unless otherwise stated); chemical shifts, , are expressed in ppm (parts per 
million), coupling constants, J, are expressed in hertz (Hz). The spectra for 76 was 
collected on a Jeol JNM-300 (1H 300 MHz; 13C 75 MHz). Carbon signal assignments 
were made also using DEPT technique. Low-resolution mass spectra were recorded 
using VG Mass Lab 20-250 EIMS or VG Quattro mass spectrometers. Elemental 
analyses were performed using an EA 1110 CE Instruments automatic analyser, at 
Medac Ltd., Brunel Science Centre, Englefield Green, Egham, TW20 0JZ, UK or a 
EA1108 automatic analyser, at University of Santiago de Compostela. 
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6.1.3 Experimental Procedures and Product Characterization 
Synthesis of 4-Acetoxy-3,3-diethyl-azetidin-2-one, 42b from 2-
ethylbutyraldehyde (48) 
1-Acetoxy-2-ethyl-1-butene (49)98 
A solution of commercial 2-ethylbutyraldehyde, 48 (1.09 mol, 136 ml), acetic 
anhydride (1.48 mol, 140 ml) and sodium acetate (0.14 mol, 11.18 g) was heated to 
reflux during 2 days. Then, the reaction mixture was slowly poured into a mixture of 
DCM, water and ice (respectively, 182 ml: 182 ml: 90.8 ml). The solution was 
neutralized (pH 7) by very slowly addition of solid sodium carbonate (100 g) (CO2 
evolution). The layers were separated, and the aqueous layer was extracted with DCM 
(200 ml). The organic layer was washed with saturated NaCl and dried over Na2SO4. 
The filtrate was concentrated and the residue was purified by distillation to yield 
131.1 g (85%) of the enol acetate as a colorless liquid, b.p. 85-115º C at 75 mm Hg 
(lit. 65 - 90 ºC at 90 mm Hg), max (film) 3088 (C=C), 1751 (C=O), 1227 (C-O), 1120 
(C-O);  1H-NMR 0.93 (3H, t, J = 7.2, CH2CH3), 0.97 (3H, t, J = 7.6, CH2CH3), 1.96 
(2H, q, J = 7.2, CH2CH3), 2.06 (3H, s, COCH3), 2.09 (2H, q, J = 7.6, CH2CH3), 6.80 
(1 H, s, C=CH). 
 
4-Acetoxy-3,3-diethyl-azetidin-2-one (42b)98 
A solution of 1-acetoxy-2-ethyl-1-butene, 49 (0.598 mol, 84.92 g) in dcm (150 ml) 
was cooled in an ice-ethanol bath. Chlorosulfonyl isocyanate (CSI, 0.709 mol, 100g) 
was added careful and slowly. The solution was allowed to warm to room temperature 
and stirred overnight. Then, the reaction mixture was diluted with ether and added 
very slowly to ice-cold NaHC03 solution containing Na2SO3, maintaining the 
temperature below 5 ºC. The solution was stirred with a mechanical stirrer for 1.5 h. 
The aqueous layer was extracted with ether and the combined organic layers were 
washed with water, saturated NaCl and dried. The solvent was removed under 
reduced pressure and recrystallized with hexane (-10 ºC), to afford a light yellow solid 
(36.92 g, 34%), m.p. 24 - 29 ºC, max (film) 3267 (NH), 1786 (C=O), 1746 (C=O), 
1233 (C-O), 1033 (C-O);  1H- NMR 1.00 (3H, t, J = 7.2, CH2CH3), 1.03 (3H, t, J = 
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7.2, CH2CH3), 1.65-1.90 (4H, m, CH3CH2), 2.14 (3H, s, OCH3), 5.60 (1H, s, C-4-H), 
6.51 (1H, brs, N-H),  13C-NMR 8.45 (CH2CH3), 8.72 (CH2CH3), 20.96 (OCH3), 
21.59 (CH2CH3), 23.56 (CH2CH3), 67.68 (C-3), 79.77 (C-4), 171.11 (C=O), 171.84 
(C=O); ESI-MS m/z 208 (MNa+). 
 
4-Phenoxyazetidin-2-one (43a) 
To a solution of phenol (2.14 mmol, 201 mg)) in acetone (2.2 ml), was added NaOH 1 
M (2.6 mmol; 2.6 ml) with stirring for 20 minutes at room temperature. Then 42a 
(1.94 mmol, 250.3 mg) in acetone (1.7 ml) was added. The solution was concentrated 
under reduced pressure and extracted with diethyl ether (2 x 70 ml). The organic 
layers were washed with NaHCO3 5% (2 x 60 ml), followed by drying (MgSO4) and 
concentration gave the crude, which was purified by column chromatography on silica 
gel (elution with DCM-EtOAc 9.5:0.5), to yield a pale yellow solid (66 mg, 21%); 
m.p. 72-73 ºC; max (film) 3234 (NH); 1744 (C=O), 1259 (C-O), 1058 (C-O);  1H- 
NMR 3.12 (1H, d, J = 15.2, 1.2, C-3-H), 3.35 (1H, ddd, J = 15.2, 3.6, 2.4, C-3-H), 
5.68 (1H, dd, J = 3.6, 1.2, C-4-H), 6.55 (1H, brs, N-H), 6.86-6.88 (2H, dd, J = 7.2, 
1.2, C-Hortho), 7.06 (1H, t, J = 7.2, C-Hpara), 7.33 (2H, dt, J = 7.2, 1.2, C-Hmeta);  13C-
NMR 46.20 (C-3), 76.31 (C-4), 115.74 (C-H), 122.64 (C-H), 129.94 (C-H), 155.90 
(C), 166.26 (C=O); ESI-MS m/z 164 (MH+). 
  
3,3-Diethyl-4-phenoxyazetidin-2-one (43b)109 
Prepared as described for 43a, using phenol (3.89 mmol, 366 mg) and 42b (3.53 
mmol, 650 mg) as starting materials. Purified by column chromatography (elution 
with diethyl ether - light petroleum (1:1) to yield white crystals (320 mg, 42%); m.p. 
56-58 ºC (lit.109 53-56 ºC); max (film) 3256 (NH), 1764 (C=O), 1231 (C-O), 1083;  
1H- NMR 1.03 (3H, t, J = 7.6, CH2CH3), 1,04 (3H, t, J = 7.6, CH2CH3), 1.73-1.87 
(3H, m, CH2CH3), 1.96 (1H, dq, J = 14.4, 7.6, CH2CH3), 5.37 (1H, s, C-4-H), 6.46 
(1H , brs, N-H), 6.88 (2H, d, J = 7.6, C-Hortho), 7.05 (1H, t, J = 7.6, C-Hpara), 7.33 
(2H, d, J = 7.6 Hz, C-Hmeta);  13C-NMR 8.64 (CH2CH3), 8.90 (CH2CH3), 21.72 
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(CH2CH3), 23.80 (CH2CH3), 64.68 (C-3), 83.41 (C-4), 115.87 (C-H), 122.41 (C-H), 
129.84 (C-H), 156.40 (C), 172.57 (C=O); ESI-MS, m/z 219 (MH+). 
 
6-(3,3-diethyl-4-oxoazetidin-2-yloxy)naphthalene-2-carboxylic acid (43c) 
Prepared from 6-hydroxynaphthalene-2-carboxylic acid (1.65 mmol, 311 mg), 42b 
(1.5 mmol, 272 mg) and NaOH 1 M (3.7 mmol; 3.7 ml), using the method described 
for 43a. The reaction mixture was acidified with HCl (pH 2) with stirring and cooled 
and the crude product was filtered-off. The organic layer was washed with water, HCl 
10 % and saturated NaCl. The combined residue was purified by flash 
chromatography using a gradient of EtOAc /ether, to yield white crystals (103 mg, 
22%), m.p. 197-200 ºC, max (film), 3216 (NH), 3200- 2600 (large O-H), 1748 (C=O), 
1684 (C=O), 1204 (C-O), 936 (C-O);  1H-NMR (DMSO) 0.98 (3H, t, J = 7.6, 
CH2CH3), 1.0 (3H, t, J = 7.6, CH2CH3), 1.64-1.93 (4H, m, CH3CH2), 5.65 (1H, s, C-
4-H), 7.27 (1H, dd, J = 8.8, 2.4, C-H), 7.40 (1H, d, J = 2.4, C-H), 7.87 (1H, d, J = 
8.8), 7.96 (1H, dd, J = 8.8, 2.4, C-H), 8.08 (1H, d, J = 8.8, C-H), 8.55 (1H, s, C-H), 
9.07 (1H, s, N-H);  13C-NMR (DMSO) 8.40 (CH2CH3), 8.82 (CH2CH3), 21.25 
(CH2CH3), 23.18 (CH2CH3), 63.42 (C-3), 82.05 (C-4), 108.70 (C-H), 119.61 (C-H), 
125.80 (C-H), 126.58 (C),127.25 (C-H), 127.87 (C), 130.52 (C-H), 131.36 (C-H), 
136.30 (C), 155.87 (C), 167.48 (C=O), 172.42 (C=O); ESI-MS, m/z 312 (M-H). 
 
4-Phenylthioazetidin-2-one (44a) 
To a solution of 4-acetoxyazetidin-2-one 42a (2 mmol, 258 mg) in benzene (20 ml) 
was added thiophenol (4 mmol, 440 l) and the reaction mixture was heated to reflux, 
adapting previously described techniques.122 The solution was washed with aqueous 
Na2CO3 (3 x 20 ml), dried (MgSO4) and concentrated under reduced pressure. The 
residue was purified by chromatography on silica gel (elution with DCM-EtOAc 
9.5:0.5), furnishing the desired product as white crystals (0.186 mg, 52%); m.p. 73 ºC; 
max (film) 3205 (NH), 1740 (C=O);  1H-NMR 2.91 (1H, ddd, J = 15.6, 2.4, 1.2, C-3-
H), 3.40 (1H, ddd, J = 15.6, 4.8, 2.4, C-3-H), 5.04 (1H, dd, J = 4.8, 2.4, C-4-H), 6.21 
(1H, brs, N-H), 7.38-7.39 (3H, m, C-H), 7.47-7.51 (2H, m, C-H);  13C-NMR 45.42 
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(C-3), 54.22 (C-4), 128.75 (C-Hpara), 129.44 (C-H), 131.27 (C), 133.58 (C-H), 165.67 
(C=O); ESI-MS, m/z 180 (MH+). 
 
3,3-Diethyl-4-(phenylthio)azetidin-2-one (44b)107, 109, 120 
Prepared as described for 44a, using 42b (2 mmol, 370 mg) and thiophenol (4 mmol, 
440 l) and purified by chromatography on silica gel (elution with diethyl ether - light 
petroleum 6:4), to yield the product (230.64 mg, 49 %) as a yellow oil, max (film) 
3240 (NH), 1755 (C=O);  1H-NMR 0.95 (3H, t, J = 7.2, CH2CH3), 1.10 (3H, t, J = 
7.2, CH2CH3); 1.68-2.05 (4H, m, CH3CH2), 4.79 (1H, s, C-4-H), 6.73 (1H, brs, N-H), 
7.26-7.44 (5H, m, C-H);  13C-NMR 8.56 (CH2CH3), 8.88 (CH2CH3), 22.84 
(CH2CH3), 24.49 (CH2CH3), 66.95 (C-3), 77.20 (C-4), 127.89 (C-Hpara), 129.44 (C-
H), 132.16 (C), 134.82 (C-H), 171.10 (C=O); EI-MS m/z 235 (M+) 
 
3,3-Diethyl-4-(benzoxazol-2-ylthio)-azetidin-2-one (44c)107, 109 
Prepared from 42b (1.01 mmol, 186 mg) and 2-mercaptobenzoxazole (1.30 mmol, 
196.44 mg), using the same method described earlier for 43a. Recrystallized from 
DCM-hexane; to yield white crystals (120 mg, 43 %), m.p. 177-179 ºC (lit.109 178-
179 ºC); max (film) 3237 (NH), 1776 (C=O); 1595, 1466, 1364, 1265 (C-O), 1141 (C-
O), 921;  1H-NMR 0.88 (3H, t, J = 7.2, CH2CH3), 1.18 (3H, t, J = 7.2, CH2CH3), 
1.52 (1H, dq, J = 14.4, 7.2, CH2CH3), 1.69 (1H, dq, J = 14.4, 7.2, CH2CH3), 1.90 (1H, 
dq, J = 14.4, 7.2, CH2CH3), 2.04 (1H, dq, J = 14.4, 7.2, CH2CH3), 6.29 (1H, s, C-4-
H), 6.34 (1H, brs, N-H), 7.29-7.31 (2H, m, C-H), 7.39-7.41 (1H, m, C-H), 7.60-7.62 
(1H, m, C-H);  13C-NMR 8.07 (CH2CH3), 8.80 (CH2CH3), 21.52 (CH2CH3), 24.09 
(CH2CH3), 67.53 (C-3), 70.39 (C-4), 110.77 (C-H), 112.00 (C-H), 124.55 (C-H), 
125.18 (C-H), 131.19 (C), 146.98 (C), 172.47 (C=O), 179.64 (C); ESI-MS m/z 277 
(MH+). 
 
2-(3,3-Diethyl-4-oxoazetidin-2-ylthio)benzoxazole-5-carboxylic acid (44d) 
Prepared as described for 43c, from 42b (1.35 mmol, 250 mg), 51 (1.49 mmol, 291 
mg) and NaOH 1 M (3.34 mmol, 3.34 ml). The product was recrystallized from THF: 
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hexane, to yield the product as a solid (0.179 mg, 42%), m.p. 205-206 ºC; max (film) 
3300-2500 (large, O-H), 1761 (C=O of lactam), 1688 (of acid), 1356, 1268 (C-O), 
1141;  1H-NMR (DMSO) 0.76 (3H, t, J = 7.2, CH2CH3), 1.06 (3H, t, J = 7.2, 
CH2CH3), 1.35 (1H, dq, J = 14.4, 7.2, CH2CH3), 1.51 (1H, dq, J = 14.4, 7.2, 
CH2CH3), 1.76-1.91 (2H, m, CH2CH3), 6.00 (1H, s, C-4-H), 7.74 (1H, d, J = 8.4, C-
7´-H), 7.98 (1H, dd, J = 8.4, 1.6, C-6´-H), 8.14 (1H, d, J = 1.6, C-4´-H), 9.15 (1H, brs, 
N-H), 13.42 (1H, brs, COOH);  13C-NMR 8.42 (CH2CH3), 9.12 (CH2CH3), 21.78 
(CH2CH3), 23.82 (CH2CH3), 66.49 (C-3), 70.46 (C-4), 111.16 (C-H), 113.33 (C-H), 
126.71 (C-H), 128.41 (C), 131.86 (C), 149.77 (C), 166.81 (C=O), 171.62 (C=O of 
lactam), 179.59 (C); ESI-MS m/z 319 (M-H). 
 
2-Mercaptobenzoxazole-5-carboxylic acid (51) 
A mixture of 3-amino-4-hydroxybenzoic acid (5 mmol, 766 mg) and potassium ethyl 
xanthate (5.5 mmol, 882 mg) in ethanol 95%-water (6:1) was refluxed for 3h. The 
reaction mixture was concentrated, and acidified to pH 2 with stirring and cooled. The 
product separated as grey crystals (517 mg, 53%) being filtered-off, dried and used 
without any further purification; max (film) 3216 (NH), 3200-2500 (large, O-H); 1699 
(C=O), 1459, 1274 (C-O), 1146, 1107;  1H-NMR (DMSO) 7.53 (1H, d, J = 8.8, C-
7´-H), 7.74 (1H, d, J =1.2, C-4´-H), 7.85 (1H, dd, J = 8.4, 1.2, C-6´-H);  13C-NMR 
109.93 (C-H), 111.24 (C-H), 125.84 (C-H), 127.42 (C), 131.22 (C), 150.93 (C), 
166.61 (C=O), 180.58 (NCS), ESI-MS m/z 194.08 (M-H). 
 
3,3-Diethyl-4-(benzothiazol-2-ylthio)-azetidin-2-one (44e) 
Prepared from 42b (1.35 mmol, 249mg) and 2-mercaptobenzothiazole (1.49 mmol, 
249 mg), as described for 43a. Purified by column chromatography on silica gel 
(elution with DCM-EtOAc 9.5 : 0.5), to furnish white crystals (67 mg, 17%), m.p. 
186-189 ºC; max (film) 3266 (NH), 1756 (C=O), 1453;  1H-NMR 0.88 (3H, t, J = 
7.2, CH2CH3), 1.20 (3H, t, J = 7.2, CH2CH3), 1.53-1.62 (1H, m, CH2CH3), 1.77 (1H, 
dq, J = 14.4, 7.2, CH2CH3), 1.97-2.13 (2H, m, CH2CH3), 6.21 (1H, brs, N-H), 6.90 
(1H, s, C-4-H), 7.32-7.40 (2H, m, C-H), 7.50 (1H, dd, J = 8.4, 1.6, C-H), 8.00 (1H, d, 
J = 8.4, C-H);  13C-NMR 7.95 (CH2CH3), 8.73 (CH2CH3), 21.72 (CH2CH3), 24.50 
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(CH2CH3), 67.68 (C-3), 71.29 (C-4), 114.43 (C-H), 121.48 (C-H), 124.70 (C-H), 
126.86 (C-H), 127.24 (C), 141.75 (C), 172.11 (C=O), 190.57 (NCS); ESI-MS m/z 293 
(MH+). 
 
3,3-Diethyl-4-(1-methyl-1H-imidazol-2-ylthio)-azetidin-2-one (44f) 
Prepared from 42b (1.62 mmol, 300 mg) and 2-mercapto-N-methylimidazole (1.79 
mmol, 204 mg), as described for 43a, and purified by column chromatography on 
silica gel (elution with DCM-EtOAc 9.5: 0.5), to yield the product as white crystals 
(92 mg, 25%). This compound was also synthesized using the method described for 
44a, from 42b (0.54 mmol, 100 mg) and 2-mercapto-N-methylimidazole (1.08 mmol, 
123.30 mg) with addition of triethylamine (1.08 mmol, 150 l), to yield white crystals 
(78.9 mg, 53%), m.p. 174-176 ºC, max (film) 3288 (NH), 1765 (C=O);  1H-RMN 
0.82 (3H, t, J = 7.6, CH2CH3), 1.14 (3H, t, J = 7.6, CH2CH3), 1.33 (1H, dq, J = 15.2, 
7.6, CH2CH3), 1.48 (1H, dq, J = 15.2, 7.6, CH2CH3), 1.86 (1H, dq, J = 15.2, 7.6, 
CH2CH3), 1.97 (1H, dq, J = 15.2, 7.6, CH2CH3), 3.67 (3H, s, N-CH3), 6.05 (1H, s, C-
4-H), 6.74 (1H, d, J = 2.4, C-H), 6.80 (1H, brs, N-H), 6.97 (1H, d, J = 2.4, C-H);  
13C-RMN 8.00 (CH2CH3), 8.82 (CH2CH3), 21.46 (CH2CH3), 23.88 (CH2CH3), 34.61 
(N-CH3), 66.41 (C-3), 67.66 (C-4), 114.43 (C-H), 118.12 (C-H), 162.29 (NCS), 
173.47 (C=O); ESI-MS m/z 240 (MH+). 
 
3,3-Diethyl-4-(5-phenyl-1,3,4-oxadiazol-2-ylthio)-azetidin-2-one (44g) 
Prepared as described for 44a, using 42b (0.81 mmol, 150 mg) and 2-mercapto-5-
phenyl-1,3,4-oxadiazole (1.62 mmol, 289 mg), with addition of triethylamine (1.62 
mmol, 226 l). The product was recrystallized from DCM/hexane, to afford pale 
yellow crystals (116 mg, 35%), m.p. 169.170 ºC, max (film) 3262 (NH), 1783 (C=O), 
1416;  1H-RMN 0.93 (3H, t, J = 7.2, CH2CH3), 1.15 (3H, t, J = 7.2, CH2CH3), 1.60 
(1H, dq, J = 14.4, 7.2, CH2CH3), 1.83-1.93 (2H, m, CH2CH3), 2.01 (1H, dq, J = 14.4, 
7.2, CH2CH3), 5.97 (1H, s, C-4-H), 6.44 (1H, brs, N-H), 7.54-7.61 (3H, m, C-H), 7.98 
(2H, d, J = 7.2, C-H); 13C-RMN 8.04 (CH2CH3), 8.79 (CH2CH3), 20.25 (CH2CH3), 
23.25 (CH2CH3), 67.42 (C-3), 68.75 (C-4), 122.09 (C), 126.63 (C-H), 129.28 (C-H), 
132.75 (C-H) 159.52 (C), 171.66 (C), 176.19 (C=O); ESI-MS m/z 304 (MH+). 
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4-Phenylsulphonylazetidin-2-one (45a)107 
To a stirred solution of 4-phenylthioazetidin-2-one, 44a (1.79 mmol, 320 mg) in 
DCM (6 ml), previously cooled in an ice bath during 10 minutes, 70% MCPBA 
(4.469 mmol, 1200 mg) was added. After 30 minutes in an ice bath, the mixture was 
allowed to reach room temperature and stirred. After completion of the reaction, 
DCM (5 ml) was added to the mixture. This organic layer was successively washed 
with 5% NaHCO3 solution (3 x 10 ml), brine (3 x 10 ml) then dried (MgSO4) and the 
solvent removed under reduced pressure. Purified by column chromatography on 
silica gel (elution with DCM till elution of vestigial 44a, then only EtOAc was used), 
to furnish the product as white solid (298.3 mg, 79%), m.p.133-135 ºCmax (film) 
3249 (NH), 1763 (C=O), 1337 (S=O), 1123 (S=O),  1H-RMN 3.25 (1H, ddd, J = 
15.6, 2.4, 1.2, C-3-H), 3.34 (1H, ddd, J = 15.6, 4.8, 2.4, C-3-H), 4.76 (1H, dd, J = 4.8, 
2.4, C-4-H), 6.43 (1H, brs, N-H), 7.66 (2H, t, J = 8.8, C-Hmeta), 7.78 (1H, dt, J = 8.8, 
1.2, C-Hpara), 7.97 (2H, dd, J = 8.8, 1.2, C-Hortho),  13C-RMN 41.67 (C-3), 64.88 (C-
4), 128.29 (C-Hpara), 129.39 (C-H), 129.78 (C-H), 134.64 (C), 164.46 (C=O); ESI-MS 
m/z 234 (MNa+). 
 
3,3-Diethyl-4-phenylsulphonylazetidin-2-one (45b)107, 109 
Prepared from 44b (1.95 mmol, 350 mg) and 70% MCPBA (3.90 mmol, 963 mg 
70%), as described for 45a. Purified by column chromatography (elution with ether - 
hexane (8:2), to yield a white solid (255.8 mg, 62%), m.p. 155-157 ºC (lit.109 156-158 
ºC), max (film) 3215 (NH), 1764 (C=O), 1458, 1335 (S=O), 1150 (S=O);  1H-RMN 
0.96 (3H, t, J = 7.6, CH2CH3), 1.09 (3H, t, J = 7.6, CH2CH3), 1.72 (1H, dq, J = 15.0, 
7.6, CH2CH3), 1.94 (1H, dq, J = 15.0, 7.6, CH2CH3), 2.06 (1H, dq, J = 15.0, 7.6, 
CH2CH3), 2.39 (1H, dq, J = 15.0, 7.6, CH2CH3), 4.33 (1H, s, C-4-H), 6.26 (1H, brs, 
N-H), 7.62 (2H, t, J = 7.2, C-Hmeta), 7.72 (1H, t, J = 7.2, C-Hpara), 7.93 (2H, d, J = 7.2, 
C-Hortho),  13C-RMN 8.57 (CH2CH3), 8.59 (CH2CH3), 20.32 (CH2CH3), 24.85 
(CH2CH3), 67.85 (C-3), 74.29 (C-4), 128.55 (C-H), 129.75 (C-H), 134.84 (C-Hpara), 
138.15 (C), 171.10 (C=O); ESI-MS m/z 268 (MH+) 
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3,3-Diethylazetidin-2-one (46)109 
To a solution of a 4-acetoxy-3,3-diethylazetidin-2-one 42b (800 mg, 4.32 mmol) in 
absolute EtOH (4 ml) at 0 ºC, was added slowly NaBH4 (178 mg, 4.72 mmol). The 
mixture was stirred for further 40 minutes. Then, the reaction mixture was filtered and 
the solvent evaporated. The resulting residue was washed with EtOAc (180 ml) and 
filtered. The solid in the filter was washed with DCM (20 ml). The organic solutions 
were combined, concentrated under reduced pressure and the residue purified by 
chromatography on silica gel (elution with DCM-EtOAc 7:3). The product was 
recovered as a colourless oil (163 mg, 30%); max (film) 3265; 1743;  1H-RMN 0.95 
(6H, t, J = 7.5, (CH2CH3)2), 1.69 (4H, q, J = 7.5, (CH2CH3)2), 3.09 (2H, s, C-4-H2), 
5.78 (1H, brs, N-H);  13C-RMN 8.78 (CH2CH3), 25.30 (CH2CH3), 45.12 (C-4), 61.59 
(C-3), 174.18 (C=O); ESI-MS m/z 128 (MH+). 
 
Synthesis of N-carbamoylazetidin-2-ones 47 
N-Benzylcarbamoylazetidin-2-one (47a)120, 173  
Benzyl isocyanate (4.22 mmol, 521 l) and subsequently triethylamine (4.22 mmol, 
588 l) were slowly added to a solution of the commercially available azetidin-2-one 
(3.52 mmol, 250 mg) in dichloromethane (3 ml). The reaction was stirred at room 
temperature. After completion of the reaction, the solution was evaporated under 
reduced pressure to give the crude product. Purified by column chromatography on 
silica gel (DCM-EtOAc 9.5:0.5) to yield white crystals (477 mg, 66%); m.p. 62-64 ºC 
(lit173 oil); max (film) 3335 (NH), 1764 (C=O of lactam), 1685 (C=O of urea);  1H-
RMN 3.08 (2H, t, J = 4.8, C-3-H), 3.68 (2H, t, J = 4.8, C-4-H), 4.50 (2H, d, J = 6.0, 
CH2Ph), 6.89 (1H, brs, N-H), 7.28 - 7.38 (5H, m, C-H);  13C-RMN 36.06 (CH2 of 
lactam), 37.21 (CH2 of lactam), 43.70 (CH2Ph), 127.59 (C-Hpara), 127.64 (C-H), 
128.72 (C-H), 137.93(C), 150.09 (C=O of urea), 167.11 (C=O of lactam); ESI-MS 
m/z 205 (MH+); Anal. calcd. for C11H12N2O2: C, 64.69, H, 5.92, N, 13.72; found: C, 
64.55, H, 6.10, N, 13.66. 
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N-Benzylcarbamoyl-4-phenoxyazetidin-2-one (47b) 
Prepared as described for 47a, using 43a (0.30 mmol, 48.3 mg), benzyl isocyanate 
(0.36 mmol, 44 l) and triethylamine (0.36 mmol, 50 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5 : 0.5) to afford white 
crystals (75 mg, 85%); m.p. 129-130 ºC; max (film) 3368 (NH), 1780 (C=O of 
lactam), 1708 (C=O of urea), 1492, 1225 (C-O), 1073 (C-O);  1H-RMN 3.17 (1H, 
dd, J = 16.0, 1.2, C-3-H), 3.46 (1H, dd, J = 16.0, 4.4, C-3-H), 4.50 (1H, dd, J = 14.4, 
5.6, CH2Ph), 4.55 (1H, dd, J = 14.4, 5.6, CH2Ph), 6.07 (1H, dd, J = 4.4, 1.2, C-4-H), 
6.88 (1H, brs, N-H), 7.10 (1H, t, J = 7.2, C-H), 7.15 (2H, d, J = 8.0, C-H), 7.31–7.39 
(7H, m, C-H);  13C-RMN 43.76 (C-3), 45.51 (CH2Ph), 78.76 (C-4), 117.14 (C-Hpara), 
123.21 (C-Hpara), 127.00 (C-H), 128.78 (C-H), 129.43 (C-H), 129.72 (C-H), 137.56 
(C), 146.13 (C), 156.14 (C=O of urea), 164.42 (C=O of lactam); ESI-MS m/z 297.5 
(MH+); Anal. calcd. for C17H16N2O3: C, 68.91, H, 5.44, N, 9.45; found, C, 69.12, H, 
5.61, N, 9.19. 
 
N-Benzylcarbamoyl-4-phenylthioazetidin-2-one (47c)120 
Prepared as described for 47a, using 44a (0.67 mmol, 120 mg), benzyl isocyanate 
(0.80 mmol, 100 l) and triethylamine (0.80 mmol, 112 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5 : 0.5) to afford white 
crystals (169 mg, 80%), m.p. 78-79 ºC (lit.120 oil), max (film) 3366 (NH), 1773 (C=O 
of lactam), 1699 (C=O of urea), 1529;  1H-RMN 2.88 (1H, dd, J = 16.4, 2.8, C-3-H), 
3.40 (1H, dd, J = 16.4, 5.6, C-3-H), 4.47 (1H, dd, J = 15.0, 6.0, CH2Ph), 4.54 (1H, dd, 
J = 15.0, 6.0, CH2Ph), 5.29 (1H, dd, J = 5.6, 2.8, C-4-H), 6.81 (1H, brs, N-H), 7.30–
7.39 (9H, m, C-H), 7.55 (1H, dd, J = 8.4, 1.6, C-H);  13C-RMN 43.68 (CH2), 43.99 
(CH2), 56.69 (C-4), 127.69 (C-Hpara), 127.72 (C-Hpara), 128.77 (C-H), 129.29 (C-H), 
129.31 (C-H), 129.36 (C-H), 135.25 (C), 137.83 (C), 149.63 (C=O of urea), 165.43 
(C=O of lactam); ESI-MS m/z 334.8 (MNa+); Anal. calcd. for C17H16N2O2S: C, 65.36, 
H, 5.16, N, 8.97; found C 65.12, H 5.11, N 8.98. 
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N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one (47d) 
Prepared as described for 47a, using 45 (0.31 mmol, 65 mg), benzyl isocyanate (0.37 
mmol, 46 l) and triethylamine (0.37 mmol, 52 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5:0.5), to yield white 
crystals (85.9 mg, 81%), m.p. 159-161 ºC, max (film) 3374 (NH), 1789 (C=O of 
lactam), 1711 (C=O of urea), 1316 (S=O), 1150 (S=O);  1H-RMN 3.48 (1H, dd, J = 
16.8, 6.0, C-3-H), 3.67 (1H, dd, J = 16.8, 2.8, C-3-H), 4.33 (1H, dd, J = 14.8, 6.0, 
CH2Ph), 4.39 (1H, dd, J = 14.8, 6.0, CH2Ph), 5.20 (1H, dd, J = 6.0, 2.8, C-4-H), 6.65 
(1H, brs, N-H), 7.23 (2H, dd, J = 8.0, 1.2, C-Hortho), 7.31 -7.38 (3H, m, C-H), 7.58 
(2H, t, J = 8.0, C-H), 7.74 (1H, dt, J = 8.0, 1.2, C-H), 7.96 (2H, dd, J = 8.0, 0.8, C-
Hortho);  13C-RMN 39.43 (C-3), 43.86 (CH2Ph), 65.84 (C-4), 127.58 (C-H), 127.79 
(C-Hpara), 128.77 (C-H), 129.28 (C-H), 129.39 (C-H), 134.88 (C-Hpara), 136.75 (C), 
137.28 (C), 148.39 (C=O of urea), 164.27 (C=O of lactam); EI-MS m/z: 344.00 
(M+)(13.74); Anal. calcd. for C17H16N2O4S: C, 59.29, H, 4.68, N, 8.13; found C, 
59.41, H, 4.55; N, 8.01. 
 
N-Benzylcarbamoyl-3,3-diethylazetidin-2-one (47e)120 
Prepared as described for 47a, using 46 (1.20 mmol, 152 mg), benzyl isocyanate (1.44 
mmol, 177 l) and triethylamine (1.44 mmol, 200 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5:0.5) to afford the product 
(257 mg, 83%) as colourless oil; max (film) 3364 (NH), 1757 (C=O of lactam), 1702 
(C=O of urea), 1535;  1H-RMN 1.00 (6H, t, J = 7.6, (CH2CH3)2), (4H, q, J = 7.6, 
(CH2CH3)2), 3.42 (2H, s, C-4-H2), 4.50 (2H, d, J = 6.0, CH2Ph), 6.93 (1H, brs, N-H), 
7.28-7.38 (5H, m, C-H);  13C-RMN 8.70 (CH2CH3), 25.71 (CH2CH3), 43.75 (CH2), 
47.04 (CH2), 59.31 (C-3), 127.55 (C-Hpara), 127.65 (C-H),128.71 (C-H), 137.98 (C), 
150.95 (C=O of urea), 172.83 (C=O of lactam); ESI-MS m/z 261 (MH+); Anal. calcd. 
for C15H20N2O2: C, 69.20, H, 7.74, N, 10.76; found C, 68.80, H, 7.80, N, 10.59. 
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N-Benzylcarbamoyl-3,3-diethyl-4-phenoxyazetidin-2-one (47f)99 
Prepared as described for 47a, using 43b (1.40 mmol, 305.50 mg), benzyl isocyanate 
(1.68 mmol, 207 l) and triethylamine (1.68 mmol, 234 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5:0.5), to furnish the 
product as white crystals (398 mg, 81%), m.p. 58-59 ºC; max (film) 3366 (NH), 1770 
(C=O of lactam), 1710 (C=O of urea), 1534, 1492, 1221 (C-O), 1086 (C-O);  1H-
RMN 1.00 (3H, t, J = 7.6, CH2CH3), 1.06 (3H, t, J = 7.6, CH2CH3), 1.77–1.84 (3H, m, 
CH2CH3), 1.99 (1 H, dq, J = 14.4, 7.2, CH2CH3), 4.47 (1H, dd, J = 15.6, 6.0, CH2Ph), 
4.51 (1H, dd, J = 15.6, 6.0, CH2Ph), 5.68 (1H, s, C-4-H), 6.93 (1H, brs, N-H), 7.07 
(1H, t, J = 7.2, C-H); 7.22-7.35 (9H, m, C-H);  13C-RMN 8.58 (CH2CH3), 8.84 
(CH2CH3), 21.23 (CH2CH3), 23.86 (CH2CH3), 43.75 (CH2Ph), 64.35 (C-3), 86.76 (C-
4), 117.76 (C-H), 123.17 (C-Hpara), 127.63 (C-Hpara), 127.67 (C-H), 128.76 (C-H), 
129.67 (C-H), 137.66 (C), 150.14 (C), 157.47 (C=O of urea), 172.23 (C=O of 
lactam); ESI-MS m/z 353 (MH+); Anal. calcd. for C21H24N2O3: C, 71.57, H, 6.86, N, 
7.95; found C, 71.84, H, 6.78, N, 8.18. 
 
N-Benzylcarbamoyl-3,3-diethyl-4-phenylthioazetidin-2-one (47g) 
Prepared as described for 47a, using 44b (1.10 mmol, 262 mg), benzyl isocyanate 
(1.43 mmol, 180 l) and triethylamine (1.43 mmol, 200 l). Purified by column 
chromatography on silica gel (elution with DCM-EtOAc 9.5:0.5), and recrystallized 
from DCM/hexane to furnish the product as white crystals (278.9 mg, 69%), m.p. 79-
80 ºC, max (film) 3360 (NH), 1758 (C=O of lactam), 1700 (C=O of urea), 1523, 845; 
 1H-RMN 0.94 (3H, t, J = 8.0, CH2CH3), 1.12 (3H, t, J = 8.0, CH2CH3), 1.75-1.98 
(3H, m, CH2CH3), 1.99 (1 H, dq, J = 14.4, 7.2, CH2CH3), 4.51 (1H, dd, J = 15.6, 6.0, 
CH2Ph), 4.55 (1H, dd, J = 15.6, 6.0, CH2Ph), 5.06 (1H, s, C-4-H), 6.95 (1H, brs, N-
H); 7.28-7.39 (8H, m, C-H); 7.77 (2H, d, J = 8.0, C-H);  13C-RMN 8.43 (CH2CH3), 
9.01 (CH2CH3), 23.11 (CH2CH3), 24.74 (CH2CH3), 43.74 (CH2Ph), 63.95 (C-3), 
71.42 (C-4), 127.60 (C-Hpara), 127.65 (C-H), 128.17 (C-Hpara), 128.74 (C-H), 129.19 
(C-H), 133.24 (C-H), 137.71 (C), 150.13 (C=O of urea), 172.04 (C=O of lactam); EI-
MS m/z 368.15 (M+)(4.08%); Anal. calcd. for C21H24N2O2S: C, 68.45, H, 6.56, N, 
7.60; found, C, 68.22, H, 6.93, N, 8.03.  
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3-Benzylpyrimidine-2,4(1H,3H)-dione (60), from large scale reaction of 47d with 
exc. sodium methoxide  
N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one, 47d (0.29 mmol, 100 mg), was 
added to a solution of sodium methoxide (1.5 mmol) in methanol (15 ml). The 
reaction mixture was stirred at room temperature and monitored by TLC. The solvent 
was removed under reduced pressure and the residue was taken up in water (20 ml), 
acidified with HCl 10% until pH 2 and extracted with EtOAc (3x 30 ml). After drying 
and evaporating off the solvent, the residue was purified by column chromatography 
on silica gel (elution with DCM-EtOAc 8:2), to yield the product 3-benzylpyrimidine-
2,4(1H,3H)-dione, 60, as a white solid (46.4 mg, 79%); m.p. 177-179 ºC (lit.,156 181-
182 ºC) ; max (film) 3084 (NH), 1625 (C=O), 1601 (NC=ON);  1H-RMN 5.12 (2H, 
s, CH2Ph), 5.81 (1H, dd, J = 7.2, 1.2, HC=CHN), 7.14 (1H, dd, J = 7.2, 6.0, 
HC=CHN), 7.26-7.34 (3H, m, C-H); 7.46 (2H, d, J = 7.2, C-Hortho); 9.35 (1H, brs, N-
H);  13C-RMN 43.71 (CH2Ph), 102.26 (HC=CHN), 127.70 (C-Hpara), 128.46 (C-
H),128.80 (C-H), 136.49 (C), 138.17 (HC=CHN), 151.09 (NHC=ON), 163.12 
(C=OCH); EI-MS m/z 202.05 (M+)(100%); Anal. calcd. for C11H10N2O2, C, 65.34, H, 
4.98, N, 13.85; found, C, 65.65, H, 5.25, N, 13.41. 
 
Attempted ring-closure of 2,2-diethylmalonamic acid and derivatives. 
Ethyl 2-cyano-2-ethylbutanoate (73)146 
Sodium metal (10 mmol, 230 mg) in small pieces was added slowly to dry EtOH (5 
ml). When the reaction had subsided, ethyl 2-cyanoacetate 72 (10 mmol, 1.07 ml) was 
added and the mixture stirred at 50 ºC for 15 min. Iodoethane (10 mmol, 808 l) was 
added dropwise and the resulting mixture refluxed for 90 min, and then cooled to 20 
ºC. Subsequently, more sodium (10 mmol, 230 mg) in dry EtOH (5 ml) was added, 
and after 5 min., an additional iodoethane (10 mmol, 808 l), and the solution 
refluxed for 4h. The solvent was removed under reduced pressure, the residue washed 
with water and extracted with diethyl ether, to yield the product as a red wine colored 
liquid (1284 mg, 76%), max (film) 2241 (CN), 1741 (C=O), 1460, 1237 (C-O), 1020 
(C-O);  1H-RMN 1.64 (6H, t, J = 7.2, (CH2CH3)2), 1.35 (3H, t, J = 7.2, OCH2CH3), 
1.87 (2H, dq, J = 14.4, 7.2, CCH2CH3), 1.98 (2H, dq, J = 14.4, 7.2, CCH2CH3), 4.30 
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(2H, q, J = 7.2, OCH2CH3);  13C-RMN 10.01 (CCH2CH3), 14.38 (OCH2CH3), 30.75 
(CCH2CH3), 51.82 (C), 62.72 (OCH2CH3), 119.41 (CN), 169.31 (C=O); EI-MS m/z 
169.22 (M+)(1.90%). 
 
2,2-Diethylmalonamic acid (74)146 
Compound 73 (6.11 mmol, 1034 mg) was added with cooling and stirring to conc. 
sulphuric acid at 90 ºC, held at 100-110 ºC for 30 min. and poured onto ice. Extracted 
with EtOAc and recrystallized from EtOH to give the product as white crystals (243 
mg, 31%), m.p. 149-150 ºC (lit.146 142-144 ºC); max (film) 3401 (NH), 3227 (NH), 
1705 (C=O of acid), 1640 (C=O of amide), 1479, 1305, 1214, 1085;  1H-RMN 
(DMSO) 0.95 (6H, t, J = 7.2, (CH2CH3)2), 1.77 (2H, dq, J = 14.4, 7.2, (CH2CH3)2), 
2.19 (2H, dq, J = 14.4, 7.2, CCH2CH3), 5.95 (1H, brs, N-H), 6.57 (1H, brs, N-H);  
13C-RMN 9.27 (CCH2CH3), 26.85 (CCH2CH3), 58.09 (C), 172.60 (C=O), 175.11 
(C=O); EI-MS m/z 159.18 (M+)(47.75%), 144 (M-CH3)+ (100.00%), 129 (M-CO2H)+ 
(91.46). 
 
2-Cyano-2-ethylbutanoyl chloride (75)147 
To compound 74 (12.58 mmol, 2000 mg) suspended in dry toluene (15 ml) in inert 
atmosphere, was added simultaneously for 15 min. dry pyridine (15 mmol, 1.22 ml) 
and thionyl choride (34 mmol, 2.48 ml) at 15-20 ºC, refluxed for 30 min, the salt 
filtered-off and the yellow filtrate distillated in reduced pressure, to yield the product 
(740 mg, 37%), b.p. 28 º C (0.4 mm Hg); max (film) 2254 (CN), 1784 (C=O), 1459;  
1H-RMN (300 MHz) 1.07 (6H, t, J = 7.2, (CH2CH3)2), 1.89 (2H, dq, J = 14.4, 7.2, 
CCH2CH3), 2.06 (2H, dq, J = 14.4, 7.2, CCH2CH3);  13C-RMN (300 MHz) 9.60 
(CCH2CH3), 30.56 (CCH2CH3), 61.36 (C), 117.27 (CN), 171.82 (C=O); ESI-MS m/z 
160 (MH+). 
 
2,2-Diethylmalonamic acid ethyl ester (76)146 
Compound 73 (5.92 mmol, 1000 mg) was added with cooling to 30 ml of conc. 
sulphuric acid at 90 ºC, the temperature maintained at 95-100 ºC for 5 min., and 
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poured onto ice. The oil was extracted with diethyl ether and ethyl acetate, the organic 
layer washed with sodium carbonate, water and dried. The solvent was removed under 
reduced pressure to give the product as a pale yellow solid (232 mg, 21%), m.p. 77-78 
ºC (lit.146 73-75 ºC), max (film) 3399 (NH), 3194(NH), 1716 (C=O of ester), 1669 
(C=O of amide), 1228, 1133, 1010;  1H-RMN 0.77 (6H, t, J = 7.2, (CH2CH3)2), 1.26 
(3H, t, J = 7.2, OCH2CH3), 1.76 (2H, dq, J = 14.4, 7.2, CCH2CH3), 1.98 (2H, dq, J = 
14.4, 7.2, CCH2CH3), 4.15 (2H; q, J = 7.2, OCH2CH3), 5.69 (1H, brs, N-H), 7.86 (1H, 
brs, N-H);  13C-RMN 9.61 (CCH2CH3), 14.00 (OCH2CH3), 30.04 (CCH2CH3), 59.36 
(C), 61.22 (OCH2CH3), 173.53 (C=O), 174.97 (C=O); EI-MS m/z 187.15 
(M+)(0.02%), 144.15 (M-CONH2)+ (7.29%). 
 
Synthesis of azetidine-2,4-diones by condensation of malonyl dichlorides with 
primary amines 
Ethyl 2-(3,3-diethyl-2,4-dioxoazetidin-1-yl)acetate (77a)151 
To a solution of diethylmalonyl dichloride (25 mmol, 4925 mg) in dry dioxane (15 
ml) was added under nitrogen ethyl glycinate hydrochloride (25 mmol, 3475 mg) in 
the same solvent (15 ml). Then, a solution of triethylamine (90 mmol, 9107 mg) in 
dry dioxane was added dropwise during 1.5 h and the reaction mixture refluxed for 
nearly 6h. The residue was purified by column chromatography on silica gel using 
mixtures of toluene and EtOAc as eluant to yield the diethylmalonyldiglycinate 78 (R 
= CH2CO2Et, R1 = R2 = Et) as the by-product, and the product as a colourless oil (920 
mg, 16%); max (film) 1887 (C=O symm), 1737 (C=O assym.);  1H-NMR 1.07 (6H, 
t, J = 7.6, (CH2CH3)2), 1.30 (3H, t, J = 7.2, OCH2CH3), 1.82, (4H, q, J = 7.6, 
(CH2CH3)2), 4.10 (2H, s, NCH2CO), 4.25 (2H, q, J = 7.2, OCH2CH3);  13C-NMR 
9.27 (CCH2CH3), 14.08 (OCH2CH3), 23.62 (CCH2CH3), 39.28 (NCH2CO), 62.23 
(OCH2CH3), 71.30 (C-3), 165.93 (C=O of ester), 173.59 (C=O of 4-oxo--lactam); 
EI-MS m/z 228.20 (M)+ (0.51%); 98.05 ((CH3CH2)2C=C=O).+  (100.00%), 83.05 
[((CH3CH2)2C=C=O)-CH3]+ (56.68%); 55 (C3H3O)+ (12.92 %); Anal. calcd. for 
C11H17NO4: C, 58.14, H, 7.54, N, 6.16; found C, 58.40, H, 7.24, N, 5.77.  
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3,3-Diethyl-1-benzylazetidine-2,4-dione (77b) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg), 
benzylamine (15 mmol, 1622 mg) and triethylamine (36 mmol, 3649 mg) as catalyst. 
Purified by chromatography on silica gel using toluene: EtOAc as eluant (from 9.8:0.2 
to 9.2:0.8) and then recrystallized from hexane to yield the product as white crystals 
(243 mg, 9%); m.p. 46-47 ºC; max (film) 1873 (C=O symm), 1717 (C=O assym.), 
1458;  1H-NMR 0.94 (6H, t, J = 7.6, (CH2CH3)2), 1.75 (4H, q, J = 7.6, (CH2CH3)2), 
4.48 (2H, s, CH2Ph), 7.32-7.37 (5H, m, C-H);  13C-NMR 9.18 (CH2CH3), 23.67 
(CH2CH3), 42.17 (CH2Ph), 70.98 (C-3), 128.14 (C-Hpara), 128.28 (C-H), 128.88 (C-
H), 135.06 (C), 174.24 (C=O); EI-MS m/z 231.15 (M)+ (4.07%), 133.05 
(PhCH2NCO)+ (1.32%), 98.05 ((CH3CH2)2C=C=O).+ (100.00%), 90.95 (C7H7)+ 
(29.31%), 82.95 [((CH3CH2)2C=C=O)-CH3]+ (65.79%), 54.95 (C3H3O)+ (38.23%); 
Anal. calcd. for C14H17NO2, C, 72.70, H, 7.41, N, 6.06; found, C 72.55 %, H 7.43 %, 
N 5.81 %. 
 
3,3-Diethyl-1-(p-methoxyphenyl)azetidine-2,4-dione (77c) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and 4-anisidine (15 mmol, 1605 mg) as primary amine. Purified by chromatography 
on silica gel using toluene: EtOAc (9.2: 0.8), yielding yellow oil (412 mg, 11%), max 
(film) 1849 (C=O symm.), 1736 (C=O assym.), 1513, 1250 (C-O), 1029 (C-O);  1H-
NMR 1.08 (6H, t, J = 7.6, (CH2CH3)2), 1.86 (4H, q, J = 7.6, (CH2CH3)2), 3.84 (3H, s, 
OCH3), 6.94 (2H, d, J = 8.8, C-H), 7.76 (2H, d, J = 8.8, C-H);  13C-NMR 9.25 
(CH2CH3), 23.95 (CH2CH3), 55.51 (OCH3), 71.94 (C-3), 114.34 (C-H), 120.89 (C-H), 
127.82 (C), 157.84 (C), 172.25 (C=O); EI-MS m/z 247.30 (M)+ (71.03%); 149.15 (4-
(OCH3)PhNCO)+ (100.00%), 134.15 (NCOC6H4O)+ (25.29%), 98.05 
((CH3CH2)2C=C=O).+ (5.85%), 82.95 [((CH3CH2)2C=C=O)-CH3]+ (7.49%); Anal. 
calcd. for C14H17NO3, C, 68.00, H, 6.93, N, 5.66; found, C, 67.60, H, 6.53, N, 5.79. 
 
3,3-Diethyl-1-(p-tolyl)azetidine-2,4-dione (77d) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and 4-toluidine (15 mmol, 1605 mg). Purified by chromatography on silica gel using 
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toluene: EtOAc (9:1) as eluant, to afford white crystals (343 mg, 10%), m.p. 41-44 ºC; 
max (film) 1844 (C=O symm.), 1739 (C=O assym.), 1517;  1H-NMR 1.08 (6H, t, J = 
7.6, (CH2CH3)2), 1.87 (4H, q, J = 7.6, (CH2CH3)2), 2.37 (3H, s, p-CH3), 7.23 (2H, d, J 
= 8.4, C-H), 7.73 (2H, d, J = 8.4, C-H);  13C-NMR 9.24 (CH2CH3), 21.18 (p-CH3), 
23.95 (CH2CH3), 72.01 (C-3), 119.19 (C-H), 129.75 (C-H), 131.33 (C), 136.69 (C), 
172.27 (C=O); EI-MS m/z 231.15 (M)+ (5.76%), 97.95 ((CH3CH2)2C=C=O)+  
(94.15%), 82.95 [((CH3CH2)2C=C=O)-CH3]+ (100.00%), 54.95 (C3H3O)+ (47.58%); 
Anal. calcd. for C14H17NO2, C, 72.70, H, 7.41, N, 6.06; found, C, 72.73, H, 6.59, N, 
6.56. 
 
3,3-Diethyl-1-phenylazetidine-2,4-dione (77e)165 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and aniline (15 mmol, 1397 mg). Purified by column chromatography on silica gel 
using toluene: EtOAc (9.0, 1.0), to give a colourless oil (474 mg, 15%) (lit165: mp. 
86–87ºC); max (film) 1863 (C=O symm.), 1740 (C=O asymm.), 1595, 1458;  1H-
NMR 1.09 (6H, t, J = 7.6, (CH2CH3)2), 1.88 (4H, q, J = 7.6, (CH2CH3)2), 7.29 (1H, dt, 
J = 7.6, 1.2, C-Hpara), 7.73 (2H, dt, J = 7.6, 1.2, C-Hmeta), 7.86 (2H, dd, J = 7.6, 1.2, C-
Hortho);  13C-NMR 9.25 (CH2CH3), 23.96 (CH2CH3), 72.14 (C-3), 119.23 (C-H), 
126.76 (C-Hpara), 129.26 (C-H), 133.85 (C), 172.26 (C=O); EI-MS m/z 217.15 (M)+ 
(18.05%); 118.95 (PhNCO)+ (14.21%), 98.05 ((CH3CH2)2C=C=O)+  (100.00 %), 
82.95 [((CH3CH2)2C=C=O)-CH3]+ (90.98%), 54.95 (C3H3O)+ (47.22%); Anal. calcd. 
for C13H15NO2, C, 71.87, H, 6.96, N, 6.45; found, C, 72.09, H, 6.83, N, 6.46. 
 
1-(p-Chlorophenyl)-3,3-diethylazetidine-2,4-dione (77f) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and 4-chloroaniline (15 mmol, 1695 mg). Purified by column chromatography on 
silica gel using toluene: EtOAc (8.0, 2.0), yielding the product as white crystals (544 
mg, 14%), m.p. 43-46 ºC; max (film) 1868 (C=O symm.), 1741 (C=O asymm.), 1496, 
1463, 1037;  1H-NMR 1.08 (6H, t, J = 7.6, (CH2CH3)2), 1.88 (4H, q, J = 7.6, 
(CH2CH3)2), 7.40 (2H, d, J = 8.8, C-H), 7.83 (2H, d, J = 8.8, C-H);  13C-NMR 9.23 
(CH2CH3), 23.93 (CH2CH3), 72.38 (C-3), 120.41 (C-H), 129.42 (C-H), 132.12 (C), 
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132.32 (C), 171.96 (C=O); EI-MS m/z 251.05 (M)+ (48.25%), 253.05 (M+2)+ 
(15.90%), 153.00 (4-ClPhNCO)+ 28.31%, 155.00 (4-ClPhNCO+2) (9.49%), 98.05 
((CH3CH2)2C=C=O)+  (100.00%), 82.95 [((CH3CH2)2C=C=O)-CH3]+ (77.26%), 55.00 
(C3H3O)+ (44.43%); Anal. calcd. for C13H14NO2Cl, C, 62.03, H, 5.61, N, 5.56, found, 
C, 62.31, H, 5.41, N, 5.81. 
 
3,3-Diethyl-p-(2,4-dioxoazetidin-1-yl)benzonitrile (77g) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and 4-cyanoaniline (15 mmol, 1772 mg). Purified by column chromatography on 
silica gel using hexane: EtOAc (8.0, 2.0), to yield the product as white crystals (687 
mg, 19%), m.p. 106-109 ºC; max (film) 2229 (CN), 1873 (C=O symm.), 1746 (C=O 
asymm.), 1385;  1H-NMR 1.09 (6H, t, J = 7.6, (CH2CH3)2), 1.90 (4H, q, J = 7.6, 
(CH2CH3)2), 7.74 (2H, d, J = 8.8, C-H), 8.03 (2H, d, J = 8.8, C-H);  13C-NMR 9.21 
(CH2CH3), 23.96 (CH2CH3), 72.87 (C-3), 110.10 (C), 118.14 (CN), 119.29 (C-H), 
133.49 (C-H), 137.19 (C), 171.70 (C=O); EI-MS m/z 242.15 (M)+ (24.63%), 144.00 
(4-(CN)PhNCO)+ (5.22%), 98.00 ((CH3CH2)2C=C=O)+  (100.00%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (89.18%), 55.00 (C3H3O)+ (28.77%); Anal. calcd. for 
C14H14N2O2, C, 69.41, H, 5.82, N, 11.56; found, C, 69.58, H, 5.87, N, 11.57. 
 
3,3-Dimethyl-1-benzylazetidine-2,4-dione (77h) 
Prepared as described for 77a, using dimethylmalonyl dichloride (15 mmol, 2535 
mg), benzylamine as primary amine (15 mmol, 1622 g) and triethylamine (36 mmol 
3649 mg) as catalyst. The resulting reaction mixture was refluxed for 14h. Purified by 
chromatography on silica gel, using toluene: EtOAc as eluant (from 9.8:0.2 to 
9.0:1.0), yielding white crystals (122 mg, 4%), m.p. 69-71 ºC, max (film) 1874 (C=O 
symm.), 1719 (C=O asymm.), 1400;  1H-NMR 1.38 (6H, s, (CH3)2), 4.46 (2H, s, 
CH2Ph), 7.33-7.39 (5H, m, C-H);  13C-NMR 17.44 (CH3), 42.78 (CH2Ph), 60.66 (C-
3), 127.99 (C-H), 128.17 (C-H), 129.00 (C-H), 134.77 (C), 175.05 (C=O); EI-MS m/z 
203.30 (M)+ (100.00%), 133.05 (PhCH2NCO)+ (36.41%), 90.95 (C7H7)+ (52.26%), 
70.05 ((CH3)2C=C=O)+ (66.30 %); Anal. calcd. for C12H13NO2, C, 70.92, H, 6.45, N, 
6.89; found, C, 71.16, H, 5.92, N, 6.81. 
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3,3-Dimethyl-1-(p-Chlorophenyl)-azetidine-2,4-dione (77i) 
Synthesized as described for 77a, using dimethylmalonyl dichloride (25 mmol, 4225 
mg) and 4-chloroaniline (25 mmol, 2820 mg), the reaction mixture being refluxed for 
8h. Purified by column chromatography using hexane: EtOAc as eluant (8.4: 1.6) to 
afford white crystals (351 mg, 6%), m.p. 81-84 ºC; max (film) 1858 (C=O symm.), 
1735 (C=O asym.), 1493;  1H-NMR 1.51 (6H, s, (CH3)2), 7.40 (2H, d, J = 8.8, C-H), 
7.82 (2H, d, J = 8.8, C-H);  13C-NMR 17.76 (CH3), 62.03 (C-3), 120.33 (C-H), 
129.42 (C-H), 132.12 (C), 132.81 (C), 172.62 (C=O); EI-MS m/z 223.00 (M)+ (96.36 
%), 225.00 (M+2)+ (32.71%), 153.00 (4-ClPhNCO)+ (33.19%), 155.00 (4-
ClPhNCO+2)+ (11.09%), 70.00 ((CH3)2C=C=O)+ (100.00%); Anal. calcd. for 
C11H10NO2Cl, C, 59.07; H, 4.51; N, 6.26; Cl, 15.85; found, C, 59.03; H, 4.12; N, 
6.38. 
 
3,3-Diethyl-1-o-tolylazetidine-2,4-dione (77j)  
Prepared as described for 77a using diethylmalonyl dichloride (15 mmol, 2956 mg) 
and ortho-toluidine (15 mmol, 1605 mg). The product was purified by 
chromatography on silica gel using hexane/EtOAc (8:2), and subsequently by 
preparative TLC, yielding the product as a colorless oil (346 mg, 6%); max (film) 
1868 (C=O symm.), 1740 (C=O a symm.);  1H-NMR 1.15 (6H, t, J = 7.6, 
(CH2CH3)2), 1.90 (4H, q, J = 7.6, (CH2CH3)2), 2.38 (3H, s, o-CH3), 7.26-7.27 (2H, m, 
C-H), 7.30-7.32 (2H, m, C-H);  13C-NMR 9.52 (CH2CH3), 18.83 (o-CH3), 24.11 
(CH2CH3), 70.80 (C-3), 125.59 (C-H), 126.68 (C-H), 129.03 (C-H), 129.83 (C), 
131.43 (C-H), 133.83 (C), 172.84 (C=O); EI-MS m/z 231 (M)+ 11.97 %, 133.00 (o-
MePhNCO)+ (4.74%), 98.00 ((CH3CH2)2C=C=O)+  (100.00%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (67.41%), 55.00 (C3H3O)+ (28.77%); Anal. calcd. for 
C14H17NO2, C, 72.70, H, 7.41, N, 6.06; found, C, 70.69, H, 7.88, N, 5.85. 
 
3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione (77k)  
Prepared as described for 77a using diethylmalonyl dichloride (15 mmol) and 3-
aminopyridine (15 mmol). Purified by column chromatography on silica gel using 
DCM/EtOAc (9.5:0.5), to give a light yellow solid, m.p. 38 ºC (1520 mg, 47%), max 
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(film) 1869 (C=O symm.), 1743 (C=O asymm.);  1H-NMR 1.10 (6H, t, J = 7.6, 
(CH2CH3)2), 1.90 (4H, q, J = 7.6, (CH2CH3)2), 7.38 (1H, ddd, J = 8.4, 4.8, 0.4, C´5-
H), 8.35 (1H, ddd, J = 8.4, 2.8, 1.6, C-H), 8.55 (1H, dd, J = 4.8, 1.6, C-H), 9.16 (1H, 
d, J = 2.8, C´2-H);  13C-NMR 9.22 (CH2CH3), 23.93 (CH2CH3), 72.40 (C-3), 123.84 
(C-H), 126.21 (C-H), 130.83 (C), 140.77 (C-H), 147.71 (C-H), 171.73 (C=O); EI-MS 
m/z 218.15 (M)+ (16.44%), 120.00 (PyrNCO) (11.45%), 98.00 ((CH3CH2)2C=C=O)+ 
75.53%, 83.00 [((CH3CH2)2C=C=O)-CH3]+ (67.41%), 58.00 (CH2NCO)+ (100.00%), 
55.00 (C3H3O)+ (42.74%); Anal. calcd. for C12H14N2O2, C, 66.04; H, 6.47; N, 12.84; 
found, C, 66.29; H, 6.53; N, 13.07. 
 
3,3-Diethyl-1-(6-methylpyridin-3-yl)azetidine-2,4-dione (77l) 
Prepared as described for 77a, using diethylmalonyl dichloride (0.0075 mol) and 5-
amino-2-methylpyridine (0.0075 mol). Purified by column chromatography on silica 
gel using DCM/EtOAc (9.5:0.5) and recrystallized from DCM-hexane, to give white 
crystals (678 mg, 39%), m.p. 44-45 ºC ; max (film) 1862 (C=O symm.), 1741 (C=O 
asymm.);  1H-NMR 1.09 (6H, t, J = 7.6, (CH2CH3)2), 1.89 (4H, q, J = 7.6, 
(CH2CH3)2), 2.59 (3H, s, p-CH3), 7.22 (1H, d, J = 8.4, C´5-H), 8.04 (1H, dd, J = 8.4, 
2.4, C´6-H), 9.01 (1H, d, J = 2.4, C´2-H);  13C-NMR 9.22 (CH2CH3), 23.91 
(CH2CH3), 24.25 (p-CH3), 72.25 (C-3), 123.34 (C), 126.74 (C-H), 129.24 (C-H), 
140.13 (C-H), 156.83 (C), 171.80 (C=O); EI-MS m/z 232.09 (M)+ 33.14%; 134.03 (6-
MePyrNCO)+ (41.21%), 98.00 ((CH3CH2)2C=C=O)+  (100.00%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (80.34%), 55.00 (C3H3O)+ (29.94%); Anal. calcd. for 
C13H16N2O2, C, 67.22; H, 6.94; N, 12.06; found, C, 66.81;  H, 6.85; N, 11.71. 
 
3,3-Diethyl-1-(naphthalen-1-yl)azetidine-2,4-dione (77m). Prepared as described 
for 77a, using diethylmalonyl dichloride (15 mmol) and naphtalen-1-amine (15 
mmol). Purified by column chromatography on silica gel using hexane/EtOAc (8:2), 
recrystallized from hexane, to yield a white solid (196 mg, 5%), m.p. 49-50 ºC, max 
(film) 1868 (C=O symm.), 1739 (C=O asymm.);  1H-NMR 1.26 (6H, t, J = 7.6, 
(CH2CH3)2), 2.00 (4H, q, J = 7.6, (CH2CH3)2), 7.50-7.64 (4H, m, C-H), 7.89-7.93 
(3H, m, C-H);  13C-NMR 9.63 (CH2CH3), 24.25 (CH2CH3), 71.32 (C-3), 123.06 (C-
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H), 123.32 (C-H), 125.21 (C-H), 126.77 (C-H), 127.17 (C), 127.20 (C-H), 127.90 (C), 
128.47 (C-H), 129.43 (C-H), 134.36 (C), 173.26 (C=O); EI-MS m/z 267.15 (M)+ 
(10.41%), 169.05 (1-NaphNCO)+ (100.00%), 98.00 ((CH3CH2)2C=C=O)+  (17.97%), 
83.00 [((CH3CH2)2C=C=O)-CH3]+ (24.44%), 55.00 (C3H3O)+ (21.72%); Anal. calcd. 
for C17H17NO2, C, 76.38; H, 6.41; N, 5.24; found, C, 76.31; H, 6.34; N, 5.23. 
 
3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione (77n). Prepared as described for 
77a using 2-ethyl-2-isobutylmalonyl dichloride 89a (14 mmol) and aniline (14 
mmol). The product was purified by chromatography on silica gel using 
hexane/EtOAc (9:1), yielding the desired product as a colorless oil (420 mg, 12%), 
max (film) 1860 (C=O symm.), 1737 (C=O asymm.);  1H-NMR 1.00 (6H, d, J = 6.4, 
CH(CH3)2), 1.08 (3H, t, J = 7.6, CH2CH3), 1.75 (2H, d, J = 6.4, CH2CH), 1.81-1.91 
(3H, m, CH + CH2CH3), 7.29 (1H, dt, J = 7.6, 1.2, C-Hpara), 7.44 (2H, dt, J = 7.6, 1.2, 
C-Hmeta), 7.86 (2H, dd, J = 7.6, 1.2, C-Hortho);  13C-NMR 9.09 (CH2CH3), 23.66 
(CH(CH3)2), 25.04 (CH2CH3), 25.26 (CH(CH3)2), 39.80 (CH2CH), 70.89 (C-3), 
119.20 (C-H), 126.77 (C-H), 129.29 (C-H), 133.93 (C), 172.46 (C=O); EI-MS m/z 
245.13 (M)+ (6.87%), 126.09 [(CH3CH2)((CH3)2CHCH2)C=C=O]+ (100.00%), 119.03 
(PhNCO)+ (6.68%), 98.00 ((CH3CH2)2C=C=O)+  (26.52%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (64.45%), 55.00 (C3H3O)+ (87.73%); Anal. calcd. for 
C15H19NO2, C, 73.44; H, 7.81; N, 5.71; found, C, 71.83; H, 7.93; N, 5.61. 
 
3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione (77o) 
Prepared as described for 77a using 2-benzyl-2-ethylmalonyl dichloride 89b (8.1 
mmol) and aniline (8.1 mmol). The product was purified by chromatography on silica 
gel using hexane/EtOAc (8:2), and recrystallized from hexane, yielding white crystals 
(488 mg, 22%), m.p. 76-77 ºC, max (film) 1855 (C=O symm.), 1733 (C=O asymm.); 
 1H-NMR 1.11 (3H, t, J = 7.6, CH2CH3), 1.95 (2H, q, J = 7.6, CH2CH3), 3.10 (2H, s, 
CH2Ph), 7.20-7.24 (2H, m, C-H), 7.27-7.28 (4H, m, C-H), 7.33 (2H, dt, J = 7.6, 1.2, 
C-H), 7.52 (2H, dd, J = 7.6, 1.2, C-H);  13C-NMR 9.33 (CH2CH3), 24.42 (CH2CH3), 
37.38 (CH2Ph), 73.37 (C-3), 119.61 (C-H), 126.90 (C-H), 127.38 (C-H), 128.57 (C-
H), 129.11 (C-H), 129.63 (C-H), 132.99 (C), 134.86 (C), 171.36 (C=O); EI-MS m/z 
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279.04 (M)+ (75.54%), 160.03 [(CH3CH2)(CH2Ph)C=C=O]+ (100.00%), 145.01 
{[(CH3CH2)(CH2Ph)C=C=O]-CH3}+ (58.10%), 119.00 (PhNCO)+ (18.09%), 117.02 
{[(CH3CH2)(CH2Ph)C=C=O]-CO}+ (78.89%), 91.00 (PhCH2)+ (75.73%), 77.01 (Ph)+ 
(21.86%); Anal. calcd. for C18H17NO2, C, 77.40; H, 6.13; N, 5.01; found, C, 77.22; H, 
6.08; N, 5.08. 
 
3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione (77p) 
Prepared as described for 77a using 2-benzyl-2-methylmalonyl dichloride 89c (16 
mmol) and aniline (16 mmol). Purified by column chromatography on silica gel using 
hexane/ethyl acetate (8:2), subsequently by preparative TLC and recrystallized from 
DCM-hexane to yield white crystals (182 mg, 5%), m.p. 54-55 ºC, max (film) 1852 
(C=O symm.), 1740 (asymm.);  1H-NMR 1.57 (3H, s, CH3), 3.10 (2H, s CH2Ph), 
7.20-7.24 (2H, m, C-H), 7.27-7.29 (4H, m, C-H), 7.33 (2H, dt, J = 7.6, 1.2, C-H), 7.56 
(2H, dd, J = 7.6, 1.2, C-H);  13C-NMR 16.27 (CH3), 38.65 (CH2Ph), 73.03 (C-3), 
119.48 (C-H), 126.92 (C-H), 127.56 (C-H), 128.60 (C-H), 129.12 (C-H), 129.56 (C-
H), 134.86 (C), 136.16 (C), 171.51 (C=O); EI-MS m/z 265.07 (M)+ (81.34%), 146.19 
[(CH3)(CH2Ph)C=C=O].+ (97.98%), 119.06 (PhNCO)+ (29.01%), 91.05 (PhCH2)+ 
(78.17%), 77.04 (Ph)+ (25.17%); Anal. calcd. for C17H15NO2, C, 76.96; H, 5.70; N, 
5.28; found, C, 76.88; H, 5.59; N, 5.24.  
 
3,3-Dimethyl-1-phenylazetidine-2,4-dione (77q) 
Prepared as described for 77a using dimethylmalonyl dichloride (6 mmol) and aniline 
(6 mmol). The addition of TEA was performed for the period of 6 h. Purified by 
column chromatography on silica gel using hexane/EtOAc (8:2), and subsequently by 
preparative TLC, recrystallized from hexane to yield white crystals (123 mg, 11%), 
m.p. 35 ºC (lit.165 m.p. 36 ºC); max (film) 1858 (C=O symm.), 1737 (C=O asymm.);  
1H-NMR 1.51 (6H, s, (CH3)2), 7.29 (1H, dt, J = 7.6, 1.2, C-Hpara), 7.34 (2H, dt, J = 
7.6, 1.2, C-Hmeta), 7.86 (2H, dd, J = 7.6, 1.2, C-Hortho);  13C-NMR 17.77 (CH3), 61.78 
(C-3), 119.10 (C-H), 126.77 (C-Hpara), 129.26 (C-H), 134.33 (C), 172.96 (C=O); EI-
MS m/z 189.00 (M)+ (22.37%); 119.00 (PhNCO)+ (8.50%), 70.00 ((CH3)2C=C=O).+ 
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(100.00%); Anal. calcd. for C11H11NO2, C, 69.83; H, 5.86; N, 7.40; found, C, 70.15, 
H, 6.37, N, 7.75.  
 
3-Butyl-3-ethyl-1-phenylazetidine-2,4-dione (77r)165 
A solution of triethylamine (12 mmol) in dry xylene (10 ml) was added dropwise over 
a period of 7 h to a solution of phenyl isocyanate (19 mmol) and 2-ethylhexanoyl 
chloride (10 mmol) in dry xylene (30 ml). The reaction mixture was refluxed for 11h, 
cooled to room temperature, filtered from triethylamine hydrochloride. The solvent 
was removed under reduced pressure, and the residue was purified by 
chromatography on silica gel, yielding the desired product as colorless oil (955 mg, 
39%) (lit. m.p. 103-104 ºC165); max (film) 1861 (C=O symm.), 1741 (C=O asymm.); 
 1H-NMR 0.92 (3H, t, J = 8.0, CH2CH3), 1.09 (3H, t, J = 8.0, CH2CH3), 1.35-1.47 
(4H, m, CH2CH2CH2CH3), 1.79-1.83 (2H, m, CH2CH2CH2CH3), 1.88 (2H, q, J = 8.0, 
CH2CH3), 7.29 (1H, t, J = 8.0, C-Hpara), 7.44 (2H, t, J = 8.0, C-Hmeta), 7.87 (2H, d, J = 
8.0, C-Hortho);  13C-NMR 9.23 (CH2CH3), 13.79 (CH2CH3), 22.84 
(CH2CH2CH2CH3), 24.34 (CH2CH2CH2CH3), 26.97 (CH2), 30.60 (CH2), 71.49 (C-3), 
119.35 (C-H), 126.75 (C-Hpara), 129.26 (C-H), 133.91 (C), 172.38 (C=O); EI-MS m/z 
245.20 (M)+ (4.38%), 126.10 [(CH3CH2)(CH3(CH2)3)C=C=O].+ (24.33%), 119.05 
(PhNCO)+ (8.31%), 98.05 ((CH3CH2)2C=C=O).+  (100.00%), 83.05 
[((CH3CH2)2C=C=O)-CH3]+ (24.44%), 55.00 (C3H3O)+ (21.72%); Anal. calcd. for 
C15H19NO2, C, 73.44; H, 7.81; N, 5.71; found, C, 71.95 %; H, 8.33 %; N, 4.59 %. 
 
2,2-Diethylmalonyldiglycinate (78, R = CH2COOEt, R1 = Et)151 
Prepared from reaction of diethylmalonyl dichloride and ethyl glycinate 
hydrochloride, being a by-product from the synthesis of 77a. Purified as described for 
77a, being the second fraction to be eluted (1620 mg, 20%), m.p. 108-109 (lit.151 109-
110 ºC), max (film) 3464 (NH), 3329 (NH), 1743 (C=O of ester), 1664 (C=O of 
amide), 1645 (C=O of amide), 1388, 1245 (C-O), 1020 (C-O);  1H-NMR 0.90 (6H, t, 
J = 7.6, (CH2CH3)2), 1.30 (6H, t, J = 7.2, 2-OCH2CH3), 1.95 (4H, q, J = 7.6, 
(CH2CH3)2), 4.06 (4H, d, J = 5.6, 2-NHCH2), 4.22 (4H, q, J = 7.2, 2-OCH2CH3), 8.04 
(2H, brs, 2 NH). 
6. Experimental Section 
 
 
 
212
N-1,N-3-Dibenzhydryl-2,2-diethylmalonamide (78, R = CHPh2, R1 = R2 =Et) 
Prepared as described for 77a, using diethylmalonyl dichloride (15 mmol, 2956 mg), 
benzhydrylamine (15 mmol, 2.66 ml) and triethylamine (36 mmol, 5 ml). Purified by 
flash column chromatography, to afford a yellow solid (882 mg, 12%), max (film) 
3303 (NH), 3254 (NH), 1697 (C=O of amide), 1437, 1171, 1084;  1H-NMR 0.83 
(6H, t, J = 7.6, (CH2CH3)2), 1.96 (4H, q, (CH2CH3)2), 6.29 (2H, d, J = 6.0, 2 
NHCHPh2), 7.22-7.38 (20H, m, C-H), 7.90 (2H, brs, 2 NH). 
 
Synthesis of 2,2-disusbtituted malonyl dichlorides 89 from malonates 91 
Dimethyl 2-ethyl-2-isobutylmalonate (91a) 
Sodium hydride (60%, 17.7 mmol, 708 mg) was added very slowly under nitrogen to 
a solution of dimethyl 2-isobutylmalonate (16 mmol, 3.0 ml) in dry THF (50 ml) at 0 
ºC. The resulting mixture was then stirred at rt for 2h (hydrogen gas evolution). Then, 
iodoethane (17.7 mol, 1.42 ml) was added dropwise and the reaction mixture was 
stirred at rt for 12 h and refluxed for 1h30. The solvent was removed under reduced 
pressure and the residue was dissolved in diethyl ether (30 ml), washed with water (3 
x 30 ml) and dried over anhydrous sodium sulfate. The solvent was removed to give 
the product as a yellow oil (2520 mg, 72%), used without any purification; max (film) 
1735 (br, C=O), 1457, 1438, 1232 (C-O), 1225 (C-O), 1150 (C-O), 1131 (C-O);  1H-
NMR 0.82 (3H, t, J = 7.6, CH2CH3), 0.88 (6H, d, J = 6.8, CH(CH3)2), 1.62 (1H, m, 
CH(CH3)2), 1.89 (2H, J = 6.8, CH2CH), 1.99 (2H, J = 7.6, CH2CH3), 3.72 (6H, s, 
OCH3);  13C-NMR 8.61 (CH2CH3), 23.65 (CH(CH3)2), 25.17 (CH(CH3)2), 25.28 
(CH2CH3), 41.02 (CH2CH), 53.53 (OCH3), 56.29 (C-2), 172.46 (C=O). 
 
Diethyl 2-benzyl-2-ethylmalonate (91b) 
Sodium metal (44 mmol, 1012 mg) was added in small pieces to dry EtOH (120 ml) 
under a nitrogen atmosphere. When the reaction had subsided, diethyl 2-
benzylmalonate (40 mmol, 9.30 ml) was added ropwise over a period of 20 min. and 
the mixture reacted for 30 min. at 50 ºC. To the resulting solution was added dropwise 
iodoethane (44 mmol, 3.53 ml) and the mixture refluxed for 2h30. The mixture was 
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cooled to rt and the solvent was removed under reduced pressure. The residue was 
diluted in diethyl ether (80 ml), washed with water (3 x 80 ml) and dried over 
anhydrous sodium sulfate. The solvent was removed under reduced pressure to give a 
colorless oil (11.11 g, 58%), used without any purification; max (film) 1731 (br, 
C=O), 1451, 1425, 1275 (C-O), 1238 (C-O), 1187, 1106 (C-O), 1024 (C-O);  1H-
NMR 0.95 (3H, t, J = 7.2, CH2CH3), 1.26 (6H, t, J = 7.2, 2-OCH2CH3), 1.85 (2H, q, J 
= 7.2, CH2CH3), 3.26 (2H, s, CH2Ph), 4.20 (4H, q, J = 7.2, 2-OCH2CH3), 7.10 (2H, d, 
J = 7.2, C-Hortho), 7.23-7.28 (3H, m, C-H);  13C-NMR 8.65 (CH2CH3), 14.10 
(OCH2CH3), 24.73 (CH2CH3), 37.45 (CH2Ph), 59.30 (C-2), 61.15 (OCH2CH3), 
126.87 (C-Hpara), 128.24 (C-H), 129.89 (C-H), 136.31 (C), 171.34 (C=O). 
 
Diethyl 2-benzyl-2-methylmalonate (91c)174 
Prepared as described for 91a, using diethyl 2-benzylmalonate (12.7 mmol, 3.0 ml), 
sodium hydride (60%, 14 mmol, 561 mg) and iodomethane (14 mmol, 0.87 ml), to 
afford the product as a yellow oil (1804 mg, 53.5%), used without any purification; 
max (film) 1732 (br, C=O), 1454, 1275 (C-O), 1241 (C-O), 1187 (C-O), 1106 (C-O); 
 1H-NMR 1.28 (6H, t, J = 7.2, OCH2CH3), 1.36 (3H, s, CCH3), 3.25 (2H, s, CH2Ph), 
4.21 (4H, q, J = 7.2, OCH2CH3), 7.13 (2H, d, J = 7.2, C-Hortho), 7.25-7.30 (3H, m, C-
H);  13C-NMR 14.21 (OCH2CH3), 20.12 (CCH3), 41.50 (CH2Ph), 55.23 (C-2), 61.70 
(OCH2CH3), 127.27 (C-Hpara), 128.57 (C-H), 130.60 (C-H), 136.63 (C), 172.33 
(C=O). 
 
2-Ethyl-2-isobutylmalonic acid (92a) 
91a (11.48 mmol, 2480 mg) was treated with a solution of sodium hydroxide (2 M) at 
rt for 6h and then the reaction mixture refluxed for 12h. The solvent was removed 
under reduced pressure and the residue was dissolved in water (60 ml), acidified to 
pH 1 (HCl conc.) and extracted with EtOAc. The organic layer was dried over 
anhydrous sodium sulfate. The solvent was removed under reduced pressure to yield 
the product as white crystals (682 mg, 32%); m.p. 117-118 ºC, max (film) 3505-2500 
(br, O-H of acid), 1705 (br, C=O), 1460, 1239 (C-O), 1025 (C-O);  1H-NMR 0.91 
(3H, t, J = 7.2, CH2CH3), 0.92 (6H, d, J = 6.8, CH(CH3)2), 1.69 (1H, m, CH(CH3)2), 
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1.98 (2H, J = 6.8, CH2CH), 2.05 (2H, J = 7.2, CH2CH3), 10.41 (2H, brs);  13C-NMR 
8.62 (CH2CH3), 23.85 (CH(CH3)2), 25.16 (CH(CH3)2), 25.08 (CH2CH3), 40.92 
(CH2CH), 58.51 (C-2), 178.02 (C=O). 
 
2-Benzyl-2-ethylmalonic acid (92b) 
Prepared as described for 92a, using 91b (18 mmol, 5000 mg) as starting material to 
afford the product as white crystals (3608 g, 75%), m.p. 129-131 ºC, max (film) 3476-
2500 (br, O-H of acid), 1703 (C=O), 1459, 1255 (C-O), 1207 (C-O);  1H-NMR 1.03 
(3H, t, J = 7.2, CH2CH3), 2.05 (2H, q, J = 7.2, CH2CH3), 3.32 (2H, s, CH2Ph), 4.20 
(4H, q, J = 7.2, 2-OCH2CH3), 7.21-7.32 (5H, m, C-H);  13C-NMR 9.05 (CH2CH3), 
26.99 (CH2CH3), 39.64 (CH2Ph), 60.06 (C-2),127.39 (C-Hpara), 128.53 (C-H), 129.67 
(C-H), 135.24 (C), 177.26 (C=O). 
 
2-Benzyl-2-methylmalonic acid (92c) 
Prepared as described for 92a, using 91c (6.17 mmol, 1632 mg) to afford the product 
as white crystals (558 mg, 43%), m.p. 115-118 ºC, max (film) 3480-2500 (br, O-H of 
acid), 1704 (C=O), 1460 (C-O-H), 1256 (C-O);  1H-NMR 1.47 (3H, s, CCH3), 3.31 
(2H, s, CH2Ph), 7.22 (2H, d, J = 7.6, C-Hortho), 7.28-7.33 (3H, m, C-H);  13C-NMR 
19.78 (CCH3), 41.20 (CH2Ph), 54.94 (C-2), 127.30 (C-Hpara), 128.43 (C-H), 130.20 
(C-H), 135.32 (C), 177.22 (C=O). 
 
2-Ethyl-2-isobutylmalonyl dichloride (89a) 
2-Ethyl-2-isobutylmalonic acid (92a, 14.24 mmol, 3204 mg) refluxed with tionyl 
chloride (10 ml) under inert atmosphere. After 24h, the remaining tionyl chloride was 
removed under reduced pressure to afford a brown oil (3494 mg, 92%), used 
immediately without any purification. 
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2-Benzyl-2-ethylmalonyl dichloride (89b) 
Prepared as described for 89a, using 92b (13.5 mmol, 3000mg) to afford the product 
as an oil (3486 mg, 83%), used immediately without any purification. 
 
2-Benzyl-2-methylmalon yl dichloride (89c) 
Prepared as described for 89a, using 92c (2.30 mmol, 480 mg), to afford the product 
as a brown oil (496 mg, 88%), used immediately without any purification. 
 
Reaction of p-toluenesulfonyl isocyanate with ethylbutylketene generated in situ 
to give 2-ethyl-N-tosylhexanamide (97) 
To a solution of p-toluenesulfonyl isocyanate (93 mmol, 1.42 ml), in dry THF (20 ml) 
at 0ºC and under an atmosphere of nitrogen, 2-ethylhexanoyl chloride (4.9 mmol, 0.85 
ml) was added. Then, triethylamine (0.82 ml) in THF (15 ml) was added dropwise 
during 5h and the mixture refluxed for 20 min.. Purified by column chromatography, 
using DCM/EtOAc (9.5: 0.5), to afford the product as white crystals (586 mg, 40%), 
m.p. 93-94 ºC, max (film) 3232, 1702, 1344 (S=O), 1172 (S=O);  1H-NMR 0.78 (3H, 
t, J = 7.2, CH3), 0.79 (3H, t, J = 7.2, CH3), 0.99-1.22 (4H, m, CH2CH2CH3), 1.35 
(4H, m, CHCH2CH3 + CHCH2CH2), 2.11 (1H, tt, J = 8.8, 5.2, CH2CHCH2), 2.46 (3H, 
s, p-CH3), 7.36 (2H, d, J = 8.4, C-H), 7.97 (2H, d, J = 8.4, C-H), 9.08 (1H, brs, N-H); 
 13C-NMR 11.55 (CH2CH3), 13.82 (CH2CH3), 21.68 (p-CH3), 22.57 (CH2CH2CH3), 
25.46 (CH2), 29.28 (CH2), 31.79 (CH2), 49.24 (CH2CHCH2), 128.34 (C-H), 129.57 
(C-H), 135.57 (C), 145.11 (C), 74.41 (C=O), EI-MS m/z 241.15 (M-C4H10)+ (2.70%), 
198.23 (M-C7H16)+ (2.02%), 91.05 (C7H7)+ (51.44%); Anal. calcd. for C15H23NO3S, 
C, 60.58, H, 7.79, N, 4.71; found, C, 61.02, H, 7.64, N, 4.58. 
 
Reaction of chlorocarbonyl isocyanate with ethylbutylketene generated in situ - 
compounds 100 and 101. 
N1-(phenylurea)-N3-carbonylaniline (100) 
To a solution of chlorocarbonyl isocyanate (11.99 mmol, 0.96 ml) in dry THF (10 ml) 
at 0 ºC under nitrogen was added 2-ethylhexanoyl chloride (9.22 mmol, 1.6 ml). Next 
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triethylamine (10.14 mmol, 1.41 ml) in THF (5 ml) was added dropwise during 4h. 
The reaction mixture was stirred for 2h30h at rt. Then, aniline (10.14 mmol, 0.93 ml) 
was added, followed by an additional stirring for 3h. The mixture was concentrated 
and cooled. An insoluble white solid was filtered-off. The solid in the filter was 
purified by column chromatography (gradient elution with DCM-EtOAc 9.5: 0.5 to 
9.0: 1.0). On the other hand, the THF from the filtrate was removed under reduced 
pressure and the residue purified by column chromatography. In both purifications, 
the most polar fraction corresponded to 100, obtained as white crystals (388 mg, 
33%), m.p. 218-219 ºC, max (film) 3729 (NH), 3382 (NH), 1684 (C=O), 1600, 1542; 
 1H-NMR (DMSO) 7.08 (2H, t, J = 7.2, C-Hpara), 7.34 (4H, t, J = 7.2, C-Hmeta), 7.49 
(4H, d, J = 7.2, C-Hortho), 9.10 (1H, s, N2-H), 9.72 (2H, brs, N1-H + N2-H);  13C-
NMR 119.23 (C-H), 123.83 (C-H), 129.43 (C-H), 138.33 (C), 152.46 (C=O); EI-MS 
m/z 255.10 (M)+ (41.33%), 135.00 (C7H7N2O)+ (45.98%), 93.00 (C6H7N)+ (100.00%); 
Anal. calcd. for C14H13N3O2, C, 65.87, H, 5.13, N, 16.46; found, C, 65.17, H, 5.94, N, 
16.11. 
 
2-Ethyl-N-phenylhexanamide (101) 
Formed as a by-product from the reaction described above for 100, and purified by 
column chromatography from the filtrate, to afford the product as white crystals (404 
mg, 20%), m.p. 66-67 ºC, max (film) 3289 (NH), 1651 (C=O), 1600, 1530, 1239;  
1H-NMR 0.90 (3H, t, J = 7.2, CH2CH3), 0.98 (3H, t, J = 7.2, CH2CH3), 1.30-1.35 (4H, 
M, CH2CH2), 1.53-1.77 (4H, m, CHCH2CH3 + CHCH2), 2.11 (1H, m, CH2CHCH2), 
713 (1H, t, J = 7.6, C-Hpara), 7.18 (1H, brs, N-H), 7.34 (2H, t, J = 7.6, C-Hmeta), 7.57 
(4H, d, J = 7.6, C-Hortho);  13C-NMR 12.11 (CH2CH3), 13.96 (CH2CH3), 22.80 
(CH2CH2CH3), 26.23 (CH2), 29.88 (CH2), 32.61 (CH2), 50.85 (CH2CHCH2), 119.93 
(C-H), 124.21 (C-H), 128.98 (C-H), 137.93 (C), 174.44 (C=O); EI-MS m/z 219.26 
(M)+ (4.82%), 177.02 (M-C4H10) (8.40%), 120.05 (C7H6NO)+ (2.50%), 93.05 
(C6H7N)+ (54.19%), 57 (C4H9)+ (100.00%), Anal. calcd. for C14H21NO, C, 76.67, H, 
9.65, N, 6.39; found, C, 76.10, H, 9.60, N, 5.98. 
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Synthesis of bromomethylarylazetidine-2,4-diones 102 
1-(4-(Bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione (102a) 
A mixture of 77d (0.346 mmol, 80.00 mg), N-bromosuccinimide (NBS) (0.364 mmol, 
64.79 mg) and benzoyl peroxide (70%, 0.0346 mmol, 11.96 mg) in 
tetrachloromethane (8 ml) was heated under reflux for nearly 12h. Benzoic acid by-
product was removed by filtration and the solvent removed under reduced pressure. 
Purified by column chromatography using hexane/EtOAc 9.5:0.5, to yield white 
crystals (76.2 mg, 71%), m.p. 71-72 ºC, max (film) 1865 (C=O symm.), 1740 (C=O 
asymm.);  1H-NMR 1.08 (6H, t, J = 7.6, CH2CH3), 1.88 (4H, q, J = 7.6, CH2CH3), 
4.50 (2H, s, CH2Ph), 7.47 (2H, dd, J = 7.2, 2.0, C-H), 7.86 (2H, dd, J = 7.2, 2.0, C-H); 
 13C-NMR 9.25 (CH2CH3), 23.98 (CH2CH3), 32.62 (CH2Br), 72.35 (C-3), 119.45 (C-
H), 130.01 (C-H), 133.73 (C), 136.27 (C-H), 172.06 (C=O); EI-MS m/z 310.00 (M)+ 
(3.42%); 312.00 (M+2)+ (3.40%); 230.15 (66.76%), 132.00 (C7H6NCO)+ (100.00%), 
98.00 ((CH3CH2)2C=C=O).+ (51.86%), 83.00 [((CH3CH2)2C=C=O)-CH3]+ (47.92%), 
55.00 (C3H3O)+ (12.21%). 
 
1-(2-(Bromomethyl)phenyl)-3,3-diethylazetidine-2,4-dione (102b) 
Prepared as described for 102a, using 77j (0.282 mmol, 65.14 mg). Purification of the 
residue by column chromatography gave the product and recovery of remaining 77j 
with the same Rf in TLC using hexane/EtOAc (8:2). Thus, the yield was determined 
on the basis of 400-MHz 1H NMR of the mixture. The product 102b (57.7 mg, 66%) 
was obtained as an oil, used without any further purification; max (film) 1869 (C=O 
symm.), 1740 (C=O asymm.);  1H-NMR 1.19 (6H, t, J = 7.6, CH2CH3), 1.97 (4H, q, 
J = 7.6, CH2CH3), 4.64 (2H, s, CH2Br), 7.35-7.44 (3H, m, C-H), 7.49 (1H, dd, J = 7.6, 
2.0, C-H); EI-MS m/z 310.00 (M)+ (1.41%); 312.00 (M+2)+ (1.39%), 230.15 (M-Br)+ 
(4.30%), 132.00 (C7H6NCO)+ (12.45%), 98.00 ((CH3CH2)2C=C=O).+ (100.00%), 
83.00 [((CH3CH2)2C=C=O)-CH3]+ (60.83%), 55.00 (C3H3O)+ (13.87%). 
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1-(6-(Bromomethyl)pyridin-3-yl)-3,3-diethylazetidine-2,4-dione (102c) 
Prepared as described for 102a, using 77l (0.522 mmol, 121.8 mg) and purified using 
DCM as eluant, to yield a pink oil (58.7 mg, 36%), max (film) 1868 (C=O symm.), 
1741 (C=O asymm.);  1H-NMR 1.10 (6H, t, J = 7.6, CH2CH3), 1.91 (4H, q, J = 7.6, 
CH2CH3); 4.61 (2H, s, CH2Br), 7.56 (1H, d, J = 8.4, C-H), 8.23 (1H, dd, J = 8.4, 2.8, 
C-H), 9.13 (1H, d, J = 2.8, C-H);  13C-NMR 9.25 (CH2CH3), 23.96 (CH2CH3), 32.45 
(CH2Br), 72.66 (C-3), 128.46 (C-H), 130.10 (C), 130.95 (C-H), 141.42 (C-H), 148.94 
(C), 171.43 (C=O); EI-MS m/z 311.00 (M)+ (8.30%), 313.00 (M+2)+ (8.27%), 231.04 
(M-Br)+ (51.9%), 98.00 ((CH3CH2)2C=C=O).+ (100.00%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (63.44%), 55.00 (C3H3O)+ (17.92%). 
 
Synthesis of thiofunctionalized azetidine-2,4-diones (103a-j) from 102 
1-(2-((Benzo[d]thiazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-dione 
(103a) 
To a solution of 102b (0.193 mmol, 60 mg) and 2-mercaptobenzothiazole (0.212 
mmol, 35.5 mg) in dry THF (5 ml), triethylamine (0.212 mmol, 29 l) was added. The 
reaction was stirred at room temperature for nearly 6h, being monitored by TLC. 
Upon completion, triethylamine hydrochloride was removed by filtration, the solvent 
removed under reduced pressure, and the residue purified first by chromatography on 
silica gel and subsequently by preparative TLC. Elution with DCM-hexane 7:3, 
yielded a white solid, m.p. 73-75 ºC (52 mg, 68%); max (film) 1868 (C=O symm.), 
1738 (C=O asymm.), 1456, 1371;  1H-NMR 1.15 (6H, t, J = 7.6, CH2CH3), 1.93 
(4H, q, J = 7.6, CH2CH3), 4.72 (2H, s, PhCH2S), 7.28-7.36 (4H, m, C-H), 7.44 (1H, t, 
J = 8.0, C-H), 7.67 (1H, ddd, J = 8.0, 1.2, 0.4, C-H), 7.75 (1H, d, J = 8.0, C-H), 7.91 
(1H, d, J = 8.0, C-H);  13C-NMR 9.45 (CH2CH3), 23.98 (CH2CH3), 34.02 (PhCH2S), 
70.80 (C-3), 121.02 (C-H), 121.69 (C-H), 124.36 (C-H), 125.98 (C-H), 126.09 (C-H), 
128.84 (C-H), 129.25 (C-H), 129.89 (C), 131.42 (C-H), 132.06 (C), 135.39 (C), 
153.05 (C), 165.42 (SCNS), 172.87 (C=O). EI-MS m/z 396.15 (M)+ (32.99%), 298.00 
[M-((CH3CH2)2C=C=O)]+ (30.36%), 132.00 (C7H6NCO)+ (100.00%), 98.00 
((CH3CH2)2C=C=O).+ (8.82%), 83.00 [((CH3CH2)2C=C=O)-CH3]+ (23.27%), 55.00 
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(C3H3O)+ (25.55%); Anal. calcd. for C21H20N2O2S2, C, 63.61, H, 5.08, N, 7.06; found, 
C, 61.43, H, 5.87, N, 6.90.  
 
1-(2-((Benzo[d]oxazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-dione 
(103b) 
Prepared from 102b (0.284 mmol, 88 mg) and 2-mercaptobenzoxazole (0.314 mmol, 
47.18 mg), as described for 103a, and purified similarly and using the same eluent, to 
give a white solid (103 mg, 95%), m.p. 63-66 ºC, max (film) 1868 (C=O symm.), 
1740 (C=O asymm.), 1498;  1H-NMR 1.17 (6H, t, J = 7.6, CH2CH3), 1.95 (4H, q, J 
= 7.6, CH2CH3), 4.66 (2H, s, PhCH2S), 7.28 (1H, dt, J = 7.6, 1.2, C-H), 7.30 (1H, dt, 
J = 7.6, 1.2, C-H), 7.33-7.38 (3H, m, C-H), 7.43 (1H, ddd, J = 7.6, 1.2, 0.4, C-H), 
7.62 (1H, ddd, J = 7.6, 1.2, 0.4, C-H); 7.68-7.71 (1H, m, C-H);  13C-NMR 9.42 
(CH2CH3), 23.94 (CH2CH3), 32.92 (PhCH2S), 70.79 (C-3), 109.92 (C-H), 118.62 (C-
H), 123.98 (C-H), 124.34 (C-H), 125.88 (C-H), 128.98 (C-H), 129.24 (C-H), 129.88 
(C), 131.46 (C-H), 131.83 (C), 141.83 (C), 151.98 (C), 163.74 (OCNS), 172.85 
(C=O); EI-MS m/z 380.15 (M)+ (29.76%); 230.15 (M-SAr)+ (7.15%), 132.00 
(C7H6NCO).+ (100.00%), 98.00 ((CH3CH2)2C=C=O).+ (8.53%), 83.00 
[((CH3CH2)2C=C=O)-CH3]+ (19.72%), 55.00 (C3H3O)+ (22.36%); Anal. calcd. for 
C21H20N2O3S, C, 66.29, H, 5.30, N, 7.36, S, 8.43; found, C, 66.54, H, 5.35, N, 7.26, S, 
8.45. 
 
1-(2-((5-Phenyl-1,3,4-oxadiazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-
dione (103c) 
Prepared as described for 103a, using 102b (0.177 mmol, 54.8 mg) and 5-phenyl-
1,3,4-oxadiazole-2-thiol (0.194 mmol, 34.6 mg), and purified similarly using DCM-
hexane 8:2 as eluant, to yield white crystals (63 mg, 87%), m.p. 110-112 ºC , max 
(film) 1857 (C=O symm.), 1740 (C=O asymm.), 1467, 1371;  1H-NMR 1.18 (6H, t, 
J = 7.6, CH2CH3), 1.95 (4H, q, J = 7.6, CH2CH3), 4.67 (2H, s, PhCH2S), 7.35-7.40 
(3H, m, C-H), 7.48-7.56 (3H, m, C-H), 7.71 (1H, dd, J = 6.0, 2.0, C-H), 7.99 (2H, dd, 
J = 8.0, 1.6, C-H);  13C-NMR 9.47 (CH2CH3), 23.99 (CH2CH3), 33.57 (PhCH2S), 
70.83 (C-3), 123.50 (C), 125.96 (C-H), 126.69 (C-H), 129.05 (C-H), 129.24 (C-H), 
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129.27 (C-H), 129.96 (C), 131.18 (C), 131.73 (C-H), 131.83 (C-H), 163.35 (NCO), 
166.03 (NCO), 172.74 (C=O); EI-MS m/z 407.20 (M)+ (11.73%), 230.05 (M-SAr)+ 
(15.70%), 132.00 (C7H6NCO)+ (100.00%), 98.00 ((CH3CH2)2C=C=O).+ (16.95%), 
83.00 [((CH3CH2)2C=C=O)-CH3]+ (34.22%), 77.00 (Ph)+ (51.84%), 55.00 (C3H3O)+ 
(30.05%); Anal. calcd. for C22H21N3O3S, C, 64.85, H, 5.19, N, 10.31, S, 7.87; found, 
C, 63.62, H, 5.29, N, 9.71, S, 7.48. 
 
1-(2-((1-Methyl-1H-imidazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-
dione (103d) 
Prepared from 102b (0.169 mmol, 52.4 mg) and 1-methyl-1H-imidazole-2-thiol 
(0.186 mmol, 21.2 mg) as described for 103a, and purified similarly using EtOAc-
acetone 9:1 as eluant, to yield a pale yellow solid (40.9 mg, 70%), m.p. 61-63 ºC, max 
(film) 1874 (C=O symm.), 1738 (C=O asymm.), 1456, 1373;  1H-NMR 1.17 (6H, t, 
J = 7.6, CH2CH3), 1.94 (4H, q, J = 7.6, CH2CH3), 3.11 (3H, s, N-CH3), 4.22 (2H, s, 
PhCH2S), 6.80 (1H, s, C-H), 6.93 (1H, d, J = 7.6, C-H), 7.10 (1H, s, C-H), 7.15 (1H, 
dt, J = 7.6, 1.6, C-H), 7.25-7.32 (2H, m, C-H);  13C-NMR 9.50 (CH2CH3), 23.95 
(CH2CH3), 33.19 (N-CH3), 37.31 (PhCH2S), 70.68 (C-3), 122.77 (C-H), 126.32 (C-
H), 128.60 (C-H), 128.96 (C-H), 129.32 (C-H), 129.42 (C), 130.90 (C-H), 133.82 (C), 
139.92 (NCNS), 172.89 (C=O); EI-MS m/z 343.00 (M)+ (14.24%), 230.05 (M-SAr)+ 
(9.11%), 132.00 (C7H6N=C=O)+ (100.00%), 98.00 ((CH3CH2)2C=C=O).+ (11.05%), 
83.00 [((CH3CH2)2C=C=O)-CH3]+ (18.10%), 55.00 (C3H3O)+ (24.05%); Anal. calcd. 
for C18H21N3O2S, C, 62.95, H, 6.16, N, 12.23, S, 9.34; found, C, 62.82, H, 6.98, N, 
11.76, S, 8.87.  
 
1-(4-((Benzo[d]thiazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-dione 
(103e) 
Prepared from 102a (0.097 mmol, 30 mg) and 2-mercaptobenzothiazole (0.106 mmol, 
17.8 mg), as described for 103a and purified similarly using DCM-hexane 7:3 as 
eluant, to yield a white solid (28 mg, 73%), m.p. 102-104 ºC, max (film) 1861 (C=O 
symm.), 1737 (C=O asymm.), 1514, 1457;  1H-NMR 1.07 (6H, t, J = 7.6, CH2CH3), 
1.86 (4H, q, J = 7.6, CH2CH3), 4.60 (2H, s, PhCH2S), 7.32 (1H, dt, J = 7.6, 1.2, C-H), 
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7.45 (1H, dt, J = 7.6, 1.2, C-H), 7.53 (2H, d, J = 8.4, C-H), 7.76 (1H, dd, J = 7.6, 0.4, 
C-H), 7.83 (2H, d, J = 8.4, C-H), 7.92 (1H, dd, J = 7.6, 0.4, C-H);  13C-NMR 9.25 
(CH2CH3), 23.96 (CH2CH3), 37.07 (PhCH2S), 72.25 (C-3), 119.37 (C-H), 121.06 (C-
H), 121.60 (C-H), 124.41 (C-H), 126.13 (C-H), 130.06 (C-H), 133.22 (C), 135.08 (C), 
135.36 (C), 153.06 (C), 165.77 (SCNS), 172.10 (C=O); EI-MS m/z 396.10 (M)+ 
(16.55%); 298.00 ([M-((CH3CH2)2C=C=O)]+ (7.91%), 132.00 (C7H6NCO)+ 
(100.00%), 83.00 [((CH3CH2)2C=C=O)-CH3]+ (6.57%), 55.00 (C3H3O)+ (6.48%); 
Anal. calcd. for C21H20N2O2S2, C, 63.61, H, 5.08, N, 7.06, S, 16.17; found C, 62.11, 
H, 5.28, N, 6.91, S, 16.03. 
 
1-(4-((Benzo[d]oxazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-dione 
(103f) 
Prepared from 102a (0.145 mmol, 45.0 mg) and 2-mercaptobenzoxazole (0.160 
mmol, 24.2 mg) as described for 103a, and purified similarly using DCM-hexane 7:3 
as eluant, to yield white crystals (32.4 mg, 59%), m.p. 96-98 ºC, max (film) 1857 
(C=O symm.), 1738 (C=O asymm.), 1506, 1453;  1H-NMR 1.07 (6H, t, J = 7.6, 
CH2CH3), 1.86 (4H, q, J =7.6, CH2CH3), 4.57 (2H, s, PhCH2S), 7.28 (1H, dt, J = 7.6, 
1.2, C-H), 7.32 (1H, dt, J = 7.6, 1.2, C-H), 7.47 (1H, d, J = 7.6, C-H), 7.55 (2H, d, J = 
8.4, C-H), 7.65 (1H, d, J = 7.6, C-H), 7.84 (2H, d, J = 8.4, C-H);  13C-NMR 9.25 
(CH2CH3), 23.97 (CH2CH3), 36.02 (PhCH2S), 72.30 (C-3), 109.98 (C-H), 118.50 (C-
H), 119.42 (C-H), 124.12 (C-H), 124.44 (C-H), 130.03 (C-H), 133.40 (C), 134.63 (C), 
141.83 (C), 151.93 (C), 164.05 (OCNS), 172.09; EI-MS m/z 380.01 (M)+ (57.89%), 
230.05 (M-SAr)+ (57.97%), 131.99 (C7H6NCO)+ (100.00%), 98.03 
((CH3CH2)2C=C=O).+ (11.05%), 83.02 [((CH3CH2)2C=C=O)-CH3]+ (10.24%), 55.00 
(C3H3O)+ (10.96%); Anal. calcd. for C21H20N2O3S, C, 66.29, H, 5.30, N, 7.36, S, 
8.43; found, C, 65.98, H, 4.88, N, 7.23, S, 8.13. 
 
2-((4-(3,3-Diethyl-2,4-dioxoazetidin-1-yl)benzyl)sulfanyl)benzo[d]oxazole-5-
carboxylic acid (103g) 
Prepared from 102a (0.225 mmol, 69.7 mg), 2-mercaptobenzoxazole-5-carboxylic 
acid, 51, (0.247 mmol, 48.5 mg) and triethylamine (0.472 mmol, 66 l), as described 
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for 103a. The reaction mixture was acidified with HCl until pH 2 and extracted with 
EtOAc. After drying and evaporating off the solvent, the residue was purified by 
column chromatography on silica gel, and subsequently by preparative TLC (elution 
with EtOAc), to yield a yellow solid (22.4 mg, 24%), m.p. 166-171 ºC, max (film) 
4000-2500 (br, O-H of acid), 1855 (C=O symm.), 1733 (C=O asymm.), 1683 (C=O of 
acid);  1H-NMR (DMSO) 1.07 (6H, t, J = 7.6, CH2CH3), 1.87 (4H, q, J = 7.6, 
CH2CH3), 4.65 (2H, s, PhCH2S), 7.52 (1H, d, J = 8.8, C-H), 7.56 (2H, d, J = 8.4, C-
H), 7.86 (2H, d, J = 8.4, C-H), 8.11 (1H, d, J = 8.8, C-H), 8.41 (1H, s, NCC-H);  
13C-NMR (DMSO) 9.25 (CH2CH3), 23.97 (CH2CH3), 36.12 (PhCH2S), 72.32 (C-3), 
109.88 (C-H), 119.47 (C-H), 121.05 (C-H), 126.78 (C-H), 130.09 (C-H), 133.48 (C), 
134.35 (C), 135.76 (C), 142.02 (C), 151.52 (C), 166.02 (C), 169.87 (C=O of acid), 
172.09 (C=O of imide); EI-MS m/z 424.20 (M)+ (1.37%), 230.15 (M-SAr)+ (12.29%), 
132.05 (C7H6NCO)+ (100.00%), 98.05 ((CH3CH2)2C=C=O).+ (6.86%), 83.05 
[((CH3CH2)2C=C=O)-CH3]+ (14.26%), 55.05 (C3H3O)+ (12.63%); Anal. calcd. for 
C22H20N2O5S, C, 62.25, H, 4.75, N, 6.60, S, 7.55; found, C, 61.87, H, 4.66, N, 6.30, S, 
7.21. 
 
1-(4-((5-Phenyl-1,3,4-oxadiazol-2-ylthio)methyl)phenyl)-3,3-diethylazetidine-2,4-
dione (103h) 
Prepared from 102a (0.290 mmol, 90.0 mg) and 5-phenyl-1,3,4-oxadiazole-2-thiol 
(0.319 mmol, 56.9 mg), as described for 103a, and purified similarly using DCM-
hexane 9:1, to yield white crystals (83.5 mg, 71%), m.p. 120-122 º, max (film) 1855 
(C=O symm.), 1735 (C=O asymm.), 1512;  1H-NMR 1.07 (6H, t, J = 7.6, CH2CH3), 
1.87 (4H, q, J = 7.6, CH2CH3), 4.53 (2H, s, PhCH2S), 7.49-7.54 (3H, m, C-H), 7.55 
(2H, d, J = 8.4, C-H), 7.85 (2H, d, J = 8.4, C-H), 8.01 (2H, dd, J = 8.4, 1.6, C-H);  
13C-NMR 9.22 (CH2CH3), 23.97 (CH2CH3), 36.27 (PhCH2S), 72.29 (C-3), 119.49 (C-
H), 123.53 (C-H), 126.68 (C-H), 129.06 (C-H), 130.10 (C-H), 131.74 (C-H), 133.34 
(C), 134.30 (C), 147.38 (C), 163.50 (NCOS), 172.07 (C=O), EI-MS m/z 407.08 (M)+ 
(39.01%), 230.08 (M-SAr)+ (61.96%), 132.02 (C7H6NCO)+ (100.00%), 98.05 
((CH3CH2)2C=C=O).+ (15.20%), 83.03 [((CH3CH2)2C=C=O)-CH3]+ (20.42%), 55.07 
(C3H3O)+ (18.60%); Anal. calcd. for C22H21N3O3S, C, 64.85; H, 5.19; N, 10.31; S, 
7.87; found, C, 64.66; H, 5.17; N, 10.41; S, 7.91. 
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1-(6-((Benzo[d]thiazol-2-ylthio)methyl)pyridin-3-yl)-3,3-diethylazetidine-2,4-
dione (103i) 
Prepared from 102c (0.151 mmol, 47.1 mg) and 2-mercaptobenzothiazole (0.166 
mmol, 27.8 mg), as described for 103a, and purified similarly using DCM as eluant, 
to yield a white solid (36.6 mg, 61%); m.p. 129-131 ºC; max (film) 1868 (C=O 
symm.), 1741 (C=O asymm.), 1489;  1H-NMR 1.08 (6H, t, J = 7.6, CH2CH3), 1.88 
(4H, q, J =7.6, CH2CH3), 4.76 (2H, s, ArCH2S), 7.33 (1H, dt, J = 8.4, 1.6, C-H), 7.44 
(1H, dt, J = 8.4, 1.6, C-H), 7.66 (1H, d, J = 8.4, C-H), 7.77 (1H, dd, J = 8.4, 0.4, C-
H), 7.91 (1H, d, J = 8.4, C-H), 8.12 (1H, dd, J = 8.4, 2.4, C-H), 9.11 (1H, d, J = 2.4 
NCCHN);  13C-NMR 9.23 (CH2CH3), 23.94 (CH2CH3), 38.60 (ArCH2S), 72.46 (C-
3), 121.09 (C-H), 121.56 (C), 123.85 (C-H), 124.42 (C-H), 126.12 (C-H), 126.87 (C-
H), 129.72 (C-H), 135.4 (C-H), 140.36 (C), 152.99 (C), 154.85 (C), 165.69 (NCSS), 
171.61 (C=O); EI-MS m/z 396.97 (M)+ (62.79%), 298.92 [M-((CH3CH2)2C=C=O)].+ 
(100.00%), 166.93 (2-mercapto-benzothiazol).+, 132.99 (93.27%), 98.05 
((CH3CH2)2C=C=O).+ (11.79%), 83.02 [((CH3CH2)2C=C=O)-CH3]+ (23.22%), 55.06 
(C3H3O)+ (29.59%); Anal. calcd. for C20H19N3O2S2, C, 60.43, H, 4.82, N, 10.57, S, 
16.13; found C, 60.01, H, 5.03, N, 10.22. 
 
3,3-Diethyl-1-(4-((phenylthio)methyl)phenyl)azetidine-2,4-dione (103j) 
Prepared as described above for 103a, by reaction of 102a (0.229 mmol, 71.1 mg) 
with thiophenol (0.252 mmol, 26 l), and purified using DCM-hexane 7:3 as eluant, 
to yield a colorless oil (61.4 mg, 79%), max (film) 1849 (C=O symm.), 1736 (C=O 
asymm.);  1H-NMR 1.08 (6H, t, J = 7.6, CH2CH3), 1.86 (4H, q, J = 7.6, CH2CH3); 
4.12 (2H, s, PhCH2S), 7.20-7.31 (5H, m, C-H); 7.34 (2H, d, J = 8.4, C-H), 7.77 (2H, 
d, J = 8.4, C-H);  13C-NMR 9.26 (CH2CH3), 23.95 (CH2CH3), 38.71 (ArCH2S), 
72.15 (C-3), 119.24 (C-H), 126.65 (C-H), 128.95 (C-H), 129.61 (C-H), 130.13 (C-H), 
132.76 (C), 135.72 (C), 136.28 (C), 172.17 (C=O); EI-MS m/z 339.20 (M)+ (2.37%), 
230.15 (M-SPh)+ (20.70%), 132.05 (C7H6NCO)+ (100.00%), 98.05 
((CH3CH2)2C=C=O).+ (1.92%), 83.05 [((CH3CH2)2C=C=O)-CH3]+ (4.45%), 77.05 
(Ph)+ (5.65%), 55.00 (C3H3O)+ (3.45%); Anal. calcd. for C20H21NO2S, C, 70.77; H, 
6.24; N, 4.13; S, 9.45; found, C, 69.66, H, 5.83; N, 3.86; S, 8.82. 
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Oxidation of 103j with 3-chloroperbenzoic acid to give 3,3-Diethyl-1-(4-
((phenylsulfonyl)methyl)phenyl)azetidine-2,4-dione (103k) 
3-Chloroperbenzoic acid (MCPBA, 0.382 mmol) was gently added to a cold solution 
of the thioether 103j (0.153 mmol, 51.9 mg) in DCM (10 ml). The reaction mixture 
was warmed to room temperature and monitored by TLC. After completion of the 
reaction (after nearly 40 min.), the solvent was removed under reduced pressure and 
the product purified by column chromatography, and recrystallized from DCM-
hexane, to yield a white solid (47.4 mg, 83%), m.p. 143-145, max (film) 1856 (C=O 
symm.), 1737 (C=O asymm.), 1315 (S=O), 1153 (S=O);  1H-NMR 1.08 (6H, t, J = 
7.6, CH2CH3), 1.88 (4H, q, J = 7.6, CH2CH3), 4.32 (2H, s, PhCH2S), 7.16 (2H, d, J = 
8.0, C-H), 7.52 (2H, t, J = 8.0, C-H), 7.66 (1H, t, J = 8.0, C-H), 7.71 (2H, dd, J = 8.0, 
1.6, C-H), 7.79 (2H, d, J = 8.0, C-H);  13C-NMR 9.24 (CH2CH3), 23.91 (CH2CH3), 
62.33 (ArCH2S), 72.31 (C-3), 119.13 (C-H), 126.43 (C), 128.60 (C-H), 129.11 (C-H), 
131.76 (C-H), 133.97 (C-H), 134.23 (C), 137.79 (C), 172.04 (C=O); EI-MS 230.15 
(M-SO2Ar)+ (22.19%), 132.05 (C7H6NCO)+ (100.00%), 98.05 ((CH3CH2)2C=C=O).+ 
(4.96%), 83.05 [((CH3CH2)2C=C=O)-CH3]+ (12.02%), 77.05 (Ph)+ (30.42%), 55.00 
(C3H3O)+ (12.21%); Anal. calcd. for C20H21NO4S, C, 64.67; H, 5.70; N, 3.77; S, 8.63; 
found C, 64.43; H, 5.94; N, 3.56; S, 8.31. 
 
Product of the hydrolysis of 4-oxo--lactam 104 
To a solution of 103a (0.2 mmol, 79.3 mg) in a mixture of water / THF (1:1, 4 ml) 
was added 1 ml of a 1M NaOH solution. When all substrate was consumed, the 
solvent was evaporated under reduced pressure, the residue suspended in a solution of 
5% HCl and extracted with ethyl acetate (25 ml). After drying with anhydrous 
Na2SO4, the solvent was evaporated and the residue was purified by column 
chromatography (elution with EtOAc) to yield 45 mg (54%) of the hydrolysis product 
104 as an oil.  1H-NMR (D2O/DMSO) 0.94 (6H, t, J = 7.4, CH2CH3), 1.82 (4H, q, J 
= 7.4, CH2CH3), 4.58 (2H, s, PhCH2S), 7.09-7.57 (5H, m, C-H), 7.85 (1H, d, J = 8.2, 
C-H), 7.94 (1H, d, J = 8.1, C-H), 7.98 (1H, d, J = 8.2, C-H). 
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6.2. ALKALINE HDROLYSIS STUDIES (CHEMICAL KINETICS) 
All kinetic measurements were carried out at 25.0  0.1 ºC and with an ionic strength 
adjusted to 0.5 M by addition of NaClO4. Due to substrate solubility problems all 
buffers contained 20% (v/v) acetonitrile. Rate constants were determined using UV 
spectrophotometry by recording the decrease of substrate absorbance at fixed 
wavelength (47b, 250; 47e, 224; 47f, 238; 77b and 77h, 221; 77c, 247, 77d, 77f and 
77i 260; 77e, 255; 77g, 280 nm), using a spectrophotometer equipped with a 
temperature controller. In a typical run, reaction was initiated by adding a 15 l 
aliquot of a 10-2 M stock solution of 47 in acetonitrile to a cuvette containing 3 ml of 
the buffer solution. The pseudo-first-order rate constants, kobs, were obtained by least-
squares treatment of log (At-A) data, where At and A represent the absorbance at 
time t and at time infinity, respectively. Rate constants derived using this method 
were reproducible to ± 5%.  
6.3. ENZYME INHIBITION STUDIES 
6.3.1 PPE Inhibition Studies 
6.3.1.1 PPE Inactivation by the Incubation Method 
Inhibition of PPE was assayed by Kitz and Wilson’s incubation method.136 In a 
typical experiment, 50 l of inhibitor solution in DMSO was incubated at 25 ºC with 
750 l of 0.1 M HEPES buffer, pH 7.2, and 200 l of PPE solution (50 M in 0.1 M 
HEPES buffer, pH 7.2). Aliquots (100 l) were withdrawn at different time intervals 
and transferred to a cuvette thermostatted at 25 ◦C, containing 895 l of 0.1 M 
HEPES buffer, pH 7.2, and 5 l of N-Suc-Ala-Ala-Ala-pNA (12.5 mM in DMSO). 
The absorbance was monitored at 390 nm for 50 seconds and the gradients of the 
slopes obtained of initial rate used as a measure of enzyme activity. The values of kobs 
for all compounds tested were determined in duplicates or triplicates from exponential 
regression-type analysis from plots of vt/vi versus incubation time, where vt is the 
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initial rate at time t and vi is the initial rate of the control incubation without inhibitor. 
Accordingly, Equation 2.3 (Section 2.3.1.3) was used. The plots of kobs versus [I] 
were linear and the inhibitory potency was determined in terms of the bimolecular 
rate constant kobs/[I] = kinact/Ki (Equation 2.5, Section 2.3.1.3). 
 
6.3.1.2 PPE Inactivation by the Progress Curve Method 
PPE inhibition was analyzed by the progress curve method.142 The enzymatic 
reactions were initiated by addition of 10 l of PPE (20 M in HEPES buffer, 0.1 M, 
pH 7.2) to a cuvette thermostated at 25 ºC, containing 940 l of HEPES buffer (0.1 
M, pH 7.2), 20 l of DMSO, 20 l of substrate (15 mM in DMSO) and 10 l of 
inhibitor (in DMSO). The absorbance was continuously monitored at 390 nm for 20 
minutes. The final concentrations were: [PPE] = 200 nM, [substrate] = 0.3 mM and 
[DMSO] = 5% (v/v). Several inhibitor concentrations from 8 to 150 M were used. 
Control assays, in which the inhibitor was omitted, ran linearly. The pseudo-first 
order rate constants, kobs, for the inhibition of PPE were determined according to the 
slow binding inhibition model142 (mechanism A of Figure 2.28, Section 2.3.2.2) and 
involved the fitting of product concentration as a function of time to Equation 2.6 by 
non-linear regression analysis using the routine ENZFIT (a Microsoft Excel™ 
workbook with in-house developped Visual Basic for Applications (VBA) procedures 
developed at the Faculty of Pharmacy, Lisbon). The inhibitory potency, given by kon, 
was determined using Equations 2.7 and 2.8 and Ki was determined using Equation 
2.9. 
6.3.1.3 Titration of PPE (Partition Ratio) 
PPE solutions (200 l of 50 M in 0.1 M HEPES buffer, pH 7.2) were incubated at 25 
ºC with different concentrations of inhibitor solutions in 0.1 M HEPES buffer, pH 7.2, 
in a final volume of 1 ml. After 30 min incubation, a 100 l aliquot of the reaction 
mixture was withdrawn and assayed for remaining enzyme activity as described 
previously in Section 6.3.1.1. The partition ratio was determined from the intercept to 
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the x axis of the linear plot of the remaining activity ([E]r/[E]0), expressed as vt/vi, 
versus the initial ratio of inhibitor to enzyme ([I]/[E]0). 
6.3.2 HLE Inhibition Studies 
6.3.3 HLE Inactivation by the Progress Curve Method 
Inactivation of HLE was studied at 25 ºC by mixing 10 l of HLE stock solution (2 
M in 0.05 M acetate buffer, pH 5.5) to a solution containing 10 l of inhibitor in 
DMSO, 20 l of substrate MeOSuc-Ala-Ala-Pro-Val-p-nitroanilide (50 mM in 
DMSO) and 960 l of 0.1 M HEPES buffer pH 7.2, and the absorbance was 
continuously monitored at 410 nm for 20 minutes. Control assays in which the 
inhibitor was omitted, ran linearly. Depending on the ratio inhibitor to enzyme, 
progress curves were fitted to Equation 2.6 or 4.1. The kobs values, calculated from the 
progress curves, were fitted against the inhibitor concentration, accordingly to the 
slow association (linear) or the isomerization (hyperbolic) mechanisms (respectively, 
mechanisms A or B of Figure 2.28). kon, Ki and koff values were determined using the 
appropriate equations given in Section 2.3.2.2. 
6.3.4 HLE Inactivation by the Incubation Method 
HLE inactivation was peformed using the incubation method to evaluate the stability 
of the acyl-enzyme complex of compounds 103a and 103e. Thus, 10 l of inhibitor 
(0.1 mM in DMSO) were incubated with 980 l of HEPES buffer (0.1 M; pH 7.2) and 
10 l of HLE stock solution (20 M in 0.05 M acetate buffer, pH 5.5) at 25 ºC. 
Aliquots (100 l) were withdrawn at different time intervals and transferred to a 
cuvette thermostated at 25 ºC, containing 880 l of 0.1 M HEPES buffer pH 7.2 and 
20 l of substrate MeOSuc-Ala-Ala-Pro-Val-p-NA (50 mM in DMSO). The 
absorbance was monitored at 410 nm for 50 seconds. The amount of enzyme activity 
vt/vi was determined by the ratio of the activity of an enzyme solution containing 
6. Experimental Section 
 
 
 
228
inhibitor by the activity of a control assay (containing no inhibitor) at the same time 
point.  
6.3.4.1 Titration of HLE (Partition Ratio) 
10 l of HLE stock solutions (20 M in 0.05 M acetate buffer, pH 5.5) were 
incubated at 25 ºC with different concentrations of inhibitor 77g in DMSO (10 l) and 
980 l of 0.1 M HEPES buffer, pH 7.2. After incubating the reaction mixture for 30 
minutes, a 100 l aliquot was withdrawn and assayed for remaining enzyme activity, 
as described previously (Section 6.3.4). The partition ratio was determined from the 
intercept to the x axis of the linear plot of the remaining activity ([E]r/[E]0), versus the 
initial ratio of inhibitor to enzyme ([I]/[E]0). 
6.3.5 Inhibition Assay for Cathepsin G 
Inactivation of cathepsin G was studied at 25 ºC using the progress curve method,142 
by mixing 100 l of enzyme stock solution (680 nM in 0.05 M acetate buffer, pH 5.5) 
to a solution containing 10 l of inhibitor in DMSO, 20 l of substrate Suc-Ala-Ala-
Pro-Phe-p-nitroanilide (42.5 mM in DMSO) and 870 l of 0.1 M HEPES buffer pH 
7.5, and the absorbance was continuously monitored at 410 nm for 20 minutes. 
Control assays, in which the inhibitor was omitted, ran linearly. Data were treated as 
described above, involving the fitting of product concentration as a function of time to 
Equation 2.6 (Section 2.3.2.2) by non-linear regression analysis, to afford kobs. The 
inhibitory potency was given as the ratio kobs/[I]. 
6.3.6 Inhibition Assay for Proteinase 3 
Inactivation of proteinase 3 was studied at 25 ºC by mixing 70 l of enzyme stock 
solution (325 nM in 0.05 M pH 6 acetate buffer, 150 mM NaCl) to a solution 
containing 10 l of inhibitor in DMSO, 75 l of substrate MeOSuc-Ala-Ala-Pro-Val-
p-nitroanilide (50 mM in DMSO) and 835 l of 0.1 M pH 7.2 HEPES buffer, and the 
absorbance was continuously monitored at 410 nm for 10000 seconds. Control assays, 
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in which the inhibitor was omitted, ran linearly. Progress curves data were treated as 
described above (Section 6.3.5). 
6.3.7 Inhibition Assay for Papain 
Papain (1mg/ml) was activated as described175 and the activated enzyme (300 l) was 
studied using the incubation method, at 25 ºC, by incubation with 50 l of the 
inhibitor in 650 l of 50 mM pH 7.0 K2HPO4/KH2PO4 buffer, containing 2.5 mM 
EDTA. At different times, aliquots (100 l) were withdrawn and transferred to a 
cuvette thermostated at 25 ºC, containing 100 l of benzoyl-S-arginine-p-nitroanilide 
substrate (10 mM in DMSO) and 800 l of 50 mM pH 7.0 K2HPO4/KH2PO4 buffer, 
containing 2.5 mM EDTA. The absorbance was monitored during 4 min at 410 nm. 
The activity of control assays, without the inhibitor, was assumed to present 100% of 
activity. Data were treated as described.175  
6.4. X-RAY CRYSTALLOGRAPHY STUDIES 
Porcine pancreatic elastase (PPE) was incubated with inhibitor 47d for 30 min. Good 
quality crystals were grown in 200 mM sodium sulfate and 100 mM sodium acetate at 
pH 5.1 (293 K) using the sitting drop vapour-diffusion method. X-Ray diffraction data 
were measured at EMBLX11 beamline at theDORISstorage ring, DESY, Hamburg 
(Germany), to 1.66 Å resolution. The data were integrated with MOSFLM176 and 
scaled using SCALA.177 Relevant statistics on data collection and processing are 
given in Appendix 1, Table A1.4. The crystals soaked with the inhibitor solution 
belong to the same space group and show similar cell parameters as the native ones, 
so the structure was solved by Fourier synthesis. The initial rigid body refinement step 
yielded an R-work and R-free of 27.7 and 30.5%, respectively. Further 
crystallographic refinement was performed with Refmac178 and the electron density 
maps were inspected with COOT.179 The refined model of PPE in complex with 
inhibitor 47d shows an R-factor of 15.6% and R-free of 18.6%. 
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The structure is generally well defined within the electron density maps, showing an 
average B factor of 10.5 A˚ 2 for all protein atoms. The final model comprises 240 
amino acid residues, 316 water molecules, the inhibitor 47d without the C-4 
phenylsulfinate leaving group, two glycerol molecules, one sulfate ion and one 
sodium ion, which is hexa-coordinated to side-chain atoms of Glu-80, Asp-77, Gln-
75, Asn-72, Glu-70 and a water molecule. Alternate conformations were modelled for 
the side chains of Gln-23, Gln-75, Val-83 and Ser-189, with 50% occupancy each. All 
protein residues lie within allowed regions of the Ramachandran plot. The overall 
protein structure of the 47d-PPE complex is very similar to that of the native enzyme 
(PDB code 1QNJ) and superposition of theC-a atoms shows a r.m.s. deviation of 
0.089Å. The numbering of 47d-PPE complex follows the common practice of using 
the bovine chymotrypsinogen A numbering.180 
The coordinates of 47d-PPE complex have been deposited in the Protein Data Bank 
(PDB)66 with identification code 2V35 and the corresponding structure factors with id 
code 2V35SF. 
6.5. HYDROLYSIS OF SELECTED 4-OXO--LACTAMS IN PHOSPHATE 
BUFFER SOLUTION (PBS) AND HUMAN PLASMA  
6.5.1 Hydrolysis of Selected -Lactams in pH 7.4 Phosphate Buffer Solution 
The kinetics of hydrolysis was studied using HPLC. Usually, a 15 µl aliquot of a 10-2 
M stock solution of the compound in acetonitrile was added to 2.5 ml of thermostated 
PBS (37ºC). At regular intervals, samples of the reaction mixture were analyzed by 
HPLC as described below (Section 6.5.3). 
6.5.2 Hydrolysis in Human Plasma 
Human plasma was obtained from the pooled, heparinised blood of healthy donors, 
and was frozen and stored at -20ºC prior to use. For the hydrolysis experiments, the 
compounds were incubated at 37ºC in human plasma that had been diluted to 80% 
(v/v) with pH 7.4 isotonic phosphate buffer. At appropriate intervals, aliquots of 100 
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µl were added to 200 µl of acetonitrile to both quench the reaction and precipitate 
plasma proteins. These samples were centrifuged and the supernatant analyzed by 
HPLC for the presence of initial compound, as described below (Section 6.5.3). 
6.5.3 HPLC Analysis 
The analytical high-performance liquid chromatography (HPLC) system comprised a 
Merck Hitachi L-7100 pump with an Shimadzu SPD-6AV UV detector, a manual 
sample injection module equipped with a 20 mL loop, a Merck LlchroCART 250-4 
RP8 (5 µm) column equipped with a Merck Lichrocart pre-column (Merck, 
Germany). As mobile phase it was used isocratic solvent systems of acetonitrile/water 
(65:35) for compounds 6a, 6e and 6i, The column effluent was monitored at 225 nm 
for 103a and 220 nm for compounds 103e and 103i. 
6.6. BIODISTRIBUTION STUDY IN MICE 
Male NMRI (20-22 g) were obtained from Charles River (Barcelona, Spain). The 
animals were kept under standard conditions and fed ad libitum. All of the 
experimental procedures were carried out with the permission of the local laboratory 
committee, and in accordance with international accepted principles. 
Each mice group received a single 30 mg/kg dose of 103k given by intraperitoneal 
(ip) injection and three mice per time point were used. At appropriate time intervals, 
blood was collected into heparinised tubes and stored at -30 ºC and mice were 
euthanized. The lung, spleen and liver of mice were removed and stored at -70 ºC. A 
control group of mice was used, which did not receive the administration of 103k.  
6.6.1 Determination of 103k by HPLC in Mice Blood and Tissues 
6.6.1.1 Chromatographic system 
Plasma and tissue levels of 103k were determined by HPLC. The HPLC system 
consisted of a 32 Katarat Software (Beckman Instruments, Inc.), a Midas Spark 1.1 
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autoinjector and a Diode-Array 168 detector (Beckman Instruments, Inc.). The 
wavelength of this detector was set to 280 nm. The analytical column was a 
LiChroCART® (250-4.6), Purospher® Star RP-8 (5µm) (Merck, Darmstadt, 
Germany). The mobile phase consisted of 0.05M potassium dihydrogen phosphate 
and 0.05M sodium acetate (pH adjusted to 4.0 with acetic acid) - acetonitrile (53:47, 
v/v) with a flow rate of 1 mL/min at 25 ºC, according to Gaspar et al181 with 
adaptations. The retention time was approximately 5.2 min. in blood samples and 5.0 
min. in organs samples. 
6.6.1.2 Preparation of Standard Solutions 
Standard solutions of 103k (5-120 µg/mL) were prepared by weighing the appropriate 
amount of bulk 103k and dissolving it in acetonitrile and further dilution with mobile 
phase. Three eight-point calibration curves, with a loop of 100 µL, were used for the 
quantification of 103k in plasma and tissues. A stock solution of 50 µg/mL was stored 
at -30 ºC and a sample of this stock solution was always injected together with the 
analysed samples to verify the precision of the obtained concentrations of 103k in 
samples and controls from their peak area concentration response. 
6.6.1.3 Extraction of 103k from Blood and Tissues 
Levels of 103k in blood and tissues were determined by HPLC after an extraction 
procedure according to Battaglia et al182 and Benedetti et al,183 adapted by Gaspar et 
al.181 Briefly, 500 µL of blood were mixed with 250 µL of buffer 0.05M potassium 
dihydrogen phosphate and 0.05M sodium acetate (pH adjusted to 4.0 with acetic acid) 
and extracted twice with 1 mL of a DCM: isooctane mixture (2:3, v/v) under stirring 
(15 min), followed by a centrifugation step at 1200×g for 10 min in a GPR centrifuge 
(Beckman Instruments, Inc.). Liver, lung and spleen tissues were thawed and aliquots 
of ca. 100 mg were weighed out for each sample mixed with 500 µL of buffer and 
extracted twice with 2300 µL of dichloromethane: isooctane mixture by mechanical 
shaking for 30 min at room temperature, followed by a centrifugation step at 1200×g 
for 10 min in a GPR centrifuge. The organic extracts were pooled and evaporated to 
dryness under nitrogen. The residue was dissolved in 1500 µL of mobile phase, 
6. Experimental Section 
 
 
 
233
filtered and then injected into the HPLC system. To determine the efficiency of the 
extraction procedures, a known amount of 103k was added to blood and solid tissues 
removed from mice that had not received 103k administration and then submitted to 
the same above-mentioned extraction protocol. 
All data are presented as mean  sd. Differences between groups were evaluated for 
statistical significance using one-way analysis of variance. A p value less than 0.05 
was considered statistically significant. 
6.7. MOLECULAR MODELING 
Molecular modeling studies of inhibitors into the active site of HLE were performed 
with the flexible GOLD 3.0 (Genetic Optimization for Ligand Docking)166 docking 
program.  
GOLD program uses a genetic algorithm in order to explore the full range of ligand 
conformational and rotational flexibility, being the results ranked using the goldscore 
scoring function.184 This function is defined as the sum of four components (protein-
ligand hydrogen bond energy, protein-ligand van der Waals energy, ligand internal 
van der Waals energy and ligand torsional strain energy). 
The HLE structure used (PDB code 1HNE185) was obtained by deletion from the 
active site of the ligand (MeOSuc-Ala-Ala-Pro-Ala chloromethyl ketone) present in 
the crystal structure. Hydrogen atoms were added and correct protonation state of 
histidine residues were assigned according to their surrounding environment. The 
HLE structure was energy minimized and charges were added (using Chimera 
software) 186,187 Then, in order to validate the optimized structure of the HLE, the 
respective deleted inhibitor was docked at the active site of the enzyme and the 
obtained final complex gave a SD < 2Å. 
Geometries of inhibitors studied were energy-minimized using density functional 
theory.188 (These calculations were performed with the B3LYP189, 190 hybrid 
functional Gaussian03 software package.191 After geometry optimizations, partial 
charges were included (Chimera software).187, 192 
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6.7.1 Virtual Screening 
For each inhibitor (Appendix 2), 20 runs for virtual screening were performed, using 
GOLD docking program. A constrain was introduced for calculations: the distance 
between the oxygen atom of Ser-195 and the carbonyl carbon C-2 should be more 
than 1.5 and less than 3.5 Å. Each run produced a score for the best fitted 
conformation of the inhibitor at the enzyme active site. 
6.7.2 Molecular Docking 
Each ligand was subjected to 10,000 docking runs (with a population size of 100; 
100,000 genetic algorithm operations; 5 islands). The top 15 solutions (i.e. those with 
the highest fitness score) were visually analyzed for: (i) the hydrophobic and 
hydrophilic interactions between the ligand and enzyme surfaces and (ii) the distance 
between the Ser-195 hydroxyl oxygen atom and the carbonyl carbon atoms of each -
lactam.  
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APPENDIX 1 
 
A1.1 Alkaline hydrolysis of compounds 47b, 47e and 47f 
 
Table A1.1 - Effect of concentration of OH- on the pseudo-first-order rate constant for the 
alkaline hydrolysis of compounds 47b, 47e and 47f, at 25 °C and ionic strength adjusted to 0.5 M 
with NaClO4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47b  
102 [OH-] / M 102 kobs / s-1 
3.06 2.48 
3.07 3.29 
4.74 3.45 
4.95 5.06 
9.85 10.90 
1.60 19.10 
19.80 19.20 
47e  
102 [OH-] / M 104 kobs / s-1 
2.95 0.54 
4.95 0.70  
10.10 1.65 
19.80 3.24 
47f  
102 [OH-] / M 104 kobs / s-1 
3.07 1.66 
4.95 2.72  
9.85 5.64 
19.80 13.65 
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Figure A1.1 - Brönsted plot for the second-order rate constant for alkaline hydrolysis of 47a-d 
against the pKa of the corresponding leaving groups at C-4, at 25ºC, in 20% acetonitrile (v/v), 
giving a lg value of -0.04. 
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Figure A1.2 - Brönsted plot for the second-order rate constant for alkaline hydrolysis of 47e-j 
against the pKa of the corresponding leaving groups at C-4, at 25ºC, in 20% acetonitrile (v/v), 
giving a lg value of -0.05. 
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A1.2 Determination of the molar extinction coefficient for p-nitroaniline, 390 
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Figure A1.3 - Beer-Lambert plot for determination of the molar extinction coefficient for p-
nitroaniline, at 390 nm, 390, 25 ºC, in 0.1 M HEPES buffer, pH 7.2, 6% DMSO (v/v), using a 
cuvette in which l = 1 cm. 
 
From this plot, the molar extinction coefficient for p-nitroaniline at 390 nm, 390, is 
1.32 x 104 M-1cm-1. This value is in good agreement with the one reported in the 
literature, 390 = 1.24 x 104 M-1cm-1.193  
 
 
 
A1.3 Determination of the Km  
 
PPE activity was monitored over a period of 1 min, at 390 nm, 25 ºC, in 0.1M HEPES 
buffer, pH 7.2, 6% DMSO (v/v), using different concentrations of substrate ([S] in the 
cuvette ranging from 75 M to 1 mM), and being [PPE] = 1 M. Each concentration 
was assayed at least two times. The initial rates, vi, were determined in A s-1. Rates 
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in Ms-1 were obtained by dividing the initial rate vi, in A s-1 by the obtained molar 
extinction coefficient for p-nitroaniline, 390. 
 
 
Table A1.2 - Concentrations of the chromogenic substrate used for determination of the Km and 
the respective initial rates of the PPE-mediated hydrolysis, in A s-1 and M-1s-1, at 390 nm, 25 °C, 
in 0.1 M pH 7.2 HEPES buffer, 6% DMSO (v/v).  
 
 
 
 
 
 
 
 
 
0 20 40 60 80 100 120
0
4.0×10 -7
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2.0×10 -6
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Figure A1.4 - Michaelis-Menten plot for the hydrolysis of the chromogenic substrate of PPE, at 
390 nm, 25 ºC, in 0.1 M pH 7.2 HEPES buffer, 6% DMSO (v/v). Concentrations of substrate [S] 
and vi in Ms-1 are from Table A1.2. Points are experimental and line is from non-linear regression 
analysis. 
105 [S] / M vi /A s-1 vi /Ms-1 
7.5 2.46 x 10-3 1.86 x 10-7 
10 3.36 x 10-3 2.55 x 10-7 
25 7.80 x 10-3 5.91 x 10-7 
50 1.53 x 10-2 1.16 x 10-6 
75 2.15 x 10-2 1.64 x 10-6 
100 2.50 x 10-2 1.89 x 10-6 
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A1.4 PPE Inhibition Studies  
 
 
Table A1.3 -Pseudo-first-order rate constant, kobs, for the inactivation of PPE by -lactams 47b-d, 
at 25 ºC, in 0.1 M HEPES buffer, pH 7.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47b  
104 [47b] / M 103 kobs / s-1 
0.20 0.26 
1.25 1.84 
2.50 2.62 
5.00 5.86 
47c  
104 [47c] / M 103 kobs / s-1 
1.00 2.40 
2.00 4.99 
3.30 7.98 
5.00 11.1 
47d  
104 [47d] / M 103 kobs / s-1 
0.10 2.45 
0.20 5.06 
0.40 10.3 
0.50 14.4 
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Figure A1.5 - Brönsted plot of the second-order rate constant for PPE inactivation kobs/[I] by 
47b-d against the pKa of the leaving group at C-4, giving a lg value of -0.16. 
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Figure A1.6 - Plot of the second-order rate constants for PPE inactivation, kobs/[I], by 47b-d 
against the I value of the substituent at C-4, giving I = 4.7. 
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Table A1.4 - Data collection and crystallographic refinement statistics for the porcine pancreatic 
elastase structure bound to 47d. 
 
 
X-ray data-collection wavelength (Å) 0.82 
Space group P212121 
Unit cell parameters (Å) a = 50.25, b = 57.94, c = 74.69 
Resolution range (Å) 37.95-1.66 
Refined model   
       R-factor (%) 15.6 
       R-free (%) 18.6 
       Nº of non H protein atoms  1833 
       Nº of solvent molecules 320 
Average B-factor (Å2)  
       Protein only 10.5 
       Inhibitor only 24.4 
       Solvent molecules 25.9 
Ramachandran plot  
       Residues in most most favoured regions of (%) 87.4 
       Residues in additional allowed regions (%) 12.6 
r.m.s. deviations   
       bond angles (º) 0.01 
       angle lengths (Å) 1.22 
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A1.5 HLE Inhibition Studies  
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Figure A1.7 - Beer-Lambert plot for determination of the molar extinction coefficient for p-
nitroaniline, at 410 nm, 410, 25 ºC, in 0.1 M HEPES buffer, pH 7.2, using a cuvette in which l = 1 
cm. 
 
From this plot, the molar extinction coefficient for p-nitroaniline at 410 nm is 410 = 
8.25 x 103 M-1cm-1. This value is in agreement with the one reported in the literature, 
410 = 8.80 x 103 M-1cm-1.194  
 
 
 
Table A1.5 - Pseudo-first-order rate constant, kobs, for the inactivation of HLE by -lactams 47f-h 
and 47k at 25 ºC, in 0.1 M HEPES buffer, pH 7.2.  
 
 
 
 
 
 
 
47f  
106 [47f] / M 103 kobs / s-1 
15 5.59 
10 4.08 
5.0 2.77 
2.0 1.72 
47g  
106 [47g] / M 103 kobs / s-1 
100 3.52 
50 3.28 
10 2.48 
2.0 1.08 
Appendix 1 
 
 
 
245
 
 
 
 
 
 
 
 
 
 
 
Table A1.6 - The dependence of the steady-state rate, vs, with the inhibitor concentration for 
compound 47f, allowing the determination of Ki. 
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Figure A1.8 - Brönsted plot of the second-order rate constant for HLE inactivation kinact/Ki 
against the pKa of the leaving group at C-4, giving a lg value of -0.047. 
47h  
106 [47h] / M 103 kobs / s-1 
25 3.63 
10 3.56 
2.0 1.96 
47k  
106 [47g] / M 103 kobs / s-1 
20 3.21 
15 3.14 
7.5 2.53 
2.0 1.43 
47f  
106 [47f] / M 105 vs / A s-1 
15 2.05 
10 1.78 
5.0 5.88 
2.0 9.41 
0 27.0 
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APPENDIX 2 
 
Table A2.1- Database of 4-oxo--lactams created for virtual screening studies with HLE. 
 
 
 
N
O
O
X
EtOOC
(CH2)n
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R Config. 
A1R Benzyl  R 
A1S Benzyl  S 
A2R Phenyl  R 
A2S Phenyl  S 
A3R C6H4-4-OCH3 R 
A3S C6H4-4-OCH3 S 
A4R C6H4-4-CH3 R 
A4S C6H4-4-CH3 S 
A5R Methyl  R 
A5S Methyl S 
A6R C6H4-2-CO2H R 
A6S C6H4-2-CO2H S 
A7R C6H4-4-CO2H R 
A7S C6H4-4-CO2H S 
Compound X n R Config. 
A8R O 0 H R 
A8S O 0 H S 
A9R O 0 4-Methyl R 
A9S O 0 4-Methyl S 
A10R O 0 4-COOH R 
A10S O 0 4-COOH S 
A11R SO 0 H R 
A11S SO 0 H S 
A12R SO2 0 H R 
A12S SO2 0 H S 
A13R SO2 1 H R 
A13S SO2 1 H S 
N
O
O
X
EtOOC
(CH2)n
R
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N
O
O
S
EtOOC
R
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R Config. 
A14R 2-(5-phenyl-1,3,4-oxadiazole) R 
A14S 2-(5-phenyl-1,3,4-oxadiazole) S 
A15R 2-benzoxazole R 
A15S 2-benzoxazole S 
A16R 2-(benzoxazole-5-COOH) R 
A16S 2-(benzoxazole-5-COOH) S 
A17R 2-(benzoxazole-6-COOH) R 
A17S 2-(benzoxazole-6-COOH) S 
A18R 2-benzothiazole R 
A18S 2-benzothiazole S 
A19R 2-(1-methylimidazole) R 
A19S 2-(1-methylimidazole) S 
A20R Phenyl R 
A20S Phenyl S 
A21R 2-(1-methylbenzimidazole) R 
A21S 2-(1-methylbenzimidazole) S 
A22R 2-(benzimidazole) R 
A22S 2-(benzimidazole) S 
A23R CH2COPh R 
A23S CH2COPh S 
A24R CH2-2-pyridinyl R 
A24S CH2-2-pyridinyl S 
Compound Y n R 
A25 NH 1 H 
A26 NH 0 H 
A27 CH2 0 H 
A28 O 0 H 
A29 NH 1 4-Me 
A30 NH 1 3-OMe, 4-Me 
A31 NH 1 3-Me, 4-OMe 
A32 NH 1 3,4-Me2 
N
O
O
Y
(CH2)n
O
R
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Compound Y R1 R Config. 
A33R NH Et H R 
A33S NH Et H S 
A34R NH Pr H R 
A34S NH Pr H S 
Compound R1 R2 Config. 
A35 COOH H R 
A36 COOH H S 
A37 H COOH R 
A38 H COOH S 
Compound 
A39 
N
O
O
COOEt
O
R1
R2
 
N
O
O
Y
O
R
R1  
N
O
O OSO2Ph  
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Compound R Config. 
A40R Benzyl  R 
A40S Benzyl  S 
A41R Ph R 
A41S Ph S 
A42R C6H4-4-OCH3 R 
A42S C6H4-4-OCH3 S 
A43R C6H4-4-CH3 R 
A43S C6H4-4-CH3 S 
A44R Methyl  R 
A44S Methyl S 
A45R C6H4-2-CO2H R 
A45S C6H4-2-CO2H S 
A46R C6H4-4-CO2H R 
A46S C6H4-4-CO2H S 
Compound X n R Config. 
A47R O 0 H R 
A47S O 0 H S 
A48R O 0 4-Methyl R 
A48S O 0 4-Methyl S 
A49R O 0 4-COOH R 
A49S O 0 4-COOH S 
A50R SO 0 H R 
A50S SO 0 H S 
A51R SO2 0 H R 
A51S SO2 0 H S 
A52R SO2 1 H R 
A52S SO2 1 H S 
N
O
O
O
EtOOC O
R
 
N
O
O
X
EtOOC
(CH2)n
R
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Compound R Config. 
A53R 2-(5-phenyl-1,3,4-oxadiazole) R 
A53S 2-(5-phenyl-1,3,4-oxadiazole) S 
A54R 2-benzoxazole R 
A54S 2-benzoxazole S 
A55R 2-(benzoxazole-5-COOH) R 
A55S 2-(benzoxazole-5-COOH) S 
A56R 2-(benzoxazole-6-COOH) R 
A56S 2-(benzoxazole-6-COOH) S 
A57R 2-benzothiazole R 
A57S 2-benzothiazole S 
A58R 2-(1-methylimidazole) R 
A58S 2-(1-methylimidazole) S 
A59R Phenyl R 
A59S Phenyl S 
A60R 2-(1-methylbenzimidazole) R 
A60S 2-(1-methylbenzimidazole) S 
A61R 2-(benzimidazole) R 
A61S 2-(benzimidazole) S 
A62R CH2COPh R 
A62S CH2COPh S 
A63R CH2-2-pyridinyl R 
A63S CH2-2-pyridinyl S 
Compound Y n R 
A64 NH 1 H 
A65 NH 0 H 
A66 CH2 0 H 
A67 O 0 H 
A68 NH 1 4-Me 
A69 NH 1 3-OMe, 4-Me 
A70 NH 1 3-Me, 4-OMe 
A71 NH 1 3,4-Me2 
N
O
O
O
Y
(CH2)n
R
 
N
O
O
S
EtOOC
R
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Compound Y R1 Config. 
A72R NH Et R 
A72S NH Et S 
A73 NH Pr R 
A74 NH Pr S 
Compound R1 R2 Config. 
A75 COOH H R 
A76 COOH H S 
A77 H COOH R 
A78 H COOH S 
Compound 
A79 
N
O
O
COOEt
O
R1
R2
 
N
O
O
O
Y
R1  
N
O
O
OSO2Ph  
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Compound R Config. 
A80R Benzyl  R 
A80S Benzyl  S 
A81R Phenyl  R 
A81S Phenyl  S 
A82R C6H4-4-OCH3 R 
A82S C6H4-4-OCH3 S 
A83R C6H4-4-CH3 R 
A83S C6H4-4-CH3 S 
A84R Methyl  R 
A84S Methyl S 
A85R C6H4-2-CO2H R 
A85S C6H4-2-CO2H S 
A86R C6H4-4-CO2H R 
A86S C6H4-4-CO2H S 
Compound X n R Config. 
A87R O 0 H R 
A87S O 0 H S 
A88R O 0 4-Methyl R 
A88S O 0 4-Methyl S 
A89R O 0 4-COOH R 
A89S O 0 4-COOH S 
A90R SO 0 H R 
A90S SO 0 H S 
A91R SO2 0 H R 
A91S SO2 0 H S 
A92R SO2 1 H R 
A92S SO2 1 H S 
N
O
O
X
EtOOC
(CH2)n
R
N
O
O
O
EtOOC O
R
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Compound R Config. 
A93R 2-(5-phenyl-1,3,4-oxadiazole) R 
A93S 2-(5-phenyl-1,3,4-oxadiazole) S 
A94R 2-benzoxazole R 
A94S 2-benzoxazole S 
A95R 2-(benzoxazole-5-COOH) R 
A95S 2-(benzoxazole-5-COOH) S 
A96R 2-(benzoxazole-6-COOH) R 
A96S 2-(benzoxazole-6-COOH) S 
A97R 2-benzothiazole R 
A97S 2-benzothiazole S 
A98R 2-(1-methyl imidazole) R 
A98S 2-(1-methyl imidazole) S 
A99R Phenyl R 
A99S Phenyl S 
A100R 2-(1-methyl benzimidazole) R 
A100S 2-(1-methyl benzimidazole) S 
A101R 2-(benzimidazole) R 
A101S 2-(benzimidazole) S 
A102R CH2COPh R 
A102S CH2COPh S 
A103R CH2-2-pyridinyl R 
A103S CH2-2-pyridinyl S 
Compound Y n R 
A104 NH 1 H 
A105 NH 0 H 
A106 CH2 0 H 
A107 O 0 H 
A108 NH 1 4-Me 
A109 NH 1 3-OMe, 4-Me 
A110 NH 1 3-Me, 4-OMe 
A111 NH 1 3,4-Me2 
N
O
O
S
EtOOC
R
N
O
O
Y
(CH2)n
O
R
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Compound Y R1 R Config. 
A112R NH Et H R 
A112S NH Et H S 
A113 NH Pr H R 
A114 NH Pr H S 
Compound Config. R1 R2 
A115 R COOH H 
A116 S COOH H 
A117 R H COOH 
A118 S H COOH 
Compound 
A119 
N
O
O
Y
O
R
R1
N
O
O
OSO2Ph  
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Compound R Config. 
A120R Benzyl  R 
A120S Benzyl  S 
A121R Phenyl  R 
A121S Phenyl  S 
A122R C6H4-4-OCH3 R 
A122S C6H4-4-OCH3 S 
A123R C6H4-4-CH3 R 
A123S C6H4-4-CH3 S 
A124R Methyl  R 
A124S Methyl S 
A125R C6H4-2-CO2H R 
A125S C6H4-2-CO2H S 
A126R C6H4-4-CO2H R 
A126S C6H4-4-CO2H S 
Compound X n R Config. 
A127R O 0 H R 
A127S O 0 H S 
A128R O 0 4-Methyl R 
A128S O 0 4-Methyl S 
A129R O 0 4-COOH R 
A129S O 0 4-COOH S 
A130R SO 0 H R 
A130S SO 0 H S 
A131R SO2 0 H R 
A131S SO2 0 H S 
A132R SO2 1 H R 
A132S SO2 1 H S 
N
O
O
O
EtOOC O
R
N
O
O
X
EtOOC
(CH2)n
R
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Compound R Config. 
A133R 2-(5-phenyl-1,3,4-oxadiazole) R 
A133S 2-(5-phenyl-1,3,4-oxadiazole) S 
A134R 2-benzoxazole R 
A134S 2-benzoxazole S 
A135R 2-(benzoxazole-5-COOH) R 
A135S 2-(benzoxazole-5-COOH) S 
A136R 2-(benzoxazole-6-COOH) R 
A136S 2-(benzoxazole-6-COOH) S 
A137R 2-benzothiazole R 
A137S 2-benzothiazole S 
A138R 2-(1-methyl imidazole) R 
A138S 2-(1-methyl imidazole) S 
A139R Phenyl R 
A139S Phenyl S 
A140R 2-(1-methyl benzimidazole) R 
A140S 2-(1-methyl benzimidazole) S 
A141R 2-(benzimidazole) R 
A141S 2-(benzimidazole) S 
A142R CH2COPh R 
A142S CH2COPh S 
A143R CH2-2-pyridinyl R 
A143S CH2-2-pyridinyl S 
Compound Y n R 
A144 NH 1 H 
A145 NH 0 H 
A146 CH2 0 H 
A147 O 0 H 
A148 NH 1 4-Me 
A149 NH 1 3-OMe, 4-Me 
A150 NH 1 3-Me, 4-OMe 
A151 NH 1 3,4-Me2 
N
O
O
S
EtOOC
R
N
O
O
Y
(CH2)n
O
R
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N
O
O
Y
O R1  
 
 
 
 
 
N
O
O
O
COOEt
R1
R2
 
 
 
 
 
 
 
 
 
 
From this database, the compounds that afforded the best fitness score were A1, A40 
and A80 (both R and S enantiomers) 
Compound Y R1 R Config. 
A152R NH Et H R 
A152S NH Et H S 
A153R NH Pr H R 
A153S NH Pr H S 
Compound R1 R2 Config. 
A154R COOH H R 
A154S COOH H S 
A155R H COOH R 
A155S H COOH S 
Compound 
A156 N
O
O OSO2Ph  
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APPENDIX 3 
 
 
A3.1 Alkaline Hydrolysis Studies of 4-Oxo--lactams 77 
 
 
Spectral scanning for the reaction of hydroxide-ion with 77d 
 
Figure A3.1 - UV spectra depicting the reaction, at 25 ºC, of 77d (10-4 M) with OH- 0.1 M (ionic 
strength 0.5 M), scan intervals: 100 sec. An isosbestic point was found. The wavelength selected to 
monitor the kinetic reaction was 260 nm. 
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Table A3.1 - Effect of concentration of OH- on the pseudo-first-order rate constant for the 
alkaline hydrolysis of compounds 77b-i, at 25 °C and ionic strength adjusted to 0.5 M with 
NaClO4. 
 
N-Benzyl derivatives 77b and 77h 
 
 
 
 
 
 
 
 
 
 
 
N-Aryl derivatives 77c-g and 77i 
 
 
 
 
77h  
103 [OH-] / M 103 kobs / s-1 
0.77 1.62 
1.7 3.81 
5.8 13.2 
9.9 19.0 
30 54.8 
77b  
103 [OH-] / M 103 kobs / s-1 
5.80 0.713 
9.90 1.04 
30.0 2.19 
51.0 4.16 
100 7.65 
77c   77d  
102[OH-] / M 103 kobs / s-1  102[OH-] / M 103 kobs / s-1 
0.50 1.03  0.50 1.08 
1.01 2.32  1.01 2.28 
2.98 6.73  3.08 6.94 
5.00 11.8  5.00 11.3 
9.94 22.2  10.1 24.2 
77e   77f  
102[OH-] / M 103 kobs / s-1  102[OH-] / M 103 kobs / s-1 
0.50 1.56  0.50 2.43 
1.01 3.30  1.01 5.12 
2.98 10.2  3.08 16.4 
5.00 16.6  5.00 27.4 
9.94 33.8  10.1 58.2 
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A3.2 - PPE Inhibition by 4-Oxo--lactams 77  
 
Table A3.2 - Pseudo-first-order rate constant, kobs, for the inactivation of PPE by 4-oxo--lactams 
77c-g, at 25 ºC, in 0.1 M HEPES buffer, pH 7.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
77i  
103[OH-] / M 103 kobs / s-1 
0.77 7.56 
1.70 18.0 
5.05 44.7 
10.1 99.6 
29.8 288 
77g  
102[OH-] / M 103 kobs / s-1 
0.50 7.53 
1.01 16.6 
3.08 53.8 
5.00 91.4 
10.10 178 
77d  
104 [77d] / M 103 kobs / s-1 
0.10 3.10 
0.15 4.20 
0.20 5.14 
0.30 7.18 
0.60 12.3 
0.75 16.0 
1.00 20.0 
77c  
104 [77c] / M 103 kobs / s-1 
0.20 3.65 
0.30 5.19 
0.60 9.26 
0.75 11.5 
1.00 14.1 
1.50 18.5 
77e  
104[77e] / M 103 kobs / s-1 
0.15 3.99 
0.30 7.79 
0.60 14.0 
0.75 17.5 
1.00 18.6 
1.50 30.9 
77f  
104 [77f] / M 103 kobs / s-1 
0.10 4.34 
0.15 5.55 
0.20 7.03 
0.30 9.91 
0.60 16.8 
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A3.2.1 - Analysis of the Inhibition Kinetics and Determination of Ki for 77e 
 
 
The analysis of the inhibition kinetics of PPE for determination of Ki by 3,3-diethyl-
N-phenylazetidine-2,4-dione 77e is illustrated in Figures A3.2 and A3.3. 
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Figure A3.2 - Progress curves for the slow-binding inhibition of PPE by compound 77e. Reaction 
conditions: [PPE] = 0.2 M, [N-Suc-(L-Ala)3-p-NA] = 0.3 mM, 0.1 M HEPES buffer, pH 7.2, 5% 
DMSO, 25 ºC. Inhibitor concentrations: (a), in absence of inhibitor; (b), 15; (c), 30; (d), 60; (e), 75; (f), 
100; (g), 150 M. 
 
 
77g  
104[77g] / M 103 kobs / s-1 
0.08 7.44 
0.15 13.07 
0.20 16.05 
0.40 32.01 
0.60 38.40 
0.80 54.47 
a 
 
 
b 
 
 
c 
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The data shown in Figure A3.2 were fitted by non-linear regression analysis 
accordingly to slow binding kinetics, as previously discussed, to obtain the best-fit 
parameters for vi, vs and kobs for 77e, Table A3.3.  
 
 
 
Table A3.3 - The dependence of the kinetic parameters of PPE inhibition, kobs, vi and vs with the 
inhibitor concentration for the 4-oxo--lactam 77e. 
 
 
 
 
 
 
 
 
 
 
 
 
The apparent second-order rate constant kon´ was obtained from kobs plotted versus [I], 
illustrated in Figure 3.14, Chapter 3, and was then corrected using Equation 2.8 
(Section 2.3.2.2) to give kon.  
The apparent steady-state dissociation constant of the enzyme-inhibitor complex, Ki´ 
was calculated using the steady-state velocities, vs (Table A3.3) fitting by non-linear 
regression to Equation 2.10, as shown in Figure A3.3. Then, Ki value was calculated 
by correction using Equation 2.11. 
 
104[77e] / M 103 kobs / s-1 104 vi / A s-1 104 vs / A s-1 
0 -  13.4 
0.15 3.99 18.2 7.53 
0.30 7.79 14.9 5.35 
0.60 14.0 14.2 3.75 
0.75 17.5 12.9 3.10 
1.00 18.6 10.9 2.58 
1.50 30.9 10.1 1.94 
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Figure A3.3 - Plot of the steady-state rates versus [I] for the inhibition of PPE by compound 77e. 
Points are experimental and were obtained from fits of the curves shown in Figure A3.2 and the line is 
from non-linear regression analysis of the steady state rates vs versus inhibitor concentration (Table 
A3.3), using Equation 2.10, for Ki´ = 21.8 ± 1.1 M. (The insert is a Dixon plot to show the linearity).  
 
 
 
 
Thus, as presented in Figure A3.3, Ki´= 21.8 ± 1.1 M for 77e. By correction using 
Equation 2.11, Ki = 20.2 ± 1.7 M for 77e.  
Then, the koff value was calculated from Ki and kon values using Equation 2.9, giving 
koff = 4.15 x 10-3 s-1.  
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A3.2.2 Inhibition of PPE by compounds 77h-i 
 
 
Table A3.4 – Kinetic data for the hydrolysis of the chromogenic substrate of PPE in the presence 
of 77i. (Initial rates for the reaction in the absence of inhibitor were given in Table A1.2). 
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Figure A3.4 - Michaelis-Menten plot for the hydrolysis of the chromogenic substrate of PPE, in 
the absence of inhibitor (), and in the presence of 60 M () and 100 M of 77i (), at 390 nm, 
25 ºC, in 0.1 M HEPES buffer, pH 7.2, 6% DMSO (v/v). Points are experimental and lines are from 
non-linear regression analysis of the data. The respective Lineweaver-Burke plot was obtained from 
linear analysis of data 1/vi/M-1s versus 1/[S]/M-1, as illustrated in Chapter 3, Section 3.4.1, Figure 3.18. 
 
 [77i] = 60 M [77i] = 100 M 
105 [S] / M vi /Ms-1 vi /Ms-1 
10.0 3.89 x 10-8 2.16 x 10-8 
25.0 9.96 x 10-8 5.61 x 10-8 
50.0 1.69 x 10-7 - 
75.0 2.19 x 10-7 1.33 x 10-7 
100 2.85 x 10-7 170 x 10-7 
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Table A3.5 – Kinetic data for the hydrolysis of the chromogenic substrate of PPE in the presence 
of 77h. (Initial rates for the reaction in the absence of inhibitor were given in Table A1.2). 
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Figure A3.5 - Michaelis-Menten plot for the hydrolysis of the chromogenic substrate of PPE, in 
the absence of inhibitor 77h (), and in the presence of 30 M () and 100 M of 77h (), at 390 
nm, 25 ºC, in 0.1 M HEPES buffer, pH 7.2, 6% DMSO (v/v). Points are experimental and lines are 
from non-linear regression analysis of the data. From this data, the respective Lineweaver-Burke plot 
was obtained from linear analysis of data 1/vi/M-1s versus 1/[S]/M-1, as illustrated in Chapter 3, Section 
3.4.1, Figure 3.19. 
 
 
 [77h] = 60 M [77h] = 100 M 
105 [S] / M vi /M-1s-1 vi /Ms-1 
5.0 - 7.63 x 10-8- 
7.5 - 9.77 x 10-8- 
10 2.19 x 10-7 1.38 x 10-7 
25 5.56 x 10-7 3.72 x 10-7 
50 1.02 x 10-6 6.55 x 10-7 
75 1.46 x 10-6 9.85 x 10-7 
100 1.81 x 10-6 1.28 x 10-6 
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A.3.2.3 Molecular Modeling of 77h at the Active Site of PPE. 
 
 
Figure A3.6 - Docking of 77h at the active site of PPE. The aromatic ring of the N-benzyl moiety lies 
in the S1 pocket of PPE. 
 
Asp 102 
Ser 195 
Val 216 
Val 99 
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Thr 213 
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APPENDIX 4 
 
 
A4.1 HLE Inactivation Studies by 4-Oxo--lactams (77 and 103) 
 
A4.1.1 Obtained Pseudo-First Order Rate Constants of HLE Inhibition 
 
Table A4.1 - Pseudo-first-order rate constant, kobs, for the inactivation of HLE by 4-oxo--
lactams 77 and 103, at 25 ºC, in 0.1 M HEPES buffer, pH 7.2. 
 
 
 
 
 
 
77a   77b  
106[77a] / M 103 kobs / s-1  106 [77b] / M 103 kobs / s-1 
2.5 1.54  3.0 1.95 
10 1.83  10 3.50 
25 3.54  30 8.23 
50 6.17  75 19.40 
77c   77d  
109 [77c] / M 103 kobs / s-1  109 [77d] / M 103 kobs / s-1 
50 3.61  75 4.19 
150 9.02  150 7.79 
300 15.2  300 13.2 
500 22.8  500 16.9 
77e   77f  
109 [77e] / M 103 kobs / s-1  109 [77f] / M 103 kobs / s-1 
50 2.95  50 3.52 
100 5.12  100 6.29 
150 6.24  300 15.2 
300 11.8  500 20.3 
600 21.3  750 23.6 
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77g    77h  
109 [77g] / M 103 kobs / s-1  106[77h] / M 103 kobs / s-1 
50 3.98  1.50 2.58 
80 5.24  3.00 4.45 
100 6.58  7.50 8.57 
250 12.2  30.0 27.3 
500 17.5    
77i   77j  
109[77i] / M 103 kobs / s-1  106[77j] / M 103 kobs / s-1 
50.0 6.94  2.5 1.96 
100 13.52  5.0 2.15 
250 19.07  10.0 2.68 
500 33.02  20.0 4.58 
77k   77l  
109 [77k] / M 103 kobs / s-1  109 [77l] / M 103 kobs / s-1 
100 2.85  75 3.18 
200 4.39  100 3.44 
500 9.51  250 7.03 
1000 15.3  375 10.04 
   500 12.4 
77m   77n  
106[77m] / M 103 kobs / s-1  109 [77n] / M 103 kobs / s-1 
0.5 1.88  500 2.55 
2.0 2.44  750 3.22 
5.0 4.60  1000 4.26 
10 7.68  1500 5.82 
20 13.4  2000 8.53 
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77o   77p  
106[77o] / M 103 kobs / s-1  106 [77p] / M 103 kobs / s-1 
2.0 1.76  20 2.25 
4.0 2.04  38 2.72 
5.0 2.72  50 3.38 
7.5 2.89    
10 3.96    
15 5.06    
20 6.74    
77q   77r  
106 [77q] / M 103 kobs / s-1  109 [77r] / M 103 kobs / s-1 
0.50 12.9  50.0 2.68 
   100 4.07 
   200 7.17 
   300 12.6 
   400 16.0 
103a   103b  
106 [103a] / M 103 kobs / s-1  106 [103b] / M 103 kobs / s-1 
0.5 2.35  0.50 2.22 
1.0 2.83  1.25 3.09 
2.5 3.87  2.50 5.08 
5.0 4.48  5.00 5.95 
   10.0 6.31 
103c   103d  
106 [103c] / M 103 kobs / s-1  106 [103d] / M 103 kobs / s-1 
0.50 2.83  2.0 1.94 
1.25 5.24  5.0 2.17 
2.50 9.15  20 5.06 
5.00 14.23  40 8.63 
10.0 15.15  50 10.0 
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103e   103f  
109 [103e] / M 103 kobs / s-1  109 [103f] / M 103 kobs / s-1 
6.25 4.07  6.25 3.18 
12.5 4.41  12.5 5.24 
25.0 5.57  25.0 6.03 
37.5 8.74  50.0 7.84 
50.0 10.7  75.0 8.80 
103g   103h  
109 [103g] / M 103 kobs / s-1  109 [103h] / M 103 kobs / s-1 
6.25 3.43  6.25 2.21 
12.5 4.55  12.5 3.79 
25.0 6.21  25.0 7.58 
37.5 8.31  37.5 11.98 
50.0 8.87    
103i   103j  
109 [103i] / M 103 kobs / s-1  106 [103j] / M 103 kobs / s-1 
6.25 3.74  10.0 3.80 
12.5 6.13  25.0 6.55 
25.0 12.6  50.0 8.77 
37.5 17.1  75.0 14.4 
   100 18.3 
103k     
109 [103k] / M 103 kobs / s-1    
6.25 4.07    
12.5 4.41    
25.0 5.57    
37.5 8.74    
50.0 10.7    
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A4.1.2 Plots of the pseudo-first-order rate constants, kobs, versus the inhibitor 
concentration for HLE inhibition by 77 and 103, in accordance to the mechanism 
A of Figure 2.28. 
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Figure A4.1 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77a () and 
77b (●). Points are experimental and the lines are from linear regression analysis of the data, giving 
kon´ = (1.01 ± 0.05) x 102 M-1s-1 for 77a and kon´ = (2.43 ± 0.03) x 102 M-1s-1 for 77b. By correction 
using Equation 2.8, kon = (7.33 ± 0.34) x 102 M-1s-1 for 77a and kon = (1.76 ± 0.02) x 103 M-1s-1 for 77b. 
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Figure A4.2 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77c (●) and 
77e (). Points are experimental and the lines are from linear regression analysis of the data, giving kon´ 
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= (4.21 ± 0.21) x 104 M-1s-1 for 77c; and kon´ = (3.32 ± 0.07) x 104 M-1s-1 for 77e. By correction using 
Equation 2.8, kon = (3.05 ± 0.16) x 105 M-1s-1 for 77c and (2.41± 0.05) x 105 M-1s-1 for 77e. 
 
 
r2 = 0.999
0
5
10
15
20
25
30
0 20 40 60 80
106 [I] / M
10
3  k
ob
s  /
 s
-1
 
Figure A4.3 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77h. Points 
are experimental and the line is from linear regression analysis of the data, giving kon´ = (8.57 ± 0.19) x 
102 M-1s-1. By correction using Equation 2.8, kon = (6.21 ± 0.14) x 103 M-1s-1. 
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Figure A4.4 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77i. Points are 
experimental and the line is from linear regression analysis of the data, giving kon´ = (5.43 ± 0.56) x 104 
M-1s-1. By correction using Equation 2.8, kon = (3.94 ± 0.40) x 105 M-1s-1. 
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Figure A4.5 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77j. Points are 
experimental and the line is from linear regression analysis of the data, giving kon´ = (1.53 ± 0.11) x 102 
M-1s-1. By correction using Equation 2.8, kon = (1.11 ± 0.08) x 103 M-1s-1. 
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Figure A4.6 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77k. Points 
are experimental and the line is from linear regression analysis of the data, giving kon´ = (1.30 ± 0.15) x 
104 M-1s-1. By correction using Equation 2.8, kon = (1.01 ± 0.11) x 105 M-1s-1. 
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Figure A4.7 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77m. Points 
are experimental and the line is from linear regression analysis of the data, giving kon´ = (6.00 ± 0.14) x 
102 M-1s-1. By correction using Equation 2.8, kon = (4.35 ± 0.10) x 103 M-1s-1. 
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Figure A4.8 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77n (●) and 
77r (). Points are experimental and the lines are from linear regression analysis of the data, giving kon´ 
= (3.93 ± 0.20) x 103 M-1s-1 for 77n and kon´ = (3.94 ± 0.17) x 104 M-1s-1 for 77r. By correction using 
Equation 2.8, kon = (2.85 ± 0.14) x 104 M-1s-1 for 77n and kon = (2.86 ± 0.12) x 105 M-1s-1 for 77r. 
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Figure A4.9 - Effect of inhibitor concentration on the onset of inhibition of HLE by 77o (●) and 
77p (). Points are experimental and the lines are from linear regression analysis of the data, giving 
kon´ = (2.76 ± 0.14) x 102 M-1s-1 for 77o and kon´ = (3.68 ± 0.41) x 101 M-1s-1 for 77p. By correction 
using Equation 2.8, kon = (2.00± 0.10) x 103 M-1s-1 for 77o and kon = (2.67 ± 0.30) x 102 M-1s-1 for 77p. 
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Figure A4.10 - Effect of inhibitor concentration on the onset of inhibition of HLE by 103d. Points 
are experimental and the line is from linear regression analysis of the data, giving kon´ = (1.74 ± 0.04) x 
102 M-1s-1. By correction using Equation 2.8, kon = (1.26 ± 0.03) x 103 M-1s-1. 
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Figure A4.11 - Effect of inhibitor concentration on the onset of inhibition of HLE by 103e (●), 
103h () and 103i (). Points are experimental and the lines are from linear regression analysis of the 
data, giving kon´ = (1.59 ± 0.13) x 105 M-1s-1 for 103e, (3.14 ± 0.13) x 105 M-1s-1 for 103h and (4.38 ± 
0.24) x 105 M-1s-1 for 103i. By correction using Equation 2.8, kon = (1.15 ± 0.09) x 106 M-1s-1 for 103e, 
(2.28 ± 0.09) x 106 M-1s-1 for 103h and (3.18 ± 0.15) x 106 M-1s-1 for 103i. 
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Figure A4.12 - Effect of inhibitor concentration on the onset of inhibition of HLE by 103j (●) and 
103k (). Points are experimental and the lines are from linear regression analysis of the data, giving 
kon´ = (1.61 ± 0.07) x 105 M-1s-1 for 103j and kon´ = (2.02 ± 0.10) x 105 M-1s-1 for 103k. By correction 
using Equation 2.8 (Section 2.3.2.1), kon = (1.17± 0.05) x 106 M-1s-1 for 103j and kon = (1.47 ± 0.07) x 
106 M-1s-1 for 103k. 
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A4.1.3 Determination of Ki for 4-oxo--lactams that inhibited HLE accordingly 
to the mechanism A of Figure 2.28. 
 
 
Table A4.2 - The dependence of the steady-state rates, vs, with the inhibitor concentration for 
HLE inhibition 
 
 
 
 
 
 
 
 
77a   77b  
106[77a] / M 105 vs / Abs.s-1  106 [77b] / M 105 vs / Abs.s-1 
0 95.6  0 68.5 
2.5 35.2  3.0 15.8 
10 14.2  10 3.15 
25 9.98  30 0.99 
50 5.05  75 0.41 
77c   77e  
109 [77c] / M 105 vs / Abs.s-1  109 [77e] / M 105 vs / Abs.s-1 
0 55.2  0 59.3 
50 5.45  50 10.3 
150 1.26  100 3.49 
300 0.63  150 2.20 
500 0.26  300 0.97 
   600 0.22 
77h   77i  
106[77h] / M 105 vs / Abs.s-1  109[77i] / M 105 vs / Abs.s-1 
0 54.69  0 67.01 
1.50 7.56  50.0 47.93 
3.00 4.56  100 44.08 
7.50 1.89  250 26.66 
30.0 0.54  500 17.42 
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77j   77k  
106 [77j] / M 105 vs / Abs.s-1  109[77k] / M 105 vs / Abs.s-1 
0 77.3  0 68.8 
2.5 34.0  100 9.78 
5.0 18.4  200 4.91 
10.0 8.20  500 2.21 
20.0 5.10  1000 0.89 
77m   77n  
106[77m] / M 105 vs / Abs.s-1  109 [77n] / M 105 vs / Abs.s-1 
0 71.1  0 128.0 
0.5 25.3  500 7.63 
2.0 4.15  750 3.68 
5.0 2.47  1000 0.00 
10 1.50  1500 2.12 
20 0.90  2000 1.41 
77o   77p  
106[77o] / M 105 vs / Abs.s-1  106 [77p] / M 105 vs / Abs.s-1 
0 149.5  0 151.6 
2.0 48.47  20 81.57 
4.0 29.17  37.5 71.89 
5.0 23.22  50 66.50 
7.5 13.29 
10 11.06 
15 6.85 
20 5.78 
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77r  
109 [77r] / M 105 vs / Abs.s-1 
0 109.2 
50.0 16.7 
100 0.21 
200 0.43 
300 0.65 
400 0.44 
103d   103e  
106 [103d] / M 105 vs / Abs.s-1  109 [103e] / M 105 vs / Abs.s-1 
0 71.21  0 65.07 
2 31.85  6.25 39.42 
5 13.95  12.5 19.51 
20 4.93  25.0 7.33 
40 2.41  37.5 9.00 
50 1.61  50.0 1.05 
103h   103i   
109 [103h] / M 105 vs / Abs.s-1  109 [103i] / M 105 vs / Abs.s-1 
0 73.76  0 73.20 
6.25 48.26  6.25 37.77 
12.5 40.53  12.5 10.17 
25.0 7.24  25.0 1.60 
37.5 2.26  37.5 0.99 
103j   103k  
106 [103j] / M 105 vs / Abs.s-1  109 [103k] / M 105 vs / Abs.s-1 
10.0 3.80  0 72.01 
25.0 6.55  6.25 34.76 
50.0 8.77  12.5 37.16 
75.0 14.4  25.0 6.94 
100 18.3  37.5 1.47 
   50.0 0.72 
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Figure A4.13 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77a. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77a, 
using Equation 2.10, for Ki´= 1590  200 nM. After correction, the Ki value for 77a is 219  27.6 nM. 
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Figure A4.14 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77b. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77b, 
using Equation 2.10, for Ki´= 825  95.5 nM. After correction, the Ki value for 77b is 114  13.2 nM. 
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Figure A4.15 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77c. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77c, 
using Equation 2.10, for Ki´= 5.14  0.45 nM. After correction, the Ki value for 77c is 0.71  0.06 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.16 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77e. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77e, 
using Equation 2.10, for Ki´= 8.79  1.14 nM. After correction, the Ki value for 77e is 1.21  0.16 nM. 
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Figure A4.17 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77h. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77h, 
using Equation 2.10, for Ki´= 250  4.48 nM. After correction, the Ki value for 77h is 34.4  1.17 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.18- Plot of the steady-state rate versus [I] for the inhibition of HLE by 77i. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77i, 
using Equation 2.10, for Ki´= 173  20.3 nM. After correction, the Ki value for 77i is 23.8  2.80 nM. 
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Figure A4.19 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77j. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77j, 
using Equation 2.10, for Ki´= 1687  180 nM. After correction, the Ki value for 77j is 233  24.8 nM. 
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Figure A4.20 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77k. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77k, 
using Equation 2.10, for Ki´= 16.2  0.36 nM. After correction, the Ki value for 77k is 2.24  0.05 nM. 
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Figure A4.21 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77m. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77m, 
using Equation 2.10, for Ki´= 246  30.9 nM. After correction, the Ki value for 77m is 33.9  4.26 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.22 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77n. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77n, 
using Equation 2.10, for Ki´= 28.1  2.57 nM. After correction, the Ki value for 77n is 3.87  0.35 nM. 
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Figure A4.23 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77o. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77o, 
using Equation 2.10, for Ki´= 920  36.3 nM. After correction, the Ki value for 77o is 126  5.01 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.24 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77p. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77p, 
using Equation 2.10, for Ki´= 32200  6550 nM. After correction, the Ki value for 77p is 4450  903 
nM. 
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Figure A4.25 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 77r. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 77r, 
using Equation 2.10, for Ki´= 6.15  2.04 nM. After correction, the Ki value for 77r is 0.85  0.28 nM. 
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Figure A4.26 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103d. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103d, 
using Equation 2.10, for Ki´= 1470  104 nM. After correction, the Ki value for 103d is 203  14 nM. 
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Figure A4.27 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103e.  Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103e, 
using Equation 2.10, for Ki´= 5.91  1.45 nM. After correction, the Ki value for 103e is 0.82  0.20 nM. 
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Figure A4.28 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103h. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103h, 
using Equation 2.10, for Ki´= 8.17  3.68 nM. After correction, the Ki value for 103h is 1.12  0.51 
nM. 
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Figure A4.29 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103i. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103i, 
using Equation 2.10, for Ki´= 3.64  1.52 nM. After correction, the Ki value for 103i is 0.50  0.21 nM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.30 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103j. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103j, 
using Equation 2.10, for Ki´= 12.9  5.20 nM. After correction, the Ki value for 103j is 1.78  0.72 nM. 
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Figure A4.31 - Plot of the steady-state rate versus [I] for the inhibition of HLE by 103k. Points are 
experimental and the line is fom non-linear regression analysis of data presented in Table A4.2, 103k, 
using Equation 2.10, for Ki´= 6.52  2.30 nM. After correction, the Ki value for 103k is 0.90  0.32 
nM. 
 
 
 
A4.1.4 - Determination of Kinetic Parameters for HLE Inhibition that Conforms 
to the Mechanism B of Figure 2.28 
 
 
 
 
 
 
 
 
 
 
 
Figure A4.32 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 77d. 
Points are experimental and the line is fom non-linear regression analysis of data presented in Table 
A4.1, 77d, using Equation 2.13, for kinact = (3.12  0.20) x 10-2 s-1, Ki´= 349  87 nM. After correction, 
the Ki value for 77d is 48.2  12.0 nM. The koff is impossible to tell apart from zero. 
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Figure A4.33 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 77f. 
Points are experimental and the line is fom non-linear regression analysis of data presented in Table 
A4.1, 77f, using Equation 2.13, for kinact = (3.83  0.17) x 10-2 s-1, Ki´= 420  63.2 nM. After 
correction, the Ki value for 77f is 57.9  8.71 nM. The koff is impossible to tell apart from zero. 
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Figure A4.34 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 77g. 
Points are experimental and the line is fom non-linear regression analysis of data presented in Table 
A4.1, 77g, using Equation 2.13, for kinact = (3.23  0.22) x 10-2 s-1, Ki´= 461  80.7 nM and koff = (7.08 
 4.32) x 10-2 s-1. After correction, the Ki value for 77g is 63.5  11.1 nM and Ki*, given by Equation 
4.4, is 1.36 nM.  
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Figure A4.35 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 
103a. Points are experimental and the line is fom non-linear regression analysis of data presented in 
Table A4.1, 103a, using Equation 2.13, for kinact = (4.23  0.24) x 10-2 s-1, Ki´= 205  71 nM and koff = 
(1.49  0.26) x 10-2 s-1. After correction, the Ki value for 103a is 283  11.1 nM and Ki*, given by 
Equation 4.4, is 73.7 nM.  
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Figure A4.36 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 
103b. Points are experimental and the line is fom non-linear regression analysis of data presented in 
Table A4.1, 103b, using Equation 2.13, for kinact = (7.15  1.08) x 10-2 s-1, Ki´= 1490  980 nM and koff 
= (2.74  1.14) x 10-4 s-1. After correction, the Ki value for 103b is 205  135 nM and Ki*, given by 
Equation 4.4, is 7.57 nM.  
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Figure A4.37 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 
103c. Points are experimental and the line is fom non-linear regression analysis of data presented in 
Table A4.1, 103c, using Equation 2.13, Section 2.3.2.2, for kinact = (2.12  0.23) x 10-2 s-1, Ki´= 2560  
1490 nM and koff is impossible to tell apart from zero. After correction, the Ki value for 103c is 353  
206 nM. 
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Figure A4.38 - Plot of the pseudo-first order rate constants for HLE inhibition by compound 
103g. Points are experimental and the line is fom non-linear regression analysis of data presented in 
Table A4.1, 103g, using Equation 2.13, Section 2.3.2.2, for kinact = (1.68  0.42) x 10-2 s-1, Ki´= 68.9  
29 nM and koff = (1.99  0.27) x 10-3 s-1. After correction, the Ki value for 103g is 9.50  3.99 nM and 
Ki*, given by Equation 4.4, is 1.01 nM. 
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A4.1.5 - Titration of HLE Activity by 77g 
 
Table A4.3 – Percentage of remaining HLE activity, vt/vi versus the initial ratio of inhibitor to 
enzyme, [I]/[E]0, after a 30 min. incubation period with 77g at 25 ºC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A4.2 Proteinase 3 Inhibition Studies 
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Figure A4.39 - Progress curve for PR3 inhibition by 103i. Reaction conditions: [PR3] = 22.75 nM, 
[MeO-Suc-(L-Ala)2-L-Pro-L-Val-p-NA] = 3.75 mM, 0.1M, pH 7.2 HEPES buffer, 25 ºC, (a) absence 
of inhibitor, (b) [103i] = 50 nM.  
[I]/[E]0 vt/vi (%) 
0 100 
0.125 94.3 
0.250 95.4 
0.375 86.2 
0.500 61.1 
0.750 59.3 
1.00 23.4 
1.50 22.3 
2.00 3.9 
4.00 2.10 
Appendix 4 
 
 
 
294
Table A4.4 - Pseudo-first-order rate constant, kobs, for the time-dependent inactivation of PR3 by 
4-oxo--lactams, at 25 ºC, in 0.1 M, pH 7.2 HEPES buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A4.5 – PR3 inhibition by 77g and 77p 
 
 
 
 
 
 
77p  
105 vi  / Abs.s-1 (in absence of 77p) 0.91  
105 vi  / Abs.s-1 (at [77p] = 60 M) 0.70 
 Inhibitory activity 22% 
103b  
106 [103b] / M 104 kobs / s-1 
1.0 3.61 
77o  
106 [77o] / M 104 kobs / s-1 
30 6.06 
103f  
106 [77f] / M 104 kobs / s-1 
10 2.96 
103g  
109 [103g] / M 104 kobs / s-1 
50 0.35 
103i  
109 [103g] / M 104 kobs / s-1 
50 20.4 
103j  
106[103j] / M 104 kobs / s-1 
10 12.2 
103k  
109 [77k] / M 104 kobs / s-1 
50 25.0 
77g  
105 vi / Abs.s-1 (in absence of 77g) 1.08  
105 vi / Abs.s-1 (at [77g] = 10 M) 0.91 
 Inhibitory activity 16% 
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A4.3 Cathepsin G Inhibition Studies 
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Figure A4.40 - Progress curve for Cat G inhibition by 77m. Reaction conditions: [Cat G] = 68 nM, 
[N-Suc-(L-Ala)2-L-Pro-L-Phe-p-NA] = 0.85 mM, 0.1M, pH 7.5 HEPES buffer, 25 ºC, (a) absence of 
inhibitor, (b) [77m] = 20 M, (c) [77m] = 40 M.  
 
 
 
 
Table A4.6 - Pseudo-first-order rate constant, kobs, for the time-dependent inactivation of Cat G 
by 4-oxo--lactams, at 25 ºC, in 0.1 M, pH 7.5 HEPES buffer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
77m  
106 [77m] / M 104 kobs / s-1 
20 7.99 
40 12.5 
77g  
106 [77g] / M 104 kobs / s-1 
60 21.9 
77r  
106 [77r] / M 104 kobs / s-1 
20 9.46 
103k  
106 [103k] / M 104 kobs / s-1 
40 16.6 
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A4.4 – Hydrolytic Stability Studies 
 
 
A4.4.1 – Calibration curves 
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Figure A4.41 - Calibration curve for 103a. Points are experimental and the line is from linear 
regression analysis of data. 
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Figure A4.42 - Calibration curve for 103e. Points are experimental and the line is from linear 
regression analysis of data. 
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Figure A4.43 - Calibration curve for 103i. Points are experimental and the line is from linear 
regression analysis of data. 
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Figure A4.44 - Calibration curve for 103k. Points are experimental and line is from linear regression 
analysis of data. 
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A4.4.2 - Stability in pH 7.4 Phosphate Buffer Saline (PBS) 
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Figure A4.45 - Profile of concentration of 103e versus time after incubation in pH 7.4 PBS, at 37 
ºC. Points are experimental and line is from exponential regression analysis of data, giving the kinetic 
rate constant of hydrolysis k = 1.13 x 10-3 min-1. From this value, the half-life was determined, t1/2 = 
10h. 
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Figure A4.46 - Profile of concentration of 103i versus time after incubation in PBS, at 37 ºC. 
Points are experimental and line is from exponential regression analysis of data, giving the kinetic rate 
constant of hydrolysis k = 8.83 x 10-4 min-1. From this value, the half-life was determined, t1/2 = 13h. 
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Figure A4.47 - Profile of concentration of 103k versus time after incubation in PBS, at 37 ºC. 
Points are experimental and line is from exponential regression analysis of data, giving the kinetic rate 
constant of hydrolysis k = 1.11 x 10-2 min-1. From this value, the half-life was determined, t1/2 = 1.04h. 
 
 
 
A4.4.3 – Stability in 80% Human Plasma 
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Figure A4.48 - Profile of concentration of 103e versus time after incubation in 80% human 
plasma, at 37 ºC. Points are experimental and line is from exponential regression analysis of data, 
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giving the kinetic rate constant of hydrolysis k = 2.72 x 10-2 min-1. From this value, the half-life was 
determined, t1/2 = 0.42h. 
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Figure A4.49 - Profile of concentration of 103i versus time after incubation in 80% human 
plasma, at 37 ºC. Points are experimental and line is from exponential regression analysis of data, 
giving the kinetic rate constant of hydrolysis k = 5.79 x 10-2 min-1. From this value, the half-life was 
determined, t1/2 = 0.20h. 
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Figure A4.50 - Profile of concentration of 103k versus time after incubation in 80% human 
plasma, at 37 ºC. Points are experimental and line is from exponential regression analysis of data, 
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giving the kinetic rate constant of hydrolysis k = 1.04 x 10-1 min-1. From this value, the half-life was 
determined, t1/2 = 0.11h. 
 
 
A4.5 – Biodistribution Studies 
 
 
Table A4.7 - Data for calibration curve of 103k in mice blood, spleen, lung and liver 
 
Blood  
[103k] / g/ml Area 
9.0 602 
13.5 1159 
22.5 1729 
45.0 5074 
67.5 7920 
 
Spleen  
[103k] / g/ml Area 
9.0 1314 
13.5 7177 
22.5 10402 
 
Lung  
[103k] / g/ml Area 
9.0 3906 
13.5 5500 
22.5 8315 
 
Liver  
[103k] / g/ml Area 
9.0 4770 
13.5 6368 
22.5 8446 
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Crystallization and Preliminary Diffraction Studies of Porcine Pancreatic 
Elastase in Complex with a Novel Inhibitor  
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Abstract: Porcine pancreatic elastase (PPE) was crystallized in complex with a novel inhibitor at pH 5 and X-ray diffrac-
tion data were collected at a synchrotron source to 1.66 Å. Crystals belong to the orthorhombic space group P212121, with 
unit cell parameters a = 50.25 Å, b = 57.94 Å and c = 74.69 Å. PPE is often used as model for drug target, due to its 
structural homology with the important therapeutic target human leukocyte elastase (HLE). Elastase is a serine protease 
that belongs to the chymotrypsin family, which has the ability to degrade elastin, an important component in connective 
tissues. Excessive elastin proteolysis leads to a number of pathological diseases.  
Keywords: Human leukocyte elastase, Porcine pancreatic elastase, -Lactams inhibitors, Crystallization. 
INTRODUCTION 
 Human leukocyte elastase (HLE, EC 3.4.21.37) is a ser-
ine protease released from polymorphonuclear leukocytes 
(neutrophils) in response to inflammatory stimuli and me-
diators [1]. HLE degrades very efficiently various tissue ma-
trix proteins such as elastin and in healthy individuals its 
proteolytic activity is regulated by potent endogenous anti-
proteases such as 1-antitrypsin and secretory leukocyte 
proteinase inhibitor [2]. Imbalance between HLE and its 
endogenous inhibitors leads to excessive elastin proteolysis 
and destruction of connective tissues in a number of inflam-
matory diseases such as pulmonary emphysema, adult respi-
ratory distress syndrome (ARDS), chronic bronchitis, 
chronic obstructive pulmonary disease (COPD), pulmonary 
hypertension and rheumatoid arthritis [3-6], as well as in 
other pulmonary pathophysiological states, e.g. cystic fibro-
sis [7]. 
 The design of low molecular-weight inhibitors of elasta-
ses has received considerable attention due to their potential 
therapeutic usefulness [8, 9]. Understanding the nature of 
inhibition and structure of the ligand-enzyme complex is a 
fundamental step in any structure-based lead optimization 
project. This is particularly true for mechanism-based in-
hibitors that can lead to a double-hit inactivation process 
[10]. -Lactams (azetidin-2-ones) are potent inhibitors of a 
wide range of enzymes that contain serine as the catalytic 
residue [11-13]. Many structural and inhibition studies with 
-lactams have been conducted with the readily available 
porcine pancreatic elastase (PPE) [14, 15]. Indeed, the se-
quence identity between PPE and HLE is ca. 40% [16], and 
despite small differences in the primary specificity pockets 
[1], PPE is considered to be a good model for HLE to be 
used in preliminary inhibition studies. 
*Address correspondence to this author at the Instituto de Tecnologia 
Química e Biológica, Universidade Nova de Lisboa, ITQB-UNL, Av. Rep-
ública, Apt. 127, 2781-901 Oeiras, Portugal; E-mail: archer@itqb.unl.pt 
 Herein we report the crystallization and preliminary 
X-ray diffraction analysis of PPE inactivated with the 
-lactam (Fig. 1), which contains a potential leaving group at 
C-4 position of the four-membered ring. Compound JM54 
(Fig. 1) is a novel potent irreversible inhibitor of PPE (kobs
/[I] of 290 M-1s-1) that requires only ca. 1 mol. equivalent to 
inactivate the enzyme [17]. We aim towards a detailed 
structural characterization of the molecular interactions of 
PPE with this potential mechanism-based inhibitor. 
Figure 1. Molecular structure of the synthesized inhibitor JM54.
MATERIALS AND METHODS 
Crystallization 
 Elastase from porcine pancreas (E.C. 3.4.21.36) was 
purchased from Serva (Cat No 20929) and was used without 
any further purification. The protein (MW of 25.9 kDa) was 
dissolved in bidistilled water to a concentration of 40 mg/ml. 
A concentrated solution (~150 mM) of the synthesized in-
hibitor JM54, was freshly prepared in DMSO. JM54 was 
incubated with PPE for 30 minutes at room temperature (in-
hibitor in a 10 molar excess, final concentration of 10% 
DMSO). The crystallization trials were set up at 293 K using 
the sitting drop vapour-diffusion method, and were based on 
previously known crystallization conditions [18, 19]. PPE 
co-crystallized with the inhibitor JM54 in 200 mM sodium 
sulfate and 100 mM sodium acetate at pH 5.1 yielded good 
quality crystals. Native crystals were also grown under the 
same experimental conditions to test soaking procedures 
with the inhibitor. 
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X-Ray Data Collection and Phasing
 Crystals were cryoprotected with the reservoir solution 
supplemented with 30% glycerol and were flash cooled in 
liquid nitrogen (100 K). X-ray diffraction data were collected 
to 1.66 Å at EMBL X11 beamline at the DORIS storage ring, 
DESY, Hamburg (Germany), using a wavelength of 0.82 Å. 
A total of 136 images were collected on a MARCCD-165 
mm detector with an oscillation angle of 1.5º and an expo-
sure time of 20 s per frame. The X-ray data were integrated 
and scaled using MOSFLM [20] and SCALA programs [21]. 
Since the crystals obtained for the enzyme:inhibitor complex 
were isomorphous to the native ones and belonged to the 
same space group, the structure was solved by Fourier syn-
thesis [18, 19]. A rigid-body refinement step was performed 
with Refmac [22] yielding an R-work and R-free of 27.7 and 
30.5%, respectively.  
RESULTS AND DISCUSSION  
 The crystal quality was optimized by varying the PPE 
concentration (10 to 40 mg/ml), and by trying different pro-
tein:reservoir volumes and ratios. The best crystals were 
obtained by mixing equal volumes (1-2 l) of PPE/JM54 
mixture (~40 mg/ml) and reservoir solution. The reservoir 
solution contained 200 mM sodium sulfate and 100 mM so-
dium acetate at pH 5.1. Crystals grew within 1 to 3 days to 
maximum dimensions of approximately 0.8 x 0.5 x 0.1 mm 
(Fig. 2). X-ray diffraction data were collected at 
EMBL/DESY synchrotron, Hamburg to 1.66 Å (Fig. 3).
Data collection and processing statistics are given in Table 1. 
Crystals belong to the orthorhombic space group P212121
with unit cell parameters a = 50.25 Å, b = 57.94 Å and c = 
74.69 Å. The calculated VM [23] is 2.1 Å
3/Da, which corre-
sponds to a solvent content of ~ 41% and one molecule per 
asymmetric unit. Crystals of native PPE [18, 19] and 
PPE/inhibitor complexes [24-26] grown under the same ex-
perimental conditions show similar cell parameters. The ini-
tial calculated maps showed electron density near the cata-
lytic triad, which corresponds to the inhibitor. Model fitting 
and further refinement is now in progress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Crystals of PPE/JM54 complex with dimensions - 0.6 x 
0.4 x 0.4 mm  
Figure 3. Diffraction pattern of the PPE/JM54 crystal collected at 
the X11 beamline at DESY-Hamburg. 
 
Table 1. X-Ray Data Collection Statistics 
Wavelength (Å) 0.82 
Resolution range (Å) 37.95 - 1.66 
Space group P212121
Unit cell parameters (Å) a = 50.25, b = 57.94, c = 74.69 
Total reflections 177649 
Unique reflections 26474 
Completeness (%) 96.9 (79.8) 
Redundancy 4.3 (4.1) 
Rmerge* (%) 3.0 (9.3) 
I/  (I) 27.4 (14.7) 
Values in parenthesis show the statistics of the highest resolution shell (1.75 - 1.66 Å). 
*                              where     is the ith measurement. 
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The presence of a leaving group at C-4 of monobactams is usually considered to be a requirement for
mechanism-based inhibition of human leukocyte elastase by these acylating agents. We report that
second-order rate constants for the alkaline hydrolysis and elastase inactivation by N-carbamoyl
monobactams are independent of the pKa of the leaving group at C-4. Indeed, the effect exerted by
these substituents is purely inductive: electron-withdrawing substituents at C-4 of
N-carbamoyl-3,3-diethylmonobactams increase the rate of alkaline hydrolysis and elastase inactivation,
with Hammett qI values of 3.4 and 2.5, respectively, which indicate the development of a negative
charge in the transition-states. The difference in magnitude between these qI values is consistent with an
earlier transition-state for the enzymatic reaction when compared with that for the chemical process.
These results suggest that the rate-limiting step in elastase inactivation is the formation of the
tetrahedral intermediate, and that b-lactam ring-opening is not concerted with the departure of a
leaving group from C-4. Monobactam sulfones emerged as potent elastase inhibitors even when the
ethyl groups at C-3, required for interaction with the primary recognition site, are absent. For one such
compound, a 1 : 1 enzyme–inhibitor complex involving porcine pancreatic elastase has been examined
by X-ray crystallography and shown to result from serine acylation and sulﬁnate departure from the
b-lactam C-4.
Introduction
b-Lactams are potent inhibitors of a wide range of enzymes
that contain a catalytic serine residue, including the hepatitis
C virus serine protease, penicillin-binding proteins (PBPs), b-
lactamases and human leukocyte elastase (HLE).1–7 The efﬁciency
of b-lactams as enzyme inhibitors depends on the molecular
recognition by the protein as well as on the intrinsic chemical
reactivity of the b-lactam, both of which affect the rate at which
these inhibitors acylate the serine residue.8
Among the most extensively studied enzymatic reactions of b-
lactams is the inhibition of class A b-lactamases by penam sulfone
inhibitors such as sulbactam, 1 (Scheme 1), tazobactam and their
analogues.9–15 Reaction of penam sulfones with the catalytic Ser70
involves b-lactam ring-opening and leads to the departure of
a sulﬁnate leaving group from C-5 and formation of an imine
(Scheme 1).1,14 The imine then undergoes a cascade of reactions
including nucleophilic attack by the Ser130 hydroxyl group to
form a stable acrylate ester capable of preventing hydrolysis of
the acyl-enzyme, and thus leading to irreversible inhibition.11 The
oxidation state of the sulfur atom in the penam plays a role
in potency: while sulbactam is a potent b-lactamase inhibitor,
its penicillanate counterpart is only a substrate of b-lactamase,
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Scheme 1
while the corresponding sulfoxides are both substrate and weak
inactivators.10 It is worth noting that b-lactamase inhibition by
clavulanic acid, 2, requires intramolecular hydrogen bonding from
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the C-9 hydroxyl group to assist the departure of an oxonium
oxygen fromC-5, i.e. 3 (species 3 results from proton transfer from
a water molecule, Wat673, to the carbon–carbon double bond of
the acyl-enzyme).16 These results suggest that departure of a good
leaving group from the C-5 carbon atom of penams and clavams is
required to achieve irreversible inhibition of enzymes containing
a catalytic serine residue.10,17
Cephalosporins are time-dependent inhibitors of HLE in-
hibitors, and, similarly to penams, the oxidation state of the
sulfur atom also plays a role in potency, with sulfones (4, n =
2) showing considerably greater activity than the corresponding
sulﬁdes (4, n = 0) or b-sulfoxides (4, n = 1), while a-sulfoxides
are inactive.18–21 However, the identity of the species giving rise to
inhibition remains to be deﬁned. X-Ray crystallography indicates
that inactivation of HLE by cephalosporin sulfones containing a
good leaving group at C-3′ (e.g. 4, X = AcO) preferably involves
reaction with His57 at this position rather than sulﬁnic acid
departure from C-6 and thiazine ring-opening.22
Monobactams containing potential leaving groups at C-4 have
also been developed as mechanism-based inhibitors of HLE,23–25
although the requirement of leaving-group departure to achieve
irreversible inactivation is still controversial. Crystallography26
and mass spectrometry27 studies indicate that the reaction of
monobactams containing a C-4 aryloxy substituent with HLE
involves the departure of a phenol, possibly concerted with C–N
bond ﬁssion and b-lactam ring-opening.28 However, the observa-
tion that the second-order rate-constants for HLE inactivation
by monobactams with no leaving group at C-4 do not differ
signiﬁcantly from those of monobactams containing a phenol28
suggests that leaving group ability is not essential to inactivate
the enzyme. Understanding how b-lactam substituents affect
molecular recognition by the enzyme and “chemical reactivity”
is most useful in designing more potent enzyme inhibitors. We
report here a study on the chemistry of elastase inactivation by
model monobactams, 5 (Scheme 2, Table 1) with the objective
of elucidating how C-4 substituents contribute to the chemical
reactivity towards the catalytic serine. The results herein presented
show that the effect exerted by these substituents is largely
inductive and that sulfones at C-4 are particularly efﬁcient in
activating the b-lactam scaffold towards elastase.
Results and discussion
1. Chemistry
The synthesis of compounds 5 used the appropriate 4-
acetoxyazetidin-2-one 624 as the starting material to give direct
access to the differently C-4-substituted azetidin-2-one key inter-
mediates 7–10 (Scheme 2). Reaction of 4-acetoxyazetidin-2-ones
6 with phenol24 (or thiols29) and sodium hydroxide in acetone
at room temperature gave the corresponding C-4-substituted b-
lactams 7 and 8, respectively. Alternatively, 8a was synthesised
by reﬂuxing 6a with thiophenol in benzene.30 Treatment of
thioethers 8 with 3-chloroperbenzoic acid (MCPBA) yielded the
Table 1 Second-order rate constants, kOH− , for the hydroxide-catalyzed hydrolysis of 4-substituted azetidin-2-ones, 5, at 25 ◦C and the kinetic parameters
for the time-dependent inactivation of porcine pancreatic elastase (5a–d) and human leukocyte elastase (5e–k) in pH 7.2 buffer at 25 ◦C
Compound R X pKa (XH) (kinact/K i)/M−1 s−1 102 kOH−/M−1 s−1 EREFf
5a H H 3553 NIf 13.0 —
5b H OPh 9.9254 11.5a 99.0 11.6
5c H SPh 6.5254 22.0a 44.1 50.0
5d H SO2Ph 1.2955 290a 416 70.0
5e Et H 3553 310b 0.164 1.89 × 105
5f Et OPh 9.9254 2280b 0.722 3.15 × 105
5g Et SPh 6.5254 5760b ,c 0.713 8.08 × 105
5h Et SO2Ph 1.2955 15 200b ,d 14.2 1.07 × 105
5i Et SCH2Ph 9.2754 4464b 0.362 1.23 × 106
5j Et SO2CH2Ph 1.4555 11 741b 12.7 9.24 × 104
5k Et OC6H4–4-CO2H 8.9054 8320b ,e NDf NDf
a Against PPE. b Against HLE. c 5g: K i = 0.633 lM, kinact = 3.64 × 10−3 s−1. d 5h: K i = 0.267 lM, kinact = 4.06 × 10−3 s−1. e 5k: K i = 0.454 lM, kinact =
3.78 × 10−3 s−1. f NI: no inhibition, ND: not determined, EREF: enzyme rate enhancement factor.
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Scheme 2 Reagents and conditions: (i) PhOH, NaOH, acetone; (ii) R2SH,
NaOH, acetone; (iii) PhSH (2 mol equiv.), C6H6, reﬂux; (iv) MCPBA,
DCM; (v) NaBH4, EtOH; (vi) PhCH2NCO, TEA, DCM.
corresponding sulfones 9 (Scheme 2). The C-4 unsubstituted
intermediate 10 was synthesised by reduction of 6b with NaBH4
in ethanol at 0 ◦C.31 Finally, reaction of intermediates 7–10 with
benzyl isocyanate gave the desired compounds 5 in good yield.
2. Enzyme inhibition studies
The series of b-lactams, 5a–d, lacking substituents at the C-3
position was prepared to assess the impact of a leaving group at C-
4 on porcine pancreatic elastase (PPE) inhibition when interaction
with the S1 primary recognition site32 of elastase is reduced. PPE is
a readily available elastase that shares a conserved catalytic triad
consisting of Ser195, His57 and Asp102 with HLE.33 The primary
speciﬁcity pocket of PPE is slightly less hydrophobic and smaller
than that of HLE, showing preference for small aliphatic side
chains such as alanine.33 The kinetic studies carried out at pH 7.2
and 25 ◦C, using the incubation method,34 showed that b-lactams
5b–d containing leaving groups are time-dependent inhibitors of
PPE, while the C-4-unsubstituted counterpart 5a is inactive up
to a concentration of 1 mM. The second-order rate constants for
PPE inactivation, kinact/K i (Table 1) were determined from the
plots of pseudo-ﬁrst-order inhibition rate constant, kobs, versus [I]
(Fig. 1). The sulfone derivative 5d proved to be a potent inhibitor
of PPE, with a kinact/K i, value of 290 M−1 s−1, thus suggesting
that the sulfone group is a very powerful activator of the b-lactam
carbonyl carbon atom towards the Ser195 hydroxyl group, even in
Fig. 1 Dependence of kobs for enzyme inhibition on inhibitor concentra-
tion: (A), 5d, porcine pancreatic elastase; (B), 5f, human leucocyte elastase.
the absence of an adequate molecular recognition moiety at C-3
in the b-lactam scaffold.
Further evidence of the efﬁciency of 5d as an irreversible
inhibitor of PPE comes from the titration of enzyme activity. The
number of equivalents required to inactivate PPE was calculated
by plotting the fraction of remaining enzyme activity, v/v0, after
a 30 min incubation period versus the initial ratio of inhibitor
to enzyme, i.e. [I]/[E]0. For levels of inhibition of up to 90%
of the original enzyme activity, the extent of inactivation was
found to depend linearly on the inhibitor-to-enzyme molar ratio
(Fig. 2), and extrapolation of the line to v/v0 = 0 shows that it
required approximately 1.2 equiv. of 5d to completely inactivate
PPE. Interestingly, such high inhibitory efﬁciency is similar to
that reported for HLE inactivation by 3,3-diethylmonobactams
and cephalosporins.33,35
In contrast to the C-3-unsubstituted series, their 3,3-diethyl
counterparts 5e–jwere completely inactive against PPE in concen-
trations up to 0.5 mM. However, b-lactams 5e–j inhibited HLE
very efﬁciently in a time-dependent fashion. The pseudo-ﬁrst-
order rate-constants, kobs, for HLE inactivation were determined
using the progress-curve method.36 For compound 5f, a linear
dependence of kobs on inhibitor concentration was observed
(Fig. 1B); and correction for the concentration and Michaelis
constant of the substrate yielded the second-order rate constant for
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Fig. 2 Inactivation of porcine pancreatic elastase as a function of the
molar ratio of inhibitor 5d to enzyme. PPE (10lM)and various amounts of
inhibitor 5d (20–0.4 lM) in 0.1 M HEPES buffer, pH 7.25, were incubated
at 25 ◦C for 30 min, and aliquots were withdrawn for assay.
inhibition, kinact/K i, as the slope (Table 1). For compounds 5g and
5h, the individual kinetic parameters K i and kinact were obtained
by determining kobs as a function of the inhibitor concentration,28
while for the remaining b-lactams (5e, 5i and 5j) the kinact/K i values
were determined by calculating kobs/[I] (Table 1). The second-
order rate-constants for HLE inactivation, kinact/K i, are within the
range of 103 to 104 M−1 s−1, which reﬂects the stringent S1 subsite
speciﬁcity of this enzyme toward hydrophobic substituents with
three or four carbon atoms.25,31,33,37
3. X-Ray crystallography studies
PPE was incubated with 5d for 30 min. Good quality crystals
were grown and subjected to X-ray analysis.38 The electron density
maps at the catalytic site indicate that PPE inactivation by 5d
involves b-lactam ring-opening, as revealed by the ester formed
with Ser195 Oc (Fig. 3). Moreover, inspection of the maps
calculated at 1.66 A˚ resolution shows that acylation of PPE by
5d also involves the departure of sulﬁnate from C-4. Interestingly,
the crystal structure reveals the presence of a hydroxyl group
at C-3 (b-lactam numbering) (Scheme 3). This hydroxyl group
establishes H-bonds to water molecules while the ester carbonyl
group is H-bonded to the NH backbone of Gln192. Furthermore,
the adjacent urea NH groups are within H-bonding distance
to water molecules, as shown in Fig. 3. This was a somewhat
unexpected result when compared with those from previous X-ray
crystallographic studies with other b-lactams containing leaving
groups at C-4. For example, inactivation of PPE by 4-aryloxy-3,3-
diethyl-b-lactams leads to a carbinolamine acyl-enzyme, resulting
Scheme 3 Covalent enzyme–inhibitor complex (see Fig. 3).
Fig. 3 A stereoview of the |F 0| − |F c| electron density map calculated, with Ser195 and inhibitor 5d (code JM54) omitted from the model. The omit
map is contoured at 3r and shows the acyl-enzyme covalently linked to Ser195 with the corresponding interactions with PPE active site.
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from reaction of water at C-4 of the imine intermediate.26 When
a single 1-hydroxyethyl substituent is present at C-3, an enamine
acyl-enzyme is formed, presumably from a retro-aldol reaction on
the imine precursor.26
We wondered if this pattern of reactivity was inherent to 5d or a
function of the enzyme active site. Therefore we undertook reac-
tion of inhibitor 5dwith sodiummethoxide inmethanol, which has
been reported as a good model reaction for the acylation of serine
enzymes.39,40 The product of this reaction was 3-benzylpyrimidine-
2,4(1H,3H)-dione, 11, in 80% yield (Scheme 4). This result is
consistent with MeO−-catalyzed b-lactam ring opening followed
by pyrimidine ring formation and phenylsulﬁnate elimination (or
ﬁrst the elimination then the ring closure). Clearly, the enzyme
active site must preclude the ring closure process; moreover,
the imine resulting from Ser195 acylation and phenylsulﬁnate
elimination would be expected to add water to C-4 (b-lactam
numbering) rather than to the C-3 atom that is evident in Fig. 3,
thus suggesting that a different pathway may be available in the
active site of PPE subsequent to b-lactam ring-opening. Although
the nature of such a pathway is currently unclear, it is unlikely to
be the rate-limiting step in the enzyme inactivation process (see
below). In this regard, it is of interest to note that the distance
between C-4 (b-lactam numbering) of the PPE–5d complex and
the C-aof Gln192 is only 3.4 A˚; this close approach might suggest
a reason as to why the presence of a hydroxyl group in the C-4
position is precluded.
Scheme 4
4. Alkaline hydrolysis
It has been suggested that the magnitude of the second-order rate-
constant, kOH− , for the alkaline hydrolysis of potential inhibitors
of enzymes containing a catalytic serine is a crude indicator for
their ability to be effective and therapeutically useful acylating
agents.39,41,42 Comparison of the kOH− values presented in Table 1
reveals that the reactivity of b-lactams 5 correlates poorly to
the pKa of the leaving group at C-4 of the b-lactam moiety.
A poor correlation between log kOH− values for the 3,3-diethyl
series 5e–j and the pKa of the leaving group at C-4 was observed,
corresponding to a blg value of −0.05, indicating that there is
essentially no change in the effective charge on the leaving group
on going from the ground state to the transition state. These results
are comparable to those reported for the alkaline hydrolysis of the
vinylogous cephalosporins containing a potential leaving group
at C-3′ (4, n = 0), for which a blg value close to zero was also
determined.43
In contrast, log kOH− values correlate with rI values for the
substituents at C-4, including those that are not expelled, yielding
Hammett qI values of 2.8 and 3.4 for the series 5a–d and 5e–j,
respectively (Fig. 4). TheHammett qI values are large and positive,
which indicates a substantial build-up of negative charge in the
transition-state and that the effect exerted by C-4 substituents on
the alkaline hydrolysis of 5 is purely inductive. The solvolysis of
penicillins and cephalosporins involves decompositionof the tetra-
hedral intermediate via general-acid-catalysed N-protonation, e.g.
12, or complexation with a metal ion, to effect C–N bond
cleavage.44 For compounds 5, N-protonation is thermodynam-
ically unfavourable. However, ureido anion expulsion from the
tetrahedral intermediate may occur at a rate that is comparable
or even faster than that for hydroxide ion, and thus the reaction
may involve the rate-limiting attack of hydroxide on the b-lactam
carbonyl atom.
Fig. 4 Plots of second-order rate-constants for the alkaline hydroly-
sis of C-3-unsubstituted b-lactams 5a–d () and 3,3-diethyl-b-lactams
5e–j (), and of second-order rate-constants for HLE inactivation by
3,3-diethyl-b-lactams 5e–j (), against rI values for the X substituents in
C-4.
The higher qI value determined for the 3,3-diethyl series when
compared to that of the C-3 unsubstituted series is consistent with
the formation of a high energy tetrahedral intermediate in which
the two C–O bonds are eclipsed with the ethyl groups at C-3.
According to the Hammond postulate, this implies that formation
of such an intermediate involves a later transition state in which
there is signiﬁcant negative charge build-up, thereby being more
susceptible to the electronic effects of the C-4 substituents. The qI
value determined here for the monobactams 5 is higher than the
corresponding qI value of 1.35 reported for the alkaline hydrolysis
of cephalosporins,44 a difference that almost certainly reﬂects the
shorter distance between the electron-withdrawing substituents
and the nitrogen atom in the b-lactam scaffold of 5.
This journal is © The Royal Society of Chemistry 2007 Org. Biomol. Chem., 2007, 5, 2617–2626 | 2621
5. Structure–activity relationships
Insight into how a particular substituent promotes the ability
of the enzyme to use its catalytic apparatus to increase the
rate of acylation through b-lactam ring-opening can be obtained
by the enzyme rate enhancement factor (EREF); this is the
ratio of second-order rate-constant for enzyme inactivation to
the second-order rate-constant for the alkaline hydrolysis, i.e.
(kinact/K i)/kOH− .39,45 Remarkably, the 3,3-diethyl b-lactams 5e–j
exhibit EREF values ca. 104 times higher than those of their
C-3 unsubstituted analogues 5b–d (Table 1). The differences in
EREF between the two series of b-lactams largely reﬂect the
importance of the alkyl substituents at C-3 in promoting efﬁcient
molecular recognition by the S1 site of the enzyme. This interaction
probably positions the b-lactam carbonyl within the oxyanion
hole, facilitating successful nucleophilic attack by Ser195, and
thus enhancing the rate of b-lactam ring-opening.31 Clearly,
the favourable binding energy between the enzyme and the C-
3 substituents overcomes the strain energy in the tetrahedral
intermediate en route to the acyl-enzyme.
As with alkaline hydrolysis, enzyme inactivation efﬁciency is
largely independent on the pKa of the leaving group at C-4. For
example, the second-order rate constant for PPE inactivation by
the 4-phenylsulfonyl derivative 5d is only 25 times higher than that
of its 4-phenoxy analogue 5b, despite the 9-fold difference between
the leaving group abilities of phenylsulﬁnate and phenolate.
Similarly, the 3,3-diethyl-4-phenylsulfonyl counterpart 5h is only
6 timesmore potent asHLE inhibitor than its 4-phenoxy analogue
5f. However, a good correlation was found between the logarithm
of the second-order rate-constants of HLE inactivation and the
rI values for the substituents at C-4, including X = H (5e), which
corresponds to a qI value of 2.5 for compounds 5e–j (Fig. 4).
This qI value is higher than that reported for HLE inactivation
by cephalosporin sulfones (4, R = MeO, n = 2; qI = 1.8320),
again reﬂecting the shorter distance between the substituents and
the nitrogen atom in the b-lactam scaffold 5. Compared with the
alkaline hydrolysis of 5 (qI of 3.4), the HLE reaction seems to
involve an earlier transition-statewith less negative charge buildup.
This effect can be ascribed, at least in part, to the favourable
non-covalent interactions with the primary speciﬁcity pocket,
which allows the enzyme to stabilize the transition-state and to
make full use of its catalytic machinery to increase the rate of
acylation through b-lactam ring-opening. This is consistent with
the EREF values for 5e–j ranging from 105 to 106, which indicate
that HLE is facilitating the expulsion of the urea anion from the
tetrahedral intermediatewhen compared to the hydroxide-induced
hydrolysis.
In conclusion, the effectiveness of monobactams as elastase
inhibitors is strongly dependent on the effect of C-3 substituents
on the molecular recognition by the enzyme as well as on the
effect of C-4 substituents on chemical reactivity that leads to
serine acylation. The rate-limiting step in elastase inactivation
is the formation of the tetrahedral intermediate, and b-lactam
ring-opening is not concerted with the departure of a leaving
group from C-4. Monobactam sulfones emerged as very potent
inhibitors of elastase due to the strong electron-withdrawing
properties of the sulfone, although the departure of sulﬁnate
from C-4 might be relevant to the chemistry of enzyme inacti-
vation.
Experimental
General
Melting points were determined using a Koﬂer camera Bock
Monoscope M and are uncorrected. The infrared spectra were
collected on a Nicolet Impact 400 FTIR infrared spectropho-
tometer and the NMR spectra on a Bruker 400 Ultra-Shield
(400 MHz) in CDCl3; chemical shifts, d, are expressed in ppm,
coupling constants, J, are expressed in Hz. Low-resolution mass
spectra were recorded using VG Mass Lab 20–250, VG Quattro or
HP5988Amass spectrometers. Elemental analyseswere performed
by Medac Ltd, Brunel Science Centre, Engleﬁeld Green, Egham,
TW20 0JZ, UK, or by ITN, Chemistry Unit, Sacave´m, Portugal.
UV-vis assays were recorded either on Shimadzu UV-1603 or UV-
2100 PC spectrophotometers. TLC was performed on Merck alu-
minium plates, silica gel 60 F254, and visualized byUV light and/or
iodine. Preparative column chromatography was performed on
silica gel 60 from Merck (70–230 mesh ASTM). DCM, TEA and
benzene were puriﬁed and dried before use. Solvents and buffer
materials for enzyme assays were of analytical reagent grade and
were purchased from Merck or Sigma. PPE, MeO-Suc-Ala-Ala-
Pro-Val-pNA and N-Suc-Ala-Ala-Ala-pNA were purchased from
Sigma, and HLE was purchased from Calbiochem.
General procedure for the synthesis of N-carbamoylazetidin-2-one
derivatives
Benzyl isocyanate (4.2 mmol) and subsequently triethylamine
(4.2 mmol) were slowly added to a solution of the appropriate
azetidin-2-one 7–10 (3.5 mmol) in dichloromethane (3 mL),
The reaction was stirred at room temperature and monitored
by TLC. After completion of the reaction, the solution was
evaporated under reduced pressure. The product was puriﬁed by
column chromatography.
N-Benzylcarbamoylazetidin-2-one, 5a. Puriﬁed by column
chromatography on silica gel (dichloromethane–ethyl acetate 9.5 :
0.5); 66%; m.p. 62–64 ◦C (lit.,46 oil); mmax (ﬁlm) 3335, 1764,
1685 cm−1; dH 3.08 (2H, t, J = 4.8); 3.68 (2H, t, J = 4.8); 4.50
(2H, d, J = 6.0); 6.89 (1H, brs); 7.28–7.38 (5H, m); dC 36.06,
37.21, 43.70, 127.59, 127.64, 128.72, 137.93, 150.59, 167.00; ESI-
MS m/z 205.37 (MH+); Anal. calcd. for C11H12N2O2: C, 64.69; H,
5.92; N, 13.72; found: C, 64.55; H, 6.10; N, 13.66.
N-Benzylcarbamoyl-4-phenoxyazetidin-2-one, 5b. Puriﬁed
by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 85%; m.p. 129–
130 ◦C; mmax (ﬁlm) 3368, 1780, 1708 cm−1; dH 3.17 (1H, dd, J =
16.0, 1.2); 3.46 (1H, dd, J = 16.0, 4.4); 4.50 (1H, dd, J = 14.4,
5.6); 4.55 (1H, dd, J = 14.4, 5.6); 6.07 (1H, dd, J = 4.4, 1.2); 6.88
(1H, brs); 7.10 (1H, t, J = 7.2); 7.15 (2H, d, J = 8.0); 7.31–7.39
(7H, m); dC 43.76, 45.51, 78.76, 117.14, 123.21, 127.00, 128.78,
129.72, 137.56, 156.14, 164.42; ESI-MS m/z 297.52 (MH+); Anal.
calcd. for C17H16N2O3: C, 68.91, H, 5.44, N, 9.45; found, C, 69.12,
H, 5.61, N, 9.19.
N-Benzylcarbamoyl-4-phenylthioazetidin-2-one, 5c. Puriﬁed
by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 80%; m.p. 78–79 ◦C, mmax
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(ﬁlm) 3366, 3036, 2908, 1773, 1698 cm−1; dH 2.88 (1H, dd, J =
16.4, 2.8); 3.40 (1H, dd, J = 16.4, 5.6); 4.47 (1H, dd, J = 15.0,
6.0); 4.54 (1H, dd, J = 15.0, 6.0); 5.29 (1H, dd, J = 5.6, 2.8),
6.81 (1H, brs); 7.30–7.39 (9H, m); 7.55 (1H, dd, J = 8.4, 1.6); dC
43.68, 43.99; 56.69; 127.69, 127.72, 128.77, 129.29, 129.31, 129.36,
135.25, 137.83, 149.63, 165.43; ESI-MSm/z 334.84 (MNa+);Anal.
calcd. for C17H16N2O2S: C, 65.36; H, 5.16; N, 8.97; found C 65.12;
H 5.11; N 8.98.
N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one, 5d. Puri-
ﬁed by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 81%; m.p. 159–161 ◦C,
mmax (ﬁlm) 3374, 3064, 3031, 2978, 1789, 1711, 1316, 1150 cm−1;
dH 3.48 (1H, dd, J = 16.8, 6.0); 3.67 (1H, dd, J = 16.8, 2.8); 4.33
(1H, dd, J = 14.8, 6.0); 4.39 (1H, dd, J = 14.8, 6.0); 5.20 (1H,
dd, J = 6.0, 2.8), 6.65 (1H, brs); 7.23 (2H, dd, J = 8.0, 1.2); 7.31–
7.38 (3H, m); 7.58 (2H, t, J = 8.0); 7.74 (1H, dt, J = 8.0, 1.2);
7.96 (2H, dd, J = 8.0, 0.8); dC 39.43, 43.86, 65.84, 127.58, 127.79,
128.77, 129.28, 129.39, 134.88, 136.75, 137.28, 148.39, 164.27; EI-
MS m/z: 344.00 (M+); Anal. calcd. for C17H16N2O4S: C, 59.29; H,
4.68; N, 8.13; found C, 59.41; H, 4.55; N, 8.01.
N-Benzylcarbamoyl-3,3-diethylazetidin-2-one, 5e. Puriﬁed
by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 83% as a colourless oil,
mmax (ﬁlm) 3364, 3071, 3031, 2969, 2924, 2875, 1757, 1702 cm−1;
dH 1.00 (6H, t, J = 7.6); (4H, q, J = 7.6); 3.42 (2H, s); 4.50 (2H,
d, J = 6.0); 6.93 (1H, brs); 7.28–7.38 (5H, m); dC 8.70, 25.71,
43.75, 47.04, 59.31, 127.44, 127.54, 127.65, 128.65,128.71, 137.98,
150.95, 172.83; ESI-MS m/z 261.10 (MH+); Anal. calcd. for
C15H20N2O2: C, 69.20, H, 7.74, N, 10.76; found C, 68.95; H, 7.80;
N, 10.59.
N-Benzylcarbamoyl-3,3-diethyl-4-phenoxyazetidin-2-one, 5f25.
Puriﬁed by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 81%; m.p. 58–59 ◦C; mmax
(ﬁlm) 3366, 3064, 3031, 2970, 2939, 2880, 1770, 1710 cm−1; dH
1.00 (3H, t, J = 7.6 Hz); 1.06 (3H, t, J = 7.6); 1.77–1.84 (3H,
m); 1.99 (1 H, dq, J = 14.4, 7.2); 4.47 (1H, dd, J = 15.6, 6.0);
4.51 (1H, dd, J = 15.6, 6.0); 5.68 (1H, s); 6.93 (1H, brs); 7.07
(1H, t, J = 7.2); 7.22–7.35 (9H, m); dC 8.58, 8.84, 21.23, 23.86,
43.75, 64.35, 86.76, 117.76, 123.17, 127.63, 127.67, 128.76, 129.67,
137.66, 150.14, 157.47, 172.23; ESI-MS m/z 353.29 (MH+); Anal.
calcd. for C21H24N2O3: C, 71.57, H, 6.86, N, 7.95; found 71.84,
6.78, 8.18.
N-Benzylcarbamoyl-3,3-diethyl-4-phenylthioazetidin-2-one, 5g.
Puriﬁed by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 70%; m.p. 80–81 ◦C; mmax
(ﬁlm) 3361, 3061, 2968, 1758, 1701 cm−1; dH 0.94 (3H, t, J =
8.0 Hz); 1.06 (3H, t, J = 8.0); 1.75–1.98 (3H, m); 1.99 (1 H, dq,
J = 14.4, 7.2); 4.51 (1H, dd, J = 15.6, 6.0); 4.55 (1H, dd, J = 15.6,
6.0); 5.06 (1H, s); 6.95 (1H, brs); 7.28–7.39 (8H, m); 7.77 (2H, d,
J = 8.0); dC 8.43, 9.01, 23.11, 24.74, 43.74, 63.95, 71.42, 127.60,
127.65, 128.17, 128.74, 129.19, 133.24, 137.71, 150.13, 172.04; EI-
MS m/z 368.15 (M+); Anal. calcd. for C21H24N2O2S: C, 68.45, H,
6.56, N, 7.60; found, C, 68.22, H, 6.65, N, 7.88.
N-Benzylcarbamoyl-3,3-diethyl-4-phenylsulfonylazetidin-2-one,
5h. Puriﬁed by column chromatography on silica gel (elution
with dichloromethane–ethyl acetate 9.5 : 0.5); 63%; m.p. 142–
144 ◦C; mmax (ﬁlm) 3366, 3060, 3041, 2971, 1778, 1711, 1312,
1151 cm−1; dH 1.01 (3H, t, J = 7.2 Hz); 1.06 (3H, t, J = 7.2);
1.68 (1 H, dq, J = 14.4, 7.2); 1.95 (1 H, dq, J = 14.4, 7.2); 2.20
(1 H, dq, J = 14.4, 7.2); 2.47 (1 H, dq, J = 14.4, 7.2); 4.21 (1H,
dd, J = 14.8, 6.0); 4.33 (1H, dd, J = 14.8, 6.0); 4.75 (1H, s); 6.66
(1H, brs); 7.14 (2H, d, J = 7.6); 7.19–7.28 (3H, m); 7.47 (2H, t,
J = 7.6); 7.61 (1H, t, J = 7.6); 7.85 (2H, t, J = 7.6); dC 8.56, 8.90,
20.86, 25.12, 43.85, 67.05, 74.72, 127.43, 127.69, 128.74, 128.88,
129.18, 134.39, 137.36, 139.84, 148.99, 171.49; EI-MS m/z 400.05
(M+); Anal. calcd. for C21H24N2O4S: C, 62.98, H, 6.04, N, 6.99;
found, C, 63.11, H, 6.25, N, 7.12.
N-Benzylcarbamoyl-3,3-diethyl-4-benzylthioazetidin-2-one, 5i.
Puriﬁed by column chromatography on silica gel (elution with
dichloromethane–ethyl acetate 9.5 : 0.5); 53% as a yellow oil, mmax
(ﬁlm) 3365, 1759, 1701 cm−1; dH 0.56 (3H, t, J = 7.4); 0.85 (3H, t,
J = 7.4); 1.44–1.69 (4H, m); 3.99 (1H, d, J = 12.8); 4.06 (1H, d,
J = 12.8); 4.31 (1H, dd, J = 15.3, 6.1); 4.36 (1H, dd, J = 15.3, 6.3);
4.70 (1H, s); 6.91 (1H, s); 7.10–7.27 (10H, m); dC 7.67; 8.90; 22.41;
24.44; 37.37; 43.61; 62.99; 65.84; 127.63; 127.72; 127.81; 129.01;
129.07; 129.80; 138.79; 139.62;150.96; 172.35; HPLC-ESIMS m/z
(MH+) 383.52; Anal. calcd. for C22H26N2O2S; C, 69.08; H, 6.85;
N, 7.32; found C, 69.10, H, 6.90; N, 7.30.
N-Benzylcarbamoyl-3,3-diethyl-4-benzylsulfonylazetidin-2-one,
5j. Puriﬁed by column chromatography on silica gel (elution
with diethyl ether–light petroleum 1 : 1; 52%; m.p. 93–94 ◦C; mmax
(ﬁlm) 3365, 1778, 1313, 1165 cm−1; dH 0.79 (3H, t, J = 7.4); 1.01
(3H, t, J = 7.5); 1.62 (1 H, dq, J = 14.5, 7.3); 1.84 (1H, dd, J =
14.5, 7.3); 2.08 (1H, dq, J = 14.5, 7.4); 2.52 (1H, dq, J = 14.6,
7.4); 4.48 (1H, d, J = 13.9); 4.53 (2H, d, J = 5.9); 4.62 (1H, s);
5.01 (1H, d, J = 13.9); 6.95 (1H, t, J = 5.9); 7.19–7.59 (10H,
m); dC 8.27, 8.87, 20.90, 24.48, 44.12, 62.27, 66.46, 69.06, 127.59,
127.89, 128.91, 129.07, 131.37, 137.08, 150.20, 171.22; EI-MS
m/z 413.8 (MH+); Anal. calcd. for C22H26N2O4S; C, 63.75; H,
6.32; N, 6.76; found C, 63.70, H, 6.40; N, 6.60.
Large scale reaction of N-benzylcarbamoyl-4-
phenylsulfonylazetidin-2-one with excess sodium methoxide
N-Benzylcarbamoyl-4-phenylsulfonylazetidin-2-one (0.29 mmol),
5d, was added to a solution of sodium methoxide (1.5 mmol)
in methanol (15 mL). The reaction mixture was stirred at room
temperature and monitored by TLC. The solvent was removed
under reduced pressure and the residue was taken up in water
(20 mL), acidiﬁed with 10% HCl until pH 2 and extracted with
ethyl acetate (3 × 30 mL). After drying and evaporating off the
solvent, the residue was puriﬁed by column chromatography on
silica gel (elution with dichloromethane–ethyl acetate 8 : 2), to
yield the product, 3-benzylpyrimidine-2,4(1H,3H)-dione, 11, as a
white solid (79%); m.p. 177–179 ◦C (lit.,47 181–182 ◦C); mmax (ﬁlm)
3084, 2965, 1625, 1601 cm−1; dH 5.12 (2H, s); 5.81 (1H, dd, J =
7.2, 1.2); 7.14 (1H, dd, J = 7.2, 6.0); 7.26–7.34 (3H, m); 7.46 (2H,
d, J = 7.2); 9.35 (1H, brs); dC 43.71, 102.26, 127.70, 128.46,128.80,
136.49, 138.17, 163.12; EI-MS m/z 202.05 (M+); Anal. calcd. for
C11H10N2O2, C, 65.34; H, 4.98; N, 13.85; found, C, 65.55, H, 5.25,
N, 13.81.
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Chemical kinetics
All kinetic measurements were carried out at 25.0 ± 0.1 ◦C
and with an ionic strength adjusted to 0.5 M by addition of
NaClO4.Due to substrate solubility problems all buffers contained
20% (v/v) acetonitrile. Rate constants were determined using
UV spectrophotometry by recording the decrease of substrate
absorbance at ﬁxed wavelength (5a, 220; 5b, 250; 5c, 260; 5d,
255; 5e, 224; 5f, 238; 5g, 260; 5h, 225; 5i, 240; 5j, 240 nm), using
a spectrophotometer equipped with a temperature controller. In a
typical run, the reaction was initiated by adding a 15 lL aliquot
of a 10−2 M stock solution of substrate in acetonitrile to a cuvette
containing 3 mL of the buffer solution. The pseudo-ﬁrst-order
rate constants, kobs, were obtained by least-squares treatment of
log(At − A∞) data, where At and A∞ represent the absorbance
at time t and at time inﬁnity, respectively. Rate constants derived
using this method were reproducible to ±5%.
Enzyme inactivation by the progress curve method
Inactivation of HLE was assayed at 25 ◦C by mixing 10 lL of
HLE stock solution (2 lM in 0.05 M acetate buffer, pH 5.5) to a
solution containing 10 lL of inhibitor in DMSO (200 lM), 20 lL
of substrate MeO-Suc-Ala-Ala-Pro-Val-pNA (50 mM in DMSO)
and 960 lL of 0.1 M HEPES buffer, pH 7.2, and the absorbance
was continuously monitored at 410 nm for 20 minutes. Control
assays, in which the inhibitor was omitted, ran linearly. The
pseudo-ﬁrst order rate constants, kobs, for the inhibition of HLE
were determined according to the slow-tight binding inhibition
model36 and involved the ﬁtting of product concentration as a
function of time to eqn (1) by non-linear regression analysis using
the routine ENZFIT (developed at the Faculty of Pharmacy,
Lisbon):
A = mst + (mi − ms)(1 − e
−kobs t)
kobs
+ A0 (1)
where A is the absorbance at 410 nm, A0 is the absorbance at
t = 0, vi is the initial rate of change of absorbance, vs is the
steady-state rate and kobs is the ﬁrst-order rate constant for the
approach to the steady-state. The individual kinetic parameters
K i and kinact were obtained by determining kobs (in duplicate
or triplicate) as a function of the inhibitor concentration and
by ﬁtting the experimental data to eqn (2).25 When a linear
dependence of kobs on inhibitor concentration was observed (e.g.
for 5f), correction for substrate concentration and Michaelis
constant yielded the second-order rate constant for inhibition
(kinact/K i) as the slope, and the ﬁrst-order rate for the dissociation
of the E·I complex (koff) as the intercept (eqn (3)) (see Fig. 1B).
For the remaining b-lactams the kinact/K i values were determined
in duplicate or triplicate by calculating kobs/[I] and then correcting
for the substrate concentration and Michaelis constant using eqn
(4).
kobs = kinact[I]Ki(1 + [S]/Km) + [I] (2)
kobs = koff + (kinact/Ki) [I]1 + [S]/Km (3)
kobs
[I]
= kinact/Ki
1 + [S]/Km (4)
Enzyme inactivation by the incubation method
Inhibition of PPE was assayed by Kitz and Wilson’s incubation
method.34 In a typical experiment, 50 lL of inhibitor solution in
DMSO was incubated at 25 ◦C with 750 lL of 0.1 M HEPES
buffer, pH 7.2, and 200 lL of PPE solution (50 lM in 0.1 M
HEPES buffer, pH 7.2). Aliquots (100 lL) were withdrawn at
different time intervals and transferred to a cuvette thermostatted
at 25 ◦C, containing 895 lL of 0.1 M HEPES buffer, pH 7.2,
and 5 lL of N-Suc-Ala-Ala-Ala-pNA (12.5 mM in DMSO). The
absorbance was monitored at 390 nm for 60 seconds and the
gradients of the slopes obtained of initial rate used as a measure
of enzyme activity. The values of kobs for compounds 5b–d were
determined in duplicates or triplicates from plots of ln(v/v0) versus
incubation time, where v is the initial rate at time t and v0 is the
initial rate of the control incubation without inhibitor. The plots
of kobs versus [I] were linear and the potency of the inhibitors was
determined in terms of the bimolecular rate constant kinact/K i =
kobs/[I].
Partition ratio
PPE solutions were incubated at 25 ◦C with different concentra-
tions of 5d solutions in 0.1 M HEPES buffer, pH 7.2, in a ﬁnal
volume of 1 mL. After 30 minutes incubation, a 100 lL aliquot
of the reaction mixture was withdrawn and assayed for remaining
enzyme activity as described previously.
X-Ray crystallographic studies
Porcine pancreatic elastase (PPE) was incubated with inhibitor 5d
for 30 min. Good quality crystals were grown in 200 mM sodium
sulfate and 100 mM sodium acetate at pH 5.1 (293 K) using the
sitting drop vapour-diffusion method.38 X-Ray diffraction data
weremeasured atEMBLX11beamline at theDORIS storage ring,
DESY, Hamburg (Germany), to 1.66 A˚ resolution. The data were
integrated with MOSFLM48 and scaled using SCALA.49 Relevant
statistics on data collection and processing are given in Table S1
(Supplementary material†). The crystals soaked with the inhibitor
solution belong to the same space group and show similar cell
parameters as the native ones, so the structure was solved by
Fourier synthesis. The initial rigid body reﬁnement step yielded
an R-work and R-free of 27.7 and 30.5%, respectively. Further
crystallographic reﬁnement was performed with Refmac50 and the
electron density maps were inspected with COOT.51 The reﬁned
model of PPE in complex with inhibitor 5d shows an R-factor of
15.6% and R-free of 18.6%.
The structure is generallywell deﬁnedwithin the electrondensity
maps, showing an average B factor of 10.5 A˚2 for all protein
atoms. The ﬁnal model comprises 240 amino acid residues, 316
water molecules, the inhibitor 5d without the C-4 PhSO2− leaving
group, two glycerol molecules, one sulfate ion and one sodium
ion, which is hexa-coordinated to side-chain atoms of Glu80,
Asp77, Gln75, Asn72, Glu70 and a water molecule. Alternate
conformations were modelled for the side chains of Gln23, Gln75,
Val83 and Ser189, with 50% occupancy each. All protein residues
lie within allowed regions of the Ramachandran plot, and the
relevant reﬁnement statistics are presented in Table 2. The overall
protein structure of the 5d–PPE complex is very similar to that
of the native enzyme (PDB code 1QNJ) and superposition of the
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Table 2 Data collection and crystallographic reﬁnement statistics for the
porcine pancreatic structure bound to 5d
Resolution range/A˚ 37.95–1.66
Reﬁned model
R-factor (%) 15.6
R-free (%) 18.6
No. of non-H protein atoms 1833
No. of solvent molecules 320
Average B-factor/A˚2
Protein only 10.5
Inhibitor only 24.4
Solvent molecules 25.9
Ramachandran plot
Residues in most favoured regions (%) 87.4
Residues in additional allowed regions (%) 12.6
Root-mean-square deviations
Bond angles/◦ 0.01
Angle lengths/A˚ 1.22
C-a atoms shows a r.m.s. deviation of 0.089 A˚. The numbering of
5d–PPE complex follows the common practice of using the bovine
chymotrypsinogen A numbering.52
The coordinates of 5d–PPE complex have been deposited in the
Protein Data Bank (PDB) with identiﬁcation code 2V35 and the
corresponding structure factors with id code 2V35SF.
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Azetidine-2,4-diones (4-Oxo--lactams) as Scaffolds for Designing Elastase Inhibitors
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A new class of inhibitors 4-oxo--lactams (azetidine-2,4-diones), containing the required structural elements
for molecular recognition, inhibit porcine pancreatic elastase (PPE) but show a dramatically lower reactivity
toward hydroxide compared with the analogous inhibitors 3-oxo--sultams. Inhibition is the result of acylation
of the active site serine and electron-withdrawing substituents at the N-(4-aryl) position in 3,3-diethyl-N-
aryl derivatives increasing the rate of enzyme acylation and generating a Hammett F-value of 0.65. Compared
with a F-value of 0.96 for the rates of alkaline hydrolysis of the same series, this is indicative of an earlier
transition state for the enzyme-catalyzed reaction. Docking studies indicate favorable noncovalent interactions
of the inhibitor with the enzyme. Compound 2i, the most potent inhibitor against PPE, emerged as a very
potent HLE inhibitor, with a second-order rate for enzyme inactivation of ∼5 × 105 M-1 s-1.
Introduction
Human leukocyte elastase (HLE)a is a member of the
chymotrypsin superfamily of serine proteases that very ef-
ficiently degrades tissue matrix proteins such as elastin when
released from the azurophilic granules of polymorphonuclear
leukocytes because of inflammatory stimuli and mediators. The
imbalance between HLE and its endogenous inhibitors leads to
excessive elastin proteolysis and destruction of connective
tissues in a number of inflammatory diseases such as pulmonary
emphysema, adult respiratory distress syndrome, chronic bron-
chitis, chronic obstructive pulmonary disease, and rheumatoid
arthritis.1–5
-Lactams are well-known as potent inhibitors of some
enzymes that contain serine as the catalytic residue, including
the bacterial penicillin binding proteins (PBPs) and Class A and
Class C -lactamases.6 -Lactams have also been appropriately
modified to develop active site-directed and mechanism-based
inhibitors of HLE.7–9 Improvement of the rate of serine acylation
by increasing the intrinsic chemical reactivity of the -lactams
has been used as a strategy to design more potent inhibitors.10
Recently, we have reported that 3-oxo--sultam, 1, is a
reasonably potent inhibitor of porcine pancreatic elastase (PPE),
a model enzyme that shares ∼40% homology and the catalytic
triad consisting of Ser-195, His-57 and Asp-102 with HLE.
Nucleophilic attack on 3-oxo--sultams 1 could involve either
acylation or sulfonylation resulting from substitution at the
carbonyl center and expulsion of the sulfonamide or from
substitution at the sulfonyl center and expulsion of the amide,
respectively. Inhibition of elastase by 1 occurs by acylation of
the active site serine and so involves C-N fission and expulsion
of sulfonamide.11 By contrast, the alkaline hydrolysis of 1 occurs
by hydroxide-ion attack on the sulfonyl center with S-N fission.
This is a very rapid process and occurs with a second-order
rate constant, kOH, value of ∼2 × 105 M-1 s-1,12 which is about
106 times higher than those of most clinically useful -lactams.13
Highly reactive scaffolds may lead to a decrease the selectivity
toward the target enzyme, increase susceptibility to metabolism,
and reduce oral bioavailability.14 The mechanism of inhibition
of elastase by 1 involves expulsion of the relatively good leaving
sulfonamide group. Selectivity could be improved by replacing
this group by a poorer leaving group such as an amide. We
now report that isosteric analogues of 1, azetidine-2,4-diones
or 4-oxo--lactams, 2, containing the required structural ele-
ments for molecular recognition by PPE and HLE, retain
inhibitory activity while dramatically decreasing the reactivity
toward hydrolysis by hydroxide ion.
Results and Discussion
Synthesis. 4-Oxo--lactams 2 were prepared in reasonable
yields from the appropriate 2,2-disubstituted malonic acid
chlorides and amines (Scheme 1). The corresponding malon-
diamides were always obtained as side-products but were easily
removed by column chromatography.
* To whom correspondence should be addressed. Phone: +44 1484
472531 (M.I.P.). Fax: +44 1484 473075 (M.I.P.). E-mail: m.i.page@hud.ac.uk
(M.I.P); rmoreira@ff.ul.pt (R.M.).
† Universidade de Lisboa.
‡ University of Huddersfield.
§ The Open University.
a Abbreviations: EREF, enzyme rate enhancement factor; HEPES, N-[2-
hydroxyethyl]piperazine-N′-[2-ethane sulfonic acid]; HLE, Human leukocyte
elastase; PBP, penicillin binding proteins; PPE, porcine pancreatic elastase;
TI, tetrahedral intermediate.
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PP Elastase Inhibition Studies. Enzyme activity was
measured by the hydrolysis of reporter substrate N-succinyl-
(L-Ala)3-p-nitroanilide at 390 nm. Incubation of PPE with 4-oxo-
-lactams 2 resulted, in most cases, in very rapid time-dependent
loss of activity (Figure 1), followed by a slower reactivation of
enzyme activity. This is presumably attributable to acylation
of the active site serine followed by slow hydrolysis and is
described by Scheme 2, where EI corresponds to the acyl-
enzyme. Therefore, inhibition was studied at 25 °C using the
progress curve method,15 and the time courses for Figure 1 were
fit by nonlinear regression analysis to eq 1
A)Vst+ (Vi -Vs)(1- e-kobst)/kobs +A0 (1)
where A is the absorbance at 390 nm, A0 is the absorbance at t
) 0, Vi is the initial rate of change of absorbance, Vs is the
steady-state rate, and kobs is the first-order rate constant for
the approach to the steady-state. The plots of kobs versus the
concentration of 2 were linear and thus were consistent with
the inhibition mechanism depicted in Scheme 2, which corre-
sponds to eq2.16 The linear dependence of kobs on [I], as well
as the observation that initial velocities, Vi, equalled the velocity
in the absence of inhibitor, V0, suggest that the acyl-enzyme EI
did not accumulate in the inhibitor concentration range used.
The graphical interpretation (Figure 2) of eq. 2 yields the second-
order rate constant for inhibition, kon, as the slope (Table 1)
and the first-order rate for deacylation, kdeacyl, as the intercept.
The Ki values were calculated as kdeacyl/kon.
kobs ) (kon[I]/{1+ ([S]/Km)})+ kdeacyl (2)
An important criterion for the successful inhibition of serine
enzymes by an acylation process depends upon the lifetime of
the acyl-enzyme intermediate. A reactive intermediate will
undergo rapid hydrolysis as in the normal pathway for the
hydrolysis of substrates. In contrast to the slow-binding inhibi-
tion model displayed by 3,3-diethyl-substituted 4-oxo--lactams,
2e-i, their 3,3-dimethyl counterparts, 2a and b presented strictly
linear time courses for the hydrolysis of substrate, that is, no
initial exponential phase toward a steady-state was observed.
Incubation of 7.5 × 10-4 M of N-benzyl-4,4-dimethyl-4-oxo-
-lactam 2a, which was in 750-fold excess to PPE concentration,
showed no decrease of enzyme activity when the incubated
enzyme was diluted into assay cells containing the substrate.
The less sterically hindered dimethyl derivative may act as a
simple substrate for elastase. However, the reaction of 2a with
elastase was followed by UV-spectroscopy at 242 nm. The plot
of absorbance versus time displayed biphasic kinetics, in which
the concentration of 4-oxo--lactam 2a decreases with time in
a zero-order manner in the first phase of the reaction but changed
to first-order kinetics in the second phase of the reaction. This
apparent “saturation” behavior is compatible with slow deacy-
lation of the acyl-enzyme intermediate, assuming the exponential
decay of absorbance against time for the second phase of the
reaction is caused by the hydrolysis of the ring-opened hy-
drolysis product (Scheme 3). The rate of formation and
breakdown of the acyl-enzyme was obtained by fitting the
absorbance versus time curve for the reaction of 2a at high
concentration of PPE to Scheme 2 using Dynafit,17 and the
derived rate constants are given in Table 1. Increasing the
enzyme concentration did not affect the rate of breakdown of
the acyl enzyme intermediate but increased the rate of formation
of the acyl-enzyme intermediate. Zero-order kinetics were
observed if the rate of acylation is at least 30-fold greater than
that of deacylation.
Interestingly, the rate of acylation in the reaction of N-benzyl-
3,3-dimethyl-4-oxo--lactam 2a with PPE elastase is 12-fold
slower than that of inhibition by its 3-oxo--sultam counterpart
1 (1, kon ) 7.68 × 102 M-1 s-1),11 with the same enzyme and
at pH 6.0, whereas the rate of deacylation in the reaction of 2a
is 500-fold faster than that of the reactivation of the enzyme
inhibited with 1 (1, kdeacyl ) 2.08 × 10-5 s-1). Nucleophilic
attack at the carbonyl center of 1 and that of 2 generates a
sulfonamide and an amide leaving group, respectively. Although
sulfonamides and amides have different electronic properties,
for example, sulfonamides are generally more acidic than amides
by about 5 pKa units,18 the stability of the acyl ester of the acyl
enzymes is unlikely to be affected by this property because the
groups are some distance from the acyl ester.19 However, the
Figure 1. Progress curves for the inhibition of 2h. Reaction conditions:
[PPE] ) 0.2 µM, [Suc-(L-Ala)3-p-NA] ) 0.3 mM, 0.1 M HEPES buffer,
pH 7.2, 5% DMSO, 25 °C. Inhibitor concentrations (µM): (a) absence
of inhibitor, (b) 10, (c) 15, (d) 20, (e) 30, (f) 60, (g) 75.
Scheme 2
E+ I98
kon[I]
EI98
kdeacyl
E+ P
Figure 2. Effect of inhibitor concentration on the onset of inhibition
of PPE by 2e (O) and 2i (b). Inhibitor concentration is corrected
according to eq 2.
1784 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 6 Mulchande et al.
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R-tertiary center containing a gem-dimethyl group together with
a sulfonyl group of a sulfonamide, 3, is likely to significantly
block attack by water at the active site, and the deacylation
would be severely impaired. If this is the case, the sulfonamide
leaving group being bigger in size, as in 3, decreases the rate
of deacylation by 500-fold compared with that observed with
an amide leaving group, 4.
The effect of bulky substituents on the rate of deacylation is
also demonstrated by the PPE catalyzed hydrolysis of N-ben-
zoyl-3,3-dimethyl--lactam 5 (Scheme 4), which shows normal
hydrolytic behavior and no accumulation of the acyl enzyme
intermediate despite the presence of an R-gem-dimethyl group.
The acyl enzyme generated from 5 has the structure 6 and
presumably moving the exocyclic carbonyl further down the
carbon chain in the ring-opened product 6 must reduce the steric
congestion around the acyl enzyme ester, allowing rapid
deacylation.
Alkaline Hydrolysis. The second-order rate constants, kOH,
for the alkaline hydrolysis of the 4-oxo--lactams 2 were also
determined for comparison with those for PPE inhibition (Table
1). It has been suggested that the magnitude of the second-
order rate constant, kOH, for the alkaline hydrolysis of potential
inhibitors of enzymes containing a catalytic serine is a crude
indicator for their ability to be effective and therapeutically
useful acylating agents.14,20,21 As a result of the symmetry of
4-oxo--lactams 2, the two acyl centers are equivalent, and the
hydrolysis products of 4-oxo--lactams 2 are the corresponding
R-amido acids 7. The second-order rate constant, kOH, for the
alkaline hydrolysis of 2a is 8.38 M-1 s-1 (Table 1), which is,
remarkably, only 7-fold greater than that for the corresponding
N-benzoyl--lactam 5 and demonstrates the surprisingly small
effect of introducing a second sp2 center into the already strained
four-membered ring. Furthermore, the strained cyclic imide 2a
shows reactivity similar to that of the acyclic imide 8 (kOH )
1.54 M-1 s-1), 14 showing that there is no significant rate
enhancement caused by ring strain, compatible with the limiting
step of alkaline hydrolysis being the formation of the tetrahedral
intermediate (TI).
It is of interest to compare the rate constants for alkaline
hydrolysis for a series of four-membered rings -lactams, 2 and
5, and -sultams, for example, 1, with those for their reactions
with elastase. The substitution of the N-benzyl by N-phenyl in
4-oxo--lactam changes the leaving group from an amide to an
anilide and causes an increase in the rate of ring opening by
hydroxide ion (e.g., 2g is 5-fold more reactive than 2d).
N-Substitution would be expected to have a large effect on rate-
limiting C-N fission but a much smaller one if nucleophilic
attack on the carbonyl carbon and formation of the tetrahedral
intermediate is the rate-limiting step. Electron-withdrawing
substituents (such as 4-cyanophenyl 2i and 4-chlorophenyl 2h)
produce a modest increase in the rate of the alkaline hydrolysis,
whereas electron-donating groups (4-methoxyphenyl, 2e), de-
crease kOH. Overall, 2i is nearly 8-fold more active than 2e.
These relative rates indicate that the rate-limiting step is
hydroxide-ion attack and formation of the tetrahedral intermediate.
There is a large steric effect of substituents R to the carbonyl
carbon on the rate of alkaline hydrolysis. The R-gem-diethyl
compounds 2d and 2h are about 20-fold less reactive than the
corresponding R-gem-dimethyl compounds 2a and 2b, which
is also compatible with rate limiting formation of the tetrahedral
intermediate.
Structure–Activity Relationships and Molecular Modeling.
Inspection of Table 1 indicates that the most potent inhibitors
contain an N-aryl group in addition to two ethyl groups at C-3.
In contrast, N-alkyl-4-oxo--lactams are either inactive (2c, d)
or weak inhibitors (2a) that regenerate the active enzyme. This
suggests that the leaving group ability of the amide formed from
the decomposition of the tetrahedral intermediate (TI) 9
contributes significantly to the time-dependent inhibition of PPE.
The most-active inhibitor contains a 4-CN electron-withdrawing
substituent on the N-aromatic ring (2i) and is nearly 5-fold more
potent than 2e, which contains an electron-donating substituent.
Interestingly, log kon values correlate with Hammett σp values,
Table 1. Kinetic Parameters for the Inhibition of PPE at pH 7.2 by, and for the Alkaline Hydrolysis of, Azetidin-24-diones, 2, at 25 °C
compound R1 R2 Ki (µM) kon (×10-2 M-1 s-1) koff (×103 s-1) kOH- (M-1 s-1) EREF
2a Me CH2Ph 184 0.63a 0.997a 1.80b; 8.38c
2b Me C6H4-4-Cl 10.0 9.67
2c Et CH2CO2Et NI NI ND
2d Et CH2Ph NI NI 0.0742
2e Et C6H4-4-OMe 9.81 1.22 1.20 0.225 542
2f Et C6H4-4-Me 7.46 1.74 1.30 0.240 725
2g Et C6H5 10.2 1.77 1.81 0.336 527
2h Et C6H4-4-Cl 8.47 2.32 1.97 0.581 400
2i Et C6H4-4-CN 6.02 5.83 3.53 1.78 328
a pH 6.0. b T ) 30 °C, 1% DMSO (v/v). c T ) 25 °C, 20% CH3CN (v/v).
Scheme 3 Scheme 4
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giving a F value of 0.65 (Figure 3), consistent with the reduction
of the positive charge on the nitrogen amide caused by resonance
rather than the development of significant negative charge on
this atom in the transition-state. This is consistent with rate
limiting formation of the tetrahedral intermediate in the enzyme
catalyzed reaction. In comparison, the alkaline hydrolysis of
4-oxo--lactams gives a Hammett F value of 0.96 (Figure 3)
suggesting a much greater change in charge on going to the
transition state. Both enzyme-catalyzed acylation and alkaline
hydrolysis of the 4-oxo--lactams involve nucleophilic attack
on the -lactam carbonyl. The different Hammett F values
indicate the enzyme-catalyzed attack of serine occurs at an
earlier position along the reaction coordinate leading to forma-
tion of the tetrahedral intermediate compared with the hydroxide-
ion-catalyzed hydrolysis. This is consistent with the Hammond
postulate in that these results suggest that the 4-oxo--lactam
scaffold promotes the enzyme’s ability to use its catalytic
apparatus to stabilize the transition state and increase the rate
of serine acylation, which might be achieved by favorable
noncovalent binding of enzyme and inhibitor, stabilization of
the TI in the oxyanion hole of the active site and compensation
for the entropy loss required in the bimolecular reaction.
It has been suggested that the effectiveness of an enzyme in
catalyzing a reaction can be indicated by the enzyme rate
enhancement factor, EREF, which is evaluated by dividing the
second-order rate constant for the enzyme catalyzed reaction,
kon, by that for hydrolysis of the same substrate catalyzed by
hydroxide ion, kOH.14 The highest value of EREF was obtained
for inhibitor 2f: the enzyme increases the rate of reaction by
725-fold.
To rationalize the trends observed in the enzyme assays, the
molecular interactions between the more active 4-oxo--lactams
2a, 2e, 2i and HLE were investigated using the automated
GOLD docking program (see Experimental Section for details).
The primary recognition pocket, S1, for porcine elastase prefers
small hydrophobic substituents with two carbon atoms.22
Docking of the most potent compound, 2i, into the active site
of PPE revealed that only one ethyl substituent of the 3,3-diethyl
group lies in the S1 pocket (Figure 4). This binding mode is
not much different than that observed for the interaction of 3,3-
diethyl--lactams with HLE, in which both ethyl substituents
are accommodated in the larger S1 pocket.10 The distance
between the Ser-195 hydroxyl oxygen atom and the closest
carbonyl carbon of 2i is 3.18 Å (4.79 Å for the other carbonyl
carbon atom), which indicates that nucleophilic attack by Ser-
195 to the 4-oxo--lactam is possible. Interestingly, the “reac-
tive” carbonyl of 2i is not involved in the H-bond network with
the so-called oxyanion hole defined by the backbone NHs of
Gly-193 and Ser-195: the distances between the amidic hydro-
gen atoms of Gly-193 and Ser-195 to the carbonyl oxygen atom
are 6.75 and 5.28 Å, respectively. This result may indicate that
the oxyanion hole is not used to stabilize the TI derived from
2i. However, several key interactions seem to stabilize 2i in
the active site. First, strong hydrogen bonds involve the oxygen
atom of the reactive carbonyl and the NH of His-57 and the
hydroxyl group of Ser-195. Second, an additional hydrogen bond
involves the oxygen atom of the unreactive carbonyl and the
amide group of Gln-192. Finally, enhanced van der Waals
contacts between the N-aryl moiety with Val-99, Phe-215, and
His-57 were observed.
For compound 2e, a less potent inhibitor, an inverted binding
mode was observed, in which the 4-OMe substituent of the
aromatic ring lies on the S1 pocket, while one of the ethyl
substituents is close to the S1′ pocket (Figure 4). The distance
between the closest carbonyl carbon and the Ser-195 hydroxyl
oxygen atom is 3.62 Å (4.38 Å for the other carbonyl carbon
atom). However, in contrast to 2i, the reactive carbonyl of 2e
is involved in the H-bond network with the NHs of Gly-193
and Ser-195, which suggests that the oxoanion hole may be
used to stabilize the resulting TI and to compensate the energy
required for the enzyme to overcome the distance between Ser-
195 and the carbonyl carbon. The 3,3-dimethyl-N-benzyl
derivative 2a also interacts with PPE with a similar binding
mode to that of 2e, that is, aromatic ring lying on the S1 pocket
(Figure 4) and with the reactive carbonyl involved in the
oxoanion hole H-bond network. Compound 2f also presents the
N-aryl moiety sitting in the S1 pocket of the enzyme (see
Supporting Information), but in this case, the distance between
the closest carbonyl carbon and the Ser-195 hydroxyl oxygen
atom is 3.27 Å, that is, close to that of 2i. This binding
confirmation suggests that nucleophilic attack by Ser-195 to the
4-oxo--lactam is feasible and is consistent with the EREF value
of 725, the highest of the present series of compounds 2.
Because the 4-oxo--lactam inhibitors 2 have two acyl
centers, there could be interaction of either the C-3 or the N-1
substituents with the S1 binding pocket. In principle, the latter
could reduce the rate of acylation as a result of nonproductive
binding. However, the dominant effect of N-substituents is their
influence the rate of C-N bond fission in breakdown of the TI
9. Compound 2h, containing a diethyl substituent at C-3 position
is a time dependent and, effectively, irreversible inhibitor of
Figure 3. Hammett plots for the second-order rate constants, kon, for
the inhibition of PPE by 4-oxo--lactams 2e-i (b) and for the
hydroxide-ion-catalyzed hydrolysis, kOH-, of the same compounds (O)
at 25 °C.
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PPE because of its relatively fast acylation of the enzyme, while
the dimethyl counterpart 2b is also a time dependent inhibitor,
but because of a relatively facile deacylation pathway of the
dimethyl acyl-enzyme does allow the enzyme to turnover. The
almost complete recovery of enzymatic activity (Figure 5),
monitored by checking the enzyme activity at different time
intervals after incubation with 2h, suggests that the interaction
of 2 with PPE leads to an labile acyl-enzyme, EI, which breaks
down and regenerates the free, active enzyme, E (Scheme 3),
within a few hours and the inhibitor function as alternate
substrate inhibitor of PPE.
HLE Inhibition. Taking into account the high kon value
obtained for compound 2i against PPE, we assayed this
compound against HLE. A nonlinear dependence of kobs
(determined by the progress curve method; eq.1)15 on inhibitor
concentration was observed (Supporting Information) and the
individual kinetic parameters Ki (63.5 nM) and kinact (0.0323
s-1) were obtained according to eq 3.22 The corresponding
second-order rate constant for inhibition, kinact/Ki, is 5.08 × 105
M-1s-1, a value close to those reported for the most potent
monocyclic -lactams developed by Merck.22 This result (i)
shows the usefulness of the 4-oxo--lactam scaffold for design-
ing inhibitors for human elastase and (ii) indicates that 2i is a
promising lead for further optimization against HLE.
kobs ) kinact[I]/{Ki(1+ [S]/Km)+ [I]} (3)
Conclusion
This study has shown that 4-oxo--lactam derivatives can
function as novel time dependent irreversible inhibitors of serine
proteases when they contain 3,3-diethyl-N-aryl substituents. The
title compounds were designed as a result of an isosteric
replacement from 3-oxo--sultam, yielding more stable com-
pounds to hydrolysis by nonspecific nucleophiles and reacting
with the enzyme as active-site-directed inhibitors. The most-
active inhibitors correspond to the most reactive compounds
toward alkaline hydrolysis and contain electron-withdrawing
substituents on the aromatic ring that increase the chemical
reactivity of the carbonyl carbon toward nucleophilic attack of
the Ser-195 hydroxyl group. The enzyme-mediated hydrolysis
has an earlier transition state because of favorable hydrophobic
and other noncovalent binding interactions between enzyme and
inhibitor that can be used to compensate for unfavorable
processes that contribute to the activation energy. In summary,
4-oxo--lactam derivatives represent an attractive new class of
acyl-enzyme inhibitors of elastases and are suitable scaffolds
that might find further applicability for the design of nonpeptidic
inhibitors of other serine proteases.
Experimental Section
General. Melting points were determined using a Kofler camera
Bock Monoscope M and are uncorrected. The infrared spectra were
collected on a Nicolet Impact 400 FTIR infrared spectrophotometer,
and the NMR spectra were collected on a Brucker 400 Ultra-Shield
(400 MHz) in CDCl3; chemical shifts, δ, are expressed in ppm,
and coupling constants, J, are expressed in Hz. Low-resolution mass
spectra were recorded using a HP5988A spectrometer, by RIAIDT,
University of Santiago de Compostela, Spain. Elemental analyses
Figure 4. Docking of 2i (A), 2e (B), and 2a (C) in the active site of
PPE (see text for details of docking procedure).
Figure 5. Time-dependent loss of enzymatic activity. Excess of
inhibitor 2h ([I]f ) 150 µM) was incubated with PPE ([E]f ) 10 µM)
in 0.1 M HEPES buffer, pH 7.2, 25 °C, aliquots were withdrawn at
different time intervals and assayed for enzymatic activity.
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were performed by Medac Ltd., Brunel Science Centre, Englefield
Green Egham TW20 0JZ, U.K., or by ITN, Chemistry Unit,
Sacavém, Portugal. UV spectra and spectrophotometric assays were
performed using Shimadzu UV-1603 or UV-2100 PC spectrometers.
Thin layer chromatographys were performed on a Merck grade
aluminum plates, silica gel 60 F254, and visualized by UV light or
iodine. Preparative column chromatography was performed on silica
gel 60 from Merck (70–230 mesh ASTM). Dioxane and TEA were
purified and dried before use. Sodium hydroxide and hydrochloric
acid solutions were prepared from dilution of standardized Tritisol
stock solutions. Solvents and buffer materials for enzyme assays
were of analytical reagent grade and were purchased from Merck
or Sigma. PPE, MeO-Suc-Ala-Ala-Pro-Val-p-NA, and N-Suc-Ala-
Ala-Ala-pNA were purchased from Sigma, and HLE was purchased
from Calbiochem.
General Procedure for the Synthesis of Azetidine-2,4-dione
Derivatives. To a solution of the appropriate malonyl dichloride
(0.015 mol) in dry dioxane (15 mL) was added under a nitrogen
atmosphere a primary amine (0.015 mol) in the same solvent (15
mL). Subsequently, a solution of triethylamine (0.036 mol) in dry
dioxane (15 mL) was added dropwise during 1.5 h, and the resulting
mixture refluxed for 6 h, with the reaction progress being monitored
by TLC. After the mixture was cooled, triethylamine hydrochloride
was filtered off, and the solvent was removed under reduced
pressure yielding a solid (malondiamide), recrystallized from
dioxane/hexane. The mother liquor was concentrated under reduced
pressure, and the residue was purified by chromatography on silica
gel, affording the desired product (azetidine-2,4-dione).
1-Benzyl-3,3-dimethylazetidine-2,4-dione, 2a. Compound 2a
was prepared as described above, using dimethylmalonyl dichloride
(2.535 g, 0.015 mol), benzylamine as primary amine (1.622 g, 0.015
mol), and triethylamine (3.649 g; 0.036 mol) as catalyst. The
resulting reaction mixture was refluxed for 14 h. The product was
purified by chromatography on silica gel, using toluene/ethyl acetate
as eluant (from 9.8:0.2 to 9.0:1.0), yielding white crystals (0.122
g, 4%): mp 69–71 °C; Anal. (C12H13NO2) C, N. H calcd 6.45; found
5.95; δ 1H NMR 1.38 (6H, s), 4.46 (2H, s), 7.33–7.39 (5H, m); δ
13C NMR 17.44, 42.78, 60.66, 127.99, 128.17, 129.00, 134.77,
175.05.
1-(4-Chlorophenyl)-3,3-dimethylazetidine-2,4-dione, 2b. Com-
pound 2b was synthesized as described for 2a, using dimethylma-
lonyl dichloride (4.225 g, 0.025 mol) and 4-chloroaniline (2.820
g, 0.025 mol), with the reaction mixture being refluxed for 8 h.
The product was purified by column chromatography using hexane/
ethyl acetate as eluant (8.4: 1.6) to afford 2b as white crystals (0.351
g, 6%): mp 81–84 °C; Anal. (C11H10NO2Cl) C, H, N; δ 1H NMR
1.51 (6H, s), 7.40 (2H, d, J ) 8.8), 7.82 (2H, d, J ) 8.8); δ 13C
NMR 17.76, 62.03, 120.33, 129.42, 132.12, 132.81, 172.62.
Ethyl 2-(3,3-Diethyl-2,4-dioxoazetidin-1-yl)acetate, 2c. 23 Com-
pound 2c was prepared as described for 2a using diethylmalonyl
dichloride (4.925 g, 0.025 mol) and ethyl glycinate hydrochloride
(3.475 g, 0.025 mol) but with more than 3 equiv of triethylamine
(9.107 g, 0.09 mol). The residue was purified by column chroma-
tography on silica gel using mixtures of toluene and ethyl acetate
as eluant to yield a colorless oil (0.920 g, 16%): Anal. (C11H17NO4)
C, H, N; δ 1H NMR 1.07 (6H, t, J ) 7.6), 1.30 (3H, t, J ) 7.2),
1.82, (4H, q, J ) 7.6), 4,10 (2H, s), 4,25 (2H, q, J ) 7,2); Lit.24
1.03 (3H, t, J ) 7), 1.30 (3H, t, J ) 7), 1.77 (4H, q, J ) 7), 3.98
(2H, s), 4.21 ((2H, q, J ) 7); δ 13C NMR 9.27, 14.08, 23.62, 39.28,
62.23, 71.30, 165.93, 173.59.
1-Benzyl-3,3-diethylazetidine-2,4-dione, 2d. Compound 2d was
prepared as described for 2a, using diethylmalonyl dichloride (2.956
g, 0.015 mol), benzylamine (1.622 g, 0.015 mol) as primary amine,
and triethylamine (3.649 g, 0.036 mol) as catalyst. The product
was purified by chromatography on silica gel using toluene/ethyl
acetate as eluant (from 9.8:0.2 to 9.2:0.8) and then recrystallized
from hexane to yield the product as white crystals (0.243 g, 9%):
mp 46–47 °C; Anal. (C14H17NO2) C, H, N; δ 1H NMR 0.94 (6H,
t, J ) 7.6), 1.75 (4H, q, J ) 7.6), 4.48 (2H, s), 7.32–7.37 (5H, m);
δ 13C NMR 9.18, 23.67, 42.17, 70.98, 128.14, 128.28, 128.88,
135.06, 174.24.
3,3-Diethyl-1-(4-methoxyphenyl)azetidine-2,4-dione, 2e. Com-
pound 2e was prepared as described for 2a, using diethylmalonyl
dichloride (2.956 g, 0.015 mol) and 4-anisidine (1.605 g, 0.015
mol) as primary amine. Purified by chromatography on silica gel
using toluene/ethyl acetate (9.2:0.8), yielding yellow oil (0.412 g,
11%): Anal. (C14H17NO3) C, H, N; δ 1H NMR 1.08 (6H, t, J )
7.6), 1.86 (4H, q, J ) 7.6), 3.84 (3H, s), 6.94 (2H, d, J ) 8.8),
7.76 (2H, d, J ) 8.8); δ 13C NMR 9.25, 23.95, 55.51, 71.94, 114.34,
120.89, 172.25.
3,3-Diethyl-1-(4-tolyl)azetidine-2,4-dione, 2f. Compound 2f was
prepared as described for 2a, using diethylmalonyl dichloride (2.956
g; 0.015 mol) and 4-toluidine (1.605 g; 0.015 mol). The product
was purified by chromatography on silica gel using toluene/ethyl
acetate (9:1) as eluant, to afford white crystals (0.343 g, 10%): mp
41–44 °C; Anal. (C14H17NO2) C. H calcd 7.41; found 6.59; N calcd
6.06; found 6.56; δ 1H NMR 1.08 (6H, t, J ) 7.6), 1.87 (4H, q, J
) 7.6), 2.37 (3H, s), 7.23 (2H, d, J ) 8.4), 7.73 (2H, d, J ) 8.4);
δ 13C NMR 9.24, 21.18, 23.95, 72.01, 119.19, 129.75, 131.33,
136.69, 172.27.
3,3-Diethyl-1-phenylazetidine-2,4-dione, 2g. Compound 2g was
prepared as described for 2a, using diethylmalonyl dichloride (2.956
g, 0.015 mol) and aniline (1.397 g, 0.015 mol). It was purified by
column chromatography on silica gel using toluene/ethyl acetate
(9.0, 1.0) to give a colorless oil (0.474 g, 15%) (Lit.24 mp. 86–87
°C): Anal. (C13H15NO2) C, H, N; δ 1H NMR 1.09 (6H, t, J ) 7,6),
1.88 (4H, q, J ) 7.6), 7.29 (1H, dt, J ) 7.6, 1.2), 7.73 (2H, dt, J
) 7.6, 1.2), 7.86 (2H, dd, J ) 7.6, 1.2); δ 13C NMR 9.25, 23.96,
72.14, 119.23, 126.76, 129.26, 133.85, 172.26.
1-(4-Chlorophenyl)-3,3-diethylazetidine-2,4-dione, 2h. Com-
pound 2h was prepared as described for 2a, using diethylmalonyl
dichloride (2.956 g; 0.015 mol) and 4-chloroaniline (1.695 g, 0.015
mol). It was purified by column chromatography on silica gel using
toluene/ethyl acetate (8.0, 2.0), yielding the product as white crystals
(0.544 g, 14%): mp 43–46 °C; Anal. (C13H14NO2Cl) C, H, N; δ
1H NMR 1.08 (6H, t, J ) 7.6), 1.88 (4H, q, J ) 7.6), 7.40 (2H, d,
J ) 8.8), 7.83 (2H, d, J ) 8.8); δ 13C NMR 9.23, 23.93, 72.38,
120.41, 129.42, 132.12, 132.32, 171.96.
4-(3,3-Diethyl-2,4-dioxoazetidin-1-yl)benzonitrile, 2i. Com-
pound 2i was prepared as described for 2a, using diethylmalonyl
dichloride (2.956 g; 0.015 mol) and 4-cyanoaniline (1.772 g, 0.015
mol). It was purified by column chromatography on silica gel using
hexane/ethyl acetate (8.0, 2.0), to yield the product as white crystals
(0.687 g, 19%): mp 106–109 °C; Anal. (C14H14N2O2) C, H, N; δ
1H NMR 1.09 (6H, t, J ) 7.6), 1.90 (4H, q, J ) 7.6), 7.74 (2H, d,
J ) 8.8), 8.03 (2H, d, J ) 8.8); δ 13C NMR 9.21, 23.96, 72.87,
110.10, 118.14, 119.29, 133.49, 137.19, 171.70.
Chemical Kinetics. For all kinetic experiments, temperatures
were maintained at 25.0 ( 0.1 °C, and the ionic strength was
adjusted to 0.5 M by addition of NaClO4. Sodium hydroxide
solutions were prepared by dilution of standardized Titrisol stock
solutions and contained 20% (v/v) CH3CN. Stock solutions of
compounds were prepared in CH3CN. In a typical run, the reaction
was initiated by the addition of a 30 µL aliquot of a 10-2 M stock
solution of substrate to a cuvette containing 3 mL of the alkaline
buffer solution. Curves were analyzed as first-order reactions. The
pseudo-first-order rate constants, kobs, were obtained by least-squares
treatment of log(At - A∞) data, where At and A∞ represent the
absorbance at time t and at time infinity, respectively. The
wavelengths (nm) used were 221 for 2a and 2d, 260 for 2b, 2f,
and 2h, 247 for 2e, 255 for 2g, and 280 nm for 2i.
Enzymatic Assays. PPE and HLE were assayed spectrophoto-
metrically by monitoring the release of p-nitroaniline at 390 and
410 nm, respectively, from the enzyme mediated hydrolysis of the
substrates, N-Suc-Ala-Ala-Ala-pNA and MeO-Suc-Ala-Ala-Pro-
Val-p-NA at 25 °C to evaluate whether the inhibition is reversible
or irreversible. Inactivation rates for time-dependent inhibition were
determined continuously, according to the slow tight-biding inhibi-
tion model. Alternatively, in cases where no time-dependent
inhibition was observed, the inhibitor constants Ki were calculated
from Dixon plots.
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Enzyme Inactivation by the Progress Curve Method. For the
most-active compounds (2e-2i), PPE inhibition was analyzed by
the progress curve method.15,25 The enzymatic reactions were
initiated by addition of 10 µL of PPE (20 µM in HEPES buffer,
0.1 M, pH 7.2) to a cuvette thermostatted at 25 °C, containing 940
µL of HEPES buffer (0.1 M, pH 7.2), 20 µL of DMSO, 20 µL of
substrate (15 mM in DMSO), and 10 µL of inhibitor (2e-2i in
DMSO). The absorbance was continuously monitored at 390 nm
for 20 min. The final concentrations were [PPE] ) 200 nM,
[substrate] ) 0.3 mM, and [DMSO] ) 5% (v/v). Several inhibitor
concentrations from 8 to 150 µM were used. Control assays, in
which the inhibitor was omitted, ran linearly. The pseudo-first-
order rate constants, kobs, for the inhibition of PPE were determined
according to the slow tight-binding inhibition model15 and involved
the fitting of product concentration as a function of time to eq 1 by
nonlinear regression analysis using the routine ENZFIT (developed
at the Faculty of Pharmacy, Lisbon).
Inactivation of HLE was assayed at 25 °C by mixing 10 µL of
HLE stock solution (2 µM in 0.05 M acetate buffer, pH 5.5) to a
solution containing 10 µL of inhibitor in DMSO (200 µM), 20 µL
of substrate MeO-Suc-Ala-Ala-Pro-Val-p-NA (50 mM in DMSO),
and 960 µL of 0.1 M HEPES buffer, pH 7.2, and the absorbance
was continuously monitored at 410 nm for 20 min.
Enzyme Inactivation by the Incubation Method. 26 In a typical
experiment, 50 µL of inhibitor 2h (3 mM in DMSO) was incubated
at 25 °C with 750 µL of HEPES buffer (0.1 M; pH 7.2) and 200
µL of PPE solution of 50 µM in HEPES buffer. Aliquots (100 µL)
were withdrawn at different time intervals (30 s, 15 min, 30 min,
1 h, 2 h, 3 h, 4 h, 5 h, and 7 h) and transferred to a cuvette
thermostatted at 25 °C, containing 895 µL of HEPES buffer (0.1
M; pH 7.2) and 5 µL of substrate (12.5 mM). The absorbance was
monitored at 390 nm for 50 s. The amount of enzyme activity was
determined by comparison of the activity of a control assay
(containing no inhibitor) with the activity of an enzyme solution
containing inhibitor at the same time point. The experiment was
repeated using inhibitor 2b (aliquots withdrawn at 30 s, 2 min, 3.5
min, 5 min, 6.5 min, 21 min, and 60 min).
Molecular Modeling. The geometries of compounds 2 were
energy minimized using density functional theory.27 These calcula-
tions were performed with the B3LYP28 hybrid functional and the
6-31+G(d,p) basis set implemented in Gaussian03 software pack-
age.29 After geometry optimizations, partial charges were included
using Amber’s Antechamber module30 (included with Chimera
software).31 The PPE structure used was obtained by deletion from
the active site of the ligand present in the crystal structure (the
-lactam ring-opened product of a N-sulfonylaryl -lactam co-
valently linked to Ser-195; PDB accession code 1BTU).32 Hydrogen
atoms were added, and the correct protonation states of histidine
residues were assigned according to their surrounding environment.
The PPE structure was energy minimized, and charges were added
using the Amber united atom force field,33 implemented in Chimera
software.31 To assess the quality of our docking results, the ligand
derived from the N-sulfonylaryl -lactam was docked back into
the 1BTU active site showing a very small root-mean-square
deviation (rmsd) when compared with 1BTU crystal structure.
Molecular docking studies of inhibitors 2 into the active site of
PPE enzyme were performed with the flexible GOLD (Genetic
Optimisation for Ligand Docking, version 3.0.1)34 docking program
using the goldscore scoring function.35 Each ligand was initially
energy minimized and then subjected to 10 000 docking runs (with
a population size of 100; 100,000 genetic algorithm operations; 5
islands). The top 10 solutions (i.e., those with the highest fitness
score) were visually analyzed for (i) the hydrophobic and hydro-
philic interactions between the ligand and enzyme surfaces and (ii)
the distance between the Ser-195 hydroxyl oxygen atom and the
carbonyl carbon atoms of each 4-oxo--lactam 2.
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